[
  {
    "id": "41265122",
    "title_en": "Synergistic strategies of sulforaphane biosynthesis and functional properties in broccoli sprouts powder obtained from sucrose stress modulation coupled with vacuum freeze-drying.",
    "pub_date": "2026 Jan",
    "journal": "Food chemistry",
    "abstract_en": "This study investigated methionine-sucrose stress treatments on glucoraphanin biosynthesis in broccoli sprouts and the impact of vacuum freeze-drying (VFD) on sprout powder quality. Results showed that sucrose treatment elevated glucoraphanin content by 316.30Â % in 4-day sprouts compared to the control (9.72Â mg/g), accompanied by increases of 42.65Â % in total isothiocyanates (ITCs) and 70.00Â % in anthocyanins. The treatment enhanced myrosinase activity and upregulated osmotic regulators. PCA confirmed that sucrose stress optimized the nutritional quality of broccoli sprouts and exhibited potential in sulforaphane enrichment. The VFD broccoli sprout powder exhibited high retention of sulforaphane (6.00Â mg/g dw) and total ITCs (7.00Â mg/g dw), with optimal water-holding capacity, oil-holding capacity, and swelling capacity. The sulforaphane extract exhibited significant antimicrobial activity against E. coli (16.00Â mm inhibition zone) and Staphylococcus aureus (10.02Â mm). The synergistic application of sucrose stress and VFD presents a promising approach for developing functional foods.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¦‚ä½•æå‡é’èŠ±æ¤°èœç‡Ÿé¤Šåƒ¹å€¼çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨é é˜²å¥åº·å•é¡Œæ–¹é¢ã€‚é’èŠ±æ¤°èœä¸­çš„è˜¿è””ç¡«ç´ è¢«èªç‚ºå°å¥åº·æœ‰ç›Šï¼Œå¯èƒ½æœ‰åŠ©æ–¼é™ä½æŸäº›ç–¾ç—…çš„é¢¨éšªã€‚é€éèª¿æ•´æ ½åŸ¹æ¢ä»¶ï¼Œä¾‹å¦‚æ–½åŠ ç‰¹å®šçš„å£“åŠ›ï¼Œå¯èƒ½èƒ½å¤ å¢åŠ é’èŠ±æ¤°èœä¸­çš„æœ‰ç›Šæˆåˆ†ï¼Œé€™å°æ–¼å¸Œæœ›æ”¹å–„é£²é£Ÿå’Œå¢å¼·å…ç–«åŠ›çš„äººä¾†èªªï¼Œæ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„æ–¹å‘ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨ç”²ç¡«æ°¨é…¸-è”—ç³–å£“åŠ›è™•ç†å°é’èŠ±æ¤°èœèŠ½ä¸­è‘¡è„ç³–æ‹‰æ³•å¯§åˆæˆçš„å½±éŸ¿ï¼Œä»¥åŠçœŸç©ºå†·å‡ä¹¾ç‡¥å°èŠ½ç²‰å“è³ªçš„å½±éŸ¿ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™äº›è™•ç†æ–¹æ³•å¦‚ä½•å½±éŸ¿é’èŠ±æ¤°èœèŠ½çš„ç‡Ÿé¤Šæˆåˆ†ï¼Œç‰¹åˆ¥æ˜¯è˜¿è””ç¡«ç´ çš„å«é‡ï¼Œä¸¦è©•ä¼°å…¶åœ¨åŠŸèƒ½æ€§é£Ÿå“é–‹ç™¼ä¸­çš„æ½›åŠ›ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å°é’èŠ±æ¤°èœèŠ½æ–½åŠ äº†ç”²ç¡«æ°¨é…¸å’Œè”—ç³–çš„å£“åŠ›è™•ç†ï¼Œä¸¦è§€å¯Ÿå…¶å°èŠ½ä¸­è‘¡è„ç³–æ‹‰æ³•å¯§åŠå…¶ä»–ç‡Ÿé¤Šæˆåˆ†çš„å½±éŸ¿ã€‚å¯¦é©—ä¸­ä½¿ç”¨äº†ä¸åŒçš„è™•ç†çµ„å’Œå°ç…§çµ„ï¼Œä¸¦é€²è¡Œäº†çœŸç©ºå†·å‡ä¹¾ç‡¥ä»¥è©•ä¼°èŠ½ç²‰çš„å“è³ªã€‚é€™äº›æ–¹æ³•çš„çµåˆæ—¨åœ¨æå‡é’èŠ±æ¤°èœèŠ½çš„ç‡Ÿé¤Šåƒ¹å€¼ï¼Œä¸¦æ¢ç´¢å…¶åœ¨é£Ÿå“ä¸­çš„æ‡‰ç”¨ã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼Œæ–½åŠ è”—ç³–è™•ç†å¾Œï¼Œé’èŠ±æ¤°èœèŠ½ä¸­çš„è‘¡è„ç³–æ‹‰æ³•å¯§å«é‡æå‡äº†316.30%ï¼Œä¸¦ä¸”ç¸½ç•°ç¡«æ°°é…¸é¹½å’ŒèŠ±é’ç´ çš„å«é‡ä¹Ÿæœ‰é¡¯è‘—å¢åŠ ã€‚æ­¤å¤–ï¼ŒçœŸç©ºå†·å‡ä¹¾ç‡¥çš„é’èŠ±æ¤°èœèŠ½ç²‰ä¿ç•™äº†é«˜æ¿ƒåº¦çš„è˜¿è””ç¡«ç´ å’Œç¸½ç•°ç¡«æ°°é…¸é¹½ï¼Œä¸¦å±•ç¾å‡ºè‰¯å¥½çš„æ°´åˆ†ä¿æŒèƒ½åŠ›å’Œæ²¹è„‚ä¿æŒèƒ½åŠ›ã€‚é€™äº›ç™¼ç¾è¡¨æ˜ï¼Œçµåˆè”—ç³–å£“åŠ›å’ŒçœŸç©ºå†·å‡ä¹¾ç‡¥çš„æ–¹å¼ï¼Œå¯èƒ½ç‚ºé–‹ç™¼åŠŸèƒ½æ€§é£Ÿå“æä¾›äº†ä¸€å€‹æœ‰å‰æ™¯çš„é€”å¾‘ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¦‚ä½•æå‡é’èŠ±æ¤°èœç‡Ÿé¤Šåƒ¹å€¼çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨é é˜²å¥åº·å•é¡Œæ–¹é¢ã€‚é’èŠ±æ¤°èœä¸­çš„è˜¿è””ç¡«ç´ è¢«èªç‚ºå°å¥åº·æœ‰ç›Šï¼Œå¯èƒ½æœ‰åŠ©æ–¼é™ä½æŸäº›ç–¾ç—…çš„é¢¨éšªã€‚é€éèª¿æ•´æ ½åŸ¹æ¢ä»¶ï¼Œä¾‹å¦‚æ–½åŠ ç‰¹å®šçš„å£“åŠ›ï¼Œå¯èƒ½èƒ½å¤ å¢åŠ é’èŠ±æ¤°èœä¸­çš„æœ‰ç›Šæˆåˆ†ï¼Œé€™å°æ–¼å¸Œæœ›æ”¹å–„é£²é£Ÿå’Œå¢å¼·å…ç–«åŠ›çš„äººä¾†èªªï¼Œæ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„æ–¹å‘ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨ç”²ç¡«æ°¨é…¸-è”—ç³–å£“åŠ›è™•ç†å°é’èŠ±æ¤°èœèŠ½ä¸­è‘¡è„ç³–æ‹‰æ³•å¯§åˆæˆçš„å½±éŸ¿ï¼Œä»¥åŠçœŸç©ºå†·å‡ä¹¾ç‡¥å°èŠ½ç²‰å“è³ªçš„å½±éŸ¿ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™äº›è™•ç†æ–¹æ³•å¦‚ä½•å½±éŸ¿é’èŠ±æ¤°èœèŠ½çš„ç‡Ÿé¤Šæˆåˆ†ï¼Œç‰¹åˆ¥æ˜¯è˜¿è””ç¡«ç´ çš„å«é‡ï¼Œä¸¦è©•ä¼°å…¶åœ¨åŠŸèƒ½æ€§é£Ÿå“é–‹ç™¼ä¸­çš„æ½›åŠ›ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å°é’èŠ±æ¤°èœèŠ½æ–½åŠ äº†ç”²ç¡«æ°¨é…¸å’Œè”—ç³–çš„å£“åŠ›è™•ç†ï¼Œä¸¦è§€å¯Ÿå…¶å°èŠ½ä¸­è‘¡è„ç³–æ‹‰æ³•å¯§åŠå…¶ä»–ç‡Ÿé¤Šæˆåˆ†çš„å½±éŸ¿ã€‚å¯¦é©—ä¸­ä½¿ç”¨äº†ä¸åŒçš„è™•ç†çµ„å’Œå°ç…§çµ„ï¼Œä¸¦é€²è¡Œäº†çœŸç©ºå†·å‡ä¹¾ç‡¥ä»¥è©•ä¼°èŠ½ç²‰çš„å“è³ªã€‚é€™äº›æ–¹æ³•çš„çµåˆæ—¨åœ¨æå‡é’èŠ±æ¤°èœèŠ½çš„ç‡Ÿé¤Šåƒ¹å€¼ï¼Œä¸¦æ¢ç´¢å…¶åœ¨é£Ÿå“ä¸­çš„æ‡‰ç”¨ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œæ–½åŠ è”—ç³–è™•ç†å¾Œï¼Œé’èŠ±æ¤°èœèŠ½ä¸­çš„è‘¡è„ç³–æ‹‰æ³•å¯§å«é‡æå‡äº†316.30%ï¼Œä¸¦ä¸”ç¸½ç•°ç¡«æ°°é…¸é¹½å’ŒèŠ±é’ç´ çš„å«é‡ä¹Ÿæœ‰é¡¯è‘—å¢åŠ ã€‚æ­¤å¤–ï¼ŒçœŸç©ºå†·å‡ä¹¾ç‡¥çš„é’èŠ±æ¤°èœèŠ½ç²‰ä¿ç•™äº†é«˜æ¿ƒåº¦çš„è˜¿è””ç¡«ç´ å’Œç¸½ç•°ç¡«æ°°é…¸é¹½ï¼Œä¸¦å±•ç¾å‡ºè‰¯å¥½çš„æ°´åˆ†ä¿æŒèƒ½åŠ›å’Œæ²¹è„‚ä¿æŒèƒ½åŠ›ã€‚é€™äº›ç™¼ç¾è¡¨æ˜ï¼Œçµåˆè”—ç³–å£“åŠ›å’ŒçœŸç©ºå†·å‡ä¹¾ç‡¥çš„æ–¹å¼ï¼Œå¯èƒ½ç‚ºé–‹ç™¼åŠŸèƒ½æ€§é£Ÿå“æä¾›äº†ä¸€å€‹æœ‰å‰æ™¯çš„é€”å¾‘ã€‚",
    "fb_post": "æ ¹æ“šã€ŠFood chemistryã€‹æ–¼ 2026 å¹´ 1 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ±ä½ çŸ¥é“é’èŠ±æ¤°èœè£¡æœ‰ä¸€ç¨®ç¥å¥‡çš„æˆåˆ†å«è˜¿è””ç¡«ç´ å—ï¼Ÿå®ƒå¯èƒ½å°æˆ‘å€‘çš„å¥åº·æœ‰ä¸å°‘å¥½è™•ï¼Œåƒæ˜¯é™ä½æŸäº›ç–¾ç—…çš„é¢¨éšªï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶è®“æˆ‘å€‘å°é’èŠ±æ¤°èœçš„ç‡Ÿé¤Šåƒ¹å€¼æœ‰äº†æ–°èªè­˜ã€‚ç ”ç©¶è€…å€‘ç™¼ç¾ï¼Œé€éæ–½åŠ ç‰¹å®šçš„å£“åŠ›ï¼Œåƒæ˜¯ç”²ç¡«æ°¨é…¸å’Œè”—ç³–ï¼Œé’èŠ±æ¤°èœèŠ½ä¸­çš„è˜¿è””ç¡«ç´ å«é‡å¯ä»¥å¤§å¹…æå‡ï¼\n\né€™é …ç ”ç©¶ä¸»è¦æ˜¯æƒ³äº†è§£é€™äº›è™•ç†æ–¹æ³•å¦‚ä½•æå‡é’èŠ±æ¤°èœèŠ½çš„ç‡Ÿé¤Šæˆåˆ†ï¼Œå°¤å…¶æ˜¯è˜¿è””ç¡«ç´ çš„å«é‡ã€‚ç ”ç©¶è€…å€‘å°é’èŠ±æ¤°èœèŠ½é€²è¡Œäº†ä¸åŒçš„è™•ç†ï¼Œä¸¦ç”¨çœŸç©ºå†·å‡ä¹¾ç‡¥æŠ€è¡“ä¾†è©•ä¼°å…¶å“è³ªã€‚çµæœé¡¯ç¤ºï¼Œæ–½åŠ è”—ç³–å¾Œï¼Œé’èŠ±æ¤°èœèŠ½ä¸­çš„ä¸€ç¨®é‡è¦æˆåˆ†è‘¡è„ç³–æ‹‰æ³•å¯§å«é‡æå‡äº†316.30%ï¼è€Œä¸”ï¼Œé€™äº›è™•ç†å¾Œçš„èŠ½ç²‰é‚„ä¿ç•™äº†é«˜æ¿ƒåº¦çš„è˜¿è””ç¡«ç´ ã€‚\n\né€™äº›ç™¼ç¾å‘Šè¨´æˆ‘å€‘ï¼Œé€™ç¨®çµåˆè”—ç³–å£“åŠ›å’ŒçœŸç©ºå†·å‡ä¹¾ç‡¥çš„æ–¹å¼ï¼Œå¯èƒ½ç‚ºé–‹ç™¼å¥åº·é£Ÿå“æä¾›äº†ä¸€å€‹æ–°æ–¹å‘ï¼\n\nğŸ” ç ”ç©¶é‡é»ï¼š\n1. è”—ç³–è™•ç†èƒ½é¡¯è‘—æå‡é’èŠ±æ¤°èœèŠ½çš„ç‡Ÿé¤Šæˆåˆ†ã€‚\n2. çœŸç©ºå†·å‡ä¹¾ç‡¥æœ‰åŠ©æ–¼ä¿æŒè˜¿è””ç¡«ç´ çš„æ¿ƒåº¦ã€‚\n3. é€™äº›æ–¹æ³•å¯èƒ½æœ‰åŠ©æ–¼é–‹ç™¼åŠŸèƒ½æ€§é£Ÿå“ï¼Œå¢å¼·æˆ‘å€‘çš„å…ç–«åŠ›ï¼",
    "image_prompt": "Create a simple infographic illustrating the experiment methods and main results of a study on broccoli sprouts. Include flat icons of broccoli and sulforaphane, simplified representations of experimental subjects like humans or cells, arrows or flow lines indicating the experimental steps, and a designated area highlighting the main results such as significant increases in certain nutrients. Use a light background with soft colors in a scientific style.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41265122/"
  },
  {
    "id": "40580757",
    "title_en": "The effect of graphene oxide-polyethylene glycol on lung cell and treatment of sulforaphane.",
    "pub_date": "2026 Jan",
    "journal": "Talanta",
    "abstract_en": "This study explores the cytotoxic and biochemical effects of PEGylated graphene oxide (GO-PEG) nanoparticles, sulforaphane, and Raphanus sativus L. (black radish) juice on BEAS-2B human bronchial epithelial cells. Sulforaphane was extracted from radish juice through pH-adjusted aqueous treatment followed by organic solvent extraction, and quantified via high-performance liquid chromatography (HPLC) at 202Â nm, with a retention time of 11.0Â min. GO-PEG nanoparticles produced from graphites (50Â nm and 400Â nm) were tested at concentrations ranging from 50-225 Î¼gÂ mL<sup>-1</sup> and 100-1000 Î¼gÂ mL<sup>-1</sup> to have IC<sub>50</sub> values, respectively. Sulforaphane and black radish juice were also administered. The MTT assay revealed IC<sub>50</sub> values of 8.7Â Î¼gÂ mL<sup>-1</sup> for sulforaphane, 197.0 mgÂ mL<sup>-1</sup> for black radish juice, 175.8Â Î¼gÂ mL<sup>-1</sup> for GO-PEG (50Â nm), and 650.6Â Î¼gÂ mL<sup>-1</sup> for GO-PEG (400Â nm). Biochemical analyses showed that sulforaphane and radish juice decreased IL-6 levels and increased antioxidant enzyme activities (GSH-Px and CAT). These results highlight the therapeutic potential of GO-PEG, sulforaphane, and black radish juice for anti-inflammatory and antioxidant applications.",
    "para1": "é€™é …ç ”ç©¶å¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–çš„é ˜åŸŸã€‚ç ”ç©¶é¡¯ç¤ºï¼ŒæŸäº›å¤©ç„¶æˆåˆ†å¦‚è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±ï¼Œå¯èƒ½å°å‘¼å¸é“ç´°èƒæœ‰ä¿è­·ä½œç”¨ï¼Œé€™å°æ–¼é é˜²èˆ‡å‘¼å¸ç³»çµ±ç›¸é—œçš„ç–¾ç—…å…·æœ‰æ½›åœ¨æ„ç¾©ã€‚é€™äº›ç™¼ç¾ä¹Ÿå¯èƒ½ä¿ƒä½¿äººå€‘æ›´åŠ é‡è¦–é£²é£Ÿä¸­å¤©ç„¶æˆåˆ†çš„æ”å–ï¼Œé€²è€Œæ”¹å–„å¥åº·ç‹€æ³ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨PEGåŒ–çŸ³å¢¨çƒ¯æ°§åŒ–ç‰©ï¼ˆGO-PEGï¼‰å¥ˆç±³ç²’å­ã€è˜¿è””ç¡«ç´ åŠé»‘è˜¿è””æ±å°äººé¡æ”¯æ°£ç®¡ä¸Šçš®ç´°èƒBEAS-2Bçš„ç´°èƒæ¯’æ€§å’Œç”ŸåŒ–æ•ˆæ‡‰ã€‚ç ”ç©¶è€…é—œå¿ƒé€™äº›ç‰©è³ªå°å‘¼å¸é“ç´°èƒçš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯å®ƒå€‘åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–æ–¹é¢çš„æ½›åŠ›ã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…æå–äº†é»‘è˜¿è””æ±ä¸­çš„è˜¿è””ç¡«ç´ ï¼Œä¸¦ä½¿ç”¨é«˜æ•ˆæ¶²ç›¸è‰²è­œæ³•é€²è¡Œå®šé‡åˆ†æã€‚GO-PEGå¥ˆç±³ç²’å­æ˜¯å¾çŸ³å¢¨è£½æˆçš„ï¼Œä¸¦åœ¨ä¸åŒæ¿ƒåº¦ä¸‹é€²è¡Œæ¸¬è©¦ã€‚ç ”ç©¶è€…ä½¿ç”¨MTTæ³•ä¾†è©•ä¼°ç´°èƒå­˜æ´»ç‡ï¼Œä¸¦æ¸¬é‡äº†ä¸åŒè™•ç†ä¸‹çš„IC50å€¼ï¼Œä»¥äº†è§£é€™äº›ç‰©è³ªçš„ç´°èƒæ¯’æ€§ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±èƒ½é™ä½IL-6çš„æ°´å¹³ï¼Œä¸¦æé«˜æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ï¼ˆå¦‚GSH-Pxå’ŒCATï¼‰ã€‚é€™äº›çµæœçªé¡¯äº†GO-PEGã€è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–æ‡‰ç”¨ä¸­çš„æ½›åœ¨ç™‚æ•ˆï¼Œä½†ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ä¾†ç¢ºèªå…¶å…·é«”æ•ˆæœã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–çš„é ˜åŸŸã€‚ç ”ç©¶é¡¯ç¤ºï¼ŒæŸäº›å¤©ç„¶æˆåˆ†å¦‚è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±ï¼Œå¯èƒ½å°å‘¼å¸é“ç´°èƒæœ‰ä¿è­·ä½œç”¨ï¼Œé€™å°æ–¼é é˜²èˆ‡å‘¼å¸ç³»çµ±ç›¸é—œçš„ç–¾ç—…å…·æœ‰æ½›åœ¨æ„ç¾©ã€‚é€™äº›ç™¼ç¾ä¹Ÿå¯èƒ½ä¿ƒä½¿äººå€‘æ›´åŠ é‡è¦–é£²é£Ÿä¸­å¤©ç„¶æˆåˆ†çš„æ”å–ï¼Œé€²è€Œæ”¹å–„å¥åº·ç‹€æ³ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨PEGåŒ–çŸ³å¢¨çƒ¯æ°§åŒ–ç‰©ï¼ˆGO-PEGï¼‰å¥ˆç±³ç²’å­ã€è˜¿è””ç¡«ç´ åŠé»‘è˜¿è””æ±å°äººé¡æ”¯æ°£ç®¡ä¸Šçš®ç´°èƒBEAS-2Bçš„ç´°èƒæ¯’æ€§å’Œç”ŸåŒ–æ•ˆæ‡‰ã€‚ç ”ç©¶è€…é—œå¿ƒé€™äº›ç‰©è³ªå°å‘¼å¸é“ç´°èƒçš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯å®ƒå€‘åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–æ–¹é¢çš„æ½›åŠ›ã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶è€…æå–äº†é»‘è˜¿è””æ±ä¸­çš„è˜¿è””ç¡«ç´ ï¼Œä¸¦ä½¿ç”¨é«˜æ•ˆæ¶²ç›¸è‰²è­œæ³•é€²è¡Œå®šé‡åˆ†æã€‚GO-PEGå¥ˆç±³ç²’å­æ˜¯å¾çŸ³å¢¨è£½æˆçš„ï¼Œä¸¦åœ¨ä¸åŒæ¿ƒåº¦ä¸‹é€²è¡Œæ¸¬è©¦ã€‚ç ”ç©¶è€…ä½¿ç”¨MTTæ³•ä¾†è©•ä¼°ç´°èƒå­˜æ´»ç‡ï¼Œä¸¦æ¸¬é‡äº†ä¸åŒè™•ç†ä¸‹çš„IC50å€¼ï¼Œä»¥äº†è§£é€™äº›ç‰©è³ªçš„ç´°èƒæ¯’æ€§ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±èƒ½é™ä½IL-6çš„æ°´å¹³ï¼Œä¸¦æé«˜æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ï¼ˆå¦‚GSH-Pxå’ŒCATï¼‰ã€‚é€™äº›çµæœçªé¡¯äº†GO-PEGã€è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–æ‡‰ç”¨ä¸­çš„æ½›åœ¨ç™‚æ•ˆï¼Œä½†ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ä¾†ç¢ºèªå…¶å…·é«”æ•ˆæœã€‚",
    "fb_post": "æ ¹æ“šã€ŠTalantaã€‹æ–¼ 2026 å¹´ 1 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± å¤§å®¶çŸ¥é“è˜¿è””ä¸åªæ˜¯ç”¨ä¾†åšæ²™æ‹‰çš„å—ï¼Ÿæœ€è¿‘æœ‰ä¸€é …ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ é€™å€‹å¤©ç„¶æˆåˆ†å¯èƒ½å°æˆ‘å€‘çš„å‘¼å¸ç³»çµ±æœ‰å¾ˆå¤§çš„å¹«åŠ©ï¼\n\né€™é …ç ”ç©¶ä¸»è¦åœ¨æ¢è¨è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±å°å‘¼å¸é“ç´°èƒçš„å½±éŸ¿ã€‚ç ”ç©¶è€…å€‘ä½¿ç”¨äº†ç‰¹åˆ¥çš„å¥ˆç±³ç²’å­ï¼Œä¸¦æ¸¬è©¦äº†é€™äº›æˆåˆ†çš„ç´°èƒæ¯’æ€§å’Œå…¶ä»–ç”ŸåŒ–æ•ˆæ‡‰ã€‚å¯¦é©—ä¸­ï¼Œä»–å€‘æå–äº†é»‘è˜¿è””æ±ä¸­çš„è˜¿è””ç¡«ç´ ï¼Œä¸¦é€²è¡Œäº†è©³ç´°çš„åˆ†æã€‚\n\nçµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±ä¸åƒ…èƒ½é™ä½ä¸€ç¨®å«åšIL-6çš„ç™¼ç‚æŒ‡æ¨™ï¼Œé‚„èƒ½æé«˜æˆ‘å€‘é«”å…§æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ï¼Œé€™å°æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–éƒ½å¾ˆé‡è¦ï¼\n\nğŸ” ç¸½çµä¸€ä¸‹é€™é …ç ”ç©¶çš„é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±å¯èƒ½æœ‰åŠ©æ–¼ä¿è­·å‘¼å¸é“ç´°èƒã€‚\n2. å®ƒå€‘èƒ½é™ä½ç™¼ç‚æŒ‡æ¨™IL-6çš„æ°´å¹³ã€‚\n3. æå‡æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ï¼Œå°å¥åº·æœ‰ç›Šã€‚\n\né›–ç„¶é€™äº›çµæœå¾ˆæœ‰å¸Œæœ›ï¼Œä½†é‚„éœ€è¦æ›´å¤šç ”ç©¶ä¾†ç¢ºèªå®ƒå€‘çš„å…·é«”æ•ˆæœå“¦ï¼",
    "image_prompt": "Create a flat design infographic that explains the experimental process and main findings of a study on the effects of daikon sulforaphane and black radish juice on human bronchial epithelial cells. Include simple icons representing daikon or broccoli, simplified human or cell figures as experimental subjects, arrows or flow lines to indicate experimental steps, and a section labeled 'Main Findings' highlighting protective effects and changes observed.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "å‘¼å¸é“ç–¾ç—… Respiratory Diseases",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40580757/"
  },
  {
    "id": "41340527",
    "title_en": "Metabolomics and Transcriptomics Analyses Reveal the Mechanisms of Sulforaphane Conversion and Adaptive Strategies in the Absence of Glucose by <i>Lactiplantibacillus plantarum</i>.",
    "pub_date": "2025 Dec",
    "journal": "Journal of agricultural and food chemistry",
    "abstract_en": "Sulforaphane is a beneficial but unstable bioactive compound that can be converted from glucoraphanin by <i>Lactiplantibacillus plantarum</i>. However, the sulforaphane conversion rate is low, and the conversion mechanism of <i>L. plantarum</i> remains unclear. This research utilized the adaptive laboratory evolution technology to enhance the sulforaphane conversion rate of <i>L. plantarum</i>. The results showed that an increase in the glucose replacement ratio significantly downregulated carbohydrate metabolism and upregulated amino acid metabolism. Transcriptomic analysis showed that the ALE-adapted strain significantly upregulated carbohydrate metabolism and amino acid metabolism. In the conversion pathway, glucoraphanin is imported into <i>L. plantarum</i> cells, and its glucose moiety is phosphorylated by bglF (the phosphate group may be derived from phosphoenolpyruvate via the phosphotransferase system). Subsequently, the S-glycosidic bond of phosphorylated glucoraphanin is hydrolyzed by bglA (6-phospho-Î²-glucosidase), followed by nonenzymatic rearrangement and sulfate elimination, ultimately yielding sulforaphane. This research can contribute to revealing the interaction mechanism between microorganisms and natural active substances.",
    "para1": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œè˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å…·æœ‰æ½›åœ¨å¥åº·ç›Šè™•çš„åŒ–åˆç‰©ï¼Œå¯èƒ½å°æŠ—æŸäº›ç–¾ç—…ã€‚ç„¶è€Œï¼Œè˜¿è””ç¡«ç´ çš„ç©©å®šæ€§è¼ƒå·®ï¼Œé€™ä½¿å¾—å®ƒçš„æ‡‰ç”¨å—åˆ°é™åˆ¶ã€‚é€éäº†è§£å¦‚ä½•æé«˜è˜¿è””ç¡«ç´ çš„è½‰æ›ç‡ï¼Œæœªä¾†æˆ–è¨±èƒ½é–‹ç™¼å‡ºæ›´æœ‰æ•ˆçš„ä¿å¥é£Ÿå“æˆ–ç™‚æ³•ï¼Œå¹«åŠ©äººå€‘æ›´å¥½åœ°åˆ©ç”¨é€™ç¨®æœ‰ç›Šæˆåˆ†ï¼Œé€²è€Œä¿ƒé€²å¥åº·æˆ–é é˜²ç–¾ç—…ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨å¦‚ä½•æé«˜ä¹³é…¸èŒï¼ˆLactiplantibacillus plantarumï¼‰å°‡é’èŠ±æ¤°èœä¸­çš„ä¸€ç¨®å‰é«”åŒ–åˆç‰©â€”â€”è‘¡è„ç³–è…ºè‹·ï¼ˆglucoraphaninï¼‰è½‰æ›ç‚ºè˜¿è””ç¡«ç´ çš„æ•ˆç‡ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯é€™å€‹è½‰æ›éç¨‹çš„æ©Ÿåˆ¶ä»¥åŠå¦‚ä½•é€éå¯¦é©—æŠ€è¡“ä¾†æ”¹å–„è½‰æ›ç‡ï¼Œä»¥ä¾¿æ›´å¥½åœ°åˆ©ç”¨é€™ç¨®æœ‰ç›Šçš„ç”Ÿç‰©æ´»æ€§åŒ–åˆç‰©ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†é©æ‡‰æ€§å¯¦é©—å®¤é€²åŒ–æŠ€è¡“ï¼Œå°ä¹³é…¸èŒé€²è¡Œæ”¹é€ ï¼Œä»¥æé«˜å…¶è½‰æ›è˜¿è””ç¡«ç´ çš„èƒ½åŠ›ã€‚ç ”ç©¶ä¸­è§€å¯Ÿäº†ä¸åŒçš„è‘¡è„ç³–æ›¿ä»£æ¯”ä¾‹å°ç´°èƒä»£è¬çš„å½±éŸ¿ï¼Œä¸¦é€²è¡Œäº†è½‰éŒ„çµ„åˆ†æï¼Œä»¥äº†è§£é€™äº›è®ŠåŒ–å¦‚ä½•å½±éŸ¿ç´°èƒå…§çš„ç¢³æ°´åŒ–åˆç‰©å’Œæ°¨åŸºé…¸ä»£è¬ã€‚é€™æ¨£çš„å¯¦é©—è¨­è¨ˆæœ‰åŠ©æ–¼æ­ç¤ºä¹³é…¸èŒåœ¨è½‰æ›éç¨‹ä¸­çš„ç”Ÿç‰©åŒ–å­¸æ©Ÿåˆ¶ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œç•¶è‘¡è„ç³–æ›¿ä»£æ¯”ä¾‹å¢åŠ æ™‚ï¼Œä¹³é…¸èŒçš„ç¢³æ°´åŒ–åˆç‰©ä»£è¬é¡¯è‘—ä¸‹é™ï¼Œè€Œæ°¨åŸºé…¸ä»£è¬å‰‡ä¸Šå‡ã€‚é€™è¡¨æ˜ï¼Œé€šéèª¿æ•´åŸ¹é¤Šæ¢ä»¶ï¼Œå¯ä»¥æœ‰æ•ˆåœ°ä¿ƒé€²è˜¿è””ç¡«ç´ çš„ç”Ÿæˆã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„æ­ç¤ºäº†è‘¡è„ç³–è…ºè‹·åœ¨ä¹³é…¸èŒç´°èƒå…§çš„è½‰æ›é€”å¾‘ï¼Œé€™äº›çµæœå°æ–¼ç†è§£å¾®ç”Ÿç‰©èˆ‡å¤©ç„¶æ´»æ€§ç‰©è³ªä¹‹é–“çš„ç›¸äº’ä½œç”¨å…·æœ‰é‡è¦æ„ç¾©ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œè˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å…·æœ‰æ½›åœ¨å¥åº·ç›Šè™•çš„åŒ–åˆç‰©ï¼Œå¯èƒ½å°æŠ—æŸäº›ç–¾ç—…ã€‚ç„¶è€Œï¼Œè˜¿è””ç¡«ç´ çš„ç©©å®šæ€§è¼ƒå·®ï¼Œé€™ä½¿å¾—å®ƒçš„æ‡‰ç”¨å—åˆ°é™åˆ¶ã€‚é€éäº†è§£å¦‚ä½•æé«˜è˜¿è””ç¡«ç´ çš„è½‰æ›ç‡ï¼Œæœªä¾†æˆ–è¨±èƒ½é–‹ç™¼å‡ºæ›´æœ‰æ•ˆçš„ä¿å¥é£Ÿå“æˆ–ç™‚æ³•ï¼Œå¹«åŠ©äººå€‘æ›´å¥½åœ°åˆ©ç”¨é€™ç¨®æœ‰ç›Šæˆåˆ†ï¼Œé€²è€Œä¿ƒé€²å¥åº·æˆ–é é˜²ç–¾ç—…ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨å¦‚ä½•æé«˜ä¹³é…¸èŒï¼ˆLactiplantibacillus plantarumï¼‰å°‡é’èŠ±æ¤°èœä¸­çš„ä¸€ç¨®å‰é«”åŒ–åˆç‰©â€”â€”è‘¡è„ç³–è…ºè‹·ï¼ˆglucoraphaninï¼‰è½‰æ›ç‚ºè˜¿è””ç¡«ç´ çš„æ•ˆç‡ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯é€™å€‹è½‰æ›éç¨‹çš„æ©Ÿåˆ¶ä»¥åŠå¦‚ä½•é€éå¯¦é©—æŠ€è¡“ä¾†æ”¹å–„è½‰æ›ç‡ï¼Œä»¥ä¾¿æ›´å¥½åœ°åˆ©ç”¨é€™ç¨®æœ‰ç›Šçš„ç”Ÿç‰©æ´»æ€§åŒ–åˆç‰©ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†é©æ‡‰æ€§å¯¦é©—å®¤é€²åŒ–æŠ€è¡“ï¼Œå°ä¹³é…¸èŒé€²è¡Œæ”¹é€ ï¼Œä»¥æé«˜å…¶è½‰æ›è˜¿è””ç¡«ç´ çš„èƒ½åŠ›ã€‚ç ”ç©¶ä¸­è§€å¯Ÿäº†ä¸åŒçš„è‘¡è„ç³–æ›¿ä»£æ¯”ä¾‹å°ç´°èƒä»£è¬çš„å½±éŸ¿ï¼Œä¸¦é€²è¡Œäº†è½‰éŒ„çµ„åˆ†æï¼Œä»¥äº†è§£é€™äº›è®ŠåŒ–å¦‚ä½•å½±éŸ¿ç´°èƒå…§çš„ç¢³æ°´åŒ–åˆç‰©å’Œæ°¨åŸºé…¸ä»£è¬ã€‚é€™æ¨£çš„å¯¦é©—è¨­è¨ˆæœ‰åŠ©æ–¼æ­ç¤ºä¹³é…¸èŒåœ¨è½‰æ›éç¨‹ä¸­çš„ç”Ÿç‰©åŒ–å­¸æ©Ÿåˆ¶ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œç•¶è‘¡è„ç³–æ›¿ä»£æ¯”ä¾‹å¢åŠ æ™‚ï¼Œä¹³é…¸èŒçš„ç¢³æ°´åŒ–åˆç‰©ä»£è¬é¡¯è‘—ä¸‹é™ï¼Œè€Œæ°¨åŸºé…¸ä»£è¬å‰‡ä¸Šå‡ã€‚é€™è¡¨æ˜ï¼Œé€šéèª¿æ•´åŸ¹é¤Šæ¢ä»¶ï¼Œå¯ä»¥æœ‰æ•ˆåœ°ä¿ƒé€²è˜¿è””ç¡«ç´ çš„ç”Ÿæˆã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„æ­ç¤ºäº†è‘¡è„ç³–è…ºè‹·åœ¨ä¹³é…¸èŒç´°èƒå…§çš„è½‰æ›é€”å¾‘ï¼Œé€™äº›çµæœå°æ–¼ç†è§£å¾®ç”Ÿç‰©èˆ‡å¤©ç„¶æ´»æ€§ç‰©è³ªä¹‹é–“çš„ç›¸äº’ä½œç”¨å…·æœ‰é‡è¦æ„ç¾©ã€‚",
    "fb_post": "æ ¹æ“šã€ŠJournal of agricultural and food chemistryã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ‰ ä½ çŸ¥é“é’èŠ±æ¤°èœè£¡æœ‰ä¸€ç¨®ç¥å¥‡çš„æˆåˆ†å«è˜¿è””ç¡«ç´ å—ï¼Ÿé€™å€‹å°å®¶ä¼™å¯èƒ½å°æˆ‘å€‘çš„å¥åº·æœ‰å¾ˆå¤§çš„å¹«åŠ©ï¼ä¸éï¼Œå®ƒçš„ç©©å®šæ€§ä¸å¤ªå¥½ï¼Œé€™è®“æˆ‘å€‘åœ¨åˆ©ç”¨å®ƒçš„æ™‚å€™æœ‰é»å›°é›£ã€‚æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶å°ˆæ³¨æ–¼å¦‚ä½•è®“ä¹³é…¸èŒï¼ˆå°±æ˜¯é‚£ç¨®æœ‰ç›Šçš„ç´°èŒï¼ï¼‰æ›´æœ‰æ•ˆåœ°æŠŠé’èŠ±æ¤°èœä¸­çš„ä¸€ç¨®æˆåˆ†è½‰æ›æˆè˜¿è””ç¡«ç´ ã€‚  \n  \nç ”ç©¶è€…å€‘ä½¿ç”¨äº†ä¸€ç¨®å«é©æ‡‰æ€§å¯¦é©—å®¤é€²åŒ–çš„æŠ€è¡“ï¼Œå°ä¹³é…¸èŒé€²è¡Œæ”¹é€ ï¼Œæƒ³çœ‹çœ‹ä¸åŒçš„åŸ¹é¤Šæ¢ä»¶æœƒå°å®ƒçš„è½‰æ›èƒ½åŠ›æœ‰ä»€éº¼å½±éŸ¿ã€‚çµæœç™¼ç¾ï¼Œç•¶ä»–å€‘èª¿æ•´äº†è‘¡è„ç³–çš„æ¯”ä¾‹æ™‚ï¼Œä¹³é…¸èŒçš„ç¢³æ°´åŒ–åˆç‰©ä»£è¬ä¸‹é™ï¼Œä½†æ°¨åŸºé…¸ä»£è¬å»ä¸Šå‡ï¼é€™æ„å‘³è‘—ï¼Œåªè¦æ”¹è®ŠåŸ¹é¤Šæ¢ä»¶ï¼Œå°±èƒ½ä¿ƒé€²è˜¿è””ç¡«ç´ çš„ç”Ÿæˆã€‚  \n  \né€™é …ç ”ç©¶çš„ç™¼ç¾ä¸åƒ…è®“æˆ‘å€‘å°è˜¿è””ç¡«ç´ æœ‰äº†æ›´æ·±å…¥çš„äº†è§£ï¼Œé‚„æœ‰åŠ©æ–¼æˆ‘å€‘æ¢ç´¢å¾®ç”Ÿç‰©å’Œå¤©ç„¶æˆåˆ†ä¹‹é–“çš„å¥‡å¦™é—œä¿‚ï¼  \n  \nğŸ” é‡é»æ•´ç†ï¼š  \n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼å¥åº·ï¼Œä½†ç©©å®šæ€§ä¸ä½³ã€‚  \n2. ç ”ç©¶å°ˆæ³¨æ–¼æé«˜ä¹³é…¸èŒè½‰æ›è˜¿è””ç¡«ç´ çš„æ•ˆç‡ã€‚  \n3. èª¿æ•´åŸ¹é¤Šæ¢ä»¶èƒ½æœ‰æ•ˆä¿ƒé€²è˜¿è””ç¡«ç´ çš„ç”Ÿæˆï¼",
    "image_prompt": "Create a flat design infographic illustrating the experiment and main results of a study on sulforaphane production from glucoraphanin in broccoli. Include simplified icons of broccoli and sulforaphane, a representation of lactobacillus bacteria, arrows or flow lines showing the experimental process, and a section highlighting the main findings, such as the increase in amino acid metabolism and the decrease in carbohydrate metabolism.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": false,
    "disease_name": "",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41340527/"
  },
  {
    "id": "41412441",
    "title_en": "Sulforaphane Ameliorates DSS-Induced Colitis and Secondary Liver Injury in Mice: Proposed Mechanism in the SCFAs-FFAR2/3-Macrophage Polarization Axis.",
    "pub_date": "2025 Dec",
    "journal": "The Journal of nutritional biochemistry",
    "abstract_en": "Sulforaphane (SFN), an isothiocyanate derived from cruciferous vegetables, has shown therapeutic potential in inflammatory diseases. Our previous studies demonstrated that SFN ameliorates ulcerative colitis (UC) and restores gut microbiota composition in dextran sulfate sodium (DSS)-induced mice. In the present study, we further investigate the protective effects and underlying mechanisms of SFN against secondary liver injury associated with UC. The results revealed that SFN significantly alleviated pathological damage in both the colon and liver, improved liver function parameters, upregulated intestinal tight junction proteins and Muc2 expression, and inhibited inflammation in DSS-induced colitis mice. Additionally, SFN significantly elevated short-chain fatty acid (SCFA) concentrations, enhanced the expression of SCFA receptors (free fatty acid receptors 2 and 3, FFAR2/3), and modulated macrophage polarization by inhibiting M1 and promoting M2 phenotypes in the colon and liver. Collectively, these findings suggest that SFN may alleviate colitis and secondary liver injury by enhancing intestinal barrier function and reducing inflammatory responses, potentially via the SCFAs-FFAR2/3-macrophage polarization signaling cascade. Thus, SFN may serve as a promising adjunctive therapeutic agent for the prevention and treatment of UC.",
    "para1": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®ä¾†è‡ªåå­—èŠ±ç§‘è”¬èœçš„åŒ–åˆç‰©ï¼Œæœ€è¿‘çš„ç ”ç©¶é¡¯ç¤ºå®ƒåœ¨æŠ—ç™¼ç‚ç–¾ç—…æ–¹é¢æœ‰æ½›åœ¨çš„ç™‚æ•ˆã€‚é€™é …ç ”ç©¶çš„çµæœå¯èƒ½å°æ–¼æ”¹å–„è…¸é“å¥åº·å’Œé é˜²èˆ‡æ½°ç˜æ€§çµè…¸ç‚ç›¸é—œçš„è‚è‡Ÿæå‚·æœ‰é‡è¦æ„ç¾©ã€‚é€éå¢å¼·è…¸é“å±éšœåŠŸèƒ½å’Œæ¸›å°‘ç™¼ç‚åæ‡‰ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æˆç‚ºä¸€ç¨®æœ‰å¸Œæœ›çš„è¼”åŠ©ç™‚æ³•ï¼Œå¹«åŠ©äººå€‘æ›´å¥½åœ°ç®¡ç†é€™äº›å¥åº·å•é¡Œã€‚",
    "para2": "é€™é …ç ”ç©¶ä¸»è¦é—œæ³¨è˜¿è””ç¡«ç´ å°æ½°ç˜æ€§çµè…¸ç‚ï¼ˆUCï¼‰ç›¸é—œçš„æ¬¡ç´šè‚æå‚·çš„ä¿è­·ä½œç”¨ã€‚ç ”ç©¶è€…å¸Œæœ›æ·±å…¥äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿è…¸é“å’Œè‚è‡Ÿçš„å¥åº·ï¼Œç‰¹åˆ¥æ˜¯åœ¨ç™¼ç‚æƒ…æ³ä¸‹çš„ä½œç”¨æ©Ÿåˆ¶ã€‚é€éé€™äº›ç ”ç©¶ï¼Œç§‘å­¸å®¶å€‘å¸Œæœ›èƒ½å¤ æ‰¾åˆ°æ›´æœ‰æ•ˆçš„æ²»ç™‚æ–¹æ³•ä¾†æ”¹å–„é€™é¡ç–¾ç—…çš„ç—…ç¨‹ã€‚",
    "para3": "ç ”ç©¶ä¸­ä½¿ç”¨äº†ä»¥å³æ—‹ç³–é…ç¡«é…¸éˆ‰ï¼ˆDSSï¼‰èª˜å°çš„æ½°ç˜æ€§çµè…¸ç‚å°é¼ ä½œç‚ºå¯¦é©—å°è±¡ã€‚ç ”ç©¶è€…è§€å¯Ÿäº†è˜¿è””ç¡«ç´ å°é€™äº›å°é¼ çš„è…¸é“å’Œè‚è‡Ÿçš„å½±éŸ¿ï¼Œä¸¦è©•ä¼°äº†å…¶å°ç—…ç†æå‚·çš„ç·©è§£æ•ˆæœã€‚å¯¦é©—ä¸­é‚„åˆ†æäº†è…¸é“ç·Šå¯†é€£æ¥è›‹ç™½å’Œé»æ¶²è›‹ç™½çš„è¡¨é”ï¼Œä»¥åŠçŸ­éˆè„‚è‚ªé…¸çš„æ¿ƒåº¦è®ŠåŒ–ï¼Œå¾è€Œæ¢è¨è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ¸›è¼•å°é¼ çš„è…¸é“å’Œè‚è‡Ÿç—…ç†æå‚·ï¼Œæ”¹å–„è‚åŠŸèƒ½åƒæ•¸ï¼Œä¸¦ä¸Šèª¿è…¸é“ç·Šå¯†é€£æ¥è›‹ç™½å’Œé»æ¶²è›‹ç™½çš„è¡¨é”ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½æé«˜çŸ­éˆè„‚è‚ªé…¸çš„æ¿ƒåº¦ï¼Œå¢å¼·çŸ­éˆè„‚è‚ªé…¸å—é«”çš„è¡¨é”ï¼Œä¸¦é€šéèª¿ç¯€å·¨å™¬ç´°èƒçš„æ¥µåŒ–ä¾†æ¸›å°‘ç™¼ç‚åæ‡‰ã€‚é€™äº›ç™¼ç¾è¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éæ”¹å–„è…¸é“å±éšœåŠŸèƒ½å’Œé™ä½ç™¼ç‚åæ‡‰ä¾†ç·©è§£æ½°ç˜æ€§çµè…¸ç‚åŠå…¶ç›¸é—œçš„è‚æå‚·ã€‚",
    "explanation_zh": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®ä¾†è‡ªåå­—èŠ±ç§‘è”¬èœçš„åŒ–åˆç‰©ï¼Œæœ€è¿‘çš„ç ”ç©¶é¡¯ç¤ºå®ƒåœ¨æŠ—ç™¼ç‚ç–¾ç—…æ–¹é¢æœ‰æ½›åœ¨çš„ç™‚æ•ˆã€‚é€™é …ç ”ç©¶çš„çµæœå¯èƒ½å°æ–¼æ”¹å–„è…¸é“å¥åº·å’Œé é˜²èˆ‡æ½°ç˜æ€§çµè…¸ç‚ç›¸é—œçš„è‚è‡Ÿæå‚·æœ‰é‡è¦æ„ç¾©ã€‚é€éå¢å¼·è…¸é“å±éšœåŠŸèƒ½å’Œæ¸›å°‘ç™¼ç‚åæ‡‰ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æˆç‚ºä¸€ç¨®æœ‰å¸Œæœ›çš„è¼”åŠ©ç™‚æ³•ï¼Œå¹«åŠ©äººå€‘æ›´å¥½åœ°ç®¡ç†é€™äº›å¥åº·å•é¡Œã€‚\n\né€™é …ç ”ç©¶ä¸»è¦é—œæ³¨è˜¿è””ç¡«ç´ å°æ½°ç˜æ€§çµè…¸ç‚ï¼ˆUCï¼‰ç›¸é—œçš„æ¬¡ç´šè‚æå‚·çš„ä¿è­·ä½œç”¨ã€‚ç ”ç©¶è€…å¸Œæœ›æ·±å…¥äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿è…¸é“å’Œè‚è‡Ÿçš„å¥åº·ï¼Œç‰¹åˆ¥æ˜¯åœ¨ç™¼ç‚æƒ…æ³ä¸‹çš„ä½œç”¨æ©Ÿåˆ¶ã€‚é€éé€™äº›ç ”ç©¶ï¼Œç§‘å­¸å®¶å€‘å¸Œæœ›èƒ½å¤ æ‰¾åˆ°æ›´æœ‰æ•ˆçš„æ²»ç™‚æ–¹æ³•ä¾†æ”¹å–„é€™é¡ç–¾ç—…çš„ç—…ç¨‹ã€‚\n\nç ”ç©¶ä¸­ä½¿ç”¨äº†ä»¥å³æ—‹ç³–é…ç¡«é…¸éˆ‰ï¼ˆDSSï¼‰èª˜å°çš„æ½°ç˜æ€§çµè…¸ç‚å°é¼ ä½œç‚ºå¯¦é©—å°è±¡ã€‚ç ”ç©¶è€…è§€å¯Ÿäº†è˜¿è””ç¡«ç´ å°é€™äº›å°é¼ çš„è…¸é“å’Œè‚è‡Ÿçš„å½±éŸ¿ï¼Œä¸¦è©•ä¼°äº†å…¶å°ç—…ç†æå‚·çš„ç·©è§£æ•ˆæœã€‚å¯¦é©—ä¸­é‚„åˆ†æäº†è…¸é“ç·Šå¯†é€£æ¥è›‹ç™½å’Œé»æ¶²è›‹ç™½çš„è¡¨é”ï¼Œä»¥åŠçŸ­éˆè„‚è‚ªé…¸çš„æ¿ƒåº¦è®ŠåŒ–ï¼Œå¾è€Œæ¢è¨è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ¸›è¼•å°é¼ çš„è…¸é“å’Œè‚è‡Ÿç—…ç†æå‚·ï¼Œæ”¹å–„è‚åŠŸèƒ½åƒæ•¸ï¼Œä¸¦ä¸Šèª¿è…¸é“ç·Šå¯†é€£æ¥è›‹ç™½å’Œé»æ¶²è›‹ç™½çš„è¡¨é”ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½æé«˜çŸ­éˆè„‚è‚ªé…¸çš„æ¿ƒåº¦ï¼Œå¢å¼·çŸ­éˆè„‚è‚ªé…¸å—é«”çš„è¡¨é”ï¼Œä¸¦é€šéèª¿ç¯€å·¨å™¬ç´°èƒçš„æ¥µåŒ–ä¾†æ¸›å°‘ç™¼ç‚åæ‡‰ã€‚é€™äº›ç™¼ç¾è¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éæ”¹å–„è…¸é“å±éšœåŠŸèƒ½å’Œé™ä½ç™¼ç‚åæ‡‰ä¾†ç·©è§£æ½°ç˜æ€§çµè…¸ç‚åŠå…¶ç›¸é—œçš„è‚æå‚·ã€‚",
    "fb_post": "æ ¹æ“šã€ŠThe Journal of nutritional biochemistryã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± è½èªªéè˜¿è””ç¡«ç´ å—ï¼Ÿé€™å¯æ˜¯ä¸€å€‹ä¾†è‡ªé’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœçš„ç¥å¥‡æˆåˆ†ï¼æœ€è¿‘çš„ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°æŠ—ç™¼ç‚æœ‰å¹«åŠ©ï¼Œç‰¹åˆ¥æ˜¯å°æ–¼æ½°ç˜æ€§çµè…¸ç‚ï¼ˆUCï¼‰å’Œç›¸é—œçš„è‚è‡Ÿå•é¡Œã€‚é€™é …ç ”ç©¶çš„ç›®çš„æ˜¯æƒ³äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿è…¸é“å’Œè‚è‡Ÿçš„å¥åº·ï¼Œå°¤å…¶æ˜¯åœ¨ç™¼ç‚çš„æƒ…æ³ä¸‹ã€‚ ç ”ç©¶è€…å€‘ä½¿ç”¨äº†ä¸€ç¨®ç‰¹æ®Šçš„æ–¹å¼ï¼Œè®“å°é¼ æ¨¡æ“¬æ½°ç˜æ€§çµè…¸ç‚çš„ç‹€æ…‹ï¼Œç„¶å¾Œè§€å¯Ÿè˜¿è””ç¡«ç´ çš„æ•ˆæœã€‚ä»–å€‘ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ ä¸åƒ…èƒ½æ¸›è¼•å°é¼ çš„è…¸é“å’Œè‚è‡Ÿæå‚·ï¼Œé‚„èƒ½æ”¹å–„è‚åŠŸèƒ½ï¼Œå¢åŠ è…¸é“ä¸­æœ‰ç›Šçš„çŸ­éˆè„‚è‚ªé…¸ï¼Œä¸¦å¹«åŠ©æ¸›å°‘ç™¼ç‚åæ‡‰ã€‚é€™äº›ç™¼ç¾è®“ç§‘å­¸å®¶å€‘å°è˜¿è””ç¡«ç´ çš„æ½›åŠ›å……æ»¿æœŸå¾…ï¼\n\nğŸ” é€™è£¡æœ‰å¹¾å€‹é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ ä¾†è‡ªåå­—èŠ±ç§‘è”¬èœï¼Œå°æŠ—ç™¼ç‚æœ‰æ½›åŠ›ã€‚\n2. å®ƒèƒ½æ¸›è¼•æ½°ç˜æ€§çµè…¸ç‚å°é¼ çš„è…¸é“å’Œè‚è‡Ÿæå‚·ã€‚\n3. è˜¿è””ç¡«ç´ é‚„èƒ½æ”¹å–„è…¸é“å±éšœåŠŸèƒ½ï¼Œå¹«åŠ©æ¸›å°‘ç™¼ç‚ã€‚ è®“æˆ‘å€‘ä¸€èµ·æœŸå¾…æ›´å¤šçš„ç ”ç©¶çµæœå§ï¼",
    "image_prompt": "Create an infographic illustrating the experiment and main results of a study on sulforaphane, a compound from cruciferous vegetables. Include simplified icons representing broccoli or sulforaphane, experimental subjects like mice, and arrows or flow lines showing the experimental steps. Highlight a section labeled 'Main Results' that summarizes protective effects and changes observed, using a flat design style with soft colors on a light background.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "æ½°ç˜æ€§çµè…¸ç‚ Ulcerative Colitis",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41412441/"
  },
  {
    "id": "40961586",
    "title_en": "Design, synthesis and biological evaluation of magnolol-sulforaphane hybrid analogues as potential therapeutics of triple-negative breast cancer.",
    "pub_date": "2025 Dec",
    "journal": "European journal of medicinal chemistry",
    "abstract_en": "Triple-negative breast cancer (TNBC) is an aggressive subtype that primarily relies on chemotherapy. Natural products like magnolol and sulforaphane, especially their synthetic hybrid, have shown promising antitumor activity. To develop more potent agents, we designed and synthesized 15 novel magnolol-sulforaphane hybrid analogues and evaluated their anticancer efficacy. Among them, compound 17a demonstrated the highest potency, exhibiting an average 7.4-fold increase in antiproliferative activity with IC<sub>50</sub> values ranging from 0.85Â Â±Â 0.04Â Î¼M to 1.34Â Â±Â 0.02Â Î¼M in TNBC cell lines compared to the parent hybrid CT1-3. In vitro, 17a significantly suppressed TNBC cell proliferation, colony formation, migration, and invasion while inducing apoptosis. In vivo, administration of 17a effectively inhibited tumor growth without apparent toxicity in an MDA-MB-231 xenograft model, as evidenced by normal organ morphology. Mechanistically, RNA sequencing revealed that 17a downregulated the nucleotide excision repair (NER) and NF-ÎºB pathways, suppressing expression of NER-related genes (ERCC2, POLE2, LIG1, GTF2H3, and DDB2) at mRNA and protein levels and inhibiting phosphorylation of IKKÎ± and p65. These findings position 17a as a potent therapeutic candidate for TNBC treatment, warranting further clinical investigation.",
    "para1": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œé‡å°ä¸‰é™°æ€§ä¹³ç™Œé€™ç¨®ä¾µç•¥æ€§å¼·çš„ç™Œç—‡é¡å‹ï¼Œå°‹æ‰¾æ–°çš„æ²»ç™‚æ–¹æ³•æ˜¯éå¸¸é‡è¦çš„ã€‚å‚³çµ±ä¸Šï¼Œé€™é¡ç™Œç—‡ä¸»è¦ä¾è³´åŒ–ç™‚ï¼Œä½†åŒ–ç™‚çš„æ•ˆæœå’Œå‰¯ä½œç”¨å¸¸å¸¸è®“æ‚£è€…æ„Ÿåˆ°å›°æ“¾ã€‚å› æ­¤ï¼Œé–‹ç™¼æ–°çš„å¤©ç„¶ç”¢å“æˆ–å…¶åˆæˆè¡ç”Ÿç‰©ï¼Œå¯èƒ½æœƒæä¾›æ›´æœ‰æ•ˆä¸”å‰¯ä½œç”¨è¼ƒå°çš„æ²»ç™‚é¸æ“‡ï¼Œé€™å°æ–¼æå‡æ‚£è€…çš„ç”Ÿæ´»å“è³ªå’Œæ²»ç™‚æ•ˆæœéƒ½å…·æœ‰æ½›åœ¨çš„æ„ç¾©ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯é‡å°ä¸‰é™°æ€§ä¹³ç™Œï¼ˆTNBCï¼‰é–‹ç™¼æ–°çš„æŠ—ç™Œè—¥ç‰©ã€‚ç ”ç©¶è€…å€‘é—œæ³¨çš„æ˜¯å¦‚ä½•åˆ©ç”¨å¤©ç„¶ç”¢ç‰©å¦‚è˜­èŠ±é†‡å’Œè˜¿è””ç¡«ç´ ï¼Œç‰¹åˆ¥æ˜¯å®ƒå€‘çš„åˆæˆæ··åˆç‰©ï¼Œä¾†å¢å¼·æŠ—è…«ç˜¤æ´»æ€§ã€‚é€éè¨­è¨ˆå’Œåˆæˆ15ç¨®æ–°çš„è˜­èŠ±é†‡-è˜¿è””ç¡«ç´ æ··åˆç‰©ï¼Œç ”ç©¶è€…å¸Œæœ›èƒ½æ‰¾åˆ°æ›´å…·æ•ˆèƒ½çš„æŠ—ç™ŒåŠ‘ï¼Œé€²è€Œæ”¹å–„ä¸‰é™°æ€§ä¹³ç™Œçš„æ²»ç™‚æ•ˆæœã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…åˆæˆäº†15ç¨®æ–°çš„æ··åˆç‰©ï¼Œä¸¦è©•ä¼°å®ƒå€‘åœ¨ä¸‰é™°æ€§ä¹³ç™Œç´°èƒä¸­çš„æŠ—ç™Œæ•ˆæœã€‚ç ”ç©¶ä¸»è¦ä½¿ç”¨äº†ç´°èƒåŸ¹é¤Šå’Œå‹•ç‰©æ¨¡å‹é€²è¡Œæ¸¬è©¦ã€‚åœ¨é«”å¤–å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…è§€å¯Ÿäº†é€™äº›åŒ–åˆç‰©å°ç™Œç´°èƒå¢æ®–ã€é›†è½å½¢æˆã€é·ç§»å’Œä¾µè¥²çš„å½±éŸ¿ï¼›è€Œåœ¨é«”å…§å¯¦é©—ä¸­ï¼Œå‰‡ä½¿ç”¨äº†MDA-MB-231è…«ç˜¤ç§»æ¤æ¨¡å‹ä¾†è©•ä¼°é€™äº›åŒ–åˆç‰©å°è…«ç˜¤ç”Ÿé•·çš„æŠ‘åˆ¶æ•ˆæœï¼Œä¸¦æª¢æŸ¥å…¶å°æ­£å¸¸å™¨å®˜çš„å½±éŸ¿ã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾æ˜¯ï¼ŒåŒ–åˆç‰©17aåœ¨æŠ—ç™Œæ´»æ€§ä¸Šè¡¨ç¾å‡ºæœ€é«˜çš„æ•ˆèƒ½ï¼Œé¡¯ç¤ºå‡ºé¡¯è‘—æŠ‘åˆ¶ä¸‰é™°æ€§ä¹³ç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»ï¼Œä¸¦ä¿ƒé€²ç´°èƒå‡‹äº¡ã€‚åœ¨å‹•ç‰©å¯¦é©—ä¸­ï¼Œ17aæœ‰æ•ˆæŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·ï¼Œä¸”æœªé¡¯ç¤ºå‡ºæ˜é¡¯çš„æ¯’æ€§ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„ç™¼ç¾17aèƒ½ä¸‹èª¿èˆ‡æ ¸è‹·é…¸åˆ‡é™¤ä¿®å¾©å’ŒNF-ÎºBé€šè·¯ç›¸é—œçš„åŸºå› è¡¨é”ï¼Œé€™äº›çµæœé¡¯ç¤º17aå¯èƒ½æ˜¯ä¸€å€‹æœ‰æ½›åŠ›çš„ä¸‰é™°æ€§ä¹³ç™Œæ²»ç™‚å€™é¸è—¥ç‰©ï¼Œå€¼å¾—é€²ä¸€æ­¥çš„è‡¨åºŠç ”ç©¶ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œé‡å°ä¸‰é™°æ€§ä¹³ç™Œé€™ç¨®ä¾µç•¥æ€§å¼·çš„ç™Œç—‡é¡å‹ï¼Œå°‹æ‰¾æ–°çš„æ²»ç™‚æ–¹æ³•æ˜¯éå¸¸é‡è¦çš„ã€‚å‚³çµ±ä¸Šï¼Œé€™é¡ç™Œç—‡ä¸»è¦ä¾è³´åŒ–ç™‚ï¼Œä½†åŒ–ç™‚çš„æ•ˆæœå’Œå‰¯ä½œç”¨å¸¸å¸¸è®“æ‚£è€…æ„Ÿåˆ°å›°æ“¾ã€‚å› æ­¤ï¼Œé–‹ç™¼æ–°çš„å¤©ç„¶ç”¢å“æˆ–å…¶åˆæˆè¡ç”Ÿç‰©ï¼Œå¯èƒ½æœƒæä¾›æ›´æœ‰æ•ˆä¸”å‰¯ä½œç”¨è¼ƒå°çš„æ²»ç™‚é¸æ“‡ï¼Œé€™å°æ–¼æå‡æ‚£è€…çš„ç”Ÿæ´»å“è³ªå’Œæ²»ç™‚æ•ˆæœéƒ½å…·æœ‰æ½›åœ¨çš„æ„ç¾©ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯é‡å°ä¸‰é™°æ€§ä¹³ç™Œï¼ˆTNBCï¼‰é–‹ç™¼æ–°çš„æŠ—ç™Œè—¥ç‰©ã€‚ç ”ç©¶è€…å€‘é—œæ³¨çš„æ˜¯å¦‚ä½•åˆ©ç”¨å¤©ç„¶ç”¢ç‰©å¦‚è˜­èŠ±é†‡å’Œè˜¿è””ç¡«ç´ ï¼Œç‰¹åˆ¥æ˜¯å®ƒå€‘çš„åˆæˆæ··åˆç‰©ï¼Œä¾†å¢å¼·æŠ—è…«ç˜¤æ´»æ€§ã€‚é€éè¨­è¨ˆå’Œåˆæˆ15ç¨®æ–°çš„è˜­èŠ±é†‡-è˜¿è””ç¡«ç´ æ··åˆç‰©ï¼Œç ”ç©¶è€…å¸Œæœ›èƒ½æ‰¾åˆ°æ›´å…·æ•ˆèƒ½çš„æŠ—ç™ŒåŠ‘ï¼Œé€²è€Œæ”¹å–„ä¸‰é™°æ€§ä¹³ç™Œçš„æ²»ç™‚æ•ˆæœã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…åˆæˆäº†15ç¨®æ–°çš„æ··åˆç‰©ï¼Œä¸¦è©•ä¼°å®ƒå€‘åœ¨ä¸‰é™°æ€§ä¹³ç™Œç´°èƒä¸­çš„æŠ—ç™Œæ•ˆæœã€‚ç ”ç©¶ä¸»è¦ä½¿ç”¨äº†ç´°èƒåŸ¹é¤Šå’Œå‹•ç‰©æ¨¡å‹é€²è¡Œæ¸¬è©¦ã€‚åœ¨é«”å¤–å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…è§€å¯Ÿäº†é€™äº›åŒ–åˆç‰©å°ç™Œç´°èƒå¢æ®–ã€é›†è½å½¢æˆã€é·ç§»å’Œä¾µè¥²çš„å½±éŸ¿ï¼›è€Œåœ¨é«”å…§å¯¦é©—ä¸­ï¼Œå‰‡ä½¿ç”¨äº†MDA-MB-231è…«ç˜¤ç§»æ¤æ¨¡å‹ä¾†è©•ä¼°é€™äº›åŒ–åˆç‰©å°è…«ç˜¤ç”Ÿé•·çš„æŠ‘åˆ¶æ•ˆæœï¼Œä¸¦æª¢æŸ¥å…¶å°æ­£å¸¸å™¨å®˜çš„å½±éŸ¿ã€‚\n\nä¸»è¦çš„ç™¼ç¾æ˜¯ï¼ŒåŒ–åˆç‰©17aåœ¨æŠ—ç™Œæ´»æ€§ä¸Šè¡¨ç¾å‡ºæœ€é«˜çš„æ•ˆèƒ½ï¼Œé¡¯ç¤ºå‡ºé¡¯è‘—æŠ‘åˆ¶ä¸‰é™°æ€§ä¹³ç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»ï¼Œä¸¦ä¿ƒé€²ç´°èƒå‡‹äº¡ã€‚åœ¨å‹•ç‰©å¯¦é©—ä¸­ï¼Œ17aæœ‰æ•ˆæŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·ï¼Œä¸”æœªé¡¯ç¤ºå‡ºæ˜é¡¯çš„æ¯’æ€§ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„ç™¼ç¾17aèƒ½ä¸‹èª¿èˆ‡æ ¸è‹·é…¸åˆ‡é™¤ä¿®å¾©å’ŒNF-ÎºBé€šè·¯ç›¸é—œçš„åŸºå› è¡¨é”ï¼Œé€™äº›çµæœé¡¯ç¤º17aå¯èƒ½æ˜¯ä¸€å€‹æœ‰æ½›åŠ›çš„ä¸‰é™°æ€§ä¹³ç™Œæ²»ç™‚å€™é¸è—¥ç‰©ï¼Œå€¼å¾—é€²ä¸€æ­¥çš„è‡¨åºŠç ”ç©¶ã€‚",
    "fb_post": "æ ¹æ“šã€ŠEuropean journal of medicinal chemistryã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ‘©â€ğŸ”¬ å¤§å®¶å¥½ï¼ä»Šå¤©æƒ³è·Ÿä½ å€‘èŠèŠä¸€å€‹æœ‰è¶£çš„ç ”ç©¶ï¼Œé—œæ–¼ä¸‰é™°æ€§ä¹³ç™Œï¼ˆTNBCï¼‰å’Œä¸€äº›å¤©ç„¶æˆåˆ†çš„æ•…äº‹ï¼é€™ç¨®ç™Œç—‡å¾ˆé›£å°ä»˜ï¼Œå‚³çµ±çš„åŒ–ç™‚é›–ç„¶æœ‰æ•ˆï¼Œä½†å‰¯ä½œç”¨å¸¸å¸¸è®“æ‚£è€…è‹¦ä¸å ªè¨€ã€‚é€™æ¬¡çš„ç ”ç©¶å°±æ˜¯å¸Œæœ›èƒ½æ‰¾åˆ°æ›´å¥½çš„æ²»ç™‚æ–¹æ³•ï¼\n\nç ”ç©¶åœ˜éšŠå°ˆæ³¨æ–¼è˜­èŠ±é†‡å’Œè˜¿è””ç¡«ç´ é€™å…©ç¨®å¤©ç„¶æˆåˆ†ï¼Œä¸¦è¨­è¨ˆäº†15ç¨®æ–°æ··åˆç‰©ä¾†çœ‹çœ‹èƒ½å¦å¢å¼·æŠ—è…«ç˜¤çš„æ•ˆæœã€‚ä»–å€‘åœ¨å¯¦é©—å®¤è£¡é€²è¡Œäº†ç´°èƒåŸ¹é¤Šå’Œå‹•ç‰©å¯¦é©—ï¼Œè§€å¯Ÿé€™äº›æ··åˆç‰©å°ç™Œç´°èƒçš„å½±éŸ¿ã€‚\n\nçµæœç™¼ç¾ï¼Œæœ‰ä¸€ç¨®å«åš17açš„åŒ–åˆç‰©ï¼Œåœ¨æŠ—ç™Œæ´»æ€§ä¸Šè¡¨ç¾å¾—éå¸¸å‡ºè‰²ï¼å®ƒä¸åƒ…èƒ½æœ‰æ•ˆæŠ‘åˆ¶ç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»ï¼Œé‚„èƒ½ä¿ƒé€²ç™Œç´°èƒçš„æ­»äº¡ï¼Œä¸¦ä¸”åœ¨å‹•ç‰©å¯¦é©—ä¸­ä¹Ÿé¡¯ç¤ºå‡ºä¸æ˜é¡¯çš„æ¯’æ€§ã€‚é€™è®“æˆ‘å€‘å°å®ƒæœªä¾†çš„è‡¨åºŠç ”ç©¶å……æ»¿æœŸå¾…ï¼\n\nğŸ” ä¸»è¦é‡é»ï¼š\n1. ä¸‰é™°æ€§ä¹³ç™Œæ˜¯ä¸€ç¨®é›£æ²»ç™‚çš„ç™Œç—‡ï¼Œå‚³çµ±åŒ–ç™‚æœ‰å‰¯ä½œç”¨ã€‚\n2. ç ”ç©¶è€…åˆ©ç”¨å¤©ç„¶æˆåˆ†é–‹ç™¼å‡ºæ–°æ··åˆç‰©ï¼Œå¸Œæœ›æ‰¾åˆ°æ›´å¥½çš„æŠ—ç™Œè—¥ç‰©ã€‚\n3. åŒ–åˆç‰©17aåœ¨å¯¦é©—ä¸­é¡¯ç¤ºå‡ºè‰¯å¥½çš„æŠ—ç™Œæ•ˆæœï¼Œå€¼å¾—é€²ä¸€æ­¥ç ”ç©¶ï¼",
    "image_prompt": "Create an infographic that explains the experimental methods and main results of a study on a compound called 17a for treating triple-negative breast cancer. The image should have a simple and clear design with a white or light-colored background and soft colors. Include symbols for broccoli or sulforaphane, simplified illustrations of experimental subjects (like humans, animals, or cells), arrows or flow lines to show the experimental steps, and a section labeled 'Main Results' highlighting protective effects or changes observed.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "ä¸‰é™°æ€§ä¹³ç™Œ Triple-negative Breast Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40961586/"
  },
  {
    "id": "41399453",
    "title_en": "Dual effect of sulforaphane on multi-walled carbon nanotube-induced lung inflammation in mice.",
    "pub_date": "2025 Dec",
    "journal": "Toxicology research",
    "abstract_en": "A previous study demonstrated that Nrf2, a transcription factor, unexpectedly promoted multi-walled carbon nanotube (MWCNT)-induced lung inflammation in mice. This finding contrasts with the well-established role of Nrf2 in suppressing inflammatory responses induced by environmental chemicals, highlighting a critical knowledge gap. The present study investigated the effect of sulforaphane, a known activator of Nrf2, on MWCNT-induced lung inflammation in mice, in order to better understand the underlying mechanisms of this response. Each of 48 C57BL/6Â J male mouse was anesthetized and exposed once via pharyngeal aspiration to MWCNTs (Mitsui-7) at doses of 0, 10, or 20Â Î¼g in 40Â Î¼l of dispersion medium per mouse and treated thereafter with subcutaneous 25Â mg/kg/day sulforaphane or vehicle for 14Â days. Bronchoalveolar lavage fluid (BALF) was collected for differential cell counts. Lung tissues were processed for histopathological analysis and quantification of cytokine or chemokine mRNA expression and Nrf2 protein in nuclear extracts. MWCNTs exposure increased lung weight, BALF lymphocytes, and lung IL-6 expression. Sulforaphane attenuated MWCNTs-induced lung weight gain, lymphocytic infiltration, and upregulation of IL-6 expression, but paradoxically enhanced low-dose MWCNT-induced neutrophil infiltration in BALF, MIP-2 expression, and histopathological inflammation scores. These effects were accompanied by increased levels of active Nrf2 protein in nuclear extracts from lung tissue. Overall, the results indicate that sulforaphane suppresses lymphocyte infiltration while promoting neutrophil recruitment in response to low-dose MWCNTs, suggesting a dual effect of sulforaphane on MWCNT-induced lung inflammation mediated through Nrf2 activation.",
    "para1": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½åœ¨æŸäº›æƒ…æ³ä¸‹å°è‚ºéƒ¨ç‚ç—‡çš„å½±éŸ¿æ˜¯é›™é‡çš„ã€‚é›–ç„¶å®ƒé€šå¸¸è¢«èªç‚ºèƒ½å¤ æ¸›å°‘ç”±ç’°å¢ƒåŒ–å­¸ç‰©è³ªå¼•èµ·çš„ç‚ç—‡ï¼Œä½†åœ¨æ¥è§¸å¤šå£ç¢³ç´ç±³ç®¡ï¼ˆMWCNTï¼‰æ™‚ï¼Œå»å¯èƒ½æœƒä¿ƒé€²æŸäº›å…ç–«ç´°èƒçš„æ‹›å‹Ÿã€‚é€™æé†’æˆ‘å€‘ï¼Œåœ¨ä½¿ç”¨æŸäº›å¤©ç„¶åŒ–åˆç‰©ä½œç‚ºå¥åº·è£œå……å“æ™‚ï¼Œå¿…é ˆè¬¹æ…ï¼Œå› ç‚ºå®ƒå€‘çš„ä½œç”¨å¯èƒ½æœƒå› ç’°å¢ƒæˆ–åŠ‘é‡çš„ä¸åŒè€Œæœ‰æ‰€è®ŠåŒ–ï¼Œé€²è€Œå½±éŸ¿å¥åº·çµæœã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°å¤šå£ç¢³ç´ç±³ç®¡å¼•èµ·çš„è‚ºéƒ¨ç‚ç—‡çš„å½±éŸ¿ã€‚ç ”ç©¶äººå“¡å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•é€éæ¿€æ´»Nrf2é€™å€‹è½‰éŒ„å› å­ï¼Œä¾†å½±éŸ¿ç”±MWCNTå¼•èµ·çš„è‚ºéƒ¨åæ‡‰ã€‚é€™æ˜¯ä¸€å€‹é‡è¦çš„ç ”ç©¶æ–¹å‘ï¼Œå› ç‚ºä¹‹å‰çš„ç ”ç©¶é¡¯ç¤ºNrf2åœ¨ç’°å¢ƒåŒ–å­¸ç‰©è³ªå¼•èµ·çš„ç‚ç—‡ä¸­æ‰®æ¼”è‘—æŠ‘åˆ¶è€…çš„è§’è‰²ï¼Œè€Œé€™é …ç ”ç©¶å‰‡æ­ç¤ºäº†å®ƒåœ¨ç‰¹å®šæƒ…æ³ä¸‹å¯èƒ½çš„ä¿ƒé€²ä½œç”¨ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶äººå“¡ä½¿ç”¨48éš»C57BL/6 Jé›„æ€§å°é¼ ï¼Œé€™äº›å°é¼ è¢«éº»é†‰å¾Œï¼Œé€šéå’½å–‰å¸å…¥çš„æ–¹å¼æ¥è§¸ä¸åŒåŠ‘é‡çš„å¤šå£ç¢³ç´ç±³ç®¡ï¼ˆ0ã€10æˆ–20å¾®å…‹ï¼‰ï¼Œä¸¦éš¨å¾Œæ¥å—ç‚ºæœŸ14å¤©çš„è˜¿è””ç¡«ç´ æˆ–å°ç…§ç‰©çš„çš®ä¸‹æ³¨å°„ã€‚ç ”ç©¶åœ˜éšŠæ”¶é›†äº†å°é¼ çš„æ”¯æ°£ç®¡è‚ºæ³¡çŒæ´—æ¶²ï¼Œé€²è¡Œç´°èƒè¨ˆæ•¸ï¼Œä¸¦å°è‚ºçµ„ç¹”é€²è¡Œç—…ç†åˆ†æï¼Œé‡æ¸¬ç´°èƒå› å­æˆ–è¶¨åŒ–å› å­çš„mRNAè¡¨é”åŠNrf2è›‹ç™½çš„å«é‡ã€‚",
    "para4": "ç ”ç©¶çš„ä¸»è¦ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æ¸›å°‘ç”±å¤šå£ç¢³ç´ç±³ç®¡å¼•èµ·çš„æ·‹å·´ç´°èƒæµ¸æ½¤å’Œè‚ºéƒ¨é‡é‡å¢åŠ ï¼Œä¸¦é™ä½IL-6çš„è¡¨é”ã€‚ç„¶è€Œï¼Œä»¤äººæ„å¤–çš„æ˜¯ï¼Œè˜¿è””ç¡«ç´ åœ¨ä½åŠ‘é‡çš„MWCNTæš´éœ²ä¸‹å»ä¿ƒé€²äº†ä¸­æ€§ç²’ç´°èƒçš„æµ¸æ½¤ï¼Œä¸¦å¢åŠ äº†MIP-2çš„è¡¨é”åŠç—…ç†ç‚ç—‡è©•åˆ†ã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨MWCNTå¼•èµ·çš„è‚ºéƒ¨ç‚ç—‡ä¸­å¯èƒ½å…·æœ‰é›™é‡ä½œç”¨ï¼Œé€éNrf2çš„æ¿€æ´»ä¾†èª¿ç¯€ä¸åŒé¡å‹çš„å…ç–«åæ‡‰ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½åœ¨æŸäº›æƒ…æ³ä¸‹å°è‚ºéƒ¨ç‚ç—‡çš„å½±éŸ¿æ˜¯é›™é‡çš„ã€‚é›–ç„¶å®ƒé€šå¸¸è¢«èªç‚ºèƒ½å¤ æ¸›å°‘ç”±ç’°å¢ƒåŒ–å­¸ç‰©è³ªå¼•èµ·çš„ç‚ç—‡ï¼Œä½†åœ¨æ¥è§¸å¤šå£ç¢³ç´ç±³ç®¡ï¼ˆMWCNTï¼‰æ™‚ï¼Œå»å¯èƒ½æœƒä¿ƒé€²æŸäº›å…ç–«ç´°èƒçš„æ‹›å‹Ÿã€‚é€™æé†’æˆ‘å€‘ï¼Œåœ¨ä½¿ç”¨æŸäº›å¤©ç„¶åŒ–åˆç‰©ä½œç‚ºå¥åº·è£œå……å“æ™‚ï¼Œå¿…é ˆè¬¹æ…ï¼Œå› ç‚ºå®ƒå€‘çš„ä½œç”¨å¯èƒ½æœƒå› ç’°å¢ƒæˆ–åŠ‘é‡çš„ä¸åŒè€Œæœ‰æ‰€è®ŠåŒ–ï¼Œé€²è€Œå½±éŸ¿å¥åº·çµæœã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°å¤šå£ç¢³ç´ç±³ç®¡å¼•èµ·çš„è‚ºéƒ¨ç‚ç—‡çš„å½±éŸ¿ã€‚ç ”ç©¶äººå“¡å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•é€éæ¿€æ´»Nrf2é€™å€‹è½‰éŒ„å› å­ï¼Œä¾†å½±éŸ¿ç”±MWCNTå¼•èµ·çš„è‚ºéƒ¨åæ‡‰ã€‚é€™æ˜¯ä¸€å€‹é‡è¦çš„ç ”ç©¶æ–¹å‘ï¼Œå› ç‚ºä¹‹å‰çš„ç ”ç©¶é¡¯ç¤ºNrf2åœ¨ç’°å¢ƒåŒ–å­¸ç‰©è³ªå¼•èµ·çš„ç‚ç—‡ä¸­æ‰®æ¼”è‘—æŠ‘åˆ¶è€…çš„è§’è‰²ï¼Œè€Œé€™é …ç ”ç©¶å‰‡æ­ç¤ºäº†å®ƒåœ¨ç‰¹å®šæƒ…æ³ä¸‹å¯èƒ½çš„ä¿ƒé€²ä½œç”¨ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶äººå“¡ä½¿ç”¨48éš»C57BL/6 Jé›„æ€§å°é¼ ï¼Œé€™äº›å°é¼ è¢«éº»é†‰å¾Œï¼Œé€šéå’½å–‰å¸å…¥çš„æ–¹å¼æ¥è§¸ä¸åŒåŠ‘é‡çš„å¤šå£ç¢³ç´ç±³ç®¡ï¼ˆ0ã€10æˆ–20å¾®å…‹ï¼‰ï¼Œä¸¦éš¨å¾Œæ¥å—ç‚ºæœŸ14å¤©çš„è˜¿è””ç¡«ç´ æˆ–å°ç…§ç‰©çš„çš®ä¸‹æ³¨å°„ã€‚ç ”ç©¶åœ˜éšŠæ”¶é›†äº†å°é¼ çš„æ”¯æ°£ç®¡è‚ºæ³¡çŒæ´—æ¶²ï¼Œé€²è¡Œç´°èƒè¨ˆæ•¸ï¼Œä¸¦å°è‚ºçµ„ç¹”é€²è¡Œç—…ç†åˆ†æï¼Œé‡æ¸¬ç´°èƒå› å­æˆ–è¶¨åŒ–å› å­çš„mRNAè¡¨é”åŠNrf2è›‹ç™½çš„å«é‡ã€‚\n\nç ”ç©¶çš„ä¸»è¦ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æ¸›å°‘ç”±å¤šå£ç¢³ç´ç±³ç®¡å¼•èµ·çš„æ·‹å·´ç´°èƒæµ¸æ½¤å’Œè‚ºéƒ¨é‡é‡å¢åŠ ï¼Œä¸¦é™ä½IL-6çš„è¡¨é”ã€‚ç„¶è€Œï¼Œä»¤äººæ„å¤–çš„æ˜¯ï¼Œè˜¿è””ç¡«ç´ åœ¨ä½åŠ‘é‡çš„MWCNTæš´éœ²ä¸‹å»ä¿ƒé€²äº†ä¸­æ€§ç²’ç´°èƒçš„æµ¸æ½¤ï¼Œä¸¦å¢åŠ äº†MIP-2çš„è¡¨é”åŠç—…ç†ç‚ç—‡è©•åˆ†ã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨MWCNTå¼•èµ·çš„è‚ºéƒ¨ç‚ç—‡ä¸­å¯èƒ½å…·æœ‰é›™é‡ä½œç”¨ï¼Œé€éNrf2çš„æ¿€æ´»ä¾†èª¿ç¯€ä¸åŒé¡å‹çš„å…ç–«åæ‡‰ã€‚",
    "fb_post": "æ ¹æ“šã€ŠToxicology researchã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± ä½ çŸ¥é“å—ï¼Ÿè˜¿è””ç¡«ç´ å¯èƒ½åœ¨è‚ºéƒ¨ç‚ç—‡ä¸­æ‰®æ¼”è‘—é›™é‡è§’è‰²ï¼é€™é …ç ”ç©¶å°ˆæ³¨æ–¼è˜¿è””ç¡«ç´ å°å¤šå£ç¢³ç´ç±³ç®¡ï¼ˆMWCNTï¼‰å¼•èµ·çš„è‚ºéƒ¨ç‚ç—‡çš„å½±éŸ¿ã€‚ç ”ç©¶äººå“¡æƒ³äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•é€éä¸€ç¨®å«åšNrf2çš„è½‰éŒ„å› å­ä¾†å½±éŸ¿è‚ºéƒ¨çš„åæ‡‰ã€‚é€™å¯ä¸æ˜¯å°äº‹ï¼Œå› ç‚ºNrf2åœ¨ç‚ç—‡ä¸­é€šå¸¸æ˜¯å€‹æŠ‘åˆ¶è€…ï¼Œä½†é€™æ¬¡å»å¯èƒ½è®Šæˆä¿ƒé€²è€…ï¼\n\nåœ¨å¯¦é©—ä¸­ï¼Œç§‘å­¸å®¶å€‘ä½¿ç”¨äº†48éš»å°é¼ ï¼Œè®“å®ƒå€‘å¸å…¥ä¸åŒåŠ‘é‡çš„å¤šå£ç¢³ç´ç±³ç®¡ï¼Œç„¶å¾Œæ³¨å°„è˜¿è””ç¡«ç´ ï¼Œè§€å¯Ÿå…¶æ•ˆæœã€‚ä»–å€‘æ”¶é›†äº†å°é¼ çš„è‚ºéƒ¨æ¨£æœ¬ï¼Œé€²è¡Œäº†è©³ç´°åˆ†æã€‚\n\nçµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½æ¸›å°‘æ·‹å·´ç´°èƒçš„æµ¸æ½¤å’Œè‚ºéƒ¨é‡é‡çš„å¢åŠ ï¼Œé‚„é™ä½äº†IL-6é€™ç¨®ç´°èƒå› å­çš„è¡¨é”ã€‚ä¸éï¼Œä»¤äººé©šè¨çš„æ˜¯ï¼Œç•¶å°é¼ æ¥è§¸ä½åŠ‘é‡çš„MWCNTæ™‚ï¼Œè˜¿è””ç¡«ç´ å»ä¿ƒé€²äº†æŸäº›å…ç–«ç´°èƒçš„æ‹›å‹Ÿï¼é€™è®“æˆ‘å€‘äº†è§£åˆ°è˜¿è””ç¡«ç´ åœ¨ä¸åŒæƒ…æ³ä¸‹å¯èƒ½æœ‰ä¸åŒçš„å½±éŸ¿ã€‚\n\nğŸ” ä¸»è¦é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½å°è‚ºéƒ¨ç‚ç—‡æœ‰é›™é‡å½±éŸ¿ã€‚\n2. Nrf2åœ¨é€™å€‹éç¨‹ä¸­æ‰®æ¼”è‘—é—œéµè§’è‰²ã€‚\n3. ä½¿ç”¨å¤©ç„¶è£œå……å“æ™‚ï¼Œç’°å¢ƒå’ŒåŠ‘é‡éƒ½éå¸¸é‡è¦ï¼",
    "image_prompt": "Create a flat design infographic with a light background. Include symbols representing broccoli or sulforaphane, simplified icons of experimental subjects like mice or cells, and arrows or flow lines to illustrate the experimental steps. Include a section labeled 'Main Results' highlighting protective effects and changes in immune response.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "è‚ºç‚ Lung Inflammation",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41399453/"
  },
  {
    "id": "41409171",
    "title_en": "Investigating the Anticancer Effects of Sulforaphane in an In Vitro Coculture Model of Prostate Cancer Cells with Engineered Heart Tissue.",
    "pub_date": "2025 Dec",
    "journal": "ACS pharmacology & translational science",
    "abstract_en": "Sulforaphane (SFN) is a phytoderived compound abundant in cruciferous plants that possesses a broad spectrum of anticancer properties. We showed that SFN-induced caspase-mediated apoptosis in grade IV bone metastasis-derived androgen-insensitive PC-3 (IC<sub>50</sub> = 4.2 Î¼M), and lymph node metastasis-derived androgen-sensitive LNCaP (IC<sub>50</sub> = 2.8 Î¼M) prostate adenocarcinoma cells. SFN-mediated cardiotoxic side effects were tested in a preclinical in vitro model that enables the study simultaneously of the impact of drugs on cancer cell death and contractile properties of engineered heart tissues generated from human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM EHT). Thereby, SFN exposure induced PC-3 cell death without affecting the contractile force of hiPSC-CM EHT. Interestingly, the irregular beating pattern of hiPSC-CM EHT observed in the presence of PC-3 coculture was normalized compared to vehicle treatment. Overall, this in vitro coculture model of hiPSC-CM EHT and cancer cells could facilitate the study of cardiotoxic cancer drug side-effects.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°ç™Œç—‡çš„æ²»ç™‚ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®åœ¨åå­—èŠ±ç§‘æ¤ç‰©ä¸­è±å¯Œçš„åŒ–åˆç‰©ï¼Œå·²çŸ¥å…·æœ‰å¤šç¨®æŠ—ç™Œç‰¹æ€§ã€‚é€™æ„å‘³è‘—ï¼Œé€éé£²é£Ÿä¸­å¢åŠ é€™é¡æ¤ç‰©çš„æ”å–ï¼Œå¯èƒ½å°é™ä½æŸäº›ç™Œç—‡é¢¨éšªæœ‰å¹«åŠ©ï¼Œå°¤å…¶æ˜¯å‰åˆ—è…ºç™Œã€‚é€™é …ç ”ç©¶çš„çµæœå¯èƒ½æœƒä¿ƒä½¿äººå€‘æ›´åŠ é‡è¦–é£²é£Ÿä¸­çš„å¤©ç„¶æˆåˆ†ï¼Œä¸¦æ¢ç´¢å®ƒå€‘åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„æ½›åœ¨æ‡‰ç”¨ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°å‰åˆ—è…ºç™Œç´°èƒçš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯é‡å°ä¸åŒé¡å‹çš„å‰åˆ—è…ºç™Œç´°èƒï¼ŒåŒ…æ‹¬å°é›„æ¿€ç´ ä¸æ•æ„Ÿçš„PC-3ç´°èƒå’Œå°é›„æ¿€ç´ æ•æ„Ÿçš„LNCaPç´°èƒã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•èª˜å°ç™Œç´°èƒæ­»äº¡ï¼Œä¸¦åŒæ™‚è©•ä¼°å…¶å°å¿ƒè‡Ÿç´°èƒçš„æ½›åœ¨å‰¯ä½œç”¨ã€‚é€™æ¨£çš„ç ”ç©¶ä¸åƒ…æœ‰åŠ©æ–¼ç†è§£ç™Œç—‡æ²»ç™‚çš„æ©Ÿåˆ¶ï¼Œä¹Ÿèƒ½æä¾›å°å¿ƒè‡Ÿå¥åº·çš„è€ƒé‡ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†å‰åˆ—è…ºç™Œç´°èƒå’Œäººé¡èª˜å°å¤šèƒ½å¹¹ç´°èƒè¡ç”Ÿçš„å¿ƒè‚Œç´°èƒï¼ˆhiPSC-CMï¼‰ä¾†é€²è¡Œå…±åŸ¹é¤Šã€‚é€™ç¨®æ–¹æ³•ä½¿ä»–å€‘èƒ½å¤ åŒæ™‚è§€å¯Ÿè˜¿è””ç¡«ç´ å°ç™Œç´°èƒæ­»äº¡çš„å½±éŸ¿ï¼Œä»¥åŠå°å¿ƒè‡Ÿçµ„ç¹”æ”¶ç¸®ç‰¹æ€§çš„å½±éŸ¿ã€‚ç ”ç©¶è€…æ¸¬è©¦äº†ä¸åŒæ¿ƒåº¦çš„è˜¿è””ç¡«ç´ ï¼Œä¸¦è©•ä¼°å…¶å°PC-3å’ŒLNCaPç´°èƒçš„ç´°èƒæ¯’æ€§ï¼Œä¸¦è§€å¯Ÿå¿ƒè‚Œç´°èƒçš„æ”¶ç¸®åŠ›æ˜¯å¦å—åˆ°å½±éŸ¿ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆèª˜å°PC-3ç´°èƒæ­»äº¡ï¼Œä½†å°å¿ƒè‚Œç´°èƒçš„æ”¶ç¸®åŠ›æ²’æœ‰æ˜é¡¯å½±éŸ¿ã€‚æ­¤å¤–ï¼Œç•¶PC-3ç´°èƒèˆ‡å¿ƒè‚Œç´°èƒå…±åŸ¹é¤Šæ™‚ï¼Œå¿ƒè‚Œç´°èƒçš„ç•°å¸¸è·³å‹•æ¨¡å¼å¾—åˆ°äº†æ”¹å–„ï¼Œé€™èˆ‡å°ç…§çµ„ç›¸æ¯”æœ‰é¡¯è‘—å·®ç•°ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ åœ¨æŠ—ç™Œæ–¹é¢çš„æ½›åŠ›ï¼ŒåŒæ™‚ä¹Ÿæä¾›äº†ä¸€å€‹æ–°çš„æ¨¡å‹ä¾†ç ”ç©¶ç™Œç—‡è—¥ç‰©çš„å¿ƒè‡Ÿæ¯’æ€§å‰¯ä½œç”¨ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°ç™Œç—‡çš„æ²»ç™‚ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®åœ¨åå­—èŠ±ç§‘æ¤ç‰©ä¸­è±å¯Œçš„åŒ–åˆç‰©ï¼Œå·²çŸ¥å…·æœ‰å¤šç¨®æŠ—ç™Œç‰¹æ€§ã€‚é€™æ„å‘³è‘—ï¼Œé€éé£²é£Ÿä¸­å¢åŠ é€™é¡æ¤ç‰©çš„æ”å–ï¼Œå¯èƒ½å°é™ä½æŸäº›ç™Œç—‡é¢¨éšªæœ‰å¹«åŠ©ï¼Œå°¤å…¶æ˜¯å‰åˆ—è…ºç™Œã€‚é€™é …ç ”ç©¶çš„çµæœå¯èƒ½æœƒä¿ƒä½¿äººå€‘æ›´åŠ é‡è¦–é£²é£Ÿä¸­çš„å¤©ç„¶æˆåˆ†ï¼Œä¸¦æ¢ç´¢å®ƒå€‘åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„æ½›åœ¨æ‡‰ç”¨ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°å‰åˆ—è…ºç™Œç´°èƒçš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯é‡å°ä¸åŒé¡å‹çš„å‰åˆ—è…ºç™Œç´°èƒï¼ŒåŒ…æ‹¬å°é›„æ¿€ç´ ä¸æ•æ„Ÿçš„PC-3ç´°èƒå’Œå°é›„æ¿€ç´ æ•æ„Ÿçš„LNCaPç´°èƒã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•èª˜å°ç™Œç´°èƒæ­»äº¡ï¼Œä¸¦åŒæ™‚è©•ä¼°å…¶å°å¿ƒè‡Ÿç´°èƒçš„æ½›åœ¨å‰¯ä½œç”¨ã€‚é€™æ¨£çš„ç ”ç©¶ä¸åƒ…æœ‰åŠ©æ–¼ç†è§£ç™Œç—‡æ²»ç™‚çš„æ©Ÿåˆ¶ï¼Œä¹Ÿèƒ½æä¾›å°å¿ƒè‡Ÿå¥åº·çš„è€ƒé‡ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†å‰åˆ—è…ºç™Œç´°èƒå’Œäººé¡èª˜å°å¤šèƒ½å¹¹ç´°èƒè¡ç”Ÿçš„å¿ƒè‚Œç´°èƒï¼ˆhiPSC-CMï¼‰ä¾†é€²è¡Œå…±åŸ¹é¤Šã€‚é€™ç¨®æ–¹æ³•ä½¿ä»–å€‘èƒ½å¤ åŒæ™‚è§€å¯Ÿè˜¿è””ç¡«ç´ å°ç™Œç´°èƒæ­»äº¡çš„å½±éŸ¿ï¼Œä»¥åŠå°å¿ƒè‡Ÿçµ„ç¹”æ”¶ç¸®ç‰¹æ€§çš„å½±éŸ¿ã€‚ç ”ç©¶è€…æ¸¬è©¦äº†ä¸åŒæ¿ƒåº¦çš„è˜¿è””ç¡«ç´ ï¼Œä¸¦è©•ä¼°å…¶å°PC-3å’ŒLNCaPç´°èƒçš„ç´°èƒæ¯’æ€§ï¼Œä¸¦è§€å¯Ÿå¿ƒè‚Œç´°èƒçš„æ”¶ç¸®åŠ›æ˜¯å¦å—åˆ°å½±éŸ¿ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆèª˜å°PC-3ç´°èƒæ­»äº¡ï¼Œä½†å°å¿ƒè‚Œç´°èƒçš„æ”¶ç¸®åŠ›æ²’æœ‰æ˜é¡¯å½±éŸ¿ã€‚æ­¤å¤–ï¼Œç•¶PC-3ç´°èƒèˆ‡å¿ƒè‚Œç´°èƒå…±åŸ¹é¤Šæ™‚ï¼Œå¿ƒè‚Œç´°èƒçš„ç•°å¸¸è·³å‹•æ¨¡å¼å¾—åˆ°äº†æ”¹å–„ï¼Œé€™èˆ‡å°ç…§çµ„ç›¸æ¯”æœ‰é¡¯è‘—å·®ç•°ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ åœ¨æŠ—ç™Œæ–¹é¢çš„æ½›åŠ›ï¼ŒåŒæ™‚ä¹Ÿæä¾›äº†ä¸€å€‹æ–°çš„æ¨¡å‹ä¾†ç ”ç©¶ç™Œç—‡è—¥ç‰©çš„å¿ƒè‡Ÿæ¯’æ€§å‰¯ä½œç”¨ã€‚",
    "fb_post": "æ ¹æ“šã€ŠACS pharmacology & translational scienceã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ½ï¸ è½èªªä½ åƒçš„é’èŠ±æ¤°èœè£¡æœ‰æŠ—ç™Œçš„ç§˜å¯†æ­¦å™¨ï¼Ÿé€™ç¯‡ç ”ç©¶æ­ç¤ºäº†è˜¿è””ç¡«ç´ é€™å€‹ç¥å¥‡çš„æˆåˆ†ï¼Œå®ƒåœ¨åå­—èŠ±ç§‘æ¤ç‰©ä¸­è±å¯Œï¼Œå¦‚é’èŠ±æ¤°èœå’Œè˜¿è””ï¼Œå°æ–¼ç™Œç—‡çš„é é˜²æœ‰è‘—æ½›åœ¨çš„å¥½è™•ï¼\n\né€™é …ç ”ç©¶å°ˆæ³¨æ–¼è˜¿è””ç¡«ç´ å°å‰åˆ—è…ºç™Œç´°èƒçš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯å°å…©ç¨®ä¸åŒé¡å‹çš„å‰åˆ—è…ºç™Œç´°èƒé€²è¡Œäº†æ¸¬è©¦ã€‚ç ”ç©¶è€…å€‘å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å¹«åŠ©ç™Œç´°èƒæ­»äº¡ï¼Œä¸¦åŒæ™‚è€ƒé‡å®ƒå°å¿ƒè‡Ÿç´°èƒçš„å½±éŸ¿ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶åœ˜éšŠä½¿ç”¨äº†å‰åˆ—è…ºç™Œç´°èƒå’Œäººé¡å¿ƒè‚Œç´°èƒé€²è¡Œå…±åŸ¹é¤Šï¼Œè§€å¯Ÿè˜¿è””ç¡«ç´ çš„æ•ˆæœã€‚ä»–å€‘ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆèª˜å°ç™Œç´°èƒæ­»äº¡ï¼Œä¸”å°å¿ƒè‚Œç´°èƒçš„æ”¶ç¸®åŠ›æ²’æœ‰æ˜é¡¯å½±éŸ¿ï¼Œé€™æ˜¯ä¸€å€‹å¥½æ¶ˆæ¯ï¼\n\nğŸ” ä¸»è¦ç™¼ç¾ï¼š\n1. è˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆèª˜å°å‰åˆ—è…ºç™Œç´°èƒæ­»äº¡ã€‚\n2. å°å¿ƒè‚Œç´°èƒçš„æ”¶ç¸®åŠ›æ²’æœ‰é¡¯è‘—å½±éŸ¿ã€‚\n3. æ”¹å–„äº†å¿ƒè‚Œç´°èƒçš„ç•°å¸¸è·³å‹•æ¨¡å¼ã€‚\n\né€™é …ç ”ç©¶ä¸åƒ…è®“æˆ‘å€‘çœ‹åˆ°é£²é£Ÿä¸­å¤©ç„¶æˆåˆ†çš„æ½›åŠ›ï¼Œä¹Ÿç‚ºæœªä¾†çš„ç™Œç—‡æ²»ç™‚æä¾›äº†æ–°çš„æ€è·¯ï¼",
    "image_prompt": "Create a flat design infographic that explains the experiment and main results of a study on sulforaphane. Include symbols representing broccoli or sulforaphane, simplified illustrations of human or cell subjects, arrows or flow lines indicating the experimental steps, and a section labeled 'Main Results' highlighting protective effects or changes observed. Use a light-colored background with soft color palettes.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "å‰åˆ—è…ºç™Œ Prostate Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41409171/"
  },
  {
    "id": "41387309",
    "title_en": "Monovalent mannose-glycoconjugates of sulforaphane reprogram human dendritic cells via NFATc1 to induce immune tolerance under inflammatory conditions.",
    "pub_date": "2025 Dec",
    "journal": "British journal of pharmacology",
    "abstract_en": "Immune tolerance prevents inflammation and autoimmunity, with dendritic cells (DCs) playing a key role. Reprogramming DCs towards a tolerogenic state represents a promising therapeutic strategy. Sulforaphane (SFN) has known immunomodulatory effects, but its clinical application is limited by poor stability and bioavailability. To enhance its therapeutic potential, SFN was conjugated with mannose (SFNMan) or fucose (SFNFuc), aiming to induce a tolerogenic phenotype in human monocyte-derived DCs (moDCs) under inflammation and to explore NFATc1's involvement. moDCs were exposed to inflammatory conditions and treated with SFN, SFNMan or SFNFuc. Their phenotype, cytokine profile, T cell-modulating capacity and NFATc1 signalling were evaluated. SFNMan selectively induced a tolerogenic phenotype, characterised by an increased PD-L1/CD86 ratio and IL-10 production; up-regulation of SOCS1 and IDO transcripts; and Treg expansion and reduced proliferation of cytotoxic T cell proliferation. Functional assays and confocal microscopy revealed that SFNMan, but not SFNFuc, promoted NFATc1 nuclear translocation. Pharmacological inhibition of NFATc1 with cyclosporin A (CsA) abolished these effects, confirming NFATc1 as a central mediator of SFNMan-induced immune tolerance. Our findings identify NFATc1 as a key transcriptional switch in moDCs tolerogenic programming and highlight the carbohydrate-dependent specificity of SFN conjugates. SFNMan represents a novel carbohydrate-engineered immunomodulator capable of driving immune tolerance through NFATc1 activation. These results provide a mechanistic framework for the development of precision therapies targeting inflammatory and autoimmune diseases.",
    "para1": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨å…ç–«è€å—æ€§æ–¹é¢ã€‚å…ç–«è€å—æ€§å¯ä»¥é˜²æ­¢èº«é«”å‡ºç¾ç‚ç—‡å’Œè‡ªé«”å…ç–«åæ‡‰ï¼Œè€Œæ¨¹çªç´°èƒåœ¨é€™å€‹éç¨‹ä¸­æ‰®æ¼”è‘—é‡è¦è§’è‰²ã€‚é€éèª¿æ•´æ¨¹çªç´°èƒçš„åŠŸèƒ½ï¼Œä½¿å…¶æœå‘è€å—æ€§ç‹€æ…‹ç™¼å±•ï¼Œå¯èƒ½æˆç‚ºä¸€ç¨®æœ‰æ•ˆçš„æ²»ç™‚ç­–ç•¥ã€‚é€™æ„å‘³è‘—æœªä¾†æœ‰å¯èƒ½é–‹ç™¼å‡ºèƒ½å¤ æ”¹å–„å…ç–«ç³»çµ±åæ‡‰çš„ç™‚æ³•ï¼Œå¾è€Œæ¸›å°‘èˆ‡ç‚ç—‡å’Œè‡ªé«”å…ç–«ç–¾ç—…ç›¸é—œçš„å¥åº·å•é¡Œã€‚",
    "para2": "æœ¬ç ”ç©¶ä¸»è¦é—œæ³¨çš„æ˜¯å¦‚ä½•åˆ©ç”¨è˜¿è””ç¡«ç´ åŠå…¶è¡ç”Ÿç‰©ä¾†èª¿æ•´äººé¡å–®æ ¸ç´°èƒè¡ç”Ÿçš„æ¨¹çªç´°èƒï¼Œä¿ƒä½¿å…¶ç”¢ç”Ÿè€å—æ€§è¡¨å‹ã€‚ç ”ç©¶è€…å¸Œæœ›é€éé€™äº›èª¿æ•´ä¾†æ”¹å–„è˜¿è””ç¡«ç´ çš„è‡¨åºŠæ‡‰ç”¨ï¼Œå› ç‚ºå…¶åœ¨ç©©å®šæ€§å’Œç”Ÿç‰©åˆ©ç”¨åº¦ä¸Šå­˜åœ¨ä¸€å®šçš„é™åˆ¶ã€‚å…·é«”è€Œè¨€ï¼Œç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ èˆ‡ç”˜éœ²ç³–æˆ–å²©è—»ç³–çµåˆå¾Œï¼Œå°æ¨¹çªç´°èƒåœ¨ç‚ç—‡ç‹€æ…‹ä¸‹çš„å½±éŸ¿ï¼Œä¸¦åˆ†æNFATc1åœ¨é€™ä¸€éç¨‹ä¸­çš„è§’è‰²ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å°‡äººé¡å–®æ ¸ç´°èƒè¡ç”Ÿçš„æ¨¹çªç´°èƒç½®æ–¼ç‚ç—‡ç’°å¢ƒä¸­ï¼Œä¸¦åˆ†åˆ¥ç”¨è˜¿è””ç¡«ç´ ã€è˜¿è””ç¡«ç´ ç”˜éœ²ç³–çµåˆç‰©ï¼ˆSFNManï¼‰å’Œè˜¿è””ç¡«ç´ å²©è—»ç³–çµåˆç‰©ï¼ˆSFNFucï¼‰é€²è¡Œè™•ç†ã€‚ç ”ç©¶è€…è©•ä¼°äº†é€™äº›è™•ç†å°æ¨¹çªç´°èƒè¡¨å‹ã€ç´°èƒå› å­ç”¢ç”Ÿã€èª¿ç¯€Tç´°èƒçš„èƒ½åŠ›ä»¥åŠNFATc1ä¿¡è™Ÿå‚³å°çš„å½±éŸ¿ã€‚é€™æ¨£çš„è¨­è¨ˆæ—¨åœ¨æ·±å…¥äº†è§£ä¸åŒè™•ç†å°æ¨¹çªç´°èƒåŠŸèƒ½çš„å…·é«”å½±éŸ¿ã€‚",
    "para4": "ä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼ŒSFNManèƒ½å¤ é¸æ“‡æ€§åœ°èª˜å°æ¨¹çªç´°èƒç”¢ç”Ÿè€å—æ€§è¡¨å‹ï¼Œé€™è¡¨ç¾ç‚ºPD-L1/CD86æ¯”ç‡çš„å¢åŠ å’ŒIL-10çš„ç”¢ç”Ÿä¸Šå‡ã€‚æ­¤å¤–ï¼ŒSFNMané‚„ä¿ƒé€²äº†SOCS1å’ŒIDOè½‰éŒ„æœ¬çš„ä¸Šèª¿ï¼Œä¸¦æ“´å±•äº†èª¿ç¯€æ€§Tç´°èƒï¼ŒåŒæ™‚æ¸›å°‘äº†ç´°èƒæ¯’æ€§Tç´°èƒçš„å¢æ®–ã€‚åŠŸèƒ½æ€§å¯¦é©—å’Œå…±èšç„¦é¡¯å¾®é¡è§€å¯Ÿé¡¯ç¤ºï¼ŒSFNManä¿ƒé€²äº†NFATc1çš„æ ¸è½‰ä½ï¼Œè€ŒSFNFucå‰‡æ²’æœ‰é€™ä¸€æ•ˆæœã€‚é€™äº›çµæœç¢ºèªäº†NFATc1åœ¨SFNManèª˜å°å…ç–«è€å—ä¸­çš„é—œéµè§’è‰²ï¼Œä¸¦ç‚ºé‡å°ç‚ç—‡å’Œè‡ªé«”å…ç–«ç–¾ç—…çš„ç²¾æº–ç™‚æ³•é–‹ç™¼æä¾›äº†æ©Ÿåˆ¶æ¡†æ¶ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨å…ç–«è€å—æ€§æ–¹é¢ã€‚å…ç–«è€å—æ€§å¯ä»¥é˜²æ­¢èº«é«”å‡ºç¾ç‚ç—‡å’Œè‡ªé«”å…ç–«åæ‡‰ï¼Œè€Œæ¨¹çªç´°èƒåœ¨é€™å€‹éç¨‹ä¸­æ‰®æ¼”è‘—é‡è¦è§’è‰²ã€‚é€éèª¿æ•´æ¨¹çªç´°èƒçš„åŠŸèƒ½ï¼Œä½¿å…¶æœå‘è€å—æ€§ç‹€æ…‹ç™¼å±•ï¼Œå¯èƒ½æˆç‚ºä¸€ç¨®æœ‰æ•ˆçš„æ²»ç™‚ç­–ç•¥ã€‚é€™æ„å‘³è‘—æœªä¾†æœ‰å¯èƒ½é–‹ç™¼å‡ºèƒ½å¤ æ”¹å–„å…ç–«ç³»çµ±åæ‡‰çš„ç™‚æ³•ï¼Œå¾è€Œæ¸›å°‘èˆ‡ç‚ç—‡å’Œè‡ªé«”å…ç–«ç–¾ç—…ç›¸é—œçš„å¥åº·å•é¡Œã€‚\n\næœ¬ç ”ç©¶ä¸»è¦é—œæ³¨çš„æ˜¯å¦‚ä½•åˆ©ç”¨è˜¿è””ç¡«ç´ åŠå…¶è¡ç”Ÿç‰©ä¾†èª¿æ•´äººé¡å–®æ ¸ç´°èƒè¡ç”Ÿçš„æ¨¹çªç´°èƒï¼Œä¿ƒä½¿å…¶ç”¢ç”Ÿè€å—æ€§è¡¨å‹ã€‚ç ”ç©¶è€…å¸Œæœ›é€éé€™äº›èª¿æ•´ä¾†æ”¹å–„è˜¿è””ç¡«ç´ çš„è‡¨åºŠæ‡‰ç”¨ï¼Œå› ç‚ºå…¶åœ¨ç©©å®šæ€§å’Œç”Ÿç‰©åˆ©ç”¨åº¦ä¸Šå­˜åœ¨ä¸€å®šçš„é™åˆ¶ã€‚å…·é«”è€Œè¨€ï¼Œç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ èˆ‡ç”˜éœ²ç³–æˆ–å²©è—»ç³–çµåˆå¾Œï¼Œå°æ¨¹çªç´°èƒåœ¨ç‚ç—‡ç‹€æ…‹ä¸‹çš„å½±éŸ¿ï¼Œä¸¦åˆ†æNFATc1åœ¨é€™ä¸€éç¨‹ä¸­çš„è§’è‰²ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å°‡äººé¡å–®æ ¸ç´°èƒè¡ç”Ÿçš„æ¨¹çªç´°èƒç½®æ–¼ç‚ç—‡ç’°å¢ƒä¸­ï¼Œä¸¦åˆ†åˆ¥ç”¨è˜¿è””ç¡«ç´ ã€è˜¿è””ç¡«ç´ ç”˜éœ²ç³–çµåˆç‰©ï¼ˆSFNManï¼‰å’Œè˜¿è””ç¡«ç´ å²©è—»ç³–çµåˆç‰©ï¼ˆSFNFucï¼‰é€²è¡Œè™•ç†ã€‚ç ”ç©¶è€…è©•ä¼°äº†é€™äº›è™•ç†å°æ¨¹çªç´°èƒè¡¨å‹ã€ç´°èƒå› å­ç”¢ç”Ÿã€èª¿ç¯€Tç´°èƒçš„èƒ½åŠ›ä»¥åŠNFATc1ä¿¡è™Ÿå‚³å°çš„å½±éŸ¿ã€‚é€™æ¨£çš„è¨­è¨ˆæ—¨åœ¨æ·±å…¥äº†è§£ä¸åŒè™•ç†å°æ¨¹çªç´°èƒåŠŸèƒ½çš„å…·é«”å½±éŸ¿ã€‚\n\nä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼ŒSFNManèƒ½å¤ é¸æ“‡æ€§åœ°èª˜å°æ¨¹çªç´°èƒç”¢ç”Ÿè€å—æ€§è¡¨å‹ï¼Œé€™è¡¨ç¾ç‚ºPD-L1/CD86æ¯”ç‡çš„å¢åŠ å’ŒIL-10çš„ç”¢ç”Ÿä¸Šå‡ã€‚æ­¤å¤–ï¼ŒSFNMané‚„ä¿ƒé€²äº†SOCS1å’ŒIDOè½‰éŒ„æœ¬çš„ä¸Šèª¿ï¼Œä¸¦æ“´å±•äº†èª¿ç¯€æ€§Tç´°èƒï¼ŒåŒæ™‚æ¸›å°‘äº†ç´°èƒæ¯’æ€§Tç´°èƒçš„å¢æ®–ã€‚åŠŸèƒ½æ€§å¯¦é©—å’Œå…±èšç„¦é¡¯å¾®é¡è§€å¯Ÿé¡¯ç¤ºï¼ŒSFNManä¿ƒé€²äº†NFATc1çš„æ ¸è½‰ä½ï¼Œè€ŒSFNFucå‰‡æ²’æœ‰é€™ä¸€æ•ˆæœã€‚é€™äº›çµæœç¢ºèªäº†NFATc1åœ¨SFNManèª˜å°å…ç–«è€å—ä¸­çš„é—œéµè§’è‰²ï¼Œä¸¦ç‚ºé‡å°ç‚ç—‡å’Œè‡ªé«”å…ç–«ç–¾ç—…çš„ç²¾æº–ç™‚æ³•é–‹ç™¼æä¾›äº†æ©Ÿåˆ¶æ¡†æ¶ã€‚",
    "fb_post": "æ ¹æ“šã€ŠBritish journal of pharmacologyã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± ä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„å…ç–«ç³»çµ±å°±åƒä¸€æ”¯éšŠä¼ï¼Œéœ€è¦æ™‚åˆ»ä¿æŒè­¦è¦ºï¼Œä½†æœ‰æ™‚å€™å®ƒä¹Ÿéœ€è¦å­¸æœƒæ”¾é¬†ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶å°ˆæ³¨æ–¼ã€Œå…ç–«è€å—æ€§ã€ï¼Œé€™æ˜¯ä¸€ç¨®è®“èº«é«”é¿å…éåº¦åæ‡‰çš„èƒ½åŠ›ï¼Œç‰¹åˆ¥æ˜¯åœ¨ç‚ç—‡å’Œè‡ªé«”å…ç–«ç–¾ç—…çš„æƒ…æ³ä¸‹ã€‚ç ”ç©¶è€…å€‘ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ ï¼ˆé€™æ˜¯ä¸€ç¨®å­˜åœ¨æ–¼é’èŠ±èœå’Œè˜¿è””ä¸­çš„æˆåˆ†ï¼‰å¯ä»¥å¹«åŠ©æˆ‘å€‘çš„å…ç–«ç³»çµ±æ›´å¥½åœ°èª¿æ•´ï¼  \n\né€™é …ç ”ç©¶çš„éç¨‹æ˜¯é€™æ¨£çš„ï¼šç§‘å­¸å®¶å€‘å°‡äººé¡çš„æ¨¹çªç´°èƒï¼ˆé€™æ˜¯ä¸€ç¨®é‡è¦çš„å…ç–«ç´°èƒï¼‰ç½®æ–¼ç‚ç—‡ç’°å¢ƒä¸­ï¼Œç„¶å¾Œç”¨è˜¿è””ç¡«ç´ åŠå…¶è¡ç”Ÿç‰©é€²è¡Œè™•ç†ã€‚ä»–å€‘è§€å¯Ÿåˆ°é€™äº›è™•ç†å°æ¨¹çªç´°èƒçš„å½±éŸ¿ï¼ŒåŒ…æ‹¬ç´°èƒçš„è¡¨å‹è®ŠåŒ–å’Œç´°èƒå› å­çš„ç”¢ç”Ÿã€‚çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ çš„æŸå€‹è¡ç”Ÿç‰©ï¼ˆSFNManï¼‰èƒ½æœ‰æ•ˆèª˜å°æ¨¹çªç´°èƒç”¢ç”Ÿè€å—æ€§ï¼Œé€™å°æ–¼æœªä¾†çš„å…ç–«æ²»ç™‚æœ‰å¾ˆå¤§çš„å•Ÿç¤ºï¼  \n\nğŸ” ä¸»è¦ç™¼ç¾ï¼š  \n1. SFNManèƒ½æå‡æ¨¹çªç´°èƒçš„è€å—æ€§ï¼Œæ¸›å°‘ä¸å¿…è¦çš„å…ç–«åæ‡‰ã€‚  \n2. å®ƒä¿ƒé€²äº†IL-10ï¼ˆä¸€ç¨®æŠ—ç™¼ç‚å› å­ï¼‰çš„ç”¢ç”Ÿï¼Œå°æŠ—ç‚ç—‡ã€‚  \n3. NFATc1é€™å€‹ä¿¡è™Ÿé€šè·¯åœ¨é€™å€‹éç¨‹ä¸­æ‰®æ¼”äº†é‡è¦è§’è‰²ã€‚  \n\né€™äº›ç™¼ç¾è®“æˆ‘å€‘å°æœªä¾†çš„å…ç–«ç™‚æ³•å……æ»¿æœŸå¾…ï¼",
    "image_prompt": "Create an infographic that explains the experimental process and main results of a study on immune tolerance using sulforaphane. The image should have a flat design style with a light background and soft colors. Include symbols representing broccoli or sulforaphane, simplified illustrations of human cells, and arrows or flow lines to indicate the experimental steps. There should be a section clearly labeled 'Main Results' highlighting protective effects and changes observed in the immune cells.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "è‡ªé«”å…ç–«ç–¾ç—… Autoimmune Diseases",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41387309/"
  },
  {
    "id": "41108925",
    "title_en": "Enhancing myocardial injury recovery: Nrf2 activation by sulforaphane regulates ferroptosis and oxidative stress in takotsubo-like models.",
    "pub_date": "2025 Dec",
    "journal": "International immunopharmacology",
    "abstract_en": "Takotsubo syndrome (TTS), once considered benign, can cause life-threatening myocardial injury. Although oxidative stress and ferroptosis are implicated in its pathogenesis, targeted therapies are not available for TTS. We demonstrate that sulforaphane (SFN), a natural Nrf2 activator, mitigates TTS-related injury in isoproterenol-induced rat models and AC16 cardiomyocytes. Isoproterenol induced ferroptosis and oxidative stress by impairing Nrf2 signaling. SFN treatment restored myocardial structure and function while enhancing antioxidant capacity, reducing mitochondrial damage, and suppressing ferroptosis markers. Additionally, similar to Fer-1 (a ferroptosis inhibitor), SFN reduced intracellular ferrous levels but uniquely activated Nrf2-driven endogenous defenses. Notably, Nrf2 inhibition abrogated the benefits of SFN in both in vitro and in vivo experiments. These findings highlight SFN as a dual-action therapeutic for TTS, simultaneously targeting oxidative stress and ferroptosis via Nrf2 activation. The therapeutic efficacy of SFN, combined with endogenous pathway modulation, underscores its translational potential for improving TTS outcomes.",
    "para1": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›é‡è¦çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°å¿ƒè‡Ÿå¥åº·ã€‚Takotsuboç—‡å€™ç¾¤ï¼ˆTTSï¼‰æ˜¯ä¸€ç¨®å¯èƒ½å°è‡´å¿ƒè‡Ÿæå‚·çš„ç–¾ç—…ï¼Œé›–ç„¶éå»è¢«èªç‚ºæ˜¯è‰¯æ€§çš„ï¼Œä½†å¯¦éš›ä¸Šå¯èƒ½æœƒå°ç”Ÿå‘½é€ æˆå¨è„…ã€‚é€™é …ç ”ç©¶æ¢è¨äº†å¦‚ä½•åˆ©ç”¨å¤©ç„¶ç‰©è³ªä¾†æ¸›è¼•é€™ç¨®ç–¾ç—…æ‰€å¼•èµ·çš„å‚·å®³ï¼Œä¸¦ä¸”å¼·èª¿äº†æŠ—æ°§åŒ–åŠ‘çš„é‡è¦æ€§ï¼Œé€™å¯èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚æ–¹æ³•æä¾›æ–°çš„æ–¹å‘ã€‚",
    "para2": "ç ”ç©¶çš„ä¸»é¡Œæ˜¯Takotsuboç—‡å€™ç¾¤ï¼ˆTTSï¼‰åŠå…¶ç›¸é—œçš„å¿ƒè‡Ÿæå‚·ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯å¦‚ä½•é€éç‰¹å®šçš„å¤©ç„¶ç‰©è³ªä¾†æ”¹å–„é€™ç¨®ç–¾ç—…çš„ç—…ç†ç‹€æ³ï¼Œç‰¹åˆ¥æ˜¯é‡å°æ°§åŒ–å£“åŠ›å’Œéµæ­»äº¡ï¼ˆferroptosisï¼‰é€™å…©å€‹å› ç´ ã€‚é€™äº›å› ç´ åœ¨TTSçš„ç™¼å±•ä¸­æ‰®æ¼”è‘—é‡è¦è§’è‰²ï¼Œä½†ç›®å‰å°šæœªæœ‰é‡å°TTSçš„æœ‰æ•ˆæ²»ç™‚æ–¹æ³•ï¼Œå› æ­¤é€™é …ç ”ç©¶çš„æ„ç¾©å°¤ç‚ºé‡è¦ã€‚",
    "para3": "å¯¦é©—ä¸­ä½¿ç”¨äº†å¤§é¼ æ¨¡å‹å’Œå¿ƒè‚Œç´°èƒï¼ˆAC16ç´°èƒï¼‰ä¾†æ¨¡æ“¬TTSçš„æƒ…æ³ã€‚ç ”ç©¶è€…ä½¿ç”¨ç•°ä¸™è…ä¸Šè…ºç´ ï¼ˆisoproterenolï¼‰ä¾†èª˜å°å¿ƒè‡Ÿçš„æ°§åŒ–å£“åŠ›å’Œéµæ­»äº¡ï¼Œç„¶å¾Œè§€å¯Ÿè˜¿è””ç¡«ç´ ï¼ˆsulforaphane, SFNï¼‰å°é€™äº›æå‚·çš„å½±éŸ¿ã€‚é€éé€™äº›å¯¦é©—ï¼Œç ”ç©¶è€…èƒ½å¤ è©•ä¼°SFNåœ¨æ”¹å–„å¿ƒè‡Ÿçµæ§‹å’ŒåŠŸèƒ½æ–¹é¢çš„æ½›åŠ›ï¼Œä»¥åŠå®ƒå¦‚ä½•å¢å¼·æŠ—æ°§åŒ–èƒ½åŠ›å’Œæ¸›å°‘ç´°èƒæå‚·ã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æœ‰æ•ˆæ¸›è¼•TTSç›¸é—œçš„å¿ƒè‡Ÿæå‚·ï¼Œä¸¦ä¸”åœ¨æ”¹å–„å¿ƒè‡Ÿçµæ§‹å’ŒåŠŸèƒ½æ–¹é¢è¡¨ç¾å‡ºè‰¯å¥½çš„æ•ˆæœã€‚ç ”ç©¶é¡¯ç¤ºï¼ŒSFNä¸åƒ…èƒ½å¤ é™ä½ç´°èƒå…§çš„éµå«é‡ï¼Œé‚„èƒ½æ¿€æ´»Nrf2é€™ä¸€å…§æºæ€§é˜²ç¦¦æ©Ÿåˆ¶ï¼Œå¾è€Œå°æŠ—æ°§åŒ–å£“åŠ›å’Œéµæ­»äº¡ã€‚å€¼å¾—æ³¨æ„çš„æ˜¯ï¼Œè‹¥æŠ‘åˆ¶Nrf2ï¼ŒSFNçš„æ•ˆæœæœƒå—åˆ°å½±éŸ¿ï¼Œé€™è¡¨æ˜Nrf2åœ¨é€™ä¸€éç¨‹ä¸­æ‰®æ¼”è‘—é—œéµè§’è‰²ã€‚é€™äº›çµæœé¡¯ç¤ºï¼ŒSFNå¯èƒ½æˆç‚ºä¸€ç¨®é›™é‡ä½œç”¨çš„æ²»ç™‚é¸æ“‡ï¼Œå°æ”¹å–„TTSçš„çµæœå…·æœ‰æ½›åœ¨çš„æ‡‰ç”¨åƒ¹å€¼ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›é‡è¦çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°å¿ƒè‡Ÿå¥åº·ã€‚Takotsuboç—‡å€™ç¾¤ï¼ˆTTSï¼‰æ˜¯ä¸€ç¨®å¯èƒ½å°è‡´å¿ƒè‡Ÿæå‚·çš„ç–¾ç—…ï¼Œé›–ç„¶éå»è¢«èªç‚ºæ˜¯è‰¯æ€§çš„ï¼Œä½†å¯¦éš›ä¸Šå¯èƒ½æœƒå°ç”Ÿå‘½é€ æˆå¨è„…ã€‚é€™é …ç ”ç©¶æ¢è¨äº†å¦‚ä½•åˆ©ç”¨å¤©ç„¶ç‰©è³ªä¾†æ¸›è¼•é€™ç¨®ç–¾ç—…æ‰€å¼•èµ·çš„å‚·å®³ï¼Œä¸¦ä¸”å¼·èª¿äº†æŠ—æ°§åŒ–åŠ‘çš„é‡è¦æ€§ï¼Œé€™å¯èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚æ–¹æ³•æä¾›æ–°çš„æ–¹å‘ã€‚\n\nç ”ç©¶çš„ä¸»é¡Œæ˜¯Takotsuboç—‡å€™ç¾¤ï¼ˆTTSï¼‰åŠå…¶ç›¸é—œçš„å¿ƒè‡Ÿæå‚·ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯å¦‚ä½•é€éç‰¹å®šçš„å¤©ç„¶ç‰©è³ªä¾†æ”¹å–„é€™ç¨®ç–¾ç—…çš„ç—…ç†ç‹€æ³ï¼Œç‰¹åˆ¥æ˜¯é‡å°æ°§åŒ–å£“åŠ›å’Œéµæ­»äº¡ï¼ˆferroptosisï¼‰é€™å…©å€‹å› ç´ ã€‚é€™äº›å› ç´ åœ¨TTSçš„ç™¼å±•ä¸­æ‰®æ¼”è‘—é‡è¦è§’è‰²ï¼Œä½†ç›®å‰å°šæœªæœ‰é‡å°TTSçš„æœ‰æ•ˆæ²»ç™‚æ–¹æ³•ï¼Œå› æ­¤é€™é …ç ”ç©¶çš„æ„ç¾©å°¤ç‚ºé‡è¦ã€‚\n\nå¯¦é©—ä¸­ä½¿ç”¨äº†å¤§é¼ æ¨¡å‹å’Œå¿ƒè‚Œç´°èƒï¼ˆAC16ç´°èƒï¼‰ä¾†æ¨¡æ“¬TTSçš„æƒ…æ³ã€‚ç ”ç©¶è€…ä½¿ç”¨ç•°ä¸™è…ä¸Šè…ºç´ ï¼ˆisoproterenolï¼‰ä¾†èª˜å°å¿ƒè‡Ÿçš„æ°§åŒ–å£“åŠ›å’Œéµæ­»äº¡ï¼Œç„¶å¾Œè§€å¯Ÿè˜¿è””ç¡«ç´ ï¼ˆsulforaphane, SFNï¼‰å°é€™äº›æå‚·çš„å½±éŸ¿ã€‚é€éé€™äº›å¯¦é©—ï¼Œç ”ç©¶è€…èƒ½å¤ è©•ä¼°SFNåœ¨æ”¹å–„å¿ƒè‡Ÿçµæ§‹å’ŒåŠŸèƒ½æ–¹é¢çš„æ½›åŠ›ï¼Œä»¥åŠå®ƒå¦‚ä½•å¢å¼·æŠ—æ°§åŒ–èƒ½åŠ›å’Œæ¸›å°‘ç´°èƒæå‚·ã€‚\n\nä¸»è¦çš„ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æœ‰æ•ˆæ¸›è¼•TTSç›¸é—œçš„å¿ƒè‡Ÿæå‚·ï¼Œä¸¦ä¸”åœ¨æ”¹å–„å¿ƒè‡Ÿçµæ§‹å’ŒåŠŸèƒ½æ–¹é¢è¡¨ç¾å‡ºè‰¯å¥½çš„æ•ˆæœã€‚ç ”ç©¶é¡¯ç¤ºï¼ŒSFNä¸åƒ…èƒ½å¤ é™ä½ç´°èƒå…§çš„éµå«é‡ï¼Œé‚„èƒ½æ¿€æ´»Nrf2é€™ä¸€å…§æºæ€§é˜²ç¦¦æ©Ÿåˆ¶ï¼Œå¾è€Œå°æŠ—æ°§åŒ–å£“åŠ›å’Œéµæ­»äº¡ã€‚å€¼å¾—æ³¨æ„çš„æ˜¯ï¼Œè‹¥æŠ‘åˆ¶Nrf2ï¼ŒSFNçš„æ•ˆæœæœƒå—åˆ°å½±éŸ¿ï¼Œé€™è¡¨æ˜Nrf2åœ¨é€™ä¸€éç¨‹ä¸­æ‰®æ¼”è‘—é—œéµè§’è‰²ã€‚é€™äº›çµæœé¡¯ç¤ºï¼ŒSFNå¯èƒ½æˆç‚ºä¸€ç¨®é›™é‡ä½œç”¨çš„æ²»ç™‚é¸æ“‡ï¼Œå°æ”¹å–„TTSçš„çµæœå…·æœ‰æ½›åœ¨çš„æ‡‰ç”¨åƒ¹å€¼ã€‚",
    "fb_post": "æ ¹æ“šã€ŠInternational immunopharmacologyã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿå¿ƒè‡Ÿä¹Ÿæœƒå› ç‚ºå£“åŠ›è€Œå—å‚·ï¼æœ€è¿‘æœ‰ä¸€é …æœ‰è¶£çš„ç ”ç©¶ï¼Œå°ˆé–€æ¢è¨ä¸€ç¨®å«åšTakotsuboç—‡å€™ç¾¤ï¼ˆTTSï¼‰çš„å¿ƒè‡Ÿç–¾ç—…ï¼Œé€™ç¨®ç—…é›–ç„¶çœ‹èµ·ä¾†æ²’é‚£éº¼åš´é‡ï¼Œä½†å…¶å¯¦å¯èƒ½æœƒå°ç”Ÿå‘½é€ æˆå¨è„…ã€‚ç ”ç©¶äººå“¡ç™¼ç¾ï¼ŒæŸäº›å¤©ç„¶ç‰©è³ªï¼Œåƒæ˜¯è˜¿è””ç¡«ç´ ï¼Œå¯èƒ½å°é€™ç¨®ç–¾ç—…æœ‰å¹«åŠ©ã€‚\n\nä»–å€‘ä½¿ç”¨å¤§é¼ å’Œå¿ƒè‚Œç´°èƒä¾†æ¨¡æ“¬é€™ç¨®å¿ƒè‡Ÿç—…çš„æƒ…æ³ï¼Œä¸¦ç”¨ä¸€ç¨®è—¥ç‰©ä¾†èª˜å°å¿ƒè‡Ÿå—æï¼Œæ¥è‘—è§€å¯Ÿè˜¿è””ç¡«ç´ çš„æ•ˆæœã€‚çµæœç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ ä¸åƒ…èƒ½æ¸›å°‘å¿ƒè‡Ÿçš„æå‚·ï¼Œé‚„èƒ½æ”¹å–„å¿ƒè‡Ÿçš„çµæ§‹å’ŒåŠŸèƒ½ï¼\n\né€™é …ç ”ç©¶çš„å¹¾å€‹é‡é»åŒ…æ‹¬ï¼š\n1. è˜¿è””ç¡«ç´ æœ‰åŠ©æ–¼æ¸›è¼•å¿ƒè‡Ÿæå‚·ã€‚\n2. å®ƒå¯ä»¥æ¿€æ´»èº«é«”çš„å¤©ç„¶é˜²ç¦¦æ©Ÿåˆ¶ï¼Œå°æŠ—æ°§åŒ–å£“åŠ›ã€‚\n3. ç ”ç©¶é¡¯ç¤ºï¼Œè‹¥æŠ‘åˆ¶é€™å€‹é˜²ç¦¦æ©Ÿåˆ¶ï¼Œè˜¿è””ç¡«ç´ çš„æ•ˆæœæœƒå—åˆ°å½±éŸ¿ï¼Œé€™æ„å‘³è‘—å®ƒåœ¨æ²»ç™‚ä¸­å¯èƒ½æ‰®æ¼”é‡è¦è§’è‰²ã€‚\n\né€™äº›ç™¼ç¾è®“æˆ‘å€‘å°æœªä¾†çš„å¿ƒè‡Ÿå¥åº·æ²»ç™‚å……æ»¿æœŸå¾…ï¼",
    "image_prompt": "Create a simple and informative illustration that explains the experimental method and main findings of a study on Takotsubo syndrome (TTS) and sulforaphane. The image should have a flat design style with a white or light-colored background and soft colors. Include symbolic representations of broccoli or sulforaphane, simplified graphics of experimental subjects (like humans, animals, or cells), arrows or flow lines to indicate the experimental steps, and a section clearly labeled 'Main Findings' that highlights protective effects or changes observed.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "Takotsuboç—‡å€™ç¾¤ Takotsubo Syndrome",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41108925/"
  },
  {
    "id": "41352012",
    "title_en": "Protection against deoxynivalenol (DON)-induced intestinal injury by sulforaphane via modulation of lysosomal function.",
    "pub_date": "2025 Dec",
    "journal": "Journal of hazardous materials",
    "abstract_en": "Deoxynivalenol (DON) is a prevalent mycotoxin commonly detected in both human and animal diets, representing a significant health risk. Sulforaphane (SFN), a bioactive compound from cruciferous vegetables known for its antioxidant. This study aimed to confirm SFN's protective effect against DON-induced intestinal injury and clarify its underlying molecular mechanism. In vivo, C57BL/6 male mice (nâ€¯=â€¯8/group) were treated with DON (2â€¯mg/kg BW) and SFN (10â€¯mg/kg BW) to assess the overall protective effects of SFN; in vitro, intestinal porcine epithelial cells (IPEC-J2) and pig intestinal organoids were treated with DON (1â€¯Î¼g/mL) and SFN (2â€¯Î¼M) to investigate the protective mechanism of SFN. Hematoxylin-eosin staining, western blot and flow cytometry were used to confirm the protective effects of SFN. RNA-seq, CETSA, ITDRF and non-targeted metabolomics was employed to investigate the mechanism of SFN supplementation. This study demonstrated that SFN significantly alleviated DON-induced intestinal toxicity: in vivo, SFN restored jejunal villus height/crypt depth and restored the balance of redox homeostasis (decreased MDA, LDH, SOD and CAT); in vitro, SFN lowered DON-induced cell apoptosis and ROS accumulation. Mechanistically, lysosomal function was critical for SFN's protection-SFN directly targeted ATP6AP1 to enhance lysosomal acidification Moreover, ATP supplementation further potentiated this acidification and SFN's cytoprotective effect. This study identified ATP6AP1-mediated lysosomal acidification as a novel mechanism for SFN to mitigate DON-induced intestinal injury. Therefore, investigating the crosstalk between the SFN-ATP6AP1 axis and gut microbiota warrants further investigation to elucidate a broader protective mechanism.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›æœ‰é—œå¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°ç”±æ–¼é£Ÿç‰©ä¸­å¸¸è¦‹çš„çœŸèŒæ¯’ç´ ï¼ˆå¦‚å»æ°§å°¼ç“¦çƒ¯é†‡ï¼Œç°¡ç¨±DONï¼‰æ‰€å¼•èµ·çš„è…¸é“æå‚·ã€‚é€™ç¨®æ¯’ç´ åœ¨æˆ‘å€‘çš„é£²é£Ÿä¸­ç›¸ç•¶æ™®éï¼Œå°äººé¡å’Œå‹•ç‰©çš„å¥åº·éƒ½æ§‹æˆäº†é‡å¤§é¢¨éšªã€‚ç ”ç©¶é¡¯ç¤ºï¼Œä¾†è‡ªåå­—èŠ±ç§‘è”¬èœçš„è˜¿è””ç¡«ç´ å¯èƒ½å°æŠ—é€™ç¨®æ¯’ç´ çš„å½±éŸ¿ï¼Œé€™å°æ–¼æ”¹å–„è…¸é“å¥åº·å’Œé é˜²ç›¸é—œç–¾ç—…æœ‰æ½›åœ¨çš„æ„ç¾©ã€‚é€éé€²ä¸€æ­¥äº†è§£è˜¿è””ç¡«ç´ çš„ä¿è­·æ©Ÿåˆ¶ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ‰¾åˆ°æ›´æœ‰æ•ˆçš„é é˜²ç­–ç•¥ï¼Œå¹«åŠ©æ¸›å°‘ç”±é£²é£Ÿå¼•èµ·çš„å¥åº·å•é¡Œã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°å»æ°§å°¼ç“¦çƒ¯é†‡å¼•èµ·çš„è…¸é“æå‚·çš„ä¿è­·æ•ˆæœã€‚ç ”ç©¶è€…å¸Œæœ›ç¢ºèªè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æœ‰æ•ˆæ¸›è¼•é€™ç¨®æ¯’ç´ å°è…¸é“çš„å‚·å®³ï¼Œä¸¦é€²ä¸€æ­¥äº†è§£å…¶èƒŒå¾Œçš„åˆ†å­æ©Ÿåˆ¶ã€‚ç”±æ–¼å»æ°§å°¼ç“¦çƒ¯é†‡åœ¨è¨±å¤šé£Ÿç‰©ä¸­éƒ½å¯èƒ½å­˜åœ¨ï¼Œå› æ­¤é€™é …ç ”ç©¶çš„çµæœå°æ–¼æå‡æˆ‘å€‘å°é£²é£Ÿå®‰å…¨çš„èªè­˜å…·æœ‰é‡è¦æ„ç¾©ã€‚",
    "para3": "å¯¦é©—ä¸­ä½¿ç”¨äº†å°é¼ å’Œè±¬è…¸é“ç´°èƒä½œç‚ºç ”ç©¶å°è±¡ã€‚åœ¨å°é¼ å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å°‡C57BL/6å‹é›„æ€§å°é¼ åˆ†æˆå…©çµ„ï¼Œåˆ†åˆ¥çµ¦äºˆå»æ°§å°¼ç“¦çƒ¯é†‡å’Œè˜¿è””ç¡«ç´ ï¼Œä»¥è©•ä¼°è˜¿è””ç¡«ç´ çš„ä¿è­·æ•ˆæœã€‚åœ¨é«”å¤–å¯¦é©—ä¸­ï¼Œå‰‡ä½¿ç”¨è±¬è…¸é“ä¸Šçš®ç´°èƒå’Œè…¸é“é¡å™¨å®˜ï¼Œè§€å¯Ÿè˜¿è””ç¡«ç´ å°å»æ°§å°¼ç“¦çƒ¯é†‡çš„å½±éŸ¿ã€‚ç ”ç©¶è€…ä½¿ç”¨äº†å¤šç¨®æŠ€è¡“ï¼ŒåŒ…æ‹¬çµ„ç¹”æŸ“è‰²ã€è›‹ç™½è³ªæª¢æ¸¬å’Œç´°èƒåˆ†æï¼Œä»¥ç¢ºèªè˜¿è””ç¡«ç´ çš„ä¿è­·ä½œç”¨åŠå…¶æ©Ÿåˆ¶ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ¸›è¼•å»æ°§å°¼ç“¦çƒ¯é†‡å¼•èµ·çš„è…¸é“æ¯’æ€§ã€‚åœ¨å°é¼ å¯¦é©—ä¸­ï¼Œè˜¿è””ç¡«ç´ æ¢å¾©äº†è…¸é“çµ¨æ¯›çš„é«˜åº¦å’Œè…ºé«”çš„æ·±åº¦ï¼Œä¸¦æ”¹å–„äº†æ°§åŒ–é‚„åŸå¹³è¡¡ã€‚åœ¨é«”å¤–å¯¦é©—ä¸­ï¼Œè˜¿è””ç¡«ç´ æ¸›å°‘äº†å»æ°§å°¼ç“¦çƒ¯é†‡å¼•èµ·çš„ç´°èƒå‡‹äº¡å’Œæ´»æ€§æ°§çš„ç©ç´¯ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ çš„ä¿è­·ä½œç”¨èˆ‡å…¶å°æº¶é…¶é«”åŠŸèƒ½çš„å½±éŸ¿æœ‰é—œï¼Œä¸¦ä¸”é€šéå¢å¼·ATP6AP1çš„é…¸åŒ–ä½œç”¨ä¾†ç™¼æ®æ•ˆæœã€‚é€™äº›çµæœç‚ºè˜¿è””ç¡«ç´ åœ¨è…¸é“å¥åº·æ–¹é¢çš„æ½›åœ¨æ‡‰ç”¨æä¾›äº†æ–°çš„è¦‹è§£ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›æœ‰é—œå¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°ç”±æ–¼é£Ÿç‰©ä¸­å¸¸è¦‹çš„çœŸèŒæ¯’ç´ ï¼ˆå¦‚å»æ°§å°¼ç“¦çƒ¯é†‡ï¼Œç°¡ç¨±DONï¼‰æ‰€å¼•èµ·çš„è…¸é“æå‚·ã€‚é€™ç¨®æ¯’ç´ åœ¨æˆ‘å€‘çš„é£²é£Ÿä¸­ç›¸ç•¶æ™®éï¼Œå°äººé¡å’Œå‹•ç‰©çš„å¥åº·éƒ½æ§‹æˆäº†é‡å¤§é¢¨éšªã€‚ç ”ç©¶é¡¯ç¤ºï¼Œä¾†è‡ªåå­—èŠ±ç§‘è”¬èœçš„è˜¿è””ç¡«ç´ å¯èƒ½å°æŠ—é€™ç¨®æ¯’ç´ çš„å½±éŸ¿ï¼Œé€™å°æ–¼æ”¹å–„è…¸é“å¥åº·å’Œé é˜²ç›¸é—œç–¾ç—…æœ‰æ½›åœ¨çš„æ„ç¾©ã€‚é€éé€²ä¸€æ­¥äº†è§£è˜¿è””ç¡«ç´ çš„ä¿è­·æ©Ÿåˆ¶ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ‰¾åˆ°æ›´æœ‰æ•ˆçš„é é˜²ç­–ç•¥ï¼Œå¹«åŠ©æ¸›å°‘ç”±é£²é£Ÿå¼•èµ·çš„å¥åº·å•é¡Œã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°å»æ°§å°¼ç“¦çƒ¯é†‡å¼•èµ·çš„è…¸é“æå‚·çš„ä¿è­·æ•ˆæœã€‚ç ”ç©¶è€…å¸Œæœ›ç¢ºèªè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æœ‰æ•ˆæ¸›è¼•é€™ç¨®æ¯’ç´ å°è…¸é“çš„å‚·å®³ï¼Œä¸¦é€²ä¸€æ­¥äº†è§£å…¶èƒŒå¾Œçš„åˆ†å­æ©Ÿåˆ¶ã€‚ç”±æ–¼å»æ°§å°¼ç“¦çƒ¯é†‡åœ¨è¨±å¤šé£Ÿç‰©ä¸­éƒ½å¯èƒ½å­˜åœ¨ï¼Œå› æ­¤é€™é …ç ”ç©¶çš„çµæœå°æ–¼æå‡æˆ‘å€‘å°é£²é£Ÿå®‰å…¨çš„èªè­˜å…·æœ‰é‡è¦æ„ç¾©ã€‚\n\nå¯¦é©—ä¸­ä½¿ç”¨äº†å°é¼ å’Œè±¬è…¸é“ç´°èƒä½œç‚ºç ”ç©¶å°è±¡ã€‚åœ¨å°é¼ å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å°‡C57BL/6å‹é›„æ€§å°é¼ åˆ†æˆå…©çµ„ï¼Œåˆ†åˆ¥çµ¦äºˆå»æ°§å°¼ç“¦çƒ¯é†‡å’Œè˜¿è””ç¡«ç´ ï¼Œä»¥è©•ä¼°è˜¿è””ç¡«ç´ çš„ä¿è­·æ•ˆæœã€‚åœ¨é«”å¤–å¯¦é©—ä¸­ï¼Œå‰‡ä½¿ç”¨è±¬è…¸é“ä¸Šçš®ç´°èƒå’Œè…¸é“é¡å™¨å®˜ï¼Œè§€å¯Ÿè˜¿è””ç¡«ç´ å°å»æ°§å°¼ç“¦çƒ¯é†‡çš„å½±éŸ¿ã€‚ç ”ç©¶è€…ä½¿ç”¨äº†å¤šç¨®æŠ€è¡“ï¼ŒåŒ…æ‹¬çµ„ç¹”æŸ“è‰²ã€è›‹ç™½è³ªæª¢æ¸¬å’Œç´°èƒåˆ†æï¼Œä»¥ç¢ºèªè˜¿è””ç¡«ç´ çš„ä¿è­·ä½œç”¨åŠå…¶æ©Ÿåˆ¶ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ¸›è¼•å»æ°§å°¼ç“¦çƒ¯é†‡å¼•èµ·çš„è…¸é“æ¯’æ€§ã€‚åœ¨å°é¼ å¯¦é©—ä¸­ï¼Œè˜¿è””ç¡«ç´ æ¢å¾©äº†è…¸é“çµ¨æ¯›çš„é«˜åº¦å’Œè…ºé«”çš„æ·±åº¦ï¼Œä¸¦æ”¹å–„äº†æ°§åŒ–é‚„åŸå¹³è¡¡ã€‚åœ¨é«”å¤–å¯¦é©—ä¸­ï¼Œè˜¿è””ç¡«ç´ æ¸›å°‘äº†å»æ°§å°¼ç“¦çƒ¯é†‡å¼•èµ·çš„ç´°èƒå‡‹äº¡å’Œæ´»æ€§æ°§çš„ç©ç´¯ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ çš„ä¿è­·ä½œç”¨èˆ‡å…¶å°æº¶é…¶é«”åŠŸèƒ½çš„å½±éŸ¿æœ‰é—œï¼Œä¸¦ä¸”é€šéå¢å¼·ATP6AP1çš„é…¸åŒ–ä½œç”¨ä¾†ç™¼æ®æ•ˆæœã€‚é€™äº›çµæœç‚ºè˜¿è””ç¡«ç´ åœ¨è…¸é“å¥åº·æ–¹é¢çš„æ½›åœ¨æ‡‰ç”¨æä¾›äº†æ–°çš„è¦‹è§£ã€‚",
    "fb_post": "æ ¹æ“šã€ŠJournal of hazardous materialsã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ½ï¸ä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘æ—¥å¸¸åƒçš„æŸäº›é£Ÿç‰©è£¡ï¼Œå¯èƒ½è—è‘—å°è…¸é“å¥åº·çš„å¨è„…ï¼é€™ç¯‡ç ”ç©¶æ­ç¤ºäº†è˜¿è””ç¡«ç´ çš„æ½›åŠ›ï¼Œé€™æ˜¯ä¸€ç¨®ä¾†è‡ªé’èŠ±èœç­‰åå­—èŠ±ç§‘è”¬èœçš„å¤©ç„¶ç‰©è³ªï¼Œèƒ½å¹«åŠ©æˆ‘å€‘å°æŠ—ä¸€ç¨®å«åšå»æ°§å°¼ç“¦çƒ¯é†‡ï¼ˆDONï¼‰çš„çœŸèŒæ¯’ç´ ã€‚é€™ç¨®æ¯’ç´ åœ¨å¾ˆå¤šé£Ÿç‰©ä¸­éƒ½å¯èƒ½å‡ºç¾ï¼Œå°æˆ‘å€‘çš„è…¸é“å¥åº·é€ æˆæå®³ã€‚  \n  \nç ”ç©¶åœ˜éšŠä½¿ç”¨å°é¼ å’Œè±¬è…¸é“ç´°èƒé€²è¡Œå¯¦é©—ï¼Œè§€å¯Ÿè˜¿è””ç¡«ç´ å°å»æ°§å°¼ç“¦çƒ¯é†‡çš„å½±éŸ¿ã€‚ä»–å€‘ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ¸›è¼•æ¯’ç´ å¼•èµ·çš„è…¸é“æå‚·ï¼Œä¸¦æ”¹å–„ç´°èƒçš„å¥åº·ç‹€æ…‹ã€‚é€™æ„å‘³è‘—ï¼Œé€éé€²ä¸€æ­¥äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ‰¾åˆ°æ›´å¥½çš„é£²é£Ÿå®‰å…¨ç­–ç•¥ï¼  \n  \nğŸ”é‡é»æ•´ç†ï¼š  \n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼å°æŠ—é£Ÿç‰©ä¸­çš„çœŸèŒæ¯’ç´ ã€‚  \n2. ç ”ç©¶ç™¼ç¾è˜¿è””ç¡«ç´ èƒ½æ”¹å–„è…¸é“å¥åº·ã€‚  \n3. é€²ä¸€æ­¥çš„ç ”ç©¶æˆ–è¨±èƒ½å¹«åŠ©æˆ‘å€‘æå‡é£²é£Ÿå®‰å…¨ï¼",
    "image_prompt": "Create a flat design infographic on the protective effects of sulforaphane against deoxynivalenol (DON) induced intestinal damage. Include symbols for broccoli or sulforaphane, simplified illustrations of experimental subjects like mice and intestinal cells, arrows or flow lines showing the experimental steps, and a section highlighting the main results such as protective effects and changes observed in the intestines.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "è…¸é“æå‚· Intestinal Injury",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41352012/"
  },
  {
    "id": "41341174",
    "title_en": "Sulforaphane attenuates oxidative stress, senescence, and ferroptosis induced by cigarette smoke extract <i>in vitro</i> and <i>in vivo via</i> upregulating the expression of SIRT1.",
    "pub_date": "2025 Dec",
    "journal": "Research in pharmaceutical sciences",
    "abstract_en": "Cigarette smoking induces lung toxicity by triggering oxidative stress, leading to apoptosis, ferroptosis, and senescence. Sulforaphane (SFN), a potent antioxidant, activates the SIRT1 pathway, enhancing cellular stress resistance and survival. This study aimed to evaluate the protective effects of SFN against cigarette smoke extract (CSE)-induced damage in human airway epithelial cells (BEAS-2B) and in mouse lungs, focusing on its role in upregulating SIRT1 expression. BEAS-2B cells were treated with CSE and SFN, and cell viability was assessed using the MTT assay. Cellular senescence was assessed using the SA-Î²-gal assay and the expression of genes associated with senescence (p16 and p21). The expression levels of SIRT1, senescence-associated secretory phenotype (SASP) cytokines (IL-1Î², IL-6, IL-8, TNF-Î±), GPX4, and SLC7A11 were quantified using qRT-PCR. Additionally, ROS production, GSH and MDA levels, and iron content were measured. An emphysema mouse model was induced by intraperitoneal administration of CSE (7.2 mg/kg) alone or in combination with SFN (10.2 mg/kg) over 28 days, and subsequent histopathological changes were evaluated. Our findings revealed that SFN co-treatment effectively mitigated CSE-induced cytotoxicity, senescence, and SASP cytokine secretion, as well as the pronounced emphysematous changes in lung tissues. Furthermore, SFN reversed CSE-induced downregulation of SIRT1 and upregulation of NF-ÎºB. Notably, SFN also inhibited CSE-induced ferroptosis by increasing GPX4 and SLC7A11 expression while reducing iron and MDA levels. The findings of the present study demonstrated that sulforaphane offers protective effects against CSE-induced toxicity by mitigating oxidative stress, ferroptosis, and cellular senescence.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨å¸ç…™å°è‚ºéƒ¨é€ æˆçš„å‚·å®³æ–¹é¢ã€‚å¸ç…™æœƒå¼•ç™¼æ°§åŒ–å£“åŠ›ï¼Œå°è‡´ç´°èƒæ­»äº¡å’Œè€åŒ–ï¼Œè€Œè˜¿è””ç¡«ç´ ä½œç‚ºä¸€ç¨®å¼·æ•ˆæŠ—æ°§åŒ–åŠ‘ï¼Œå¯èƒ½æœ‰åŠ©æ–¼ä¿è­·ç´°èƒå…å—é€™äº›æå®³ã€‚é€™æ„å‘³è‘—ï¼Œé€éå¢åŠ è˜¿è””ç¡«ç´ çš„æ”å–ï¼Œæˆ–è¨±èƒ½æ¸›å°‘å¸ç…™æ‰€å¸¶ä¾†çš„è‚ºéƒ¨æ¯’æ€§ï¼Œå¾è€Œå°å¥åº·ç”¢ç”Ÿæ­£é¢å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯å°æ–¼å¸ç…™è€…æˆ–é•·æœŸæš´éœ²æ–¼ç…™éœ§ä¸­çš„äººç¾¤ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°æ–¼å¸ç…™å¼•èµ·çš„è‚ºéƒ¨æå‚·çš„ä¿è­·ä½œç”¨ã€‚ç ”ç©¶è€…é—œæ³¨çš„æ˜¯å¸ç…™æå–ç‰©å°äººé¡æ°£é“ä¸Šçš®ç´°èƒåŠå°é¼ è‚ºéƒ¨çš„å½±éŸ¿ï¼Œä¸¦ç‰¹åˆ¥åˆ†æè˜¿è””ç¡«ç´ å¦‚ä½•èª¿ç¯€SIRT1çš„è¡¨é”ã€‚é€™é …ç ”ç©¶ä¸åƒ…æ¶‰åŠç´°èƒå±¤é¢çš„å¯¦é©—ï¼Œé‚„åŒ…æ‹¬å‹•ç‰©æ¨¡å‹ï¼Œä»¥æ›´å…¨é¢åœ°äº†è§£è˜¿è””ç¡«ç´ çš„æ½›åœ¨ç›Šè™•ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†BEAS-2Bäººé¡æ°£é“ä¸Šçš®ç´°èƒï¼Œé€™äº›ç´°èƒè¢«è™•ç†äº†å¸ç…™æå–ç‰©å’Œè˜¿è””ç¡«ç´ ï¼Œä¸¦é€šéMTTæ¸¬è©¦ä¾†è©•ä¼°ç´°èƒçš„å­˜æ´»ç‡ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„ä½¿ç”¨SA-Î²-galæ¸¬è©¦ä¾†è©•ä¼°ç´°èƒçš„è€åŒ–æƒ…æ³ï¼Œä¸¦é‡æ¸¬èˆ‡è€åŒ–ç›¸é—œçš„åŸºå› è¡¨é”ã€‚å°æ–¼å°é¼ æ¨¡å‹ï¼Œç ”ç©¶è€…é€éè…¹è…”æ³¨å°„å¸ç…™æå–ç‰©å’Œè˜¿è””ç¡«ç´ ï¼ŒæŒçºŒ28å¤©ä¾†è§€å¯Ÿè‚ºéƒ¨çš„çµ„ç¹”è®ŠåŒ–ï¼Œé€™æ¨£çš„è¨­è¨ˆä½¿å¾—ç ”ç©¶çµæœæ›´å…·èªªæœåŠ›ã€‚",
    "para4": "ä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ çš„å…±åŒè™•ç†æœ‰æ•ˆæ¸›å°‘äº†å¸ç…™æå–ç‰©å¼•èµ·çš„ç´°èƒæ¯’æ€§ã€è€åŒ–åŠç›¸é—œç´°èƒå› å­çš„åˆ†æ³Œï¼Œä¸¦æ”¹å–„äº†å°é¼ è‚ºéƒ¨çš„è‚ºæ°£è…«è®ŠåŒ–ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½é€†è½‰å¸ç…™æå–ç‰©å°SIRT1çš„ä¸‹èª¿å’ŒNF-ÎºBçš„ä¸Šèª¿ï¼Œä¸¦é€éæé«˜GPX4å’ŒSLC7A11çš„è¡¨é”ä¾†æŠ‘åˆ¶å¸ç…™å¼•èµ·çš„éµæ­»äº¡ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ åœ¨æ¸›è¼•æ°§åŒ–å£“åŠ›ã€éµæ­»äº¡å’Œç´°èƒè€åŒ–æ–¹é¢å…·æœ‰æ½›åœ¨çš„ä¿è­·ä½œç”¨ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨å¸ç…™å°è‚ºéƒ¨é€ æˆçš„å‚·å®³æ–¹é¢ã€‚å¸ç…™æœƒå¼•ç™¼æ°§åŒ–å£“åŠ›ï¼Œå°è‡´ç´°èƒæ­»äº¡å’Œè€åŒ–ï¼Œè€Œè˜¿è””ç¡«ç´ ä½œç‚ºä¸€ç¨®å¼·æ•ˆæŠ—æ°§åŒ–åŠ‘ï¼Œå¯èƒ½æœ‰åŠ©æ–¼ä¿è­·ç´°èƒå…å—é€™äº›æå®³ã€‚é€™æ„å‘³è‘—ï¼Œé€éå¢åŠ è˜¿è””ç¡«ç´ çš„æ”å–ï¼Œæˆ–è¨±èƒ½æ¸›å°‘å¸ç…™æ‰€å¸¶ä¾†çš„è‚ºéƒ¨æ¯’æ€§ï¼Œå¾è€Œå°å¥åº·ç”¢ç”Ÿæ­£é¢å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯å°æ–¼å¸ç…™è€…æˆ–é•·æœŸæš´éœ²æ–¼ç…™éœ§ä¸­çš„äººç¾¤ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°æ–¼å¸ç…™å¼•èµ·çš„è‚ºéƒ¨æå‚·çš„ä¿è­·ä½œç”¨ã€‚ç ”ç©¶è€…é—œæ³¨çš„æ˜¯å¸ç…™æå–ç‰©å°äººé¡æ°£é“ä¸Šçš®ç´°èƒåŠå°é¼ è‚ºéƒ¨çš„å½±éŸ¿ï¼Œä¸¦ç‰¹åˆ¥åˆ†æè˜¿è””ç¡«ç´ å¦‚ä½•èª¿ç¯€SIRT1çš„è¡¨é”ã€‚é€™é …ç ”ç©¶ä¸åƒ…æ¶‰åŠç´°èƒå±¤é¢çš„å¯¦é©—ï¼Œé‚„åŒ…æ‹¬å‹•ç‰©æ¨¡å‹ï¼Œä»¥æ›´å…¨é¢åœ°äº†è§£è˜¿è””ç¡«ç´ çš„æ½›åœ¨ç›Šè™•ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†BEAS-2Bäººé¡æ°£é“ä¸Šçš®ç´°èƒï¼Œé€™äº›ç´°èƒè¢«è™•ç†äº†å¸ç…™æå–ç‰©å’Œè˜¿è””ç¡«ç´ ï¼Œä¸¦é€šéMTTæ¸¬è©¦ä¾†è©•ä¼°ç´°èƒçš„å­˜æ´»ç‡ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„ä½¿ç”¨SA-Î²-galæ¸¬è©¦ä¾†è©•ä¼°ç´°èƒçš„è€åŒ–æƒ…æ³ï¼Œä¸¦é‡æ¸¬èˆ‡è€åŒ–ç›¸é—œçš„åŸºå› è¡¨é”ã€‚å°æ–¼å°é¼ æ¨¡å‹ï¼Œç ”ç©¶è€…é€éè…¹è…”æ³¨å°„å¸ç…™æå–ç‰©å’Œè˜¿è””ç¡«ç´ ï¼ŒæŒçºŒ28å¤©ä¾†è§€å¯Ÿè‚ºéƒ¨çš„çµ„ç¹”è®ŠåŒ–ï¼Œé€™æ¨£çš„è¨­è¨ˆä½¿å¾—ç ”ç©¶çµæœæ›´å…·èªªæœåŠ›ã€‚\n\nä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ çš„å…±åŒè™•ç†æœ‰æ•ˆæ¸›å°‘äº†å¸ç…™æå–ç‰©å¼•èµ·çš„ç´°èƒæ¯’æ€§ã€è€åŒ–åŠç›¸é—œç´°èƒå› å­çš„åˆ†æ³Œï¼Œä¸¦æ”¹å–„äº†å°é¼ è‚ºéƒ¨çš„è‚ºæ°£è…«è®ŠåŒ–ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½é€†è½‰å¸ç…™æå–ç‰©å°SIRT1çš„ä¸‹èª¿å’ŒNF-ÎºBçš„ä¸Šèª¿ï¼Œä¸¦é€éæé«˜GPX4å’ŒSLC7A11çš„è¡¨é”ä¾†æŠ‘åˆ¶å¸ç…™å¼•èµ·çš„éµæ­»äº¡ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ åœ¨æ¸›è¼•æ°§åŒ–å£“åŠ›ã€éµæ­»äº¡å’Œç´°èƒè€åŒ–æ–¹é¢å…·æœ‰æ½›åœ¨çš„ä¿è­·ä½œç”¨ã€‚",
    "fb_post": "æ ¹æ“šã€ŠResearch in pharmaceutical sciencesã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± è½èªªè˜¿è””ç¡«ç´ å¯ä»¥å¹«åŠ©æˆ‘å€‘å°æŠ—å¸ç…™å¸¶ä¾†çš„è‚ºéƒ¨å‚·å®³ï¼Ÿé€™å¯ä¸æ˜¯é–‹ç©ç¬‘çš„å“¦ï¼\n\næœ€è¿‘æœ‰ä¸€é …ç ”ç©¶å°ˆé–€æ¢è¨äº†è˜¿è””ç¡«ç´ å°å¸ç…™å¼•èµ·çš„è‚ºéƒ¨æå‚·çš„ä¿è­·ä½œç”¨ã€‚ç ”ç©¶è€…å€‘ç”¨å¸ç…™æå–ç‰©ä¾†æ¨¡æ“¬å¸ç…™å°è‚ºéƒ¨çš„å½±éŸ¿ï¼Œç„¶å¾Œè§€å¯Ÿè˜¿è””ç¡«ç´ çš„æ•ˆæœã€‚ä»–å€‘åœ¨å¯¦é©—ä¸­ä½¿ç”¨äº†äººé¡æ°£é“ç´°èƒå’Œå°é¼ ï¼Œä¾†çœ‹çœ‹è˜¿è””ç¡«ç´ æ€éº¼å¹«åŠ©æˆ‘å€‘çš„ç´°èƒæŠµæŠ—å‚·å®³ã€‚\n\nå¯¦é©—çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆæ¸›å°‘å¸ç…™å¼•èµ·çš„ç´°èƒæ¯’æ€§å’Œè€åŒ–ï¼Œé‚„èƒ½æ”¹å–„å°é¼ çš„è‚ºéƒ¨ç‹€æ³ï¼é€™çœŸæ˜¯å€‹å¥½æ¶ˆæ¯ï¼Œå°¤å…¶æ˜¯å°æ–¼å¸ç…™è€…æˆ–é•·æœŸæ¥è§¸ç…™éœ§çš„äººä¾†èªªã€‚\n\nğŸ” ä¸»è¦ç™¼ç¾ï¼š\n1. è˜¿è””ç¡«ç´ èƒ½æ¸›å°‘ç´°èƒå‚·å®³å’Œè€åŒ–ã€‚\n2. æœ‰åŠ©æ–¼æ”¹å–„è‚ºéƒ¨å¥åº·ã€‚\n3. å¯èƒ½é€éèª¿ç¯€ä¸€äº›é—œéµè›‹ç™½è³ªä¾†ç™¼æ®ä¿è­·ä½œç”¨ã€‚\n\nä¸éï¼Œè¨˜å¾—é€™äº›çµæœé‚„éœ€é€²ä¸€æ­¥ç ”ç©¶ä¾†ç¢ºèªï¼Œä¿æŒå¥åº·çš„ç”Ÿæ´»æ–¹å¼æ‰æ˜¯æœ€é‡è¦çš„ï¼",
    "image_prompt": "Create an infographic that explains the experimental methods and main results of a study on the protective effects of sulforaphane against smoking-induced lung damage. The style should be flat design with a white or light-colored background and soft color palette. Include symbols representing broccoli or sulforaphane, simplified illustrations of human, animal, and cell subjects. Use arrows or flow lines to show the experimental steps. Include a section labeled 'Main Results' highlighting protective effects and changes observed.",
    "is_human_study": true,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "è‚ºæ°£è…« Emphysema",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41341174/"
  },
  {
    "id": "41039785",
    "title_en": "Integrative Network Pharmacology and Proteomics Decipher the Immunomodulatory Mechanism of Sulforaphane Against Intrinsic Skin Aging.",
    "pub_date": "2025 Dec",
    "journal": "Molecular nutrition & food research",
    "abstract_en": "Skin aging is characterized by declines in structural functions, contributing to age-associated frailty. Sulforaphane (SFN), a natural anti-inflammatory substance, has been widely applied in multiple types of cancer therapies. However, its role in alleviating intrinsic skin aging remains to be elucidated. Integrative network pharmacology and proteomics were utilized to investigate the underlying mechanisms of SFN in intrinsic skin aging. Fifty-one anti-aging targets of SFN were identified, highlighting its promising regulatory impact on the aging process. Based on an 18-month-old natural aging mouse model, significant alleviation in skin structure, redox homeostasis, and immune cell composition was noted after 2 months of SFN supplementation. Additionally, proteomic analysis demonstrated that SFN reversed the proteomic profile of intrinsic skin aging, with 233 differentially expressed proteins (DEPs) identified in SFN-fed aging mice. Of note, the up-regulated DEPs were highly enriched in the apelin signaling pathway (pÂ =Â 0.010). Furthermore, immune cell infiltration and whole blood cell analysis revealed that SFN rescued T cells depletion in dermal tissue, which was strongly correlated with DEPs enriched in the SFN-activated apelin signaling pathway. SFN improves skin morphology and immune functions via activating the apelin signaling pathway, suggesting new prime targets in counteracting intrinsic skin aging.",
    "para1": "éš¨è‘—å¹´é½¡å¢é•·ï¼Œçš®è†šè€åŒ–æœƒå½±éŸ¿æˆ‘å€‘çš„å¥åº·ï¼Œå°è‡´èº«é«”æ©Ÿèƒ½ä¸‹é™ï¼Œé€™å¯èƒ½æœƒå¢åŠ ç½¹æ‚£å„ç¨®ç–¾ç—…çš„é¢¨éšªã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ é€™ç¨®å¤©ç„¶çš„æŠ—ç™¼ç‚ç‰©è³ªï¼Œå¯èƒ½åœ¨å»¶ç·©çš®è†šè€åŒ–æ–¹é¢æœ‰æ½›åŠ›ã€‚é€™æ„å‘³è‘—ï¼Œå¦‚æœèƒ½æœ‰æ•ˆåˆ©ç”¨è˜¿è””ç¡«ç´ ï¼Œæˆ–è¨±èƒ½æ”¹å–„çš®è†šå¥åº·ï¼Œä¸¦æ¸›å°‘èˆ‡å¹´é½¡ç›¸é—œçš„å¥åº·å•é¡Œï¼Œé€™å°æ–¼å¸Œæœ›ä¿æŒå¹´è¼•è‚Œè†šçš„äººä¾†èªªï¼Œç„¡ç–‘æ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„æ–¹å‘ã€‚",
    "para2": "é€™é …ç ”ç©¶ä¸»è¦é—œæ³¨è˜¿è””ç¡«ç´ åœ¨å…§éƒ¨çš®è†šè€åŒ–éç¨‹ä¸­çš„ä½œç”¨ã€‚é›–ç„¶è˜¿è””ç¡«ç´ å·²ç¶“åœ¨å¤šç¨®ç™Œç—‡æ²»ç™‚ä¸­è¢«å»£æ³›æ‡‰ç”¨ï¼Œä½†å®ƒå°æ–¼çš®è†šè€åŒ–çš„å½±éŸ¿ä»ç„¶ä¸å¤ æ˜ç¢ºã€‚å› æ­¤ï¼Œç ”ç©¶è€…å¸Œæœ›é€éé€™é …ç ”ç©¶ï¼Œæ·±å…¥æ¢è¨è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿çš®è†šçš„çµæ§‹å’ŒåŠŸèƒ½ï¼Œä¸¦æ‰¾å‡ºå…¶èƒŒå¾Œçš„æ©Ÿåˆ¶ã€‚",
    "para3": "ç ”ç©¶ä¸­ä½¿ç”¨äº†ä¸€ç¨®18å€‹æœˆå¤§çš„è‡ªç„¶è€åŒ–å°é¼ æ¨¡å‹ï¼Œä¾†æ¨¡æ“¬çš®è†šè€åŒ–çš„éç¨‹ã€‚ç ”ç©¶è€…å°é€™äº›å°é¼ é€²è¡Œäº†è˜¿è””ç¡«ç´ çš„è£œå……ï¼Œä¸¦è§€å¯Ÿå…¶å°çš®è†šçµæ§‹ã€æ°§åŒ–é‚„åŸå¹³è¡¡åŠå…ç–«ç´°èƒçµ„æˆçš„å½±éŸ¿ã€‚é€éæ•´åˆç¶²çµ¡è—¥ç†å­¸å’Œè›‹ç™½è³ªçµ„å­¸çš„æ–¹æ³•ï¼Œç ”ç©¶è€…è­˜åˆ¥å‡º51å€‹èˆ‡æŠ—è€åŒ–ç›¸é—œçš„ç›®æ¨™ï¼Œä¸¦åˆ†æäº†è˜¿è””ç¡«ç´ å°é€™äº›ç›®æ¨™çš„èª¿æ§æ•ˆæœã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼Œç¶“éå…©å€‹æœˆçš„è˜¿è””ç¡«ç´ è£œå……å¾Œï¼Œå°é¼ çš„çš®è†šçµæ§‹å’Œå…ç–«åŠŸèƒ½æœ‰é¡¯è‘—æ”¹å–„ã€‚æ­¤å¤–ï¼Œè›‹ç™½è³ªçµ„å­¸åˆ†æç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ èƒ½é€†è½‰çš®è†šè€åŒ–çš„è›‹ç™½è³ªè¡¨ç¾å‹ï¼Œä¸¦è­˜åˆ¥å‡º233ç¨®å·®ç•°è¡¨é”çš„è›‹ç™½è³ªã€‚ç‰¹åˆ¥æ˜¯ï¼Œé€™äº›ä¸Šèª¿çš„è›‹ç™½è³ªåœ¨apelinä¿¡è™Ÿé€šè·¯ä¸­é«˜åº¦å¯Œé›†ï¼Œé¡¯ç¤ºè˜¿è””ç¡«ç´ å¯èƒ½é€éæ¿€æ´»é€™ä¸€ä¿¡è™Ÿé€šè·¯ä¾†æ”¹å–„çš®è†šå½¢æ…‹å’Œå…ç–«åŠŸèƒ½ï¼Œç‚ºå°æŠ—çš®è†šè€åŒ–æä¾›äº†æ–°çš„ç ”ç©¶æ–¹å‘ã€‚",
    "explanation_zh": "éš¨è‘—å¹´é½¡å¢é•·ï¼Œçš®è†šè€åŒ–æœƒå½±éŸ¿æˆ‘å€‘çš„å¥åº·ï¼Œå°è‡´èº«é«”æ©Ÿèƒ½ä¸‹é™ï¼Œé€™å¯èƒ½æœƒå¢åŠ ç½¹æ‚£å„ç¨®ç–¾ç—…çš„é¢¨éšªã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ é€™ç¨®å¤©ç„¶çš„æŠ—ç™¼ç‚ç‰©è³ªï¼Œå¯èƒ½åœ¨å»¶ç·©çš®è†šè€åŒ–æ–¹é¢æœ‰æ½›åŠ›ã€‚é€™æ„å‘³è‘—ï¼Œå¦‚æœèƒ½æœ‰æ•ˆåˆ©ç”¨è˜¿è””ç¡«ç´ ï¼Œæˆ–è¨±èƒ½æ”¹å–„çš®è†šå¥åº·ï¼Œä¸¦æ¸›å°‘èˆ‡å¹´é½¡ç›¸é—œçš„å¥åº·å•é¡Œï¼Œé€™å°æ–¼å¸Œæœ›ä¿æŒå¹´è¼•è‚Œè†šçš„äººä¾†èªªï¼Œç„¡ç–‘æ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„æ–¹å‘ã€‚\n\né€™é …ç ”ç©¶ä¸»è¦é—œæ³¨è˜¿è””ç¡«ç´ åœ¨å…§éƒ¨çš®è†šè€åŒ–éç¨‹ä¸­çš„ä½œç”¨ã€‚é›–ç„¶è˜¿è””ç¡«ç´ å·²ç¶“åœ¨å¤šç¨®ç™Œç—‡æ²»ç™‚ä¸­è¢«å»£æ³›æ‡‰ç”¨ï¼Œä½†å®ƒå°æ–¼çš®è†šè€åŒ–çš„å½±éŸ¿ä»ç„¶ä¸å¤ æ˜ç¢ºã€‚å› æ­¤ï¼Œç ”ç©¶è€…å¸Œæœ›é€éé€™é …ç ”ç©¶ï¼Œæ·±å…¥æ¢è¨è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿çš®è†šçš„çµæ§‹å’ŒåŠŸèƒ½ï¼Œä¸¦æ‰¾å‡ºå…¶èƒŒå¾Œçš„æ©Ÿåˆ¶ã€‚\n\nç ”ç©¶ä¸­ä½¿ç”¨äº†ä¸€ç¨®18å€‹æœˆå¤§çš„è‡ªç„¶è€åŒ–å°é¼ æ¨¡å‹ï¼Œä¾†æ¨¡æ“¬çš®è†šè€åŒ–çš„éç¨‹ã€‚ç ”ç©¶è€…å°é€™äº›å°é¼ é€²è¡Œäº†è˜¿è””ç¡«ç´ çš„è£œå……ï¼Œä¸¦è§€å¯Ÿå…¶å°çš®è†šçµæ§‹ã€æ°§åŒ–é‚„åŸå¹³è¡¡åŠå…ç–«ç´°èƒçµ„æˆçš„å½±éŸ¿ã€‚é€éæ•´åˆç¶²çµ¡è—¥ç†å­¸å’Œè›‹ç™½è³ªçµ„å­¸çš„æ–¹æ³•ï¼Œç ”ç©¶è€…è­˜åˆ¥å‡º51å€‹èˆ‡æŠ—è€åŒ–ç›¸é—œçš„ç›®æ¨™ï¼Œä¸¦åˆ†æäº†è˜¿è””ç¡«ç´ å°é€™äº›ç›®æ¨™çš„èª¿æ§æ•ˆæœã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œç¶“éå…©å€‹æœˆçš„è˜¿è””ç¡«ç´ è£œå……å¾Œï¼Œå°é¼ çš„çš®è†šçµæ§‹å’Œå…ç–«åŠŸèƒ½æœ‰é¡¯è‘—æ”¹å–„ã€‚æ­¤å¤–ï¼Œè›‹ç™½è³ªçµ„å­¸åˆ†æç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ èƒ½é€†è½‰çš®è†šè€åŒ–çš„è›‹ç™½è³ªè¡¨ç¾å‹ï¼Œä¸¦è­˜åˆ¥å‡º233ç¨®å·®ç•°è¡¨é”çš„è›‹ç™½è³ªã€‚ç‰¹åˆ¥æ˜¯ï¼Œé€™äº›ä¸Šèª¿çš„è›‹ç™½è³ªåœ¨apelinä¿¡è™Ÿé€šè·¯ä¸­é«˜åº¦å¯Œé›†ï¼Œé¡¯ç¤ºè˜¿è””ç¡«ç´ å¯èƒ½é€éæ¿€æ´»é€™ä¸€ä¿¡è™Ÿé€šè·¯ä¾†æ”¹å–„çš®è†šå½¢æ…‹å’Œå…ç–«åŠŸèƒ½ï¼Œç‚ºå°æŠ—çš®è†šè€åŒ–æä¾›äº†æ–°çš„ç ”ç©¶æ–¹å‘ã€‚",
    "fb_post": "æ ¹æ“šã€ŠMolecular nutrition & food researchã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿéš¨è‘—å¹´é½¡å¢é•·ï¼Œçš®è†šæœƒè®Šå¾—è¶Šä¾†è¶Šä¸å¦‚ä»¥å‰ï¼Œé€™å¯èƒ½æœƒå½±éŸ¿æˆ‘å€‘çš„å¥åº·ï¼Œç”šè‡³å¢åŠ ç½¹æ‚£ç–¾ç—…çš„é¢¨éšªã€‚ä¸éï¼Œæœ‰ä¸€ç¨®å¤©ç„¶çš„ç‰©è³ªå«åšè˜¿è””ç¡«ç´ ï¼Œæœ€è¿‘çš„ç ”ç©¶é¡¯ç¤ºå®ƒæˆ–è¨±èƒ½å¹«åŠ©æˆ‘å€‘å»¶ç·©çš®è†šè€åŒ–ï¼\n\né€™é …ç ”ç©¶å°ˆæ³¨æ–¼è˜¿è””ç¡«ç´ å°çš®è†šè€åŒ–çš„å½±éŸ¿ã€‚é›–ç„¶å®ƒåœ¨ç™Œç—‡æ²»ç™‚ä¸­å·²ç¶“æœ‰äº†ä¸å°‘æ‡‰ç”¨ï¼Œä½†å°æ–¼çš®è†šçš„å½±éŸ¿ä»ç„¶æœ‰å¾ˆå¤šæœªçŸ¥ã€‚ç ”ç©¶è€…å€‘ä½¿ç”¨äº†18å€‹æœˆå¤§çš„å°é¼ ä¾†æ¨¡æ“¬çš®è†šè€åŒ–ï¼Œä¸¦çµ¦å®ƒå€‘è£œå……è˜¿è””ç¡«ç´ ï¼Œè§€å¯Ÿçš®è†šçµæ§‹å’Œå…ç–«åŠŸèƒ½çš„è®ŠåŒ–ã€‚\n\nçµæœé¡¯ç¤ºï¼Œç¶“éå…©å€‹æœˆçš„è£œå……å¾Œï¼Œå°é¼ çš„çš®è†šçµæ§‹å’Œå…ç–«åŠŸèƒ½éƒ½æœ‰æ˜é¡¯æ”¹å–„ï¼æ›´æœ‰è¶£çš„æ˜¯ï¼Œè˜¿è””ç¡«ç´ ä¼¼ä¹èƒ½é€†è½‰çš®è†šè€åŒ–çš„æŸäº›è›‹ç™½è³ªè¡¨ç¾ï¼Œé‚„æ¿€æ´»äº†ä¸€æ¢èˆ‡çš®è†šå¥åº·æœ‰é—œçš„ä¿¡è™Ÿé€šè·¯ï¼Œé€™ç‚ºæˆ‘å€‘å°æŠ—çš®è†šè€åŒ–æä¾›äº†æ–°çš„æ€è·¯ã€‚\n\nç¸½çµä¸€ä¸‹ï¼š\n1. è˜¿è””ç¡«ç´ æˆ–è¨±èƒ½å¹«åŠ©å»¶ç·©çš®è†šè€åŒ–ã€‚\n2. ç ”ç©¶é¡¯ç¤ºå®ƒèƒ½æ”¹å–„çš®è†šçµæ§‹å’Œå…ç–«åŠŸèƒ½ã€‚\n3. æœ‰å¯èƒ½é€éæ¿€æ´»ç‰¹å®šä¿¡è™Ÿé€šè·¯ä¾†é”æˆé€™äº›æ•ˆæœã€‚\n\né€™æ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„æ–¹å‘ï¼Œè®“æˆ‘å€‘ä¸€èµ·æœŸå¾…æœªä¾†çš„ç ”ç©¶æˆæœå§ï¼",
    "image_prompt": "Create an infographic that explains the experiment and main results of a study on sulforaphane. Use a flat design style with a white or light-colored background and soft color palette. Include simple icons representing sulforaphane (like broccoli or radish), simplified illustrations of experimental subjects (like mice), arrows or flow lines showing the experimental steps, and a section labeled 'Main Results' highlighting protective effects and changes observed.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "çš®è†šè€åŒ– Skin Aging",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41039785/"
  },
  {
    "id": "41027171",
    "title_en": "Multi-omics analysis of gut-liver axis reveals the mechanism by which sulforaphane alleviates liver injury in Cyprinus carpio exposed to triphenyltin.",
    "pub_date": "2025 Dec",
    "journal": "Comparative biochemistry and physiology. Part D, Genomics & proteomics",
    "abstract_en": "This study investigates the protective effects of sulforaphane (SFN) against triphenyltin (TPT)-induced hepatotoxicity, immune dysfunction and gut microbiota dysbiosis in Cyprinus carpio. Cyprinus carpio were divided into three groups and exposed for 8Â weeks, including control, 10Â Î¼g/L TPT and 10Â Î¼g/L TPTÂ +Â 10Â mg/kg SFN group. This result showed that TPT exposure induced significantly (PÂ <Â 0.05) hepatotoxicity, evidenced by increasing hepatic total bile acid (TBA) and total cholesterol levels, while upregulating Hsp70/90 and downregulating lysozyme gene expression. SFN supplementation reduced TBA accumulation, normalized Hsp90 and lysozyme expression, mitigating TPT-induced lipid dysregulation and immunosuppression. Transcriptomic analysis revealed that TPT exposure activated lipid metabolism pathways (PPAR signaling and cholesterol metabolism), but suppressed immune-related pathways. SFN supplementation restored metabolic homeostasis by enriching glucose and amino acid metabolism pathways and activating AMPK signaling, while also modulating the expression of key genes (PLIN1, ME1, CPT1B). The microbiota composition were changed in SFNÂ +Â TPT, including the increased of beneficial Fusobacteriota and Cetobacterium, and the decreased of pathogenic Proteobacteria and Aeromonas. The gut transcriptome dysregulation were restored in SFNÂ +Â TPT by enhancing immune pathways in Toll-like/NOD-like receptors. The significant correlations linked were found in gut microbes (Kaistia, Vagococcus) to hepatic/intestinal gene expression in SFNÂ +Â TPT. Overall, these findings elucidate novel mechanisms underlying TPT-induced immunotoxicity in liver and intestine and demonstrate the protective role of SFN, providing a theoretical foundation for its application in toxicity mitigation strategies.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°è‚è‡Ÿæ¯’æ€§å’Œå…ç–«åŠŸèƒ½å¤±èª¿çš„å•é¡Œã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘ç”±ä¸‰è‹¯éŒ«å¼•èµ·çš„è‚è‡Ÿæå‚·å’Œå…ç–«ç³»çµ±çš„å•é¡Œï¼Œé€™å°æ–¼å°‹æ‰¾æ–°çš„ä¿è­·æ€§ç‡Ÿé¤Šç´ å…·æœ‰é‡è¦æ„ç¾©ã€‚é€™æ„å‘³è‘—é€éé£²é£Ÿä¸­çš„æŸäº›æˆåˆ†ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½å¤ æ”¹å–„å¥åº·ç‹€æ³ï¼Œæ¸›å°‘ç’°å¢ƒæ¯’ç´ å°èº«é«”çš„å½±éŸ¿ï¼Œé€²è€Œå¢å¼·å…ç–«ç³»çµ±çš„åŠŸèƒ½ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°ä¸‰è‹¯éŒ«å¼•èµ·çš„è‚è‡Ÿæ¯’æ€§ã€å…ç–«åŠŸèƒ½å¤±èª¿åŠè…¸é“å¾®ç”Ÿç‰©å¤±èª¿çš„ä¿è­·æ•ˆæœã€‚ä¸‰è‹¯éŒ«æ˜¯ä¸€ç¨®ç’°å¢ƒæ±¡æŸ“ç‰©ï¼Œå°ç”Ÿç‰©é«”çš„å¥åº·é€ æˆå¨è„…ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿é€™äº›ä¸è‰¯å½±éŸ¿ï¼Œä¸¦å°‹æ‰¾å¯èƒ½çš„æ©Ÿåˆ¶ï¼Œä»¥ä¾¿æœªä¾†èƒ½å¤ é–‹ç™¼å‡ºæ›´æœ‰æ•ˆçš„ä¿è­·ç­–ç•¥ã€‚",
    "para3": "å¯¦é©—ä¸­ä½¿ç”¨äº†é¯‰é­šï¼ˆCyprinus carpioï¼‰ä½œç‚ºç ”ç©¶å°è±¡ï¼Œå°‡å…¶åˆ†ç‚ºä¸‰çµ„ï¼Œåˆ†åˆ¥ç‚ºå°ç…§çµ„ã€10å¾®å…‹/å‡çš„ä¸‰è‹¯éŒ«çµ„ï¼Œä»¥åŠ10å¾®å…‹/å‡çš„ä¸‰è‹¯éŒ«åŠ 10æ¯«å…‹/å…¬æ–¤çš„è˜¿è””ç¡«ç´ çµ„ã€‚é€™äº›é­šåœ¨å¯¦é©—ä¸­æš´éœ²æ–¼é€™äº›ç‰©è³ªé”8é€±ï¼Œç ”ç©¶è€…è§€å¯Ÿäº†å®ƒå€‘çš„è‚è‡Ÿå¥åº·ã€å…ç–«ç³»çµ±åŠè…¸é“å¾®ç”Ÿç‰©çš„è®ŠåŒ–ï¼Œä¸¦é€²è¡Œäº†åŸºå› è¡¨é”çš„åˆ†æï¼Œä»¥äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œä¸‰è‹¯éŒ«çš„æš´éœ²ç¢ºå¯¦å¼•èµ·äº†è‚è‡Ÿæ¯’æ€§ï¼Œä¸¦å½±éŸ¿äº†å…ç–«ç³»çµ±å’Œè…¸é“å¾®ç”Ÿç‰©çš„çµ„æˆã€‚ç„¶è€Œï¼Œè˜¿è””ç¡«ç´ çš„è£œå……èƒ½å¤ æ¸›å°‘è‚è‡Ÿä¸­çš„è†½é¹½ç©ç´¯ï¼Œä¸¦æ¢å¾©æŸäº›åŸºå› çš„è¡¨é”ï¼Œé¡¯ç¤ºå‡ºå…¶åœ¨æ”¹å–„è„‚è³ªä»£è¬å’Œå…ç–«åŠŸèƒ½æ–¹é¢çš„æ½›åŠ›ã€‚æ­¤å¤–ï¼Œè…¸é“å¾®ç”Ÿç‰©çš„çµ„æˆä¹Ÿç™¼ç”Ÿäº†è®ŠåŒ–ï¼Œé¡¯ç¤ºå‡ºè˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼ä¿ƒé€²æœ‰ç›ŠèŒçš„å¢é•·ï¼Œä¸¦æŠ‘åˆ¶æœ‰å®³èŒçš„ç¹æ®–ï¼Œé€™äº›çµæœç‚ºæœªä¾†çš„æ¯’æ€§æ¸›ç·©ç­–ç•¥æä¾›äº†ç†è«–åŸºç¤ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°è‚è‡Ÿæ¯’æ€§å’Œå…ç–«åŠŸèƒ½å¤±èª¿çš„å•é¡Œã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘ç”±ä¸‰è‹¯éŒ«å¼•èµ·çš„è‚è‡Ÿæå‚·å’Œå…ç–«ç³»çµ±çš„å•é¡Œï¼Œé€™å°æ–¼å°‹æ‰¾æ–°çš„ä¿è­·æ€§ç‡Ÿé¤Šç´ å…·æœ‰é‡è¦æ„ç¾©ã€‚é€™æ„å‘³è‘—é€éé£²é£Ÿä¸­çš„æŸäº›æˆåˆ†ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½å¤ æ”¹å–„å¥åº·ç‹€æ³ï¼Œæ¸›å°‘ç’°å¢ƒæ¯’ç´ å°èº«é«”çš„å½±éŸ¿ï¼Œé€²è€Œå¢å¼·å…ç–«ç³»çµ±çš„åŠŸèƒ½ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°ä¸‰è‹¯éŒ«å¼•èµ·çš„è‚è‡Ÿæ¯’æ€§ã€å…ç–«åŠŸèƒ½å¤±èª¿åŠè…¸é“å¾®ç”Ÿç‰©å¤±èª¿çš„ä¿è­·æ•ˆæœã€‚ä¸‰è‹¯éŒ«æ˜¯ä¸€ç¨®ç’°å¢ƒæ±¡æŸ“ç‰©ï¼Œå°ç”Ÿç‰©é«”çš„å¥åº·é€ æˆå¨è„…ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿é€™äº›ä¸è‰¯å½±éŸ¿ï¼Œä¸¦å°‹æ‰¾å¯èƒ½çš„æ©Ÿåˆ¶ï¼Œä»¥ä¾¿æœªä¾†èƒ½å¤ é–‹ç™¼å‡ºæ›´æœ‰æ•ˆçš„ä¿è­·ç­–ç•¥ã€‚\n\nå¯¦é©—ä¸­ä½¿ç”¨äº†é¯‰é­šï¼ˆCyprinus carpioï¼‰ä½œç‚ºç ”ç©¶å°è±¡ï¼Œå°‡å…¶åˆ†ç‚ºä¸‰çµ„ï¼Œåˆ†åˆ¥ç‚ºå°ç…§çµ„ã€10å¾®å…‹/å‡çš„ä¸‰è‹¯éŒ«çµ„ï¼Œä»¥åŠ10å¾®å…‹/å‡çš„ä¸‰è‹¯éŒ«åŠ 10æ¯«å…‹/å…¬æ–¤çš„è˜¿è””ç¡«ç´ çµ„ã€‚é€™äº›é­šåœ¨å¯¦é©—ä¸­æš´éœ²æ–¼é€™äº›ç‰©è³ªé”8é€±ï¼Œç ”ç©¶è€…è§€å¯Ÿäº†å®ƒå€‘çš„è‚è‡Ÿå¥åº·ã€å…ç–«ç³»çµ±åŠè…¸é“å¾®ç”Ÿç‰©çš„è®ŠåŒ–ï¼Œä¸¦é€²è¡Œäº†åŸºå› è¡¨é”çš„åˆ†æï¼Œä»¥äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œä¸‰è‹¯éŒ«çš„æš´éœ²ç¢ºå¯¦å¼•èµ·äº†è‚è‡Ÿæ¯’æ€§ï¼Œä¸¦å½±éŸ¿äº†å…ç–«ç³»çµ±å’Œè…¸é“å¾®ç”Ÿç‰©çš„çµ„æˆã€‚ç„¶è€Œï¼Œè˜¿è””ç¡«ç´ çš„è£œå……èƒ½å¤ æ¸›å°‘è‚è‡Ÿä¸­çš„è†½é¹½ç©ç´¯ï¼Œä¸¦æ¢å¾©æŸäº›åŸºå› çš„è¡¨é”ï¼Œé¡¯ç¤ºå‡ºå…¶åœ¨æ”¹å–„è„‚è³ªä»£è¬å’Œå…ç–«åŠŸèƒ½æ–¹é¢çš„æ½›åŠ›ã€‚æ­¤å¤–ï¼Œè…¸é“å¾®ç”Ÿç‰©çš„çµ„æˆä¹Ÿç™¼ç”Ÿäº†è®ŠåŒ–ï¼Œé¡¯ç¤ºå‡ºè˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼ä¿ƒé€²æœ‰ç›ŠèŒçš„å¢é•·ï¼Œä¸¦æŠ‘åˆ¶æœ‰å®³èŒçš„ç¹æ®–ï¼Œé€™äº›çµæœç‚ºæœªä¾†çš„æ¯’æ€§æ¸›ç·©ç­–ç•¥æä¾›äº†ç†è«–åŸºç¤ã€‚",
    "fb_post": "æ ¹æ“šã€ŠComparative biochemistry and physiology. Part D, Genomics & proteomicsã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ¥•ä½ çŸ¥é“å—ï¼Ÿè˜¿è””è£¡çš„ç§˜å¯†æˆåˆ†ï¼Œå¯èƒ½å°æˆ‘å€‘çš„å¥åº·æœ‰å¤§å¹«åŠ©ï¼é€™é …ç ”ç©¶å°ˆæ³¨åœ¨è˜¿è””ç¡«ç´ å°è‚è‡Ÿå’Œå…ç–«ç³»çµ±çš„å½±éŸ¿ï¼Œå°¤å…¶æ˜¯å°ä¸€ç¨®å«ä¸‰è‹¯éŒ«çš„ç’°å¢ƒæ±¡æŸ“ç‰©ã€‚ä¸‰è‹¯éŒ«æœƒå°æˆ‘å€‘çš„èº«é«”é€ æˆå‚·å®³ï¼Œé€™è®“ç ”ç©¶äººå“¡æƒ³çŸ¥é“è˜¿è””ç¡«ç´ èƒ½å¦å¹«åŠ©æˆ‘å€‘æŠµæŠ—é€™äº›ä¸è‰¯å½±éŸ¿ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ç”¨é¯‰é­šä½œç‚ºç ”ç©¶å°è±¡ï¼ŒæŠŠå®ƒå€‘åˆ†æˆä¸‰çµ„ï¼Œåˆ†åˆ¥æ˜¯æ²’æœ‰ä¸‰è‹¯éŒ«çš„å°ç…§çµ„ã€åªæš´éœ²æ–¼ä¸‰è‹¯éŒ«çš„çµ„ï¼Œä»¥åŠæš´éœ²æ–¼ä¸‰è‹¯éŒ«åŠ ä¸Šè˜¿è””ç¡«ç´ çš„çµ„ã€‚é€™äº›é­šåœ¨é€™äº›ç‰©è³ªçš„å½±éŸ¿ä¸‹è§€å¯Ÿäº†8é€±ï¼Œçµæœç™¼ç¾è˜¿è””ç¡«ç´ æœ‰åŠ©æ–¼æ¸›å°‘è‚è‡Ÿæå‚·ï¼Œä¸¦æ”¹å–„å…ç–«ç³»çµ±çš„åŠŸèƒ½ã€‚\n\nä¸»è¦ç™¼ç¾æœ‰ä¸‰å€‹é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ èƒ½æ¸›å°‘è‚è‡Ÿä¸­çš„è†½é¹½ç©ç´¯ï¼Œå°è„‚è³ªä»£è¬æœ‰å¹«åŠ©ã€‚\n2. å®ƒæœ‰å¯èƒ½ä¿ƒé€²æœ‰ç›Šè…¸é“èŒçš„å¢é•·ï¼ŒæŠ‘åˆ¶æœ‰å®³èŒçš„ç¹æ®–ã€‚\n3. é€™äº›çµæœç‚ºæœªä¾†çš„å¥åº·ä¿è­·ç­–ç•¥æä¾›äº†æ–°çš„æ€è·¯ï¼\n\né€™é …ç ”ç©¶è®“æˆ‘å€‘çœ‹åˆ°ï¼Œé€éé£²é£Ÿä¸­çš„æŸäº›æˆåˆ†ï¼Œæˆ–è¨±èƒ½æ”¹å–„æˆ‘å€‘çš„å¥åº·ï¼Œå¢å¼·å…ç–«åŠ›ï¼",
    "image_prompt": "Create a flat design infographic that explains the experimental method and main results of a study on the protective effects of sulforaphane from radishes against a harmful substance called tributyltin. Include simple icons representing radishes or broccoli, a simplified illustration of fish as experimental subjects, arrows or flow lines indicating the experimental steps, and a section highlighting the main results, such as protective effects and changes observed in liver health and gut microbiota composition.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "è‚è‡Ÿæ¯’æ€§ Hepatotoxicity",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41027171/"
  },
  {
    "id": "40714240",
    "title_en": "Gut microbiota-related glutathione metabolism is key mechanism for sulforaphane ameliorating ulcerative colitis.",
    "pub_date": "2025 Dec",
    "journal": "The Journal of nutritional biochemistry",
    "abstract_en": "Gut barrier dysfunction is associated with dysbiosis of the gut microbiota and its metabolites, which is closely linked to the pathogenesis of ulcerative colitis (UC). Recent studies have demonstrated that Sulforaphane (SFN) exerts beneficial effects on UC. However, the role of the gut microbiota and microbial metabolism in the anti-UC mechanisms of SFN remains inadequately understood. In this study, we observed that SFN administration significantly improved the pathological phenotype, restored gut barrier integrity, and reduced colon inflammation in dextran sulfate sodium (DSS)-induced colitis mice. Gut microbiota analysis illustrated that SFN administration rebalances the alterations in gut microbiota composition, including genera such as Turicibacter, Lactobacillus and Bacteroides, in DSS-induced mice. Furthermore, untargeted metabolomics analysis indicated that the levels of microbial arachidonic acid metabolism, as well as the metabolism of alanine, aspartate, and glutamate, and glutathione metabolism in the gastrointestinal tract, were significantly altered in DSS-induced mice. Interestingly, SFN treatment significantly restore the alterations in glutathione metabolism and the levels of associated metabolites. Additionally, we observed that the MAPK/NF-ÎºB signaling pathway, regulated by glutathione metabolism, was inhibited in the colon of DSS-induced mice following SFN treatment. Collectively, these results suggest that SFN can alleviate DSS-induced colitis in mice by restoring dysregulated gut microbiota and glutathione metabolism, thereby modulating the MAPK/NF-ÎºB signaling pathway, enhancing intestinal barrier function and reducing colonic inflammation. Importantly, our findings elucidate a novel mechanism by which SFN improves gut barrier function, highlighting its potential to advance the development of SFN-derived therapeutics for the clinical management of colitis.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è…¸é“å¥åº·æ–¹é¢ã€‚è…¸é“å±éšœåŠŸèƒ½çš„å¤±èª¿èˆ‡è…¸é“å¾®ç”Ÿç‰©ç¾¤çš„å¤±è¡¡æœ‰é—œï¼Œé€™å¯èƒ½æœƒå°è‡´æ½°ç˜æ€§çµè…¸ç‚ç­‰ç–¾ç—…çš„ç™¼å±•ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„è…¸é“å±éšœçš„å®Œæ•´æ€§ï¼Œä¸¦æ¸›å°‘è…¸é“ç‚ç—‡ï¼Œé€™å°æ–¼æ½°ç˜æ€§çµè…¸ç‚çš„æ‚£è€…ä¾†èªªï¼Œå¯èƒ½æ˜¯ä¸€å€‹æ–°çš„æ²»ç™‚æ–¹å‘ã€‚é€™äº›ç™¼ç¾å¼·èª¿äº†è…¸é“å¾®ç”Ÿç‰©ç¾¤å’Œä»£è¬ç‰©åœ¨è…¸é“å¥åº·ä¸­çš„é‡è¦æ€§ï¼Œä¸¦å¯èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚ç­–ç•¥æä¾›æ–°çš„æ€è·¯ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨æ½°ç˜æ€§çµè…¸ç‚ä¸­çš„ä½œç”¨ï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•å½±éŸ¿è…¸é“å¾®ç”Ÿç‰©ç¾¤å’Œç›¸é—œçš„ä»£è¬éç¨‹ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æ”¹å–„è…¸é“å±éšœåŠŸèƒ½ï¼Œä¸¦æ¸›å°‘ç”±æ–¼è…¸é“å¾®ç”Ÿç‰©å¤±è¡¡æ‰€å¼•èµ·çš„ç‚ç—‡åæ‡‰ã€‚é€™é …ç ”ç©¶å¸Œæœ›æ­ç¤ºè˜¿è””ç¡«ç´ çš„æŠ—æ½°ç˜æ€§çµè…¸ç‚æ©Ÿåˆ¶ï¼Œä¸¦äº†è§£è…¸é“å¾®ç”Ÿç‰©ç¾¤åœ¨é€™ä¸€éç¨‹ä¸­çš„è§’è‰²ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ä»¥å³æ—‹ç³–é…ç¡«é…¸éˆ‰ï¼ˆDSSï¼‰èª˜å°çš„çµè…¸ç‚å°é¼ ä½œç‚ºç ”ç©¶å°è±¡ã€‚ç ”ç©¶æ–¹æ³•åŒ…æ‹¬çµ¦äºˆå°é¼ è˜¿è””ç¡«ç´ ï¼Œä¸¦è§€å¯Ÿå…¶å°ç—…ç†è¡¨å‹çš„æ”¹å–„ã€è…¸é“å±éšœçš„å®Œæ•´æ€§æ¢å¾©ä»¥åŠçµè…¸ç‚ç—‡çš„æ¸›å°‘ã€‚ç ”ç©¶è€…é‚„é€²è¡Œäº†è…¸é“å¾®ç”Ÿç‰©ç¾¤çš„åˆ†æï¼Œè©•ä¼°è˜¿è””ç¡«ç´ å°è…¸é“å¾®ç”Ÿç‰©çµ„æˆçš„å½±éŸ¿ï¼Œä¸¦ä½¿ç”¨ä»£è¬çµ„å­¸åˆ†æä¾†äº†è§£è…¸é“å…§çš„ä»£è¬è®ŠåŒ–ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ çš„çµ¦äºˆé¡¯è‘—æ”¹å–„äº†DSSèª˜å°çš„å°é¼ çš„ç—…ç†è¡¨ç¾ï¼Œæ¢å¾©äº†è…¸é“å±éšœçš„å®Œæ•´æ€§ï¼Œä¸¦æ¸›å°‘äº†çµè…¸çš„ç‚ç—‡ã€‚æ­¤å¤–ï¼Œè…¸é“å¾®ç”Ÿç‰©ç¾¤çš„åˆ†æé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ é‡æ–°å¹³è¡¡è…¸é“å¾®ç”Ÿç‰©çš„çµ„æˆï¼Œä¸¦ä¸”ä»£è¬çµ„å­¸åˆ†æé¡¯ç¤ºï¼Œèˆ‡è…¸é“ç›¸é—œçš„å¤šç¨®ä»£è¬ç‰©çš„æ°´å¹³ä¹Ÿç™¼ç”Ÿäº†é¡¯è‘—è®ŠåŒ–ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€šéèª¿ç¯€è…¸é“å¾®ç”Ÿç‰©ç¾¤å’Œä»£è¬éç¨‹ä¾†æ”¹å–„è…¸é“åŠŸèƒ½ï¼Œä¸¦æ¸›å°‘çµè…¸ç‚ç—‡ï¼Œé€™ç‚ºæ½°ç˜æ€§çµè…¸ç‚çš„è‡¨åºŠç®¡ç†æä¾›äº†æ–°çš„æ½›åœ¨æ²»ç™‚ç­–ç•¥ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è…¸é“å¥åº·æ–¹é¢ã€‚è…¸é“å±éšœåŠŸèƒ½çš„å¤±èª¿èˆ‡è…¸é“å¾®ç”Ÿç‰©ç¾¤çš„å¤±è¡¡æœ‰é—œï¼Œé€™å¯èƒ½æœƒå°è‡´æ½°ç˜æ€§çµè…¸ç‚ç­‰ç–¾ç—…çš„ç™¼å±•ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„è…¸é“å±éšœçš„å®Œæ•´æ€§ï¼Œä¸¦æ¸›å°‘è…¸é“ç‚ç—‡ï¼Œé€™å°æ–¼æ½°ç˜æ€§çµè…¸ç‚çš„æ‚£è€…ä¾†èªªï¼Œå¯èƒ½æ˜¯ä¸€å€‹æ–°çš„æ²»ç™‚æ–¹å‘ã€‚é€™äº›ç™¼ç¾å¼·èª¿äº†è…¸é“å¾®ç”Ÿç‰©ç¾¤å’Œä»£è¬ç‰©åœ¨è…¸é“å¥åº·ä¸­çš„é‡è¦æ€§ï¼Œä¸¦å¯èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚ç­–ç•¥æä¾›æ–°çš„æ€è·¯ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨æ½°ç˜æ€§çµè…¸ç‚ä¸­çš„ä½œç”¨ï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•å½±éŸ¿è…¸é“å¾®ç”Ÿç‰©ç¾¤å’Œç›¸é—œçš„ä»£è¬éç¨‹ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æ”¹å–„è…¸é“å±éšœåŠŸèƒ½ï¼Œä¸¦æ¸›å°‘ç”±æ–¼è…¸é“å¾®ç”Ÿç‰©å¤±è¡¡æ‰€å¼•èµ·çš„ç‚ç—‡åæ‡‰ã€‚é€™é …ç ”ç©¶å¸Œæœ›æ­ç¤ºè˜¿è””ç¡«ç´ çš„æŠ—æ½°ç˜æ€§çµè…¸ç‚æ©Ÿåˆ¶ï¼Œä¸¦äº†è§£è…¸é“å¾®ç”Ÿç‰©ç¾¤åœ¨é€™ä¸€éç¨‹ä¸­çš„è§’è‰²ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ä»¥å³æ—‹ç³–é…ç¡«é…¸éˆ‰ï¼ˆDSSï¼‰èª˜å°çš„çµè…¸ç‚å°é¼ ä½œç‚ºç ”ç©¶å°è±¡ã€‚ç ”ç©¶æ–¹æ³•åŒ…æ‹¬çµ¦äºˆå°é¼ è˜¿è””ç¡«ç´ ï¼Œä¸¦è§€å¯Ÿå…¶å°ç—…ç†è¡¨å‹çš„æ”¹å–„ã€è…¸é“å±éšœçš„å®Œæ•´æ€§æ¢å¾©ä»¥åŠçµè…¸ç‚ç—‡çš„æ¸›å°‘ã€‚ç ”ç©¶è€…é‚„é€²è¡Œäº†è…¸é“å¾®ç”Ÿç‰©ç¾¤çš„åˆ†æï¼Œè©•ä¼°è˜¿è””ç¡«ç´ å°è…¸é“å¾®ç”Ÿç‰©çµ„æˆçš„å½±éŸ¿ï¼Œä¸¦ä½¿ç”¨ä»£è¬çµ„å­¸åˆ†æä¾†äº†è§£è…¸é“å…§çš„ä»£è¬è®ŠåŒ–ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ çš„çµ¦äºˆé¡¯è‘—æ”¹å–„äº†DSSèª˜å°çš„å°é¼ çš„ç—…ç†è¡¨ç¾ï¼Œæ¢å¾©äº†è…¸é“å±éšœçš„å®Œæ•´æ€§ï¼Œä¸¦æ¸›å°‘äº†çµè…¸çš„ç‚ç—‡ã€‚æ­¤å¤–ï¼Œè…¸é“å¾®ç”Ÿç‰©ç¾¤çš„åˆ†æé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ é‡æ–°å¹³è¡¡è…¸é“å¾®ç”Ÿç‰©çš„çµ„æˆï¼Œä¸¦ä¸”ä»£è¬çµ„å­¸åˆ†æé¡¯ç¤ºï¼Œèˆ‡è…¸é“ç›¸é—œçš„å¤šç¨®ä»£è¬ç‰©çš„æ°´å¹³ä¹Ÿç™¼ç”Ÿäº†é¡¯è‘—è®ŠåŒ–ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€šéèª¿ç¯€è…¸é“å¾®ç”Ÿç‰©ç¾¤å’Œä»£è¬éç¨‹ä¾†æ”¹å–„è…¸é“åŠŸèƒ½ï¼Œä¸¦æ¸›å°‘çµè…¸ç‚ç—‡ï¼Œé€™ç‚ºæ½°ç˜æ€§çµè…¸ç‚çš„è‡¨åºŠç®¡ç†æä¾›äº†æ–°çš„æ½›åœ¨æ²»ç™‚ç­–ç•¥ã€‚",
    "fb_post": "æ ¹æ“šã€ŠThe Journal of nutritional biochemistryã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿè˜¿è””ä¸åªæ˜¯ç¾å‘³çš„é£Ÿæï¼Œé‚„å¯èƒ½å°è…¸é“å¥åº·æœ‰å¹«åŠ©å“¦ï¼æœ€è¿‘æœ‰ç ”ç©¶æ¢è¨äº†è˜¿è””ä¸­çš„ä¸€ç¨®æˆåˆ†â€”â€”è˜¿è””ç¡«ç´ ï¼Œçœ‹çœ‹å®ƒèƒ½å¦æ”¹å–„æ½°ç˜æ€§çµè…¸ç‚çš„æƒ…æ³ã€‚é€™ç¨®ç—…ç—‡æœƒå½±éŸ¿è…¸é“çš„å¥åº·ï¼Œè®“äººæ„Ÿåˆ°ä¸é©ã€‚\n\nç ”ç©¶äººå“¡ä½¿ç”¨äº†ä¸€ç¨®ç‰¹æ®Šçš„å¯¦é©—æ–¹æ³•ï¼Œè®“å°é¼ æ¨¡æ“¬æ½°ç˜æ€§çµè…¸ç‚çš„æƒ…æ³ï¼Œç„¶å¾Œçµ¦äºˆå®ƒå€‘è˜¿è””ç¡«ç´ ã€‚ä»–å€‘è§€å¯Ÿåˆ°å°é¼ çš„è…¸é“å±éšœå¾—åˆ°äº†æ”¹å–„ï¼Œç‚ç—‡ä¹Ÿæ¸›å°‘äº†ï¼æ›´æœ‰è¶£çš„æ˜¯ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½èª¿æ•´è…¸é“å…§çš„å¾®ç”Ÿç‰©çµ„æˆï¼Œè®“è…¸é“ç’°å¢ƒè®Šå¾—æ›´å¥åº·ã€‚\n\né€™é …ç ”ç©¶å‘Šè¨´æˆ‘å€‘ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„è…¸é“å¥åº·ã€‚\n2. å®ƒèƒ½æ¸›å°‘è…¸é“ç‚ç—‡ï¼Œå°æ½°ç˜æ€§çµè…¸ç‚æ‚£è€…æˆ–è¨±æœ‰å¹«åŠ©ã€‚\n3. è…¸é“å¾®ç”Ÿç‰©çš„å¹³è¡¡å°å¥åº·è‡³é—œé‡è¦ï¼\n\né›–ç„¶é€™äº›ç™¼ç¾ä»¤äººæŒ¯å¥®ï¼Œä½†ä»éœ€è¦æ›´å¤šç ”ç©¶ä¾†ç¢ºèªè˜¿è””ç¡«ç´ çš„æ•ˆæœï¼Œè®“æˆ‘å€‘ä¸€èµ·æœŸå¾…æœªä¾†çš„å¥åº·æ–°çŸ¥å§ï¼",
    "image_prompt": "Create a flat design infographic illustrating the experiment and main results of a study on the effects of sulforaphane from radishes on colitis. Include simple icons representing radishes or broccoli, simplified images of experimental subjects like mice or cells, arrows or flow lines to indicate the steps of the experiment, and a section that clearly shows the main results, such as protective effects or changes observed. Use a light background with soft colors for a clear and informative look.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "æ½°ç˜æ€§çµè…¸ç‚ Ulcerative Colitis",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40714240/"
  },
  {
    "id": "41291551",
    "title_en": "Nanoliposome-mediated delivery of sulforaphane suppresses Ehrlich ascites carcinoma growth and improves liver integrity and therapeutic outcomes in a murine model.",
    "pub_date": "2025 Nov",
    "journal": "BMC cancer",
    "abstract_en": "The anticancer activity of sulforaphane (SFN) involves multiple signaling pathways, but its mechanism against Ehrlich Ascites Carcinoma (EAC) in mice remains unclear. This study evaluated the antitumor efficacy of SFN-loaded nanoliposomes (SFN-NLPs). Ninety female Swiss albino mice were allocated into six groups: (1) untreated control, (2) SFN alone (50Â mg/kg/day, orally), (3) SFN-NLPs alone (50Â mg/kg/day, orally), (4) EAC-bearing mice (2.5â€‰Ã—â€‰10â¶ cells, intraperitoneally), (5) EACâ€‰+â€‰SFN, and (6) EACâ€‰+â€‰SFN-NLPs. with treatment lasting 20 days in tumor-bearing groups. SFN-NLPs significantly reduced EAC tumor volume, viable cell count, and tumor marker levels, while prolonging survival more effectively than free SFN. SFN-NLPs modulated key molecular pathways by suppressing inflammatory gene expression (NF-ÎºB, COX-2) and shifting the balance toward apoptosis via upregulation of TP53 and Bax and concomitant downregulation of Bcl-2. Regarding liver integrity, SFN-NLPs significantly reduced DNA fragmentation and hepatic oxidative stress, while modulating systemic inflammation through reductions in total leukocyte count, TNF-Î±, and C-reactive protein. In addition, SFN-NLPs conferred superior protection against both histopathological and ultrastructural liver damage. Furthermore, molecular docking analysis suggested plausible interactions of SFN with proteins associated with antioxidant defense, inflammation regulation, and apoptosis, indicating a potential modulatory role. In conclusion, nanoformulated SFN enhances stability, augments efficacy, and facilitates sustained release and bioavailability, thereby strengthening its antitumor, anti-inflammatory, antioxidant, and pro-apoptotic effects in EAC-bearing mice. These findings highlight the potential of SFN-NLPs to suppress tumor growth by modulating inflammatory and apoptotic gene expression while preserving liver integrity.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç™Œç—‡æ²»ç™‚æ–¹é¢ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰é€™ç¨®å¤©ç„¶åŒ–åˆç‰©å¯èƒ½å°æŠ—ç™Œç—‡æœ‰æ½›åœ¨çš„å¹«åŠ©ï¼Œå°¤å…¶æ˜¯é‡å°æŸäº›ç‰¹å®šçš„è…«ç˜¤ã€‚é€éæ”¹è‰¯çš„ç´ç±³æŠ€è¡“ï¼Œå°‡è˜¿è””ç¡«ç´ åŒ…è£¹åœ¨ç´ç±³è„‚è³ªé«”ä¸­ï¼Œèƒ½å¤ æé«˜å…¶ç©©å®šæ€§å’Œç”Ÿç‰©åˆ©ç”¨åº¦ï¼Œé€™å¯èƒ½ç‚ºæœªä¾†çš„ç™Œç—‡æ²»ç™‚æä¾›æ–°çš„æ€è·¯ã€‚é€™äº›ç™¼ç¾ä¸åƒ…æœ‰åŠ©æ–¼ç†è§£è˜¿è””ç¡«ç´ çš„æŠ—ç™Œæ©Ÿåˆ¶ï¼Œé‚„å¯èƒ½ä¿ƒé€²æ–°å‹æ²»ç™‚æ–¹æ³•çš„ç™¼å±•ï¼Œé€²ä¸€æ­¥æ”¹å–„æ‚£è€…çš„å¥åº·ç‹€æ³ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨å°é¼ æ¨¡å‹ä¸­å°Ehrlichè…¹æ°´ç™Œï¼ˆEACï¼‰çš„æŠ—è…«ç˜¤æ•ˆæœã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯è˜¿è””ç¡«ç´ å¦‚ä½•é€éä¸åŒçš„ä¿¡è™Ÿé€šè·¯ä¾†æŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·ï¼Œä¸¦ä¸”å¸Œæœ›äº†è§£å…¶åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„æ½›åœ¨æ‡‰ç”¨ã€‚ç‰¹åˆ¥æ˜¯ï¼Œç ”ç©¶è‘—é‡æ–¼è˜¿è””ç¡«ç´ èˆ‡ç´ç±³è„‚è³ªé«”çµåˆå¾Œçš„æ•ˆæœï¼Œé€™æ¨£çš„çµåˆæ˜¯å¦èƒ½å¢å¼·å…¶æŠ—è…«ç˜¤æ´»æ€§ï¼Œä¸¦æ”¹å–„å°è…«ç˜¤çš„æ²»ç™‚æ•ˆæœã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†90éš»é›Œæ€§ç‘å£«ç™½é¼ ï¼Œå°‡å®ƒå€‘åˆ†æˆå…­çµ„é€²è¡Œä¸åŒçš„è™•ç†ã€‚é€™äº›çµ„åˆ¥åŒ…æ‹¬æœªè™•ç†çš„å°ç…§çµ„ã€å–®ç¨çµ¦äºˆè˜¿è””ç¡«ç´ çš„çµ„åˆ¥ã€å–®ç¨çµ¦äºˆè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”çš„çµ„åˆ¥ï¼Œä»¥åŠå¸¶æœ‰EACè…«ç˜¤çš„å°é¼ çµ„åˆ¥ã€‚æ²»ç™‚æŒçºŒ20å¤©ï¼Œç ”ç©¶è€…è§€å¯Ÿäº†è…«ç˜¤é«”ç©ã€å­˜æ´»ç‡ä»¥åŠç›¸é—œçš„ç”Ÿç‰©æ¨™è¨˜ç‰©ã€‚é€™æ¨£çš„è¨­è¨ˆä½¿å¾—ç ”ç©¶è€…èƒ½å¤ æ¯”è¼ƒä¸åŒè™•ç†å°è…«ç˜¤çš„å½±éŸ¿ï¼Œä¸¦è©•ä¼°è˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”çš„æ•ˆæœã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”åœ¨æ¸›å°‘EACè…«ç˜¤é«”ç©ã€æ´»ç´°èƒæ•¸é‡å’Œè…«ç˜¤æ¨™è¨˜ç‰©æ°´å¹³æ–¹é¢ï¼Œæ•ˆæœé¡¯è‘—å„ªæ–¼å–®ç¨çš„è˜¿è””ç¡«ç´ ã€‚æ­¤å¤–ï¼Œé€™ç¨®ç´ç±³å½¢å¼çš„è˜¿è””ç¡«ç´ é‚„èƒ½å¤ æ”¹å–„å°é¼ çš„ç”Ÿå­˜ç‡ï¼Œä¸¦æœ‰æ•ˆæŠ‘åˆ¶èˆ‡ç‚ç—‡ç›¸é—œçš„åŸºå› è¡¨é”ï¼Œä¿ƒé€²ç´°èƒå‡‹äº¡ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œç´ç±³è„‚è³ªé«”èƒ½æ¸›å°‘è‚è‡Ÿçš„æ°§åŒ–å£“åŠ›å’ŒDNAæ–·è£‚ï¼Œä¸¦æ”¹å–„ç³»çµ±æ€§ç‚ç—‡åæ‡‰ã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”å¯èƒ½åœ¨æŠ—è…«ç˜¤ã€æŠ—ç‚å’ŒæŠ—æ°§åŒ–æ–¹é¢å…·æœ‰æ½›åœ¨çš„æ‡‰ç”¨åƒ¹å€¼ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç™Œç—‡æ²»ç™‚æ–¹é¢ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰é€™ç¨®å¤©ç„¶åŒ–åˆç‰©å¯èƒ½å°æŠ—ç™Œç—‡æœ‰æ½›åœ¨çš„å¹«åŠ©ï¼Œå°¤å…¶æ˜¯é‡å°æŸäº›ç‰¹å®šçš„è…«ç˜¤ã€‚é€éæ”¹è‰¯çš„ç´ç±³æŠ€è¡“ï¼Œå°‡è˜¿è””ç¡«ç´ åŒ…è£¹åœ¨ç´ç±³è„‚è³ªé«”ä¸­ï¼Œèƒ½å¤ æé«˜å…¶ç©©å®šæ€§å’Œç”Ÿç‰©åˆ©ç”¨åº¦ï¼Œé€™å¯èƒ½ç‚ºæœªä¾†çš„ç™Œç—‡æ²»ç™‚æä¾›æ–°çš„æ€è·¯ã€‚é€™äº›ç™¼ç¾ä¸åƒ…æœ‰åŠ©æ–¼ç†è§£è˜¿è””ç¡«ç´ çš„æŠ—ç™Œæ©Ÿåˆ¶ï¼Œé‚„å¯èƒ½ä¿ƒé€²æ–°å‹æ²»ç™‚æ–¹æ³•çš„ç™¼å±•ï¼Œé€²ä¸€æ­¥æ”¹å–„æ‚£è€…çš„å¥åº·ç‹€æ³ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨å°é¼ æ¨¡å‹ä¸­å°Ehrlichè…¹æ°´ç™Œï¼ˆEACï¼‰çš„æŠ—è…«ç˜¤æ•ˆæœã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯è˜¿è””ç¡«ç´ å¦‚ä½•é€éä¸åŒçš„ä¿¡è™Ÿé€šè·¯ä¾†æŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·ï¼Œä¸¦ä¸”å¸Œæœ›äº†è§£å…¶åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„æ½›åœ¨æ‡‰ç”¨ã€‚ç‰¹åˆ¥æ˜¯ï¼Œç ”ç©¶è‘—é‡æ–¼è˜¿è””ç¡«ç´ èˆ‡ç´ç±³è„‚è³ªé«”çµåˆå¾Œçš„æ•ˆæœï¼Œé€™æ¨£çš„çµåˆæ˜¯å¦èƒ½å¢å¼·å…¶æŠ—è…«ç˜¤æ´»æ€§ï¼Œä¸¦æ”¹å–„å°è…«ç˜¤çš„æ²»ç™‚æ•ˆæœã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†90éš»é›Œæ€§ç‘å£«ç™½é¼ ï¼Œå°‡å®ƒå€‘åˆ†æˆå…­çµ„é€²è¡Œä¸åŒçš„è™•ç†ã€‚é€™äº›çµ„åˆ¥åŒ…æ‹¬æœªè™•ç†çš„å°ç…§çµ„ã€å–®ç¨çµ¦äºˆè˜¿è””ç¡«ç´ çš„çµ„åˆ¥ã€å–®ç¨çµ¦äºˆè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”çš„çµ„åˆ¥ï¼Œä»¥åŠå¸¶æœ‰EACè…«ç˜¤çš„å°é¼ çµ„åˆ¥ã€‚æ²»ç™‚æŒçºŒ20å¤©ï¼Œç ”ç©¶è€…è§€å¯Ÿäº†è…«ç˜¤é«”ç©ã€å­˜æ´»ç‡ä»¥åŠç›¸é—œçš„ç”Ÿç‰©æ¨™è¨˜ç‰©ã€‚é€™æ¨£çš„è¨­è¨ˆä½¿å¾—ç ”ç©¶è€…èƒ½å¤ æ¯”è¼ƒä¸åŒè™•ç†å°è…«ç˜¤çš„å½±éŸ¿ï¼Œä¸¦è©•ä¼°è˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”çš„æ•ˆæœã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”åœ¨æ¸›å°‘EACè…«ç˜¤é«”ç©ã€æ´»ç´°èƒæ•¸é‡å’Œè…«ç˜¤æ¨™è¨˜ç‰©æ°´å¹³æ–¹é¢ï¼Œæ•ˆæœé¡¯è‘—å„ªæ–¼å–®ç¨çš„è˜¿è””ç¡«ç´ ã€‚æ­¤å¤–ï¼Œé€™ç¨®ç´ç±³å½¢å¼çš„è˜¿è””ç¡«ç´ é‚„èƒ½å¤ æ”¹å–„å°é¼ çš„ç”Ÿå­˜ç‡ï¼Œä¸¦æœ‰æ•ˆæŠ‘åˆ¶èˆ‡ç‚ç—‡ç›¸é—œçš„åŸºå› è¡¨é”ï¼Œä¿ƒé€²ç´°èƒå‡‹äº¡ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œç´ç±³è„‚è³ªé«”èƒ½æ¸›å°‘è‚è‡Ÿçš„æ°§åŒ–å£“åŠ›å’ŒDNAæ–·è£‚ï¼Œä¸¦æ”¹å–„ç³»çµ±æ€§ç‚ç—‡åæ‡‰ã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”å¯èƒ½åœ¨æŠ—è…«ç˜¤ã€æŠ—ç‚å’ŒæŠ—æ°§åŒ–æ–¹é¢å…·æœ‰æ½›åœ¨çš„æ‡‰ç”¨åƒ¹å€¼ã€‚",
    "fb_post": "æ ¹æ“šã€ŠBMC cancerã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿè˜¿è””è£¡é¢æœ‰ç¨®ç¥å¥‡çš„æˆåˆ†å«è˜¿è””ç¡«ç´ ï¼Œå¯èƒ½å°æŠ—ç™Œç—‡æœ‰å¹«åŠ©å“¦ï¼æœ€è¿‘ä¸€é …ç ”ç©¶ç™¼ç¾ï¼Œé€™ç¨®å¤©ç„¶åŒ–åˆç‰©åœ¨å°é¼ æ¨¡å‹ä¸­å°æŠ—Ehrlichè…¹æ°´ç™Œï¼ˆEACï¼‰é¡¯ç¤ºå‡ºä¸éŒ¯çš„æ•ˆæœã€‚ç ”ç©¶è€…å€‘ä½¿ç”¨äº†90éš»å°ç™½é¼ ï¼Œåˆ†æˆå¹¾çµ„é€²è¡Œä¸åŒçš„å¯¦é©—ï¼Œåƒæ˜¯å–®ç¨çµ¦äºˆè˜¿è””ç¡«ç´ æˆ–æ˜¯ç”¨ç´ç±³è„‚è³ªé«”åŒ…è£¹çš„è˜¿è””ç¡«ç´ ã€‚ç¶“é20å¤©çš„è§€å¯Ÿï¼Œä»–å€‘ç™¼ç¾ä½¿ç”¨ç´ç±³è„‚è³ªé«”çš„è˜¿è””ç¡«ç´ èƒ½æ›´æœ‰æ•ˆåœ°æ¸›å°‘è…«ç˜¤é«”ç©ï¼Œç”šè‡³æå‡å°é¼ çš„å­˜æ´»ç‡ï¼\n\né€™äº›çµæœå‘Šè¨´æˆ‘å€‘ï¼Œè˜¿è””ç¡«ç´ çš„ç´ç±³å½¢å¼ä¸åƒ…èƒ½æŠ‘åˆ¶è…«ç˜¤ï¼Œé‚„èƒ½æ”¹å–„èˆ‡ç‚ç—‡ç›¸é—œçš„åŸºå› è¡¨é”ï¼Œé€™å°æœªä¾†çš„ç™Œç—‡æ²»ç™‚æˆ–è¨±æœ‰æ–°çš„å•Ÿç¤ºã€‚\n\nğŸ” ç ”ç©¶é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½å°æŠ—ç‰¹å®šè…«ç˜¤æœ‰æ½›åŠ›ã€‚\n2. ç´ç±³è„‚è³ªé«”èƒ½æå‡è˜¿è””ç¡«ç´ çš„æŠ—è…«ç˜¤æ•ˆæœã€‚\n3. é€™é …ç ”ç©¶ç‚ºæœªä¾†ç™Œç—‡æ²»ç™‚æä¾›æ–°çš„æ€è·¯ï¼",
    "image_prompt": "Create a flat design infographic that explains the experimental method and main results of a study on sulforaphane. Include simple icons representing broccoli or sulforaphane, simplified representations of experimental subjects like mice or cells, and arrows or flow lines to indicate the steps of the experiment. Include a section labeled 'Main Results' highlighting protective effects or changes observed in the study.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "è…¹æ°´ç™Œ Ehrlich Ascites Carcinoma",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41291551/"
  },
  {
    "id": "41135276",
    "title_en": "Sulforaphane targets STAT3-CKMT2-AS1 to suppress gastric cancer via PSMB8 downregulation and AIMP1 stabilization.",
    "pub_date": "2025 Nov",
    "journal": "Phytomedicine : international journal of phytotherapy and phytopharmacology",
    "abstract_en": "Gastric cancer (GC) remains one of the most formidable threats to human health with limited therapeutic options. Sulforaphane (SFN), a natural isothiocyanate, exhibits antitumor activity; however, its molecular mechanisms of action in GC remain unclear. To investigate the mechanism of action of SFN in gastric cancer. The antitumor effects of SFN were comprehensively assessed in vitro and in vivo, followed by sequencing analysis to identify the targeted lncRNA. Subsequently, the mechanical verification experiments were carried out to determine the upstream and downstream regulatory components involved in the STAT3-CKMT2-AS1 regulatory axis. We demonstrated that SFN strongly inhibits GC. SFN downregulated the expression of the lncRNA CKMT2-AS1. Elevated expression levels of CKMT2-AS1 in human GC tissues are correlated with poor patient survival rates. Knockdown of CKMT2-AS1 significantly inhibited GC proliferation and migration both in vivo and in vitro, whereas CKMT2-AS1 overexpression enhanced malignant phenotypes. Mechanistically, we identified STAT3 as the transcriptional activator driving CKMT2-AS1 expression, with SFN directly binding to, and inhibiting, STAT3 phosphorylation to decrease its transcriptional activity. Interestingly, cytoplasmic CKMT2-AS1 competitively adsorbs miR-451a, leading to the expression of PSMB8, ultimately promoting the progression of the malignant phenotype of GC. Moreover, we discovered that CKMT2-AS1 directly binds to the RNA-binding protein (RBP) AIMP1, promoting ubiquitination-mediated degradation of AIMP1 protein via the proteasomal pathway. The highly expressed AIMP1 protein, in turn, inhibits the phosphorylation of the PI3K/AKT signaling pathway, which is hyperactivated in virtually all solid tumors. Our findings not only elucidate a novel SFN-mediated tumor-suppressive mechanism via the STAT3/CKMT2-AS1 regulatory axis, but also validate CKMT2-AS1 as a promising therapeutic target for GC intervention.",
    "para1": "èƒƒç™Œæ˜¯å°äººé¡å¥åº·çš„ä¸€å¤§å¨è„…ï¼Œç›®å‰å¯ç”¨çš„æ²»ç™‚é¸æ“‡æœ‰é™ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ åœ¨èƒƒç™Œä¸­çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œé€™å¯èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚æä¾›æ–°çš„æ€è·¯ã€‚é€éäº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·å’Œæ“´æ•£ï¼Œæˆ–è¨±èƒ½æ‰¾åˆ°æ›´æœ‰æ•ˆçš„é é˜²å’Œæ²»ç™‚æ–¹æ³•ï¼Œå¹«åŠ©æ”¹å–„æ‚£è€…çš„ç”Ÿå­˜ç‡ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯è˜¿è””ç¡«ç´ åœ¨èƒƒç™Œä¸­çš„æŠ—è…«ç˜¤ä½œç”¨åŠå…¶åˆ†å­æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…å¸Œæœ›æ·±å…¥äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿èƒƒç™Œç´°èƒçš„è¡Œç‚ºï¼Œç‰¹åˆ¥æ˜¯å®ƒå°æŸäº›é•·éˆéç·¨ç¢¼RNAï¼ˆlncRNAï¼‰çš„èª¿æ§ä½œç”¨ï¼Œé€™äº›RNAå¯èƒ½èˆ‡ç™Œç—‡çš„é€²å±•æœ‰é—œã€‚",
    "para3": "ç ”ç©¶åœ˜éšŠé€²è¡Œäº†é«”å…§å’Œé«”å¤–çš„å¯¦é©—ä¾†è©•ä¼°è˜¿è””ç¡«ç´ çš„æŠ—è…«ç˜¤æ•ˆæœï¼Œä¸¦é€éåŸºå› æ¸¬åºåˆ†æä¾†è­˜åˆ¥å…¶ç›®æ¨™çš„lncRNAã€‚æ¥è‘—ï¼Œä»–å€‘é€²è¡Œäº†æ©Ÿåˆ¶é©—è­‰å¯¦é©—ï¼Œä»¥ç¢ºå®šåƒèˆ‡STAT3-CKMT2-AS1èª¿æ§è»¸çš„ä¸Šæ¸¸å’Œä¸‹æ¸¸èª¿æ§æˆåˆ†ï¼Œé€™äº›å¯¦é©—å¹«åŠ©æ­ç¤ºäº†è˜¿è””ç¡«ç´ çš„ä½œç”¨è·¯å¾‘ã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¼·çƒˆæŠ‘åˆ¶èƒƒç™Œçš„ç”Ÿé•·ï¼Œä¸¦é™ä½lncRNA CKMT2-AS1çš„è¡¨é”ã€‚CKMT2-AS1åœ¨èƒƒç™Œçµ„ç¹”ä¸­çš„é«˜è¡¨é”èˆ‡æ‚£è€…çš„ç”Ÿå­˜ç‡è¼ƒä½æœ‰é—œã€‚ç•¶CKMT2-AS1è¢«æŠ‘åˆ¶æ™‚ï¼Œèƒƒç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»é¡¯è‘—æ¸›å°‘ï¼Œè€ŒCKMT2-AS1çš„éåº¦è¡¨é”å‰‡åŠ åŠ‡äº†ç™Œç—‡çš„æƒ¡æ€§ç‰¹å¾µã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„ç™¼ç¾STAT3æ˜¯é©…å‹•CKMT2-AS1è¡¨é”çš„è½‰éŒ„æ¿€æ´»å› å­ï¼Œè˜¿è””ç¡«ç´ èƒ½ç›´æ¥æŠ‘åˆ¶STAT3çš„ç£·é…¸åŒ–ï¼Œå¾è€Œé™ä½å…¶è½‰éŒ„æ´»æ€§ã€‚",
    "explanation_zh": "èƒƒç™Œæ˜¯å°äººé¡å¥åº·çš„ä¸€å¤§å¨è„…ï¼Œç›®å‰å¯ç”¨çš„æ²»ç™‚é¸æ“‡æœ‰é™ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ åœ¨èƒƒç™Œä¸­çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œé€™å¯èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚æä¾›æ–°çš„æ€è·¯ã€‚é€éäº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·å’Œæ“´æ•£ï¼Œæˆ–è¨±èƒ½æ‰¾åˆ°æ›´æœ‰æ•ˆçš„é é˜²å’Œæ²»ç™‚æ–¹æ³•ï¼Œå¹«åŠ©æ”¹å–„æ‚£è€…çš„ç”Ÿå­˜ç‡ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯è˜¿è””ç¡«ç´ åœ¨èƒƒç™Œä¸­çš„æŠ—è…«ç˜¤ä½œç”¨åŠå…¶åˆ†å­æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…å¸Œæœ›æ·±å…¥äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿èƒƒç™Œç´°èƒçš„è¡Œç‚ºï¼Œç‰¹åˆ¥æ˜¯å®ƒå°æŸäº›é•·éˆéç·¨ç¢¼RNAï¼ˆlncRNAï¼‰çš„èª¿æ§ä½œç”¨ï¼Œé€™äº›RNAå¯èƒ½èˆ‡ç™Œç—‡çš„é€²å±•æœ‰é—œã€‚\n\nç ”ç©¶åœ˜éšŠé€²è¡Œäº†é«”å…§å’Œé«”å¤–çš„å¯¦é©—ä¾†è©•ä¼°è˜¿è””ç¡«ç´ çš„æŠ—è…«ç˜¤æ•ˆæœï¼Œä¸¦é€éåŸºå› æ¸¬åºåˆ†æä¾†è­˜åˆ¥å…¶ç›®æ¨™çš„lncRNAã€‚æ¥è‘—ï¼Œä»–å€‘é€²è¡Œäº†æ©Ÿåˆ¶é©—è­‰å¯¦é©—ï¼Œä»¥ç¢ºå®šåƒèˆ‡STAT3-CKMT2-AS1èª¿æ§è»¸çš„ä¸Šæ¸¸å’Œä¸‹æ¸¸èª¿æ§æˆåˆ†ï¼Œé€™äº›å¯¦é©—å¹«åŠ©æ­ç¤ºäº†è˜¿è””ç¡«ç´ çš„ä½œç”¨è·¯å¾‘ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¼·çƒˆæŠ‘åˆ¶èƒƒç™Œçš„ç”Ÿé•·ï¼Œä¸¦é™ä½lncRNA CKMT2-AS1çš„è¡¨é”ã€‚CKMT2-AS1åœ¨èƒƒç™Œçµ„ç¹”ä¸­çš„é«˜è¡¨é”èˆ‡æ‚£è€…çš„ç”Ÿå­˜ç‡è¼ƒä½æœ‰é—œã€‚ç•¶CKMT2-AS1è¢«æŠ‘åˆ¶æ™‚ï¼Œèƒƒç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»é¡¯è‘—æ¸›å°‘ï¼Œè€ŒCKMT2-AS1çš„éåº¦è¡¨é”å‰‡åŠ åŠ‡äº†ç™Œç—‡çš„æƒ¡æ€§ç‰¹å¾µã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„ç™¼ç¾STAT3æ˜¯é©…å‹•CKMT2-AS1è¡¨é”çš„è½‰éŒ„æ¿€æ´»å› å­ï¼Œè˜¿è””ç¡«ç´ èƒ½ç›´æ¥æŠ‘åˆ¶STAT3çš„ç£·é…¸åŒ–ï¼Œå¾è€Œé™ä½å…¶è½‰éŒ„æ´»æ€§ã€‚",
    "fb_post": "æ ¹æ“šã€ŠPhytomedicine : international journal of phytotherapy and phytopharmacologyã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± ä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„é¤æ¡Œä¸Šç«Ÿç„¶è—è‘—å°æŠ—èƒƒç™Œçš„æ½›åŠ›ï¼é€™é …ç ”ç©¶èšç„¦åœ¨è˜¿è””ç¡«ç´ ï¼Œé€™æ˜¯ä¸€ç¨®å¾è˜¿è””å’Œé’èŠ±æ¤°èœä¸­æå–çš„å¤©ç„¶æˆåˆ†ï¼Œå¯èƒ½å°èƒƒç™Œæœ‰æ„æƒ³ä¸åˆ°çš„å¥½è™•ã€‚  \n  \nç ”ç©¶è€…å€‘æƒ³è¦äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿èƒƒç™Œç´°èƒï¼Œç‰¹åˆ¥æ˜¯å®ƒå°æŸäº›é•·éˆéç·¨ç¢¼RNAï¼ˆlncRNAï¼‰çš„å½±éŸ¿ï¼Œé€™äº›RNAå¯èƒ½å’Œç™Œç—‡çš„é€²å±•æœ‰é—œã€‚ä»–å€‘é€²è¡Œäº†å¤šé …å¯¦é©—ï¼ŒåŒ…å«åœ¨å¯¦é©—å®¤å’Œå‹•ç‰©èº«ä¸Šæ¸¬è©¦è˜¿è””ç¡«ç´ çš„æ•ˆæœï¼Œä¸¦åˆ†æäº†åŸºå› çš„è®ŠåŒ–ã€‚  \n  \nçµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆæŠ‘åˆ¶èƒƒç™Œç´°èƒçš„ç”Ÿé•·ï¼Œä¸¦é™ä½ä¸€ç¨®å«åšCKMT2-AS1çš„RNAçš„è¡¨é”ï¼Œé€™ç¨®RNAçš„é«˜è¡¨é”èˆ‡æ‚£è€…çš„ç”Ÿå­˜ç‡è¼ƒä½æœ‰é—œã€‚ç•¶CKMT2-AS1è¢«æŠ‘åˆ¶æ™‚ï¼Œèƒƒç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»æ˜é¡¯æ¸›å°‘ï¼Œé€™æˆ–è¨±èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚æä¾›æ–°çš„æ–¹å‘ã€‚  \n  \nâœ¨ ç¸½çµä¾†èªªï¼š  \n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æŠ‘åˆ¶èƒƒç™Œç´°èƒçš„ç”Ÿé•·ã€‚  \n2. CKMT2-AS1çš„é«˜è¡¨é”èˆ‡æ‚£è€…ç”Ÿå­˜ç‡ä½ç›¸é—œã€‚  \n3. æŠ‘åˆ¶CKMT2-AS1æœ‰æœ›æ”¹å–„ç™Œç—‡çš„é å¾Œã€‚",
    "image_prompt": "Create an infographic that explains the research on the anti-tumor effects of sulforaphane in gastric cancer. Use a flat design style with a white or light-colored background and soft colors. Include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects like humans, animals, or cells, and arrows or flow lines to indicate the experimental steps. Add a section to highlight the main results, such as protective effects or changes observed in the study.",
    "is_human_study": true,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "èƒƒç™Œ Gastric Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41135276/"
  },
  {
    "id": "41275316",
    "title_en": "Investigating the clinical efficacy, safety and molecular mechanism of sulforaphane in autism spectrum disorder: an integrated study combining meta-analysis, network pharmacology, and computational biology.",
    "pub_date": "2025 Nov",
    "journal": "BMC pharmacology & toxicology",
    "abstract_en": "Sulforaphane, a natural antioxidant rich in cruciferous vegetables, has emerged as a promising dietary supplement for autism spectrum disorder (ASD). However, its therapeutic efficacy remains controversial, and the pharmacological mechanisms are not fully elucidated. Eligible randomized controlled trials were retrieved from PubMed, Web of Science, Embase, and Cochrane Library databases. Review Manager 5.4 was used for meta-analysis and bias risk assessment. Network pharmacology, Mendelian randomization, GEO data analyses, molecular docking, and molecular dynamics simulation were employed to explore the mechanisms of sulforaphane in ASD. Six trials involving 333 participants were included in the meta-analysis. Pooled results demonstrated that both 4-5 weeks and 8-10 weeks of sulforaphane supplementation significantly decreased the scores on the Social Responsiveness Scale compared to placebo controls. No significant difference was observed in the incidence of adverse events. Network pharmacology identified 10 core targets of sulforaphane in ASD, including AKT1, EGFR, HSP90AA1, SRC, CASP3, STAT1, MAPK1, MMP9, MAPK8, and JAK2. These targets were implicated in the PI3K-Akt signaling pathway, MAPK signaling pathway, Chemokine signaling pathway, Chemical carcinogenesis - reactive oxygen species, TNF signaling pathway, Th17 cell differentiation, mTOR signaling pathway, and IL-17 signaling pathway. Mendelian randomization further revealed an inverse association between STAT1 levels and ASD risk. GEO transcriptomic data provided independent validation for the network pharmacology predictions. The binding energies between sulforaphane and the top 10 core targets are all â‰¤ -4.0Â kcal/mol. Molecular dynamics simulations further validated the stable interaction between MMP-9 and sulforaphane. Sulforaphane may serve as an efficacious and safe adjunctive therapy for ASD, mediated by its anti-oxidant and anti-inflammatory effects along with the modulation of autophagy. CRD42025635045.",
    "para1": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å¤©ç„¶æŠ—æ°§åŒ–åŠ‘ï¼Œä¸»è¦å­˜åœ¨æ–¼åå­—èŠ±ç§‘è”¬èœä¸­ï¼Œæœ€è¿‘è¢«èªç‚ºå¯èƒ½å°è‡ªé–‰ç—‡è­œç³»éšœç¤™ï¼ˆASDï¼‰æœ‰å¹«åŠ©ã€‚é›–ç„¶æœ‰äº›ç ”ç©¶é¡¯ç¤ºå®ƒå¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„è‡ªé–‰ç—‡çš„ç—‡ç‹€ï¼Œä½†ç›®å‰å°æ–¼å®ƒçš„ç™‚æ•ˆä»å­˜åœ¨çˆ­è­°ï¼Œä¸”å…¶ä½œç”¨æ©Ÿåˆ¶å°šæœªå®Œå…¨æ˜ç­ã€‚å› æ­¤ï¼Œäº†è§£è˜¿è””ç¡«ç´ çš„æ½›åœ¨ç›Šè™•å’Œé¢¨éšªï¼Œå°æ–¼è‡ªé–‰ç—‡æ‚£è€…åŠå…¶å®¶åº­ä¾†èªªï¼Œéƒ½æ˜¯éå¸¸é‡è¦çš„ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨è‡ªé–‰ç—‡è­œç³»éšœç¤™ï¼ˆASDï¼‰ä¸­çš„ç™‚æ•ˆåŠå…¶ä½œç”¨æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…å¸Œæœ›é€šéç³»çµ±æ€§å›é¡§å’Œåˆ†æç¾æœ‰çš„éš¨æ©Ÿå°ç…§è©¦é©—ï¼Œä¾†è©•ä¼°è˜¿è””ç¡«ç´ çš„è£œå……å°è‡ªé–‰ç—‡ç—‡ç‹€çš„å½±éŸ¿ï¼Œä¸¦æ­ç¤ºå…¶å¯èƒ½çš„ç”Ÿç‰©å­¸æ©Ÿåˆ¶ã€‚é€™æ¨£çš„ç ”ç©¶ä¸åƒ…æœ‰åŠ©æ–¼äº†è§£è˜¿è””ç¡«ç´ çš„æ½›åœ¨ç™‚æ•ˆï¼Œä¹Ÿèƒ½ç‚ºæœªä¾†çš„è‡¨åºŠæ‡‰ç”¨æä¾›ä¾æ“šã€‚",
    "para3": "ç ”ç©¶è€…å¾å¤šå€‹è³‡æ–™åº«ä¸­æª¢ç´¢ç¬¦åˆæ¢ä»¶çš„éš¨æ©Ÿå°ç…§è©¦é©—ï¼Œæœ€çµ‚ç´å…¥äº†å…­é …è©¦é©—ï¼Œæ¶‰åŠ333ååƒèˆ‡è€…ã€‚ç ”ç©¶ä½¿ç”¨äº†å¤šç¨®æ–¹æ³•ï¼ŒåŒ…æ‹¬ç¶²çµ¡è—¥ç†å­¸ã€å­Ÿå¾·çˆ¾éš¨æ©ŸåŒ–ã€åŸºå› è¡¨é”æ•¸æ“šåˆ†æã€åˆ†å­å°æ¥å’Œåˆ†å­å‹•åŠ›å­¸æ¨¡æ“¬ï¼Œä¾†æ¢è¨è˜¿è””ç¡«ç´ åœ¨è‡ªé–‰ç—‡ä¸­çš„ä½œç”¨æ©Ÿåˆ¶ã€‚é€™äº›æ–¹æ³•å¹«åŠ©ç ”ç©¶è€…æ›´å…¨é¢åœ°ç†è§£è˜¿è””ç¡«ç´ çš„ç”Ÿç‰©å­¸æ•ˆæ‡‰åŠå…¶èˆ‡è‡ªé–‰ç—‡çš„é—œè¯ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œç¶“é4è‡³5é€±å’Œ8è‡³10é€±çš„è˜¿è””ç¡«ç´ è£œå……å¾Œï¼Œåƒèˆ‡è€…åœ¨ç¤¾äº¤åæ‡‰é‡è¡¨ä¸Šçš„å¾—åˆ†é¡¯è‘—é™ä½ï¼Œé€™è¡¨æ˜è˜¿è””ç¡«ç´ å¯èƒ½å°æ”¹å–„è‡ªé–‰ç—‡ç—‡ç‹€æœ‰ä¸€å®šçš„å¹«åŠ©ã€‚æ­¤å¤–ï¼Œç ”ç©¶ä¸­ä¸¦æœªç™¼ç¾é¡¯è‘—çš„å‰¯ä½œç”¨äº‹ä»¶ã€‚ç¶²çµ¡è—¥ç†å­¸åˆ†ææŒ‡å‡ºè˜¿è””ç¡«ç´ åœ¨è‡ªé–‰ç—‡ä¸­çš„åå€‹æ ¸å¿ƒé¶é»ï¼Œé€™äº›é¶é»èˆ‡å¤šæ¢ä¿¡è™Ÿé€šè·¯æœ‰é—œï¼Œå¯èƒ½è§£é‡‹äº†è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ã€‚é€™äº›çµæœç‚ºè˜¿è””ç¡«ç´ ä½œç‚ºè‡ªé–‰ç—‡è¼”åŠ©ç™‚æ³•çš„æ½›åŠ›æä¾›äº†åˆæ­¥çš„æ”¯æŒã€‚",
    "explanation_zh": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å¤©ç„¶æŠ—æ°§åŒ–åŠ‘ï¼Œä¸»è¦å­˜åœ¨æ–¼åå­—èŠ±ç§‘è”¬èœä¸­ï¼Œæœ€è¿‘è¢«èªç‚ºå¯èƒ½å°è‡ªé–‰ç—‡è­œç³»éšœç¤™ï¼ˆASDï¼‰æœ‰å¹«åŠ©ã€‚é›–ç„¶æœ‰äº›ç ”ç©¶é¡¯ç¤ºå®ƒå¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„è‡ªé–‰ç—‡çš„ç—‡ç‹€ï¼Œä½†ç›®å‰å°æ–¼å®ƒçš„ç™‚æ•ˆä»å­˜åœ¨çˆ­è­°ï¼Œä¸”å…¶ä½œç”¨æ©Ÿåˆ¶å°šæœªå®Œå…¨æ˜ç­ã€‚å› æ­¤ï¼Œäº†è§£è˜¿è””ç¡«ç´ çš„æ½›åœ¨ç›Šè™•å’Œé¢¨éšªï¼Œå°æ–¼è‡ªé–‰ç—‡æ‚£è€…åŠå…¶å®¶åº­ä¾†èªªï¼Œéƒ½æ˜¯éå¸¸é‡è¦çš„ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨è‡ªé–‰ç—‡è­œç³»éšœç¤™ï¼ˆASDï¼‰ä¸­çš„ç™‚æ•ˆåŠå…¶ä½œç”¨æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…å¸Œæœ›é€šéç³»çµ±æ€§å›é¡§å’Œåˆ†æç¾æœ‰çš„éš¨æ©Ÿå°ç…§è©¦é©—ï¼Œä¾†è©•ä¼°è˜¿è””ç¡«ç´ çš„è£œå……å°è‡ªé–‰ç—‡ç—‡ç‹€çš„å½±éŸ¿ï¼Œä¸¦æ­ç¤ºå…¶å¯èƒ½çš„ç”Ÿç‰©å­¸æ©Ÿåˆ¶ã€‚é€™æ¨£çš„ç ”ç©¶ä¸åƒ…æœ‰åŠ©æ–¼äº†è§£è˜¿è””ç¡«ç´ çš„æ½›åœ¨ç™‚æ•ˆï¼Œä¹Ÿèƒ½ç‚ºæœªä¾†çš„è‡¨åºŠæ‡‰ç”¨æä¾›ä¾æ“šã€‚\n\nç ”ç©¶è€…å¾å¤šå€‹è³‡æ–™åº«ä¸­æª¢ç´¢ç¬¦åˆæ¢ä»¶çš„éš¨æ©Ÿå°ç…§è©¦é©—ï¼Œæœ€çµ‚ç´å…¥äº†å…­é …è©¦é©—ï¼Œæ¶‰åŠ333ååƒèˆ‡è€…ã€‚ç ”ç©¶ä½¿ç”¨äº†å¤šç¨®æ–¹æ³•ï¼ŒåŒ…æ‹¬ç¶²çµ¡è—¥ç†å­¸ã€å­Ÿå¾·çˆ¾éš¨æ©ŸåŒ–ã€åŸºå› è¡¨é”æ•¸æ“šåˆ†æã€åˆ†å­å°æ¥å’Œåˆ†å­å‹•åŠ›å­¸æ¨¡æ“¬ï¼Œä¾†æ¢è¨è˜¿è””ç¡«ç´ åœ¨è‡ªé–‰ç—‡ä¸­çš„ä½œç”¨æ©Ÿåˆ¶ã€‚é€™äº›æ–¹æ³•å¹«åŠ©ç ”ç©¶è€…æ›´å…¨é¢åœ°ç†è§£è˜¿è””ç¡«ç´ çš„ç”Ÿç‰©å­¸æ•ˆæ‡‰åŠå…¶èˆ‡è‡ªé–‰ç—‡çš„é—œè¯ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œç¶“é4è‡³5é€±å’Œ8è‡³10é€±çš„è˜¿è””ç¡«ç´ è£œå……å¾Œï¼Œåƒèˆ‡è€…åœ¨ç¤¾äº¤åæ‡‰é‡è¡¨ä¸Šçš„å¾—åˆ†é¡¯è‘—é™ä½ï¼Œé€™è¡¨æ˜è˜¿è””ç¡«ç´ å¯èƒ½å°æ”¹å–„è‡ªé–‰ç—‡ç—‡ç‹€æœ‰ä¸€å®šçš„å¹«åŠ©ã€‚æ­¤å¤–ï¼Œç ”ç©¶ä¸­ä¸¦æœªç™¼ç¾é¡¯è‘—çš„å‰¯ä½œç”¨äº‹ä»¶ã€‚ç¶²çµ¡è—¥ç†å­¸åˆ†ææŒ‡å‡ºè˜¿è””ç¡«ç´ åœ¨è‡ªé–‰ç—‡ä¸­çš„åå€‹æ ¸å¿ƒé¶é»ï¼Œé€™äº›é¶é»èˆ‡å¤šæ¢ä¿¡è™Ÿé€šè·¯æœ‰é—œï¼Œå¯èƒ½è§£é‡‹äº†è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ã€‚é€™äº›çµæœç‚ºè˜¿è””ç¡«ç´ ä½œç‚ºè‡ªé–‰ç—‡è¼”åŠ©ç™‚æ³•çš„æ½›åŠ›æä¾›äº†åˆæ­¥çš„æ”¯æŒã€‚",
    "fb_post": "æ ¹æ“šã€ŠBMC pharmacology & toxicologyã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ±ä½ çŸ¥é“å—ï¼Ÿè˜¿è””ç¡«ç´ é€™ç¨®å¤©ç„¶æˆåˆ†ï¼Œæœ€è¿‘è¢«ç™¼ç¾å¯èƒ½å°è‡ªé–‰ç—‡æœ‰å¹«åŠ©ï¼\n\nè˜¿è””ç¡«ç´ ä¸»è¦å­˜åœ¨æ–¼åƒé’èŠ±æ¤°èœé€™é¡çš„åå­—èŠ±ç§‘è”¬èœè£¡ï¼Œç§‘å­¸å®¶å€‘é–‹å§‹ç ”ç©¶å®ƒå°è‡ªé–‰ç—‡è­œç³»éšœç¤™ï¼ˆASDï¼‰çš„å½±éŸ¿ã€‚é€™é …ç ”ç©¶é€éåˆ†æå¤šå€‹éš¨æ©Ÿå°ç…§è©¦é©—ï¼Œæƒ³è¦äº†è§£è˜¿è””ç¡«ç´ èƒ½å¦æ”¹å–„è‡ªé–‰ç—‡çš„ç—‡ç‹€ï¼Œä»¥åŠå®ƒèƒŒå¾Œçš„é‹ä½œæ©Ÿåˆ¶ã€‚\n\nç ”ç©¶è€…å€‘å¾ä¸åŒè³‡æ–™åº«ä¸­æ‰¾åˆ°å…­é …ç¬¦åˆæ¢ä»¶çš„è©¦é©—ï¼Œç¸½å…±æœ‰333ä½åƒèˆ‡è€…ã€‚ä»–å€‘ä½¿ç”¨äº†å¤šç¨®æ–¹æ³•ä¾†æ¢è¨è˜¿è””ç¡«ç´ çš„ä½œç”¨ï¼ŒåŒ…æ‹¬åˆ†æåŸºå› å’Œæ¨¡æ“¬åˆ†å­é‹å‹•ï¼Œé€™æ¨£å¯ä»¥æ›´å…¨é¢åœ°äº†è§£å®ƒçš„æ•ˆæœã€‚\n\nçµæœé¡¯ç¤ºï¼Œç¶“é4åˆ°10é€±çš„è˜¿è””ç¡«ç´ è£œå……å¾Œï¼Œåƒèˆ‡è€…åœ¨ç¤¾äº¤åæ‡‰é‡è¡¨ä¸Šçš„å¾—åˆ†æ˜é¡¯é™ä½ï¼Œé€™è¡¨ç¤ºè˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„è‡ªé–‰ç—‡ç—‡ç‹€ã€‚è€Œä¸”ï¼Œç ”ç©¶ä¸­ä¸¦æ²’æœ‰ç™¼ç¾é¡¯è‘—çš„å‰¯ä½œç”¨ï¼\n\nâœ¨é‡é»æ•´ç†ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½å°è‡ªé–‰ç—‡ç—‡ç‹€æœ‰å¹«åŠ©ã€‚\n2. ç ”ç©¶ä¸­æœªè¦‹é¡¯è‘—å‰¯ä½œç”¨ã€‚\n3. é€™äº›çµæœç‚ºè˜¿è””ç¡«ç´ ä½œç‚ºè¼”åŠ©ç™‚æ³•æä¾›äº†åˆæ­¥æ”¯æŒã€‚",
    "image_prompt": "Create an infographic that explains the research study on sulforaphane and its effects on autism. Use a flat design style with a white or light-colored background and soft color palette. Include symbols for broccoli or sulforaphane, simplified representations of experiment subjects (like people or cells), arrows or flow lines to indicate the experimental process, and a section labeled 'Main Results' showing protective effects or changes observed.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "è‡ªé–‰ç—‡è­œç³»éšœç¤™ Autism Spectrum Disorder",
    "is_clinical_trial": true,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41275316/"
  },
  {
    "id": "41159773",
    "title_en": "Sulforaphane-Loaded Hydrogel Prolongs Fully MHC-Mismatched Skin Allograft Survival.",
    "pub_date": "2025 Nov",
    "journal": "ACS applied bio materials",
    "abstract_en": "Despite immunosuppression, acute rejection (AR) is still a common setback among transplantation patients and is a risk factor for graft survival. Sulforaphane (SFN), a phytochemical present in crucifers, has been shown to have anti-inflammatory and immunoregulatory properties, yet its influences on immune cell activation as well as in graft survival are still unknown. Thus, the aim was to evaluate SFN's effect, and to improve efficacy, efficiency, and availability, it was incorporated into thermosensitive polymeric hydrogels, to prevent AR in skin transplant (Tx) model mice. A thermosensitive hydrogel containing SFN (0.1%) and hyaluronic acid (HA) (0.5%) dispersed in a poloxamer matrix (PL407 at 20% w/v) was developed (GS-PL407 20%, HA and SFN) and characterized as a liquid-viscous hydrogel. The fully MHC-incompatible skin Tx procedure was performed by using donor skin Balb/c mice, transplanted into C57BL/6 recipient mice. The cytotoxicity test of GS was performed using in vitro assays with bone marrow-derived dendritic cells (BMDC). Treatment of BMDC with GS for 24 h presents no cytotoxicity. Untreated allograft mice present 100% of graft loss at day 9 post Tx. Remarkably, subcutaneous GS injection every 3 days promoted 80% of allograft survival for more than 14 days when compared with untreated recipients (<i>p</i> < 0.001). Histological analysis showed a lower level of inflammatory cells in the skin Tx of GS-treated mice. Flow cytometry analysis of draining lymph nodes at day 5 post Tx revealed that GS treatment reduced the frequency of DC and subtypes and function of the CD4<sup>+</sup> T cells. In vitro GS-treated lipopolysaccharide-activated BMDC present less activation of costimulatory markers. Taken together, GS treatment reduced immune cell activation, postponing AR onset and prolonging allograft survival in Tx animals. This strategy highlights the role of SFN as a promising candidate for further studies in organ transplantation experiments and being tested combined with current immunosuppression protocols.",
    "para1": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œç§»æ¤æ‰‹è¡“å¾Œçš„æ€¥æ€§æ’æ–¥åæ‡‰ï¼ˆARï¼‰ä»ç„¶æ˜¯ä¸€å€‹å¸¸è¦‹çš„å•é¡Œï¼Œé€™å¯èƒ½å½±éŸ¿åˆ°ç§»æ¤å™¨å®˜çš„å­˜æ´»ç‡ã€‚é€éä½¿ç”¨è˜¿è””ç¡«ç´ é€™ç¨®æ¤ç‰©åŒ–å­¸ç‰©è³ªï¼Œç ”ç©¶è€…å¸Œæœ›èƒ½æ‰¾åˆ°ä¸€ç¨®æ–¹æ³•ä¾†æ¸›å°‘é€™ç¨®æ’æ–¥åæ‡‰ï¼Œé€²è€Œæé«˜ç§»æ¤æˆåŠŸçš„æ©Ÿæœƒã€‚é€™å°æ–¼éœ€è¦å™¨å®˜ç§»æ¤çš„æ‚£è€…ä¾†èªªï¼Œå¯èƒ½æ˜¯ä¸€å€‹é‡è¦çš„é€²å±•ï¼Œå› ç‚ºå®ƒæœ‰åŠ©æ–¼æ”¹å–„ä»–å€‘çš„ç”Ÿæ´»å“è³ªå’Œå¥åº·ç‹€æ³ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°æ–¼æ€¥æ€§æ’æ–¥åæ‡‰çš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯åœ¨çš®è†šç§»æ¤æ¨¡å‹ä¸­çš„æ•ˆæœã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½å¤ æ”¹å–„å…ç–«ç´°èƒçš„æ´»åŒ–æƒ…æ³ï¼Œä¸¦ä¸”æé«˜ç§»æ¤å™¨å®˜çš„å­˜æ´»ç‡ã€‚é›–ç„¶ä¹‹å‰å·²çŸ¥è˜¿è””ç¡«ç´ å…·æœ‰æŠ—ç™¼ç‚å’Œå…ç–«èª¿ç¯€çš„ç‰¹æ€§ï¼Œä½†å…¶å…·é«”çš„ä½œç”¨æ©Ÿåˆ¶ä»ç„¶ä¸æ˜ï¼Œå› æ­¤é€™é …ç ”ç©¶æ—¨åœ¨å¡«è£œé€™ä¸€çŸ¥è­˜ç©ºç™½ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ç†±æ•æ€§èšåˆç‰©æ°´å‡è† ï¼Œå°‡è˜¿è””ç¡«ç´ å’Œé€æ˜è³ªé…¸æ··åˆï¼Œè£½æˆä¸€ç¨®æ–°çš„æ°´å‡è† ï¼Œä¸¦å°‡å…¶æ‡‰ç”¨æ–¼å°é¼ çš„çš®è†šç§»æ¤æ¨¡å‹ä¸­ã€‚å¯¦é©—ä¸­ï¼Œå°‡ä¾›é«”å°é¼ çš„çš®è†šç§»æ¤åˆ°æ¥å—è€…å°é¼ èº«ä¸Šï¼Œä¸¦é€²è¡Œäº†ç´°èƒæ¯’æ€§æ¸¬è©¦ä»¥ç¢ºä¿æ–°æ°´å‡è† çš„å®‰å…¨æ€§ã€‚ç ”ç©¶è€…è§€å¯Ÿäº†ä¸åŒè™•ç†ä¸‹çš„ç§»æ¤å™¨å®˜å­˜æ´»æƒ…æ³ï¼Œä¸¦é€²è¡Œäº†çµ„ç¹”å­¸å’Œæµå¼ç´°èƒè¡“åˆ†æï¼Œä»¥è©•ä¼°å…ç–«åæ‡‰çš„è®ŠåŒ–ã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾æ˜¯ï¼Œä½¿ç”¨è˜¿è””ç¡«ç´ çš„æ°´å‡è† è™•ç†å¾Œï¼Œå°é¼ çš„ç§»æ¤å™¨å®˜å­˜æ´»ç‡é¡¯è‘—æé«˜ï¼Œé”åˆ°80%ï¼Œè€Œæœªè™•ç†çš„å°é¼ åœ¨ç¬¬9å¤©æ™‚å‰‡100%å‡ºç¾æ’æ–¥åæ‡‰ã€‚æ­¤å¤–ï¼Œçµ„ç¹”å­¸åˆ†æé¡¯ç¤ºï¼Œæ¥å—è™•ç†çš„å°é¼ çš®è†šä¸­ç‚ç—‡ç´°èƒçš„æ•¸é‡è¼ƒå°‘ï¼Œæµå¼ç´°èƒè¡“çš„çµæœä¹Ÿé¡¯ç¤ºï¼Œå…ç–«ç´°èƒçš„æ´»åŒ–ç¨‹åº¦é™ä½ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼å»¶é²æ€¥æ€§æ’æ–¥åæ‡‰çš„ç™¼ç”Ÿï¼Œä¸¦å»¶é•·ç§»æ¤å™¨å®˜çš„å­˜æ´»æ™‚é–“ï¼Œç‚ºæœªä¾†çš„å™¨å®˜ç§»æ¤ç ”ç©¶æä¾›äº†æ–°çš„æ–¹å‘ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œç§»æ¤æ‰‹è¡“å¾Œçš„æ€¥æ€§æ’æ–¥åæ‡‰ï¼ˆARï¼‰ä»ç„¶æ˜¯ä¸€å€‹å¸¸è¦‹çš„å•é¡Œï¼Œé€™å¯èƒ½å½±éŸ¿åˆ°ç§»æ¤å™¨å®˜çš„å­˜æ´»ç‡ã€‚é€éä½¿ç”¨è˜¿è””ç¡«ç´ é€™ç¨®æ¤ç‰©åŒ–å­¸ç‰©è³ªï¼Œç ”ç©¶è€…å¸Œæœ›èƒ½æ‰¾åˆ°ä¸€ç¨®æ–¹æ³•ä¾†æ¸›å°‘é€™ç¨®æ’æ–¥åæ‡‰ï¼Œé€²è€Œæé«˜ç§»æ¤æˆåŠŸçš„æ©Ÿæœƒã€‚é€™å°æ–¼éœ€è¦å™¨å®˜ç§»æ¤çš„æ‚£è€…ä¾†èªªï¼Œå¯èƒ½æ˜¯ä¸€å€‹é‡è¦çš„é€²å±•ï¼Œå› ç‚ºå®ƒæœ‰åŠ©æ–¼æ”¹å–„ä»–å€‘çš„ç”Ÿæ´»å“è³ªå’Œå¥åº·ç‹€æ³ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°æ–¼æ€¥æ€§æ’æ–¥åæ‡‰çš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯åœ¨çš®è†šç§»æ¤æ¨¡å‹ä¸­çš„æ•ˆæœã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½å¤ æ”¹å–„å…ç–«ç´°èƒçš„æ´»åŒ–æƒ…æ³ï¼Œä¸¦ä¸”æé«˜ç§»æ¤å™¨å®˜çš„å­˜æ´»ç‡ã€‚é›–ç„¶ä¹‹å‰å·²çŸ¥è˜¿è””ç¡«ç´ å…·æœ‰æŠ—ç™¼ç‚å’Œå…ç–«èª¿ç¯€çš„ç‰¹æ€§ï¼Œä½†å…¶å…·é«”çš„ä½œç”¨æ©Ÿåˆ¶ä»ç„¶ä¸æ˜ï¼Œå› æ­¤é€™é …ç ”ç©¶æ—¨åœ¨å¡«è£œé€™ä¸€çŸ¥è­˜ç©ºç™½ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ç†±æ•æ€§èšåˆç‰©æ°´å‡è† ï¼Œå°‡è˜¿è””ç¡«ç´ å’Œé€æ˜è³ªé…¸æ··åˆï¼Œè£½æˆä¸€ç¨®æ–°çš„æ°´å‡è† ï¼Œä¸¦å°‡å…¶æ‡‰ç”¨æ–¼å°é¼ çš„çš®è†šç§»æ¤æ¨¡å‹ä¸­ã€‚å¯¦é©—ä¸­ï¼Œå°‡ä¾›é«”å°é¼ çš„çš®è†šç§»æ¤åˆ°æ¥å—è€…å°é¼ èº«ä¸Šï¼Œä¸¦é€²è¡Œäº†ç´°èƒæ¯’æ€§æ¸¬è©¦ä»¥ç¢ºä¿æ–°æ°´å‡è† çš„å®‰å…¨æ€§ã€‚ç ”ç©¶è€…è§€å¯Ÿäº†ä¸åŒè™•ç†ä¸‹çš„ç§»æ¤å™¨å®˜å­˜æ´»æƒ…æ³ï¼Œä¸¦é€²è¡Œäº†çµ„ç¹”å­¸å’Œæµå¼ç´°èƒè¡“åˆ†æï¼Œä»¥è©•ä¼°å…ç–«åæ‡‰çš„è®ŠåŒ–ã€‚\n\nä¸»è¦çš„ç™¼ç¾æ˜¯ï¼Œä½¿ç”¨è˜¿è””ç¡«ç´ çš„æ°´å‡è† è™•ç†å¾Œï¼Œå°é¼ çš„ç§»æ¤å™¨å®˜å­˜æ´»ç‡é¡¯è‘—æé«˜ï¼Œé”åˆ°80%ï¼Œè€Œæœªè™•ç†çš„å°é¼ åœ¨ç¬¬9å¤©æ™‚å‰‡100%å‡ºç¾æ’æ–¥åæ‡‰ã€‚æ­¤å¤–ï¼Œçµ„ç¹”å­¸åˆ†æé¡¯ç¤ºï¼Œæ¥å—è™•ç†çš„å°é¼ çš®è†šä¸­ç‚ç—‡ç´°èƒçš„æ•¸é‡è¼ƒå°‘ï¼Œæµå¼ç´°èƒè¡“çš„çµæœä¹Ÿé¡¯ç¤ºï¼Œå…ç–«ç´°èƒçš„æ´»åŒ–ç¨‹åº¦é™ä½ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼å»¶é²æ€¥æ€§æ’æ–¥åæ‡‰çš„ç™¼ç”Ÿï¼Œä¸¦å»¶é•·ç§»æ¤å™¨å®˜çš„å­˜æ´»æ™‚é–“ï¼Œç‚ºæœªä¾†çš„å™¨å®˜ç§»æ¤ç ”ç©¶æä¾›äº†æ–°çš„æ–¹å‘ã€‚",
    "fb_post": "æ ¹æ“šã€ŠACS applied bio materialsã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± ä½ çŸ¥é“å—ï¼Ÿè˜¿è””è£¡é¢æœ‰ä¸€ç¨®ç¥å¥‡çš„æˆåˆ†å«åšè˜¿è””ç¡«ç´ ï¼Œç§‘å­¸å®¶å€‘æœ€è¿‘ç™¼ç¾å®ƒå¯èƒ½å°å™¨å®˜ç§»æ¤æœ‰å¹«åŠ©å“¦ï¼\n\né€™é …ç ”ç©¶é—œå¿ƒçš„å•é¡Œæ˜¯ï¼šè˜¿è””ç¡«ç´ èƒ½å¦æ¸›å°‘ç§»æ¤å¾Œçš„æ’æ–¥åæ‡‰ï¼Œè®“å™¨å®˜å­˜æ´»å¾—æ›´ä¹…ï¼Ÿç ”ç©¶è€…å€‘åœ¨å°é¼ çš„çš®è†šç§»æ¤å¯¦é©—ä¸­ï¼Œä½¿ç”¨äº†è˜¿è””ç¡«ç´ å’Œé€æ˜è³ªé…¸è£½æˆäº†ä¸€ç¨®æ–°çš„æ°´å‡è† ï¼Œç„¶å¾Œé€²è¡Œäº†ä¸€ç³»åˆ—çš„æ¸¬è©¦ï¼Œçœ‹çœ‹é€™ç¨®æ°´å‡è† å°ç§»æ¤å™¨å®˜çš„å½±éŸ¿ã€‚\n\nçµæœé¡¯ç¤ºï¼Œä½¿ç”¨è˜¿è””ç¡«ç´ çš„æ°´å‡è† å¾Œï¼Œå°é¼ çš„ç§»æ¤å™¨å®˜å­˜æ´»ç‡é”åˆ°80%ï¼Œè€Œæœªè™•ç†çš„å°é¼ åœ¨ç¬¬9å¤©æ™‚å…¨éƒ¨å‡ºç¾æ’æ–¥åæ‡‰ï¼é€™æ„å‘³è‘—è˜¿è””ç¡«ç´ å¯èƒ½å¹«åŠ©å»¶é²æ’æ–¥åæ‡‰ï¼Œè®“ç§»æ¤å™¨å®˜çš„å£½å‘½æ›´é•·ã€‚\n\nğŸ” ä¸»è¦ç™¼ç¾ï¼š\n1. è˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æé«˜ç§»æ¤å™¨å®˜çš„å­˜æ´»ç‡ã€‚\n2. ä½¿ç”¨è˜¿è””ç¡«ç´ å¾Œï¼Œç‚ç—‡ç´°èƒçš„æ•¸é‡æ¸›å°‘ï¼Œå…ç–«åæ‡‰é™ä½ã€‚\n3. é€™é …ç ”ç©¶ç‚ºæœªä¾†çš„å™¨å®˜ç§»æ¤æä¾›äº†æ–°æ–¹å‘ï¼",
    "image_prompt": "Create a flat design infographic that explains the experiment and main results of a study on the effects of a compound called sulforaphane from radishes on organ transplantation. Include symbols of radishes and sulforaphane, simplified illustrations of experimental subjects like mice or cells, arrows or flow lines to indicate the experimental steps, and a section highlighting the main results, such as increased organ survival rates and decreased inflammation.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "æ€¥æ€§æ’æ–¥åæ‡‰ Acute Rejection",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41159773/"
  },
  {
    "id": "41196460",
    "title_en": "Sulforaphane: a natural organosulfur having potential to modulate apoptosis and survival signalling in cancer.",
    "pub_date": "2025 Nov",
    "journal": "Discover oncology",
    "abstract_en": "Owing to its ever-growing range of pharmacological advantages, sulforaphane, an isothiocyanate from cruciferous vegetables such as broccoli, is becoming increasingly popular. This review aims to provide a thorough understanding and a current update on the application of sulforaphane in cancer treatment. Sulforaphane interacts with many signaling molecules that control various pathways in malignant cells, including angiogenesis, apoptosis, cell cycle arrest, metastasis, and inflammation pathways. This review examines the effects of this isothiocyanate on inflammatory mediators, caspases, MMPs, cytokines, and the proteins Bax and Bcl-2. Furthermore, the advantages of nanotechnology and synergistic effects in sulforaphane applications are also reviewed. As per evidence, sulforaphane is a shining example of how ethno-pharmacological expertise can be used to create modern medications.",
    "para1": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®ä¾†è‡ªé’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœçš„åŒ–åˆç‰©ï¼Œå› å…¶æ½›åœ¨çš„è—¥ç†å„ªå‹¢è€Œå—åˆ°è¶Šä¾†è¶Šå¤šçš„é—œæ³¨ã€‚é€™é …ç ”ç©¶æä¾›äº†æœ‰é—œè˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„æ‡‰ç”¨çš„æœ€æ–°è³‡è¨Šï¼Œé€™å°æ–¼å¥åº·ä¿ƒé€²å’Œç–¾ç—…é é˜²å…·æœ‰é‡è¦æ„ç¾©ã€‚äº†è§£é€™ç¨®åŒ–åˆç‰©å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„ä¸åŒç”Ÿç‰©é€”å¾‘ï¼Œå¯èƒ½æœ‰åŠ©æ–¼é–‹ç™¼æ–°çš„æ²»ç™‚æ–¹æ³•ï¼Œä¸¦ä¿ƒé€²äººå€‘å°å¥åº·é£²é£Ÿçš„é‡è¦–ï¼Œç‰¹åˆ¥æ˜¯å¢åŠ é’èŠ±æ¤°èœç­‰è”¬èœçš„æ”å–ï¼Œå¾è€Œå¯èƒ½é™ä½æŸäº›ç™Œç—‡çš„é¢¨éšªã€‚",
    "para2": "é€™ç¯‡ç¶œè¿°çš„ä¸»é¡Œæ˜¯è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„æ‡‰ç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯è˜¿è””ç¡«ç´ å¦‚ä½•èˆ‡ç™Œç´°èƒä¸­çš„å¤šç¨®ä¿¡è™Ÿåˆ†å­äº’å‹•ï¼Œä¸¦å½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·å’Œæ“´æ•£ã€‚ç‰¹åˆ¥æ˜¯ï¼Œé€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ å°æ–¼ç™Œç´°èƒçš„å¤šå€‹ç”Ÿç‰©é€”å¾‘çš„å½±éŸ¿ï¼ŒåŒ…æ‹¬è¡€ç®¡ç”Ÿæˆã€ç´°èƒå‡‹äº¡ã€ç´°èƒé€±æœŸåœæ»¯ã€è½‰ç§»ä»¥åŠç‚ç—‡åæ‡‰ç­‰ï¼Œé€™äº›éƒ½æ˜¯ç™Œç—‡ç™¼å±•éç¨‹ä¸­é‡è¦çš„ç’°ç¯€ã€‚",
    "para3": "é€™é …ç ”ç©¶ä¸»è¦æ˜¯æ–‡ç»ç¶œè¿°ï¼Œé€šéåˆ†æç¾æœ‰çš„ç ”ç©¶è³‡æ–™ï¼Œä¾†æ¢è¨è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶å’Œæ•ˆæœã€‚ç ”ç©¶è€…å›é¡§äº†è˜¿è””ç¡«ç´ å°æ–¼ç‚ç—‡ä»‹è³ªã€å‡‹äº¡é…¶ã€åŸºè³ªé‡‘å±¬è›‹ç™½é…¶ã€ç´°èƒå› å­ä»¥åŠBaxå’ŒBcl-2ç­‰è›‹ç™½è³ªçš„å½±éŸ¿ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„æ¢è¨äº†ç´ç±³æŠ€è¡“å’Œè˜¿è””ç¡«ç´ æ‡‰ç”¨ä¸­çš„å”åŒæ•ˆæ‡‰ï¼Œé€™äº›éƒ½æ˜¯æå‡å…¶æ²»ç™‚æ½›åŠ›çš„é‡è¦å› ç´ ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨èª¿ç¯€å¤šç¨®èˆ‡ç™Œç—‡ç›¸é—œçš„ç”Ÿç‰©é€”å¾‘ä¸­æ‰®æ¼”è‘—é‡è¦è§’è‰²ï¼Œä¸¦å¯èƒ½å°ç™Œç´°èƒçš„ç”Ÿé•·å’Œæ“´æ•£ç”¢ç”Ÿå½±éŸ¿ã€‚é›–ç„¶ç›®å‰çš„è­‰æ“šé¡¯ç¤ºè˜¿è””ç¡«ç´ å…·æœ‰æ½›åœ¨çš„æ²»ç™‚æ•ˆæœï¼Œä½†ä»éœ€é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºå®šå…¶å…·é«”çš„ç™‚æ•ˆå’Œæ‡‰ç”¨æ–¹å¼ã€‚é€™é …ç ”ç©¶å¼·èª¿äº†å‚³çµ±è—¥ç†çŸ¥è­˜åœ¨ç¾ä»£è—¥ç‰©é–‹ç™¼ä¸­çš„é‡è¦æ€§ï¼Œä¸¦ç‚ºæœªä¾†çš„ç ”ç©¶æä¾›äº†æ–¹å‘ã€‚",
    "explanation_zh": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®ä¾†è‡ªé’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœçš„åŒ–åˆç‰©ï¼Œå› å…¶æ½›åœ¨çš„è—¥ç†å„ªå‹¢è€Œå—åˆ°è¶Šä¾†è¶Šå¤šçš„é—œæ³¨ã€‚é€™é …ç ”ç©¶æä¾›äº†æœ‰é—œè˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„æ‡‰ç”¨çš„æœ€æ–°è³‡è¨Šï¼Œé€™å°æ–¼å¥åº·ä¿ƒé€²å’Œç–¾ç—…é é˜²å…·æœ‰é‡è¦æ„ç¾©ã€‚äº†è§£é€™ç¨®åŒ–åˆç‰©å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„ä¸åŒç”Ÿç‰©é€”å¾‘ï¼Œå¯èƒ½æœ‰åŠ©æ–¼é–‹ç™¼æ–°çš„æ²»ç™‚æ–¹æ³•ï¼Œä¸¦ä¿ƒé€²äººå€‘å°å¥åº·é£²é£Ÿçš„é‡è¦–ï¼Œç‰¹åˆ¥æ˜¯å¢åŠ é’èŠ±æ¤°èœç­‰è”¬èœçš„æ”å–ï¼Œå¾è€Œå¯èƒ½é™ä½æŸäº›ç™Œç—‡çš„é¢¨éšªã€‚\n\né€™ç¯‡ç¶œè¿°çš„ä¸»é¡Œæ˜¯è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„æ‡‰ç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯è˜¿è””ç¡«ç´ å¦‚ä½•èˆ‡ç™Œç´°èƒä¸­çš„å¤šç¨®ä¿¡è™Ÿåˆ†å­äº’å‹•ï¼Œä¸¦å½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·å’Œæ“´æ•£ã€‚ç‰¹åˆ¥æ˜¯ï¼Œé€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ å°æ–¼ç™Œç´°èƒçš„å¤šå€‹ç”Ÿç‰©é€”å¾‘çš„å½±éŸ¿ï¼ŒåŒ…æ‹¬è¡€ç®¡ç”Ÿæˆã€ç´°èƒå‡‹äº¡ã€ç´°èƒé€±æœŸåœæ»¯ã€è½‰ç§»ä»¥åŠç‚ç—‡åæ‡‰ç­‰ï¼Œé€™äº›éƒ½æ˜¯ç™Œç—‡ç™¼å±•éç¨‹ä¸­é‡è¦çš„ç’°ç¯€ã€‚\n\né€™é …ç ”ç©¶ä¸»è¦æ˜¯æ–‡ç»ç¶œè¿°ï¼Œé€šéåˆ†æç¾æœ‰çš„ç ”ç©¶è³‡æ–™ï¼Œä¾†æ¢è¨è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶å’Œæ•ˆæœã€‚ç ”ç©¶è€…å›é¡§äº†è˜¿è””ç¡«ç´ å°æ–¼ç‚ç—‡ä»‹è³ªã€å‡‹äº¡é…¶ã€åŸºè³ªé‡‘å±¬è›‹ç™½é…¶ã€ç´°èƒå› å­ä»¥åŠBaxå’ŒBcl-2ç­‰è›‹ç™½è³ªçš„å½±éŸ¿ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„æ¢è¨äº†ç´ç±³æŠ€è¡“å’Œè˜¿è””ç¡«ç´ æ‡‰ç”¨ä¸­çš„å”åŒæ•ˆæ‡‰ï¼Œé€™äº›éƒ½æ˜¯æå‡å…¶æ²»ç™‚æ½›åŠ›çš„é‡è¦å› ç´ ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨èª¿ç¯€å¤šç¨®èˆ‡ç™Œç—‡ç›¸é—œçš„ç”Ÿç‰©é€”å¾‘ä¸­æ‰®æ¼”è‘—é‡è¦è§’è‰²ï¼Œä¸¦å¯èƒ½å°ç™Œç´°èƒçš„ç”Ÿé•·å’Œæ“´æ•£ç”¢ç”Ÿå½±éŸ¿ã€‚é›–ç„¶ç›®å‰çš„è­‰æ“šé¡¯ç¤ºè˜¿è””ç¡«ç´ å…·æœ‰æ½›åœ¨çš„æ²»ç™‚æ•ˆæœï¼Œä½†ä»éœ€é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºå®šå…¶å…·é«”çš„ç™‚æ•ˆå’Œæ‡‰ç”¨æ–¹å¼ã€‚é€™é …ç ”ç©¶å¼·èª¿äº†å‚³çµ±è—¥ç†çŸ¥è­˜åœ¨ç¾ä»£è—¥ç‰©é–‹ç™¼ä¸­çš„é‡è¦æ€§ï¼Œä¸¦ç‚ºæœªä¾†çš„ç ”ç©¶æä¾›äº†æ–¹å‘ã€‚",
    "fb_post": "æ ¹æ“šã€ŠDiscover oncologyã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ±ä½ çŸ¥é“å—ï¼Ÿåƒé’èŠ±æ¤°èœä¸åƒ…èƒ½è®“ä½ çš„é¤ç›¤æ›´è±å¯Œï¼Œé‚„å¯èƒ½å°æŠ—ç™Œç—‡ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶å°ˆæ³¨æ–¼ä¸€ç¨®å«åšè˜¿è””ç¡«ç´ çš„åŒ–åˆç‰©ï¼Œå®ƒä¾†è‡ªé’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœï¼Œä¸¦è¢«èªç‚ºå°å¥åº·æœ‰å¾ˆå¤šå¥½è™•ã€‚é€™é …ç ”ç©¶çš„ç§‘å­¸å®¶å€‘æƒ³äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·èˆ‡æ“´æ•£ã€‚  \n  \nä»–å€‘ä»”ç´°ç ”ç©¶äº†è˜¿è””ç¡«ç´ å¦‚ä½•èˆ‡ç™Œç´°èƒä¸­çš„ä¿¡è™Ÿåˆ†å­äº’å‹•ï¼Œä¸¦æ¢è¨äº†å®ƒå°å¤šç¨®ç”Ÿç‰©é€”å¾‘çš„å½±éŸ¿ï¼Œæ¯”å¦‚ç´°èƒçš„æ­»äº¡ã€è¡€ç®¡ç”Ÿæˆï¼ˆå½¢æˆæ–°è¡€ç®¡çš„éç¨‹ï¼‰ã€ä»¥åŠç‚ç—‡åæ‡‰ç­‰ã€‚é€™äº›éƒ½æ˜¯ç™Œç—‡ç™¼å±•ä¸­éå¸¸é‡è¦çš„ç’°ç¯€ã€‚  \n  \nç ”ç©¶è€…å€‘å›é¡§äº†è¨±å¤šæ—¢æœ‰çš„æ–‡ç»ï¼Œåˆ†æäº†è˜¿è””ç¡«ç´ å°ä¸åŒç”Ÿç‰©åˆ†å­çš„å½±éŸ¿ï¼Œä¸¦è€ƒæ…®äº†ç´ç±³æŠ€è¡“å¦‚ä½•æå‡é€™ç¨®åŒ–åˆç‰©çš„æ²»ç™‚æ½›åŠ›ã€‚  \n  \né€™é …ç ”ç©¶çš„ä¸»è¦ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ å°ç™Œç´°èƒçš„ç”Ÿé•·å’Œæ“´æ•£æœ‰æ½›åœ¨çš„å½±éŸ¿ï¼Œä½†ä»éœ€è¦æ›´å¤šçš„ç ”ç©¶ä¾†ç¢ºå®šå…·é«”çš„æ•ˆæœã€‚é€™å‘Šè¨´æˆ‘å€‘ï¼Œå‚³çµ±çš„è—¥ç†çŸ¥è­˜åœ¨ç¾ä»£è—¥ç‰©é–‹ç™¼ä¸­ä»ç„¶éå¸¸é‡è¦ã€‚  \n  \nâœ¨é‡é»æ•´ç†ï¼š  \n1. è˜¿è””ç¡«ç´ ä¾†è‡ªé’èŠ±æ¤°èœï¼Œå¯èƒ½æœ‰åŠ©æ–¼ç™Œç—‡æ²»ç™‚ã€‚  \n2. ç ”ç©¶ç™¼ç¾å®ƒå½±éŸ¿ç™Œç´°èƒçš„å¤šå€‹ç”Ÿç‰©é€”å¾‘ã€‚  \n3. é‚„éœ€è¦æ›´å¤šç ”ç©¶ä¾†ç¢ºèªå…¶æ•ˆæœå’Œæ‡‰ç”¨ã€‚  \nä¸€èµ·ä¾†é‡è¦–å¥åº·é£²é£Ÿï¼Œè®“æˆ‘å€‘çš„èº«é«”æ›´å¼·å£¯å§ï¼",
    "image_prompt": "Create a flat design infographic with a light background, illustrating the research process and main findings about sulforaphane from broccoli. Include simplified icons of broccoli and sulforaphane, as well as representations of experimental subjects like cells or animals. Use arrows or flow lines to show the steps of the experiment. Include a section labeled 'Main Findings' highlighting protective effects or changes observed in cancer cells.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "ç™Œç—‡ Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41196460/"
  },
  {
    "id": "41184790",
    "title_en": "Efficacy and safety of sulforaphane in schizophrenia: a systematic review and meta-analysis of randomized controlled trials.",
    "pub_date": "2025 Nov",
    "journal": "BMC psychiatry",
    "abstract_en": "Sulforaphane, an isothiocyanate derived from cruciferous vegetables (e.g., broccoli sprouts), has been explored for its antioxidant and anti-inflammatory properties. This is the first systematic review and meta-analysis to explore the therapeutic potentials of sulforaphane in schizophrenia. We searched PubMed, Scopus, Web of Science, and Cochrane Central for studies from inception to April 2025. We included randomized controlled trials (RCTs) evaluating the efficacy of sulforaphane in schizophrenia. The primary outcomes were changes in the Positive and Negative Syndrome Scale (PANSS) total and its subscales. Secondary outcomes included cognitive measures, metabolic markers, and safety. Four RCTs with 369 schizophrenia patients were included. Sulforaphane did not significantly improve PANSS total or positive symptom scores at the latest follow-up (ranging from 24 weeks to 18 weeks) or at a consistent 12-week time point. However, a modest improvement in negative symptoms was found at 12 week- time point (MD= -1.06; 95% CI: -1.95 to -0.16; pâ€‰=â€‰0.02), which was not maintained at the latest follow-up. General psychopathology scores improved significantly (MD= -1.5; 95% CI: -2.78 to -0.23; pâ€‰=â€‰0.02). No cognitive benefits were observed. Sulforaphane led to significant reductions in metabolic markers, including LDL, triglycerides, and cholesterol. Discontinuation rates were lower in the sulforaphane group (RRâ€‰=â€‰0.68; 95% CI: 0.49 to 0.95; pâ€‰=â€‰0.02). The study provides initial insights into sulforaphane's potential therapeutic effects in schizophrenia, showing modest improvements in general psychopathology and negative symptoms, with favorable metabolic changes and lower discontinuation rates. Due to limited data and heterogeneity, the study findings should be interpreted with caution. Not applicable.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç²¾ç¥å¥åº·æ–¹é¢ã€‚ç ”ç©¶æŒ‡å‡ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°ç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…æœ‰ä¸€å®šçš„å¹«åŠ©ï¼Œå°¤å…¶æ˜¯åœ¨æ”¹å–„ä¸€äº›è² é¢ç—‡ç‹€å’Œæ•´é«”å¿ƒç†ç‹€æ…‹ä¸Šã€‚é›–ç„¶é€™äº›æ”¹å–„ä¸ä¸€å®šèƒ½å¤ å®Œå…¨æ²»ç™’ç–¾ç—…ï¼Œä½†å»é¡¯ç¤ºå‡ºè˜¿è””ç¡«ç´ åœ¨ç²¾ç¥å¥åº·é ˜åŸŸçš„æ½›åŠ›ï¼Œå€¼å¾—é€²ä¸€æ­¥æ¢ç´¢å’Œç ”ç©¶ã€‚é€™ä¹Ÿæé†’æˆ‘å€‘ï¼Œé£²é£Ÿä¸­çš„æŸäº›æˆåˆ†å¯èƒ½å°å¿ƒç†å¥åº·æœ‰å½±éŸ¿ï¼Œé¼“å‹µäººå€‘å¤šæ”å–å¯Œå«é€™é¡æˆåˆ†çš„é£Ÿç‰©ï¼Œå¦‚é’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨ç²¾ç¥åˆ†è£‚ç—‡æ²»ç™‚ä¸­çš„æ½›åœ¨ç™‚æ•ˆã€‚ç²¾ç¥åˆ†è£‚ç—‡æ˜¯ä¸€ç¨®è¤‡é›œçš„ç²¾ç¥ç–¾ç—…ï¼Œå½±éŸ¿æ‚£è€…çš„æ€ç¶­ã€æƒ…æ„Ÿå’Œè¡Œç‚ºã€‚ç ”ç©¶è€…å¸Œæœ›é€šéç³»çµ±æ€§å›é¡§å’Œçµ±åˆåˆ†æï¼Œäº†è§£è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æ”¹å–„é€™ç¨®ç–¾ç—…çš„ç—‡ç‹€ï¼Œç‰¹åˆ¥æ˜¯é‡å°æ­£å‘å’Œè² å‘ç—‡ç‹€çš„å½±éŸ¿ã€‚é€™æ˜¯é¦–å€‹é‡å°æ­¤ä¸»é¡Œé€²è¡Œçš„ç³»çµ±æ€§ç ”ç©¶ï¼Œç›®çš„æ˜¯ç‚ºäº†æä¾›æ›´æ¸…æ™°çš„è­‰æ“šï¼Œå¹«åŠ©æœªä¾†çš„è‡¨åºŠæ‡‰ç”¨ã€‚",
    "para3": "åœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…é€²è¡Œäº†ç³»çµ±æ€§çš„æ–‡ç»æœå°‹ï¼Œå¾å¤šå€‹è³‡æ–™åº«ä¸­æ”¶é›†ç›¸é—œçš„éš¨æ©Ÿå°ç…§è©¦é©—ï¼ˆRCTsï¼‰ï¼Œé€™äº›è©¦é©—è©•ä¼°äº†è˜¿è””ç¡«ç´ å°ç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…çš„ç™‚æ•ˆã€‚æœ€çµ‚ç´å…¥äº†å››é …RCTï¼Œæ¶‰åŠ369åç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…ã€‚ç ”ç©¶ä¸»è¦è©•ä¼°çš„çµæœåŒ…æ‹¬æ­£è² ç—‡ç‹€é‡è¡¨ï¼ˆPANSSï¼‰çš„è®ŠåŒ–ï¼Œä»¥åŠå…¶ä»–èªçŸ¥æŒ‡æ¨™å’Œä»£è¬æ¨™è¨˜ã€‚ç ”ç©¶è€…ä¹Ÿé—œæ³¨äº†å®‰å…¨æ€§å•é¡Œï¼Œä»¥ç¢ºä¿è˜¿è””ç¡«ç´ çš„ä½¿ç”¨ä¸æœƒå°æ‚£è€…é€ æˆä¸è‰¯å½±éŸ¿ã€‚",
    "para4": "ä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨æ”¹å–„PANSSç¸½åˆ†å’Œæ­£å‘ç—‡ç‹€æ–¹é¢ä¸¦æ²’æœ‰é¡¯è‘—æ•ˆæœï¼Œä½†åœ¨12é€±çš„æ™‚é–“é»ä¸Šï¼Œè² å‘ç—‡ç‹€æœ‰è¼•å¾®æ”¹å–„ã€‚æ­¤å¤–ï¼Œæ•´é«”å¿ƒç†ç—…ç†å­¸çš„è©•åˆ†ä¹Ÿé¡¯ç¤ºå‡ºé¡¯è‘—æ”¹å–„ã€‚å„˜ç®¡å¦‚æ­¤ï¼Œé€™äº›æ”¹å–„åœ¨å¾ŒçºŒçš„éš¨è¨ªä¸­ä¸¦æœªæŒçºŒã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—é™ä½ä¸€äº›ä»£è¬æ¨™è¨˜ï¼Œå¦‚ä½å¯†åº¦è„‚è›‹ç™½ï¼ˆLDLï¼‰ã€ä¸‰é…¸ç”˜æ²¹è„‚å’Œè†½å›ºé†‡ï¼Œä¸”åœ¨è˜¿è””ç¡«ç´ çµ„çš„æ‚£è€…ä¸­ï¼Œåœè—¥ç‡è¼ƒä½ã€‚é€™äº›çµæœæä¾›äº†è˜¿è””ç¡«ç´ åœ¨ç²¾ç¥åˆ†è£‚ç—‡æ²»ç™‚ä¸­çš„åˆæ­¥è¦‹è§£ï¼Œä½†ç”±æ–¼æ•¸æ“šæœ‰é™ï¼Œç ”ç©¶çµæœéœ€è¬¹æ…è§£è®€ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç²¾ç¥å¥åº·æ–¹é¢ã€‚ç ”ç©¶æŒ‡å‡ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°ç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…æœ‰ä¸€å®šçš„å¹«åŠ©ï¼Œå°¤å…¶æ˜¯åœ¨æ”¹å–„ä¸€äº›è² é¢ç—‡ç‹€å’Œæ•´é«”å¿ƒç†ç‹€æ…‹ä¸Šã€‚é›–ç„¶é€™äº›æ”¹å–„ä¸ä¸€å®šèƒ½å¤ å®Œå…¨æ²»ç™’ç–¾ç—…ï¼Œä½†å»é¡¯ç¤ºå‡ºè˜¿è””ç¡«ç´ åœ¨ç²¾ç¥å¥åº·é ˜åŸŸçš„æ½›åŠ›ï¼Œå€¼å¾—é€²ä¸€æ­¥æ¢ç´¢å’Œç ”ç©¶ã€‚é€™ä¹Ÿæé†’æˆ‘å€‘ï¼Œé£²é£Ÿä¸­çš„æŸäº›æˆåˆ†å¯èƒ½å°å¿ƒç†å¥åº·æœ‰å½±éŸ¿ï¼Œé¼“å‹µäººå€‘å¤šæ”å–å¯Œå«é€™é¡æˆåˆ†çš„é£Ÿç‰©ï¼Œå¦‚é’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨ç²¾ç¥åˆ†è£‚ç—‡æ²»ç™‚ä¸­çš„æ½›åœ¨ç™‚æ•ˆã€‚ç²¾ç¥åˆ†è£‚ç—‡æ˜¯ä¸€ç¨®è¤‡é›œçš„ç²¾ç¥ç–¾ç—…ï¼Œå½±éŸ¿æ‚£è€…çš„æ€ç¶­ã€æƒ…æ„Ÿå’Œè¡Œç‚ºã€‚ç ”ç©¶è€…å¸Œæœ›é€šéç³»çµ±æ€§å›é¡§å’Œçµ±åˆåˆ†æï¼Œäº†è§£è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æ”¹å–„é€™ç¨®ç–¾ç—…çš„ç—‡ç‹€ï¼Œç‰¹åˆ¥æ˜¯é‡å°æ­£å‘å’Œè² å‘ç—‡ç‹€çš„å½±éŸ¿ã€‚é€™æ˜¯é¦–å€‹é‡å°æ­¤ä¸»é¡Œé€²è¡Œçš„ç³»çµ±æ€§ç ”ç©¶ï¼Œç›®çš„æ˜¯ç‚ºäº†æä¾›æ›´æ¸…æ™°çš„è­‰æ“šï¼Œå¹«åŠ©æœªä¾†çš„è‡¨åºŠæ‡‰ç”¨ã€‚\n\nåœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…é€²è¡Œäº†ç³»çµ±æ€§çš„æ–‡ç»æœå°‹ï¼Œå¾å¤šå€‹è³‡æ–™åº«ä¸­æ”¶é›†ç›¸é—œçš„éš¨æ©Ÿå°ç…§è©¦é©—ï¼ˆRCTsï¼‰ï¼Œé€™äº›è©¦é©—è©•ä¼°äº†è˜¿è””ç¡«ç´ å°ç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…çš„ç™‚æ•ˆã€‚æœ€çµ‚ç´å…¥äº†å››é …RCTï¼Œæ¶‰åŠ369åç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…ã€‚ç ”ç©¶ä¸»è¦è©•ä¼°çš„çµæœåŒ…æ‹¬æ­£è² ç—‡ç‹€é‡è¡¨ï¼ˆPANSSï¼‰çš„è®ŠåŒ–ï¼Œä»¥åŠå…¶ä»–èªçŸ¥æŒ‡æ¨™å’Œä»£è¬æ¨™è¨˜ã€‚ç ”ç©¶è€…ä¹Ÿé—œæ³¨äº†å®‰å…¨æ€§å•é¡Œï¼Œä»¥ç¢ºä¿è˜¿è””ç¡«ç´ çš„ä½¿ç”¨ä¸æœƒå°æ‚£è€…é€ æˆä¸è‰¯å½±éŸ¿ã€‚\n\nä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨æ”¹å–„PANSSç¸½åˆ†å’Œæ­£å‘ç—‡ç‹€æ–¹é¢ä¸¦æ²’æœ‰é¡¯è‘—æ•ˆæœï¼Œä½†åœ¨12é€±çš„æ™‚é–“é»ä¸Šï¼Œè² å‘ç—‡ç‹€æœ‰è¼•å¾®æ”¹å–„ã€‚æ­¤å¤–ï¼Œæ•´é«”å¿ƒç†ç—…ç†å­¸çš„è©•åˆ†ä¹Ÿé¡¯ç¤ºå‡ºé¡¯è‘—æ”¹å–„ã€‚å„˜ç®¡å¦‚æ­¤ï¼Œé€™äº›æ”¹å–„åœ¨å¾ŒçºŒçš„éš¨è¨ªä¸­ä¸¦æœªæŒçºŒã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—é™ä½ä¸€äº›ä»£è¬æ¨™è¨˜ï¼Œå¦‚ä½å¯†åº¦è„‚è›‹ç™½ï¼ˆLDLï¼‰ã€ä¸‰é…¸ç”˜æ²¹è„‚å’Œè†½å›ºé†‡ï¼Œä¸”åœ¨è˜¿è””ç¡«ç´ çµ„çš„æ‚£è€…ä¸­ï¼Œåœè—¥ç‡è¼ƒä½ã€‚é€™äº›çµæœæä¾›äº†è˜¿è””ç¡«ç´ åœ¨ç²¾ç¥åˆ†è£‚ç—‡æ²»ç™‚ä¸­çš„åˆæ­¥è¦‹è§£ï¼Œä½†ç”±æ–¼æ•¸æ“šæœ‰é™ï¼Œç ”ç©¶çµæœéœ€è¬¹æ…è§£è®€ã€‚",
    "fb_post": "æ ¹æ“šã€ŠBMC psychiatryã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ±ä½ çŸ¥é“å—ï¼Ÿè˜¿è””ç¡«ç´ ä¸åƒ…æ˜¯å¥åº·é£²é£Ÿçš„ä¸€éƒ¨åˆ†ï¼Œé‚„å¯èƒ½å°ç²¾ç¥å¥åº·æœ‰å¹«åŠ©ï¼é€™é …æ–°ç ”ç©¶å°ˆæ³¨æ–¼è˜¿è””ç¡«ç´ å°ç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…çš„å½±éŸ¿ï¼Œæƒ³äº†è§£å®ƒæ˜¯å¦èƒ½æ”¹å–„ç—‡ç‹€ã€‚ç ”ç©¶è€…å€‘é€²è¡Œäº†ç³»çµ±æ€§çš„åˆ†æï¼Œå¾å¤šå€‹è³‡æ–™åº«ä¸­æ‰¾å‡ºç›¸é—œçš„éš¨æ©Ÿå°ç…§è©¦é©—ï¼Œé€™äº›è©¦é©—å…±æ¶‰åŠ369åæ‚£è€…ã€‚çµæœé¡¯ç¤ºï¼Œé›–ç„¶åœ¨æ”¹å–„ç¸½åˆ†å’Œæ­£å‘ç—‡ç‹€ä¸Šæ²’æœ‰é¡¯è‘—æ•ˆæœï¼Œä½†è² å‘ç—‡ç‹€æœ‰è¼•å¾®æ”¹å–„ï¼Œæ•´é«”å¿ƒç†ç‹€æ…‹ä¹Ÿæœ‰æå‡ï¼é€™äº›çµæœè®“æˆ‘å€‘çœ‹åˆ°è˜¿è””ç¡«ç´ åœ¨ç²¾ç¥å¥åº·æ–¹é¢çš„æ½›åŠ›ï¼Œä½†ä»éœ€æ›´å¤šç ”ç©¶ä¾†é©—è­‰ã€‚ é€™è£¡æœ‰å¹¾å€‹é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½å°æ”¹å–„ç²¾ç¥åˆ†è£‚ç—‡çš„è² å‘ç—‡ç‹€æœ‰å¹«åŠ©ã€‚\n2. æ•´é«”å¿ƒç†ç—…ç†å­¸çš„è©•åˆ†æœ‰é¡¯è‘—æ”¹å–„ã€‚\n3. è˜¿è””ç¡«ç´ èƒ½é™ä½ä¸€äº›ä¸è‰¯çš„ä»£è¬æ¨™è¨˜ï¼Œé¡¯ç¤ºå‡ºæ½›åœ¨çš„å¥åº·ç›Šè™•ã€‚è®“æˆ‘å€‘ä¸€èµ·é—œæ³¨é£²é£Ÿå°å¿ƒç†å¥åº·çš„å½±éŸ¿å§ï¼",
    "image_prompt": "Create an infographic that explains the experimental design and main results of the study on sulforaphane. Include simplified illustrations of broccoli or sulforaphane, simplified representations of human subjects, and arrows or flow lines to indicate the steps of the experiment. Include a section labeled 'Main Results' highlighting the effects on negative symptoms and overall psychological state improvements.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "ç²¾ç¥åˆ†è£‚ç—‡ Schizophrenia",
    "is_clinical_trial": true,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41184790/"
  },
  {
    "id": "40992247",
    "title_en": "Assessing the transplacental passage and breastmilk levels of broccoli sprout-derived sulforaphane.",
    "pub_date": "2025 Nov",
    "journal": "Placenta",
    "abstract_en": "Preeclampsia is characterised by hypertension with maternal end-organ dysfunction and/or fetal growth restriction. Sulforaphane, an antioxidant found in broccoli sprouts, has potential as a future therapeutic. With its ability to attenuate the injurious impacts of endothelial dysfunction in vitro, sulforaphane is uniquely positioned to protect against the harmful effects of preeclampsia. However, the transferability of sulforaphane from mother to fetus/baby remains unknown in humans. Uncomplicated pregnant patients (nÂ =Â 8) scheduled for elective caesarean sections (>37 weeks gestation) provided written and informed consent. A single oral dose of EnduraCell, a broccoli sprout extract (equivalent to 21Â mg of sulforaphane), was administered prior to caesarean section. Baseline blood pressure, blood and urine were collected and again at time of operation, alongside umbilical cord blood (vein and artery) and placental samples. 2-4 days post-delivery, a second dose was administered. Two hours later, maternal bloods and breast milk were collected. Samples were processed and analysed by liquid-chromatography mass-spectrometry to measure sulforaphane. Besides an increase in peripheral diastolic blood pressure on the day of caesarean section (pÂ =Â 0.028), there were no changes in maternal blood pressure or heart rate after ingestion of EnduraCell. Sulforaphane was found in maternal serum (70.10Â ng/mlÂ Â±Â 11.90), umbilical cord blood (vein: 25.18Â ng/mLÂ Â±Â 3.11, artery: 18.81Â ng/mLÂ Â±Â 2.36), urine (5726.00Â ng/mLÂ Â±Â 1175.00), placental tissue (10.99Â ng/mgÂ Â±Â 2.11) and breast milk (1.33Â ng/mLÂ Â±Â 2.29). Sulforaphane is present in the umbilical cord and breast milk, providing the world's first evidence of sulforaphane maternal-fetal transfer in humans, and opening avenues for future research into relevant fetal implications.",
    "para1": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†é‡è¦çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨å¦Šå¨ é«˜è¡€å£“ç—‡ï¼ˆå­ç™²å‰ç—‡ï¼‰çš„èƒŒæ™¯ä¸‹ã€‚å­ç™²å‰ç—‡æ˜¯ä¸€ç¨®å¦Šå¨ æœŸé–“çš„ä½µç™¼ç—‡ï¼Œå¯èƒ½å°æ¯è¦ªå’Œèƒå…’é€ æˆåš´é‡å½±éŸ¿ã€‚ç ”ç©¶æŒ‡å‡ºï¼Œè˜¿è””ç¡«ç´ é€™ç¨®å­˜åœ¨æ–¼é’èŠ±æ¤°èœä¸­çš„æŠ—æ°§åŒ–åŠ‘ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ¸›è¼•å…§çš®åŠŸèƒ½éšœç¤™çš„å‚·å®³ï¼Œå¾è€Œå°æŠ—å­ç™²å‰ç—‡çš„æœ‰å®³å½±éŸ¿ã€‚é€™æ„å‘³è‘—ï¼Œé€éé£²é£Ÿä¸­çš„æŸäº›æˆåˆ†ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„å¦Šå¨ æœŸé–“çš„å¥åº·ç‹€æ³ï¼Œä¸¦ç‚ºæœªä¾†çš„æ²»ç™‚æ–¹æ³•æä¾›æ–°çš„æ–¹å‘ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨å¦Šå¨ é«˜è¡€å£“ç—‡ï¼ˆå­ç™²å‰ç—‡ï¼‰ä¸­çš„æ½›åœ¨æ‡‰ç”¨ï¼Œç‰¹åˆ¥æ˜¯å®ƒæ˜¯å¦èƒ½å¤ å¾æ¯é«”è½‰ç§»åˆ°èƒå…’æˆ–å¬°å…’ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯ï¼Œé€™ç¨®æŠ—æ°§åŒ–åŠ‘åœ¨å¦Šå¨ æœŸé–“çš„å®‰å…¨æ€§åŠå…¶å°æ¯å¬°å¥åº·çš„å½±éŸ¿ï¼Œå°¤å…¶æ˜¯å®ƒåœ¨æ¯é«”è¡€æ¶²ã€è‡å¸¶è¡€å’Œæ¯ä¹³ä¸­çš„å­˜åœ¨æƒ…æ³ã€‚é€™äº›å•é¡Œçš„è§£ç­”å°‡æœ‰åŠ©æ–¼äº†è§£è˜¿è””ç¡«ç´ åœ¨å¦Šå¨ æœŸé–“çš„ä½œç”¨ï¼Œä¸¦ç‚ºæœªä¾†çš„è‡¨åºŠæ‡‰ç”¨é‹ªè·¯ã€‚",
    "para3": "é€™é …ç ”ç©¶æ‹›å‹Ÿäº†8åå¥åº·çš„å­•å©¦ï¼Œé€™äº›å­•å©¦åœ¨æ‡·å­•è¶…é37é€±æ™‚ï¼Œè¨ˆåŠƒé€²è¡Œå‰–è…¹ç”¢æ‰‹è¡“ã€‚åƒèˆ‡è€…åœ¨æ‰‹è¡“å‰æ¥å—äº†æ›¸é¢åŒæ„ï¼Œä¸¦æœç”¨äº†å–®åŠ‘é‡çš„é’èŠ±æ¤°èœèƒå–ç‰©EnduraCellï¼Œé€™ç›¸ç•¶æ–¼21æ¯«å…‹çš„è˜¿è””ç¡«ç´ ã€‚åœ¨æ‰‹è¡“å‰ï¼Œç ”ç©¶äººå“¡æ”¶é›†äº†åŸºç·šçš„è¡€å£“ã€è¡€æ¶²å’Œå°¿æ¶²æ¨£æœ¬ï¼Œä¸¦åœ¨æ‰‹è¡“æ™‚æ”¶é›†è‡å¸¶è¡€å’Œèƒç›¤æ¨£æœ¬ã€‚æ‰‹è¡“å¾Œ2è‡³4å¤©ï¼Œåƒèˆ‡è€…å†æ¬¡æœç”¨è˜¿è””ç¡«ç´ ï¼Œä¸¦åœ¨å…©å°æ™‚å¾Œæ”¶é›†æ¯é«”è¡€æ¶²å’Œæ¯ä¹³é€²è¡Œåˆ†æã€‚",
    "para4": "ç ”ç©¶çš„ä¸»è¦ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ åœ¨æ¯é«”è¡€æ¸…ã€è‡å¸¶è¡€ã€å°¿æ¶²ã€èƒç›¤çµ„ç¹”å’Œæ¯ä¹³ä¸­å‡æœ‰æª¢æ¸¬åˆ°ï¼Œé€™æ˜¯é¦–æ¬¡åœ¨äººé«”ä¸­è­‰å¯¦è˜¿è””ç¡«ç´ å¯ä»¥å¾æ¯é«”è½‰ç§»åˆ°èƒå…’å’Œæ¯ä¹³ä¸­ã€‚é›–ç„¶åœ¨å‰–è…¹ç”¢ç•¶å¤©ï¼Œæ¯é«”çš„èˆ’å¼µå£“æœ‰è¼•å¾®ä¸Šå‡ï¼Œä½†æ•´é«”ä¸Šæ¯é«”çš„è¡€å£“å’Œå¿ƒç‡ä¸¦æœªç™¼ç”Ÿé¡¯è‘—è®ŠåŒ–ã€‚é€™äº›çµæœç‚ºæœªä¾†é€²ä¸€æ­¥ç ”ç©¶è˜¿è””ç¡«ç´ å°èƒå…’çš„å½±éŸ¿æä¾›äº†åŸºç¤ï¼Œä¸¦å¯èƒ½é–‹å•Ÿæ–°çš„ç ”ç©¶æ–¹å‘ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†é‡è¦çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨å¦Šå¨ é«˜è¡€å£“ç—‡ï¼ˆå­ç™²å‰ç—‡ï¼‰çš„èƒŒæ™¯ä¸‹ã€‚å­ç™²å‰ç—‡æ˜¯ä¸€ç¨®å¦Šå¨ æœŸé–“çš„ä½µç™¼ç—‡ï¼Œå¯èƒ½å°æ¯è¦ªå’Œèƒå…’é€ æˆåš´é‡å½±éŸ¿ã€‚ç ”ç©¶æŒ‡å‡ºï¼Œè˜¿è””ç¡«ç´ é€™ç¨®å­˜åœ¨æ–¼é’èŠ±æ¤°èœä¸­çš„æŠ—æ°§åŒ–åŠ‘ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ¸›è¼•å…§çš®åŠŸèƒ½éšœç¤™çš„å‚·å®³ï¼Œå¾è€Œå°æŠ—å­ç™²å‰ç—‡çš„æœ‰å®³å½±éŸ¿ã€‚é€™æ„å‘³è‘—ï¼Œé€éé£²é£Ÿä¸­çš„æŸäº›æˆåˆ†ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„å¦Šå¨ æœŸé–“çš„å¥åº·ç‹€æ³ï¼Œä¸¦ç‚ºæœªä¾†çš„æ²»ç™‚æ–¹æ³•æä¾›æ–°çš„æ–¹å‘ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨å¦Šå¨ é«˜è¡€å£“ç—‡ï¼ˆå­ç™²å‰ç—‡ï¼‰ä¸­çš„æ½›åœ¨æ‡‰ç”¨ï¼Œç‰¹åˆ¥æ˜¯å®ƒæ˜¯å¦èƒ½å¤ å¾æ¯é«”è½‰ç§»åˆ°èƒå…’æˆ–å¬°å…’ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯ï¼Œé€™ç¨®æŠ—æ°§åŒ–åŠ‘åœ¨å¦Šå¨ æœŸé–“çš„å®‰å…¨æ€§åŠå…¶å°æ¯å¬°å¥åº·çš„å½±éŸ¿ï¼Œå°¤å…¶æ˜¯å®ƒåœ¨æ¯é«”è¡€æ¶²ã€è‡å¸¶è¡€å’Œæ¯ä¹³ä¸­çš„å­˜åœ¨æƒ…æ³ã€‚é€™äº›å•é¡Œçš„è§£ç­”å°‡æœ‰åŠ©æ–¼äº†è§£è˜¿è””ç¡«ç´ åœ¨å¦Šå¨ æœŸé–“çš„ä½œç”¨ï¼Œä¸¦ç‚ºæœªä¾†çš„è‡¨åºŠæ‡‰ç”¨é‹ªè·¯ã€‚\n\né€™é …ç ”ç©¶æ‹›å‹Ÿäº†8åå¥åº·çš„å­•å©¦ï¼Œé€™äº›å­•å©¦åœ¨æ‡·å­•è¶…é37é€±æ™‚ï¼Œè¨ˆåŠƒé€²è¡Œå‰–è…¹ç”¢æ‰‹è¡“ã€‚åƒèˆ‡è€…åœ¨æ‰‹è¡“å‰æ¥å—äº†æ›¸é¢åŒæ„ï¼Œä¸¦æœç”¨äº†å–®åŠ‘é‡çš„é’èŠ±æ¤°èœèƒå–ç‰©EnduraCellï¼Œé€™ç›¸ç•¶æ–¼21æ¯«å…‹çš„è˜¿è””ç¡«ç´ ã€‚åœ¨æ‰‹è¡“å‰ï¼Œç ”ç©¶äººå“¡æ”¶é›†äº†åŸºç·šçš„è¡€å£“ã€è¡€æ¶²å’Œå°¿æ¶²æ¨£æœ¬ï¼Œä¸¦åœ¨æ‰‹è¡“æ™‚æ”¶é›†è‡å¸¶è¡€å’Œèƒç›¤æ¨£æœ¬ã€‚æ‰‹è¡“å¾Œ2è‡³4å¤©ï¼Œåƒèˆ‡è€…å†æ¬¡æœç”¨è˜¿è””ç¡«ç´ ï¼Œä¸¦åœ¨å…©å°æ™‚å¾Œæ”¶é›†æ¯é«”è¡€æ¶²å’Œæ¯ä¹³é€²è¡Œåˆ†æã€‚\n\nç ”ç©¶çš„ä¸»è¦ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ åœ¨æ¯é«”è¡€æ¸…ã€è‡å¸¶è¡€ã€å°¿æ¶²ã€èƒç›¤çµ„ç¹”å’Œæ¯ä¹³ä¸­å‡æœ‰æª¢æ¸¬åˆ°ï¼Œé€™æ˜¯é¦–æ¬¡åœ¨äººé«”ä¸­è­‰å¯¦è˜¿è””ç¡«ç´ å¯ä»¥å¾æ¯é«”è½‰ç§»åˆ°èƒå…’å’Œæ¯ä¹³ä¸­ã€‚é›–ç„¶åœ¨å‰–è…¹ç”¢ç•¶å¤©ï¼Œæ¯é«”çš„èˆ’å¼µå£“æœ‰è¼•å¾®ä¸Šå‡ï¼Œä½†æ•´é«”ä¸Šæ¯é«”çš„è¡€å£“å’Œå¿ƒç‡ä¸¦æœªç™¼ç”Ÿé¡¯è‘—è®ŠåŒ–ã€‚é€™äº›çµæœç‚ºæœªä¾†é€²ä¸€æ­¥ç ”ç©¶è˜¿è””ç¡«ç´ å°èƒå…’çš„å½±éŸ¿æä¾›äº†åŸºç¤ï¼Œä¸¦å¯èƒ½é–‹å•Ÿæ–°çš„ç ”ç©¶æ–¹å‘ã€‚",
    "fb_post": "æ ¹æ“šã€ŠPlacentaã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ€ å­•åª½å’ªå€‘æ³¨æ„ï¼ä½ çŸ¥é“é’èŠ±æ¤°èœè£¡çš„è˜¿è””ç¡«ç´ å¯èƒ½å°å¦Šå¨ é«˜è¡€å£“æœ‰å¹«åŠ©å—ï¼Ÿé€™é …ç ”ç©¶é‡å°å¦Šå¨ é«˜è¡€å£“ç—‡ï¼ˆå­ç™²å‰ç—‡ï¼‰é€²è¡Œæ¢è¨ï¼Œé€™æ˜¯ä¸€ç¨®å¯èƒ½å°æ¯è¦ªå’Œèƒå…’é€ æˆå½±éŸ¿çš„å¦Šå¨ ä½µç™¼ç—‡ã€‚ç ”ç©¶è€…æƒ³çŸ¥é“ï¼Œé€™ç¨®å­˜åœ¨æ–¼é’èŠ±æ¤°èœä¸­çš„æŠ—æ°§åŒ–åŠ‘æ˜¯å¦èƒ½å¾æ¯é«”è½‰ç§»åˆ°èƒå…’æˆ–æ¯ä¹³ä¸­ï¼Œä»¥åŠå®ƒå°æ¯å¬°å¥åº·çš„å½±éŸ¿ã€‚  \n\né€™é …ç ”ç©¶æ‹›å‹Ÿäº†8ä½å¥åº·çš„å­•å©¦ï¼Œé€™äº›å­•å©¦åœ¨æ‡·å­•è¶…é37é€±æ™‚é€²è¡Œå‰–è…¹ç”¢ã€‚åƒèˆ‡è€…åœ¨æ‰‹è¡“å‰æœç”¨äº†å«æœ‰21æ¯«å…‹è˜¿è””ç¡«ç´ çš„é’èŠ±æ¤°èœèƒå–ç‰©ï¼Œä¸¦æ”¶é›†äº†ç›¸é—œçš„è¡€æ¶²ã€å°¿æ¶²å’Œè‡å¸¶è¡€æ¨£æœ¬ã€‚  \n\nçµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨æ¯é«”è¡€æ¶²ã€è‡å¸¶è¡€ã€å°¿æ¶²å’Œæ¯ä¹³ä¸­å‡æœ‰æª¢æ¸¬åˆ°ï¼Œé€™æ˜¯é¦–æ¬¡åœ¨äººé¡ä¸­è­‰å¯¦å®ƒå¯ä»¥å¾æ¯é«”è½‰ç§»åˆ°èƒå…’åŠæ¯ä¹³ã€‚é›–ç„¶åœ¨æ‰‹è¡“ç•¶å¤©æ¯é«”çš„è¡€å£“æœ‰è¼•å¾®ä¸Šå‡ï¼Œä½†æ•´é«”è®ŠåŒ–ä¸å¤§ã€‚é€™äº›ç™¼ç¾ç‚ºæœªä¾†ç ”ç©¶è˜¿è””ç¡«ç´ å°èƒå…’çš„å½±éŸ¿é‹ªå¹³äº†é“è·¯ã€‚  \n\nğŸ” ä¸»è¦é‡é»ï¼š  \n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„å¦Šå¨ æœŸé–“çš„å¥åº·ç‹€æ³ã€‚  \n2. é¦–æ¬¡è­‰å¯¦è˜¿è””ç¡«ç´ èƒ½å¾æ¯é«”è½‰ç§»åˆ°èƒå…’å’Œæ¯ä¹³ä¸­ã€‚  \n3. æœªä¾†æœ‰æœ›é€²ä¸€æ­¥ç ”ç©¶å…¶å°èƒå…’çš„å½±éŸ¿ã€‚",
    "image_prompt": "Create a flat design infographic explaining the experiment and main findings of a study on sulforaphane in pregnant women. Include simple symbols for broccoli or sulforaphane, simplified icons representing human subjects, arrows or flow lines indicating the steps of the experiment, and a section highlighting the main results, such as transfer to fetal blood and breast milk. Use a light background with soft colors in a scientific illustration style.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "å¦Šå¨ é«˜è¡€å£“ç—‡ Preeclampsia",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40992247/"
  },
  {
    "id": "40633511",
    "title_en": "Synthesis and biological evaluation of Sulforaphane derivatives with dual functions: Ischemia-reperfusion injury protection and antitumor effects.",
    "pub_date": "2025 Nov",
    "journal": "Bioorganic & medicinal chemistry",
    "abstract_en": "Reperfusion therapy for the treatment of acute myocardial infarction (AMI) often leads to ischemia-reperfusion (I/R) injuries, characterized by excessive ROS. Sulforaphane (SFN) homologous, known for their anti-inflammatory and antioxidant properties, activate the nuclear factor-erythroid 2-related factor 2 (Nrf2) pathway and reduce mitochondrial ROS but are limited by poor stability and short half-life. SFN derivatives were synthesized through structural modifications of the dithiocarbamate and thiourea moieties at the isothiocyanate group, aiming to enhance stability and maintain therapeutic efficacy. Compound 3g emerged as a promising candidate, demonstrating superior protection against hypoxia-reoxygenation (H/R) injury in cardiac microvascular endothelial cells (CMECs) and exhibiting good antitumor activity. Specifically, 3g reduced ROS levels by 24.5Â % (compared to nifedipine at 17.8Â %), increased NO production to 48.0Â Î¼M (vs. 44.0Â Î¼M), lowered TNF-Î± secretion to 22.6Â pg/mL (vs. 23.9Â pg/mL). Concurrently, 3g showed potent antiproliferative activity (IC<sub>50</sub>Â =Â 7.5Â Î¼M), with 3.8-fold greater potency than 5-fluorouracil (IC<sub>50</sub>Â =Â 28.2Â Î¼M). Stability studies showed enhanced resistance in both protic and aprotic solvents. Density functional theory (DFT) was applied to characterize the molecular properties of the optimal compounds. Molecular docking and ADMET analysis revealed that aromatic substitution and sulfur oxidation significantly improved Nrf2/Keap1 pathway targeting, highlighting the derivative's potential for stability and therapeutic efficacy. These findings suggest that 3g is a promising candidate for treating I/R-induced injury and oxidative stress-related cardiovascular conditions.",
    "para1": "é€™é …ç ”ç©¶å°æ–¼å¿ƒè‡Ÿç—…çš„æ²»ç™‚å’Œé é˜²æä¾›äº†ä¸€äº›æ–°çš„è¦‹è§£ã€‚æ€¥æ€§å¿ƒè‚Œæ¢—å¡çš„å†çŒæµç™‚æ³•é›–ç„¶èƒ½å¤ æŒ½æ•‘å¿ƒè‡Ÿï¼Œä½†å»å¯èƒ½å¼•ç™¼ç¼ºè¡€å†çŒæµæå‚·ï¼Œé€™ç¨®æå‚·é€šå¸¸ä¼´éš¨è‘—éé‡çš„æ´»æ€§æ°§ï¼ˆROSï¼‰ç”¢ç”Ÿã€‚ç ”ç©¶è€…å€‘å¸Œæœ›é€éæ”¹è‰¯è˜¿è””ç¡«ç´ çš„è¡ç”Ÿç‰©ï¼Œä¾†å¢å¼·å…¶ç©©å®šæ€§å’Œç™‚æ•ˆï¼Œå¾è€Œæ¸›å°‘é€™äº›æå‚·çš„ç™¼ç”Ÿï¼Œé€™å°æ–¼æ”¹å–„å¿ƒè¡€ç®¡å¥åº·æœ‰è‘—æ½›åœ¨çš„æ„ç¾©ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯é‡å°æ€¥æ€§å¿ƒè‚Œæ¢—å¡å¾Œçš„ç¼ºè¡€å†çŒæµæå‚·ï¼Œç‰¹åˆ¥æ˜¯å¦‚ä½•åˆ©ç”¨è˜¿è””ç¡«ç´ åŠå…¶è¡ç”Ÿç‰©ä¾†æ¸›å°‘é€™ç¨®æå‚·ã€‚ç ”ç©¶è€…å€‘é—œå¿ƒçš„æ˜¯å¦‚ä½•é€éåŒ–å­¸çµæ§‹çš„æ”¹è®Šä¾†æå‡é€™äº›åŒ–åˆç‰©çš„ç©©å®šæ€§å’ŒæŠ—æ°§åŒ–èƒ½åŠ›ï¼Œä»¥ä¾¿æ›´æœ‰æ•ˆåœ°å°æŠ—å¿ƒè‡Ÿçš„æ°§åŒ–å£“åŠ›å’Œç‚ç—‡åæ‡‰ã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…åˆæˆäº†å¹¾ç¨®è˜¿è””ç¡«ç´ çš„è¡ç”Ÿç‰©ï¼Œç‰¹åˆ¥æ˜¯3gé€™å€‹åŒ–åˆç‰©ï¼Œä¸¦åœ¨å¿ƒè‡Ÿå¾®è¡€ç®¡å…§çš®ç´°èƒä¸­é€²è¡Œæ¸¬è©¦ã€‚ç ”ç©¶æ–¹æ³•åŒ…æ‹¬æ¸¬é‡æ´»æ€§æ°§çš„æ°´å¹³ã€æ°®æ°§åŒ–ç‰©çš„ç”¢ç”Ÿä»¥åŠè…«ç˜¤å£æ­»å› å­Î±çš„åˆ†æ³Œé‡ï¼Œä¸¦æ¯”è¼ƒé€™äº›è¡ç”Ÿç‰©èˆ‡å…¶ä»–è—¥ç‰©çš„æ•ˆæœã€‚æ­¤å¤–ï¼Œé‚„é€²è¡Œäº†ç©©å®šæ€§ç ”ç©¶å’Œåˆ†å­å°æ¥åˆ†æï¼Œä»¥è©•ä¼°é€™äº›åŒ–åˆç‰©çš„æ½›åœ¨ç™‚æ•ˆã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œ3gåŒ–åˆç‰©åœ¨æ¸›å°‘æ´»æ€§æ°§æ–¹é¢è¡¨ç¾å‡ºè‰²ï¼Œé™ä½äº†24.5%çš„æ´»æ€§æ°§æ°´å¹³ï¼Œä¸¦ä¸”åœ¨ä¿ƒé€²æ°®æ°§åŒ–ç‰©ç”¢ç”Ÿå’Œé™ä½è…«ç˜¤å£æ­»å› å­Î±çš„åˆ†æ³Œæ–¹é¢ä¹Ÿæœ‰è‰¯å¥½æ•ˆæœã€‚æ­¤å¤–ï¼Œ3gçš„æŠ—å¢æ®–æ´»æ€§æ¯”å¸¸ç”¨çš„åŒ–ç™‚è—¥ç‰©5-æ°Ÿå°¿å˜§å•¶æ›´å¼·ï¼Œé¡¯ç¤ºå‡ºå…¶åœ¨æ²»ç™‚ç¼ºè¡€å†çŒæµæå‚·åŠç›¸é—œå¿ƒè¡€ç®¡ç–¾ç—…æ–¹é¢çš„æ½›åŠ›ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°æ–¼å¿ƒè‡Ÿç—…çš„æ²»ç™‚å’Œé é˜²æä¾›äº†ä¸€äº›æ–°çš„è¦‹è§£ã€‚æ€¥æ€§å¿ƒè‚Œæ¢—å¡çš„å†çŒæµç™‚æ³•é›–ç„¶èƒ½å¤ æŒ½æ•‘å¿ƒè‡Ÿï¼Œä½†å»å¯èƒ½å¼•ç™¼ç¼ºè¡€å†çŒæµæå‚·ï¼Œé€™ç¨®æå‚·é€šå¸¸ä¼´éš¨è‘—éé‡çš„æ´»æ€§æ°§ï¼ˆROSï¼‰ç”¢ç”Ÿã€‚ç ”ç©¶è€…å€‘å¸Œæœ›é€éæ”¹è‰¯è˜¿è””ç¡«ç´ çš„è¡ç”Ÿç‰©ï¼Œä¾†å¢å¼·å…¶ç©©å®šæ€§å’Œç™‚æ•ˆï¼Œå¾è€Œæ¸›å°‘é€™äº›æå‚·çš„ç™¼ç”Ÿï¼Œé€™å°æ–¼æ”¹å–„å¿ƒè¡€ç®¡å¥åº·æœ‰è‘—æ½›åœ¨çš„æ„ç¾©ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯é‡å°æ€¥æ€§å¿ƒè‚Œæ¢—å¡å¾Œçš„ç¼ºè¡€å†çŒæµæå‚·ï¼Œç‰¹åˆ¥æ˜¯å¦‚ä½•åˆ©ç”¨è˜¿è””ç¡«ç´ åŠå…¶è¡ç”Ÿç‰©ä¾†æ¸›å°‘é€™ç¨®æå‚·ã€‚ç ”ç©¶è€…å€‘é—œå¿ƒçš„æ˜¯å¦‚ä½•é€éåŒ–å­¸çµæ§‹çš„æ”¹è®Šä¾†æå‡é€™äº›åŒ–åˆç‰©çš„ç©©å®šæ€§å’ŒæŠ—æ°§åŒ–èƒ½åŠ›ï¼Œä»¥ä¾¿æ›´æœ‰æ•ˆåœ°å°æŠ—å¿ƒè‡Ÿçš„æ°§åŒ–å£“åŠ›å’Œç‚ç—‡åæ‡‰ã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶è€…åˆæˆäº†å¹¾ç¨®è˜¿è””ç¡«ç´ çš„è¡ç”Ÿç‰©ï¼Œç‰¹åˆ¥æ˜¯3gé€™å€‹åŒ–åˆç‰©ï¼Œä¸¦åœ¨å¿ƒè‡Ÿå¾®è¡€ç®¡å…§çš®ç´°èƒä¸­é€²è¡Œæ¸¬è©¦ã€‚ç ”ç©¶æ–¹æ³•åŒ…æ‹¬æ¸¬é‡æ´»æ€§æ°§çš„æ°´å¹³ã€æ°®æ°§åŒ–ç‰©çš„ç”¢ç”Ÿä»¥åŠè…«ç˜¤å£æ­»å› å­Î±çš„åˆ†æ³Œé‡ï¼Œä¸¦æ¯”è¼ƒé€™äº›è¡ç”Ÿç‰©èˆ‡å…¶ä»–è—¥ç‰©çš„æ•ˆæœã€‚æ­¤å¤–ï¼Œé‚„é€²è¡Œäº†ç©©å®šæ€§ç ”ç©¶å’Œåˆ†å­å°æ¥åˆ†æï¼Œä»¥è©•ä¼°é€™äº›åŒ–åˆç‰©çš„æ½›åœ¨ç™‚æ•ˆã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œ3gåŒ–åˆç‰©åœ¨æ¸›å°‘æ´»æ€§æ°§æ–¹é¢è¡¨ç¾å‡ºè‰²ï¼Œé™ä½äº†24.5%çš„æ´»æ€§æ°§æ°´å¹³ï¼Œä¸¦ä¸”åœ¨ä¿ƒé€²æ°®æ°§åŒ–ç‰©ç”¢ç”Ÿå’Œé™ä½è…«ç˜¤å£æ­»å› å­Î±çš„åˆ†æ³Œæ–¹é¢ä¹Ÿæœ‰è‰¯å¥½æ•ˆæœã€‚æ­¤å¤–ï¼Œ3gçš„æŠ—å¢æ®–æ´»æ€§æ¯”å¸¸ç”¨çš„åŒ–ç™‚è—¥ç‰©5-æ°Ÿå°¿å˜§å•¶æ›´å¼·ï¼Œé¡¯ç¤ºå‡ºå…¶åœ¨æ²»ç™‚ç¼ºè¡€å†çŒæµæå‚·åŠç›¸é—œå¿ƒè¡€ç®¡ç–¾ç—…æ–¹é¢çš„æ½›åŠ›ã€‚",
    "fb_post": "æ ¹æ“šã€ŠBioorganic & medicinal chemistryã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿå¿ƒè‡Ÿç—…çš„æ²»ç™‚å¯èƒ½æœƒå› ç‚ºä¸€ç¨®å«åšè˜¿è””ç¡«ç´ çš„ç‰©è³ªè€Œè®Šå¾—æ›´æœ‰æ•ˆï¼é€™é …ç ”ç©¶å°ˆæ³¨æ–¼æ€¥æ€§å¿ƒè‚Œæ¢—å¡å¾Œçš„æå‚·ï¼Œè©¦åœ–æ‰¾åˆ°æ¸›å°‘é€™äº›æå‚·çš„æ–¹æ³•ã€‚ç ”ç©¶è€…å€‘ç™¼ç¾ï¼Œç•¶å¿ƒè‡Ÿå—åˆ°æå‚·å¾Œï¼Œæœƒç”¢ç”Ÿéå¤šçš„æ´»æ€§æ°§ï¼Œé€™å°å¿ƒè‡Ÿå¥åº·æ˜¯å€‹å¤§å¨è„…ã€‚ç‚ºäº†å°æŠ—é€™å€‹å•é¡Œï¼Œä»–å€‘é–‹å§‹æ”¹è‰¯è˜¿è””ç¡«ç´ çš„è¡ç”Ÿç‰©ï¼Œç‰¹åˆ¥æ˜¯ä¸€ç¨®å«åš3gçš„åŒ–åˆç‰©ã€‚åœ¨å¯¦é©—ä¸­ï¼Œä»–å€‘æ¸¬è©¦äº†é€™äº›åŒ–åˆç‰©å°å¿ƒè‡Ÿå¾®è¡€ç®¡å…§çš®ç´°èƒçš„å½±éŸ¿ï¼Œä¸¦è§€å¯Ÿåˆ°äº†ä»¤äººé©šå–œçš„çµæœï¼3gåŒ–åˆç‰©ä¸åƒ…èƒ½æœ‰æ•ˆé™ä½æ´»æ€§æ°§çš„æ°´å¹³ï¼Œé‚„èƒ½ä¿ƒé€²æ°®æ°§åŒ–ç‰©çš„ç”¢ç”Ÿï¼Œé€™äº›éƒ½æ˜¯ä¿è­·å¿ƒè‡Ÿçš„é‡è¦å› ç´ ã€‚æœ€æ£’çš„æ˜¯ï¼Œ3gçš„æŠ—å¢æ®–æ•ˆæœæ¯”å¸¸è¦‹çš„åŒ–ç™‚è—¥ç‰©æ›´å¼·ï¼Œé¡¯ç¤ºå‡ºå®ƒåœ¨å¿ƒè¡€ç®¡ç–¾ç—…æ²»ç™‚ä¸Šçš„æ½›åŠ›ã€‚ä»¥ä¸‹æ˜¯é€™é …ç ”ç©¶çš„å¹¾å€‹é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ çš„è¡ç”Ÿç‰©å¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘å¿ƒè‡Ÿæå‚·ã€‚\n2. 3gåŒ–åˆç‰©åœ¨æŠ—æ°§åŒ–æ–¹é¢è¡¨ç¾å„ªç•°ã€‚\n3. é€™äº›ç ”ç©¶æˆæœå¯èƒ½å°å¿ƒè‡Ÿç—…æ²»ç™‚å¸¶ä¾†æ–°å¸Œæœ›ï¼",
    "image_prompt": "Create an informative infographic that visually explains the experimental methods and main results of a study on a compound derived from sulforaphane (found in broccoli) for heart protection. Include simple illustrations of broccoli or sulforaphane, simplified representations of experimental subjects like cells, arrows or flow lines to indicate the experimental steps, and a section labeled 'Main Results' highlighting protective effects and changes observed in the study.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "å¿ƒè‚Œæ¢—å¡ Acute Myocardial Infarction",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40633511/"
  },
  {
    "id": "40617372",
    "title_en": "Antioxidant effect of esculin and sulforaphane in zebrafish larvae: A comparative study.",
    "pub_date": "2025 Nov",
    "journal": "Comparative biochemistry and physiology. Toxicology & pharmacology : CBP",
    "abstract_en": "Antioxidants are crucial for maintaining cellular redox homeostasis by neutralizing free radicals, including reactive oxygen species (ROS). Nuclear factor erythroid-2-related factor 2 (Nrf2) is a transcription factor that activates various cytoprotective genes to counteract oxidative damage. The present study aimed to compare the antioxidant potential of natural phytochemicals, esculin (ESC), and sulforaphane (SFN) in zebrafish larvae, focusing on Nrf2 activation. Zebrafish larvae were treated with ESC (100Â Î¼M) and SFN (40Â Î¼M) along with control for 6Â h. The levels of ROS, lipid peroxidation (LPO), nitric oxide (NO), glutathione S-transferase (GST), glutathione peroxidase (GPx), catalase (CAT), and reduced glutathione (GSH) were measured. Further, RT-PCR and Western blotting methods were employed to determine the antioxidant genes and protein levels, respectively. In addition, Nrf2 localization within the cell was assessed using nuclear/cytosolic fractionation assay and wholemount immunohistochemistry method. Our results demonstrate that ESC treatment significantly increased antioxidant enzyme activities (GST, GPx, CAT), similar to the effects observed with SFN. Further, ESC enhanced the mRNA levels of antioxidant genes expression, such as nrf2, gstp1, hmox1a, prdx1, nqo1, gss, gsr, sqstm1, hsp90aa1.2 than SFN. Antioxidant proteins Nrf2, Gstp1, Cat, and Sod2 were upregulated in the ESC-treated groups. Subsequently, nuclear localization of Nrf2 was detected in both SFN- and ESC-treated groups, confirming Nrf2 translocation into the nucleus. Our findings suggest that ESC possesses potent antioxidant activity as SFN in 72-hpf zebrafish larvae through the Keap1-Nrf2 signaling pathway.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†é—œæ–¼æŠ—æ°§åŒ–åŠ‘åœ¨å¥åº·ç¶­è­·å’Œç–¾ç—…é é˜²ä¸­çš„é‡è¦æ€§å•Ÿç¤ºã€‚æŠ—æ°§åŒ–åŠ‘èƒ½å¤ ä¸­å’Œè‡ªç”±åŸºï¼Œç‰¹åˆ¥æ˜¯åæ‡‰æ€§æ°§ç‰©è³ªï¼Œå¾è€Œä¿è­·ç´°èƒå…å—æ°§åŒ–æå‚·ã€‚é€™å°æ–¼ç¶­æŒç´°èƒçš„ç´…æ°§å¹³è¡¡è‡³é—œé‡è¦ï¼Œå¯èƒ½å°æ–¼é é˜²èˆ‡æ°§åŒ–å£“åŠ›ç›¸é—œçš„ç–¾ç—…æœ‰å¹«åŠ©ã€‚äº†è§£ä¸åŒå¤©ç„¶æ¤ç‰©åŒ–å­¸ç‰©è³ªçš„æŠ—æ°§åŒ–æ½›åŠ›ï¼Œå°¤å…¶æ˜¯è˜¿è””ç¡«ç´ å’Œå…¶ä»–åŒ–åˆç‰©ï¼Œå¯èƒ½ç‚ºæœªä¾†çš„å¥åº·ä¿ƒé€²ç­–ç•¥æä¾›æ–°çš„æ–¹å‘ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¯”è¼ƒå…©ç¨®å¤©ç„¶æ¤ç‰©åŒ–å­¸ç‰©è³ªâ€”â€”è˜¿è””ç¡«ç´ å’Œesculinçš„æŠ—æ°§åŒ–æ½›åŠ›ï¼Œç‰¹åˆ¥æ˜¯å®ƒå€‘å°æ–¼Nrf2é€™ç¨®è½‰éŒ„å› å­çš„æ¿€æ´»ä½œç”¨ã€‚Nrf2åœ¨ç´°èƒä¸­æ‰®æ¼”è‘—é‡è¦è§’è‰²ï¼Œèƒ½å•Ÿå‹•å¤šç¨®ä¿è­·åŸºå› ä»¥æŠµæŠ—æ°§åŒ–æå‚·ã€‚ç ”ç©¶è€…å¸Œæœ›é€šéé€™é …ç ”ç©¶ï¼Œèƒ½æ›´æ·±å…¥äº†è§£é€™äº›åŒ–åˆç‰©å¦‚ä½•å½±éŸ¿ç´°èƒçš„æŠ—æ°§åŒ–é˜²ç¦¦æ©Ÿåˆ¶ã€‚",
    "para3": "å¯¦é©—ä½¿ç”¨äº†æ–‘é¦¬é­šå¹¼é«”ä½œç‚ºç ”ç©¶å°è±¡ï¼Œé€™æ˜¯ä¸€ç¨®å¸¸ç”¨æ–¼ç”Ÿç‰©é†«å­¸ç ”ç©¶çš„æ¨¡å¼ç”Ÿç‰©ã€‚ç ”ç©¶ä¸­ï¼Œæ–‘é¦¬é­šå¹¼é«”è¢«åˆ†åˆ¥è™•ç†äº†100Î¼Mçš„esculinå’Œ40Î¼Mçš„è˜¿è””ç¡«ç´ ï¼Œä¸¦èˆ‡å°ç…§çµ„é€²è¡Œæ¯”è¼ƒï¼Œè™•ç†æ™‚é–“ç‚º6å°æ™‚ã€‚ç ”ç©¶è€…æ¸¬é‡äº†å¤šç¨®æŒ‡æ¨™ï¼ŒåŒ…æ‹¬åæ‡‰æ€§æ°§ç‰©è³ªã€è„‚è³ªéæ°§åŒ–ã€æ°®æ°§åŒ–ç‰©ç­‰ï¼Œä¸¦ä½¿ç”¨RT-PCRå’Œè¥¿æ–¹å°è·¡æ³•ä¾†åˆ†ææŠ—æ°§åŒ–åŸºå› å’Œè›‹ç™½è³ªçš„è¡¨é”ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œesculinçš„è™•ç†é¡¯è‘—æé«˜äº†æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ï¼Œèˆ‡è˜¿è””ç¡«ç´ çš„æ•ˆæœç›¸ä¼¼ã€‚æ­¤å¤–ï¼Œesculiné‚„ä¿ƒé€²äº†å¤šç¨®æŠ—æ°§åŒ–åŸºå› çš„mRNAè¡¨é”ï¼Œé¡¯ç¤ºå‡ºå…¶å¼·å¤§çš„æŠ—æ°§åŒ–æ´»æ€§ã€‚ç ”ç©¶ä¸­é‚„ç™¼ç¾ï¼ŒNrf2åœ¨ç´°èƒå…§çš„å®šä½ç™¼ç”Ÿäº†è®ŠåŒ–ï¼Œè­‰å¯¦äº†Nrf2çš„è½‰ä½é€²å…¥ç´°èƒæ ¸ï¼Œé€™è¡¨æ˜esculinå’Œè˜¿è””ç¡«ç´ éƒ½èƒ½æœ‰æ•ˆæ¿€æ´»Nrf2ä¿¡è™Ÿé€šè·¯ï¼Œé€²ä¸€æ­¥å¢å¼·ç´°èƒçš„æŠ—æ°§åŒ–èƒ½åŠ›ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†é—œæ–¼æŠ—æ°§åŒ–åŠ‘åœ¨å¥åº·ç¶­è­·å’Œç–¾ç—…é é˜²ä¸­çš„é‡è¦æ€§å•Ÿç¤ºã€‚æŠ—æ°§åŒ–åŠ‘èƒ½å¤ ä¸­å’Œè‡ªç”±åŸºï¼Œç‰¹åˆ¥æ˜¯åæ‡‰æ€§æ°§ç‰©è³ªï¼Œå¾è€Œä¿è­·ç´°èƒå…å—æ°§åŒ–æå‚·ã€‚é€™å°æ–¼ç¶­æŒç´°èƒçš„ç´…æ°§å¹³è¡¡è‡³é—œé‡è¦ï¼Œå¯èƒ½å°æ–¼é é˜²èˆ‡æ°§åŒ–å£“åŠ›ç›¸é—œçš„ç–¾ç—…æœ‰å¹«åŠ©ã€‚äº†è§£ä¸åŒå¤©ç„¶æ¤ç‰©åŒ–å­¸ç‰©è³ªçš„æŠ—æ°§åŒ–æ½›åŠ›ï¼Œå°¤å…¶æ˜¯è˜¿è””ç¡«ç´ å’Œå…¶ä»–åŒ–åˆç‰©ï¼Œå¯èƒ½ç‚ºæœªä¾†çš„å¥åº·ä¿ƒé€²ç­–ç•¥æä¾›æ–°çš„æ–¹å‘ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¯”è¼ƒå…©ç¨®å¤©ç„¶æ¤ç‰©åŒ–å­¸ç‰©è³ªâ€”â€”è˜¿è””ç¡«ç´ å’Œesculinçš„æŠ—æ°§åŒ–æ½›åŠ›ï¼Œç‰¹åˆ¥æ˜¯å®ƒå€‘å°æ–¼Nrf2é€™ç¨®è½‰éŒ„å› å­çš„æ¿€æ´»ä½œç”¨ã€‚Nrf2åœ¨ç´°èƒä¸­æ‰®æ¼”è‘—é‡è¦è§’è‰²ï¼Œèƒ½å•Ÿå‹•å¤šç¨®ä¿è­·åŸºå› ä»¥æŠµæŠ—æ°§åŒ–æå‚·ã€‚ç ”ç©¶è€…å¸Œæœ›é€šéé€™é …ç ”ç©¶ï¼Œèƒ½æ›´æ·±å…¥äº†è§£é€™äº›åŒ–åˆç‰©å¦‚ä½•å½±éŸ¿ç´°èƒçš„æŠ—æ°§åŒ–é˜²ç¦¦æ©Ÿåˆ¶ã€‚\n\nå¯¦é©—ä½¿ç”¨äº†æ–‘é¦¬é­šå¹¼é«”ä½œç‚ºç ”ç©¶å°è±¡ï¼Œé€™æ˜¯ä¸€ç¨®å¸¸ç”¨æ–¼ç”Ÿç‰©é†«å­¸ç ”ç©¶çš„æ¨¡å¼ç”Ÿç‰©ã€‚ç ”ç©¶ä¸­ï¼Œæ–‘é¦¬é­šå¹¼é«”è¢«åˆ†åˆ¥è™•ç†äº†100Î¼Mçš„esculinå’Œ40Î¼Mçš„è˜¿è””ç¡«ç´ ï¼Œä¸¦èˆ‡å°ç…§çµ„é€²è¡Œæ¯”è¼ƒï¼Œè™•ç†æ™‚é–“ç‚º6å°æ™‚ã€‚ç ”ç©¶è€…æ¸¬é‡äº†å¤šç¨®æŒ‡æ¨™ï¼ŒåŒ…æ‹¬åæ‡‰æ€§æ°§ç‰©è³ªã€è„‚è³ªéæ°§åŒ–ã€æ°®æ°§åŒ–ç‰©ç­‰ï¼Œä¸¦ä½¿ç”¨RT-PCRå’Œè¥¿æ–¹å°è·¡æ³•ä¾†åˆ†ææŠ—æ°§åŒ–åŸºå› å’Œè›‹ç™½è³ªçš„è¡¨é”ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œesculinçš„è™•ç†é¡¯è‘—æé«˜äº†æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ï¼Œèˆ‡è˜¿è””ç¡«ç´ çš„æ•ˆæœç›¸ä¼¼ã€‚æ­¤å¤–ï¼Œesculiné‚„ä¿ƒé€²äº†å¤šç¨®æŠ—æ°§åŒ–åŸºå› çš„mRNAè¡¨é”ï¼Œé¡¯ç¤ºå‡ºå…¶å¼·å¤§çš„æŠ—æ°§åŒ–æ´»æ€§ã€‚ç ”ç©¶ä¸­é‚„ç™¼ç¾ï¼ŒNrf2åœ¨ç´°èƒå…§çš„å®šä½ç™¼ç”Ÿäº†è®ŠåŒ–ï¼Œè­‰å¯¦äº†Nrf2çš„è½‰ä½é€²å…¥ç´°èƒæ ¸ï¼Œé€™è¡¨æ˜esculinå’Œè˜¿è””ç¡«ç´ éƒ½èƒ½æœ‰æ•ˆæ¿€æ´»Nrf2ä¿¡è™Ÿé€šè·¯ï¼Œé€²ä¸€æ­¥å¢å¼·ç´°èƒçš„æŠ—æ°§åŒ–èƒ½åŠ›ã€‚",
    "fb_post": "æ ¹æ“šã€ŠComparative biochemistry and physiology. Toxicology & pharmacology : CBPã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± ä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„èº«é«”è£¡æœ‰ä¸€äº›å°è‹±é›„ï¼Œå°ˆé–€å¹«åŠ©æˆ‘å€‘æŠµæŠ—å£æ±è¥¿ï¼é€™ç¯‡ç ”ç©¶å°±è®“æˆ‘å€‘æ›´åŠ äº†è§£é€™äº›è‹±é›„çš„æ•…äº‹ã€‚ é€™é …ç ”ç©¶ä¸»è¦é—œæ³¨å…©ç¨®å¤©ç„¶æ¤ç‰©åŒ–å­¸ç‰©è³ªâ€”â€”è˜¿è””ç¡«ç´ å’Œesculinï¼ˆé€™æ˜¯ä¸€ç¨®ä¾†è‡ªæ¤ç‰©çš„æˆåˆ†ï¼‰ï¼Œçœ‹çœ‹å®ƒå€‘å°æˆ‘å€‘èº«é«”è£¡ä¸€ç¨®å«Nrf2çš„è½‰éŒ„å› å­æœ‰ä»€éº¼å½±éŸ¿ã€‚Nrf2å°±åƒæ˜¯ç´°èƒçš„å®ˆè­·è€…ï¼Œèƒ½å•Ÿå‹•ä¿è­·åŸºå› ï¼Œå¹«åŠ©æˆ‘å€‘æŠµæŠ—æ°§åŒ–æå‚·ã€‚ ç ”ç©¶è€…ä½¿ç”¨æ–‘é¦¬é­šå¹¼é«”ï¼ˆé€™ç¨®å°é­šåœ¨ç§‘å­¸ç ”ç©¶ä¸­å¾ˆå¸¸è¦‹ï¼‰ä¾†é€²è¡Œå¯¦é©—ï¼Œåˆ†åˆ¥çµ¦å®ƒå€‘ä¸åŒçš„è™•ç†ï¼Œè§€å¯Ÿå®ƒå€‘çš„åæ‡‰ã€‚çµæœç™¼ç¾ï¼Œesculinå’Œè˜¿è””ç¡«ç´ éƒ½èƒ½æœ‰æ•ˆæ¿€æ´»Nrf2ï¼Œé€™æ¨£ä¸€ä¾†ï¼Œç´°èƒçš„æŠ—æ°§åŒ–èƒ½åŠ›å°±æœƒå¢å¼·ï¼ ç¸½çµä¸€ä¸‹é€™é …ç ”ç©¶çš„é‡é»ï¼š 1ï¸âƒ£ è˜¿è””ç¡«ç´ å’Œesculinéƒ½æœ‰åŠ©æ–¼æå‡æŠ—æ°§åŒ–èƒ½åŠ›ã€‚ 2ï¸âƒ£ Nrf2æ˜¯ç´°èƒçš„å®ˆè­·è€…ï¼Œèƒ½å•Ÿå‹•ä¿è­·åŸºå› ã€‚ 3ï¸âƒ£ é€™äº›å¤©ç„¶æˆåˆ†å¯èƒ½æˆç‚ºæœªä¾†å¥åº·ä¿ƒé€²çš„å¥½å¹«æ‰‹ï¼",
    "image_prompt": "Create a flat design infographic with a light background. Include symbols representing broccoli or sulforaphane, and simplified illustrations of experimental subjects like humans or zebrafish. Use arrows or flow lines to show the experimental steps. Add a section labeled 'Main Findings' highlighting protective effects and changes observed in the study.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40617372/"
  },
  {
    "id": "40533430",
    "title_en": "Monovalent glycoconjugates of sulforaphane prevent inflammation induced by lipopolysaccharide in human dendritic cells by inhibiting NF-Ä¸B signalling pathway.",
    "pub_date": "2025 Nov",
    "journal": "British journal of pharmacology",
    "abstract_en": "Sulforaphane (SFN) has notable health benefits but faces challenges due to its poor solubility and delivery. This study investigates SFN-glycoconjugates effects on lipopolysaccharide (LPS)-induced inflammation in dendritic cells (DCs). With the aiming to enhance their therapeutic potential against inflammatory diseases. Novel monovalent SFN-glycoconjugates with mannose (Man) and fucose (0Fuc) were developed and tested for their anti-inflammatory and immune-modulatory properties in DCs from healthy donors under chronic LPS exposure. By leveraging therapeutic strategies, SFN-glycoconjugates significantly improved the solubility and bioavailability of SFN, thereby overcoming the limitations of traditional delivery methods. Monocyte-derived DCs were treated with SFN-glycoconjugates and subsequently exposed to a chronic inflammatory environment induced by LPS. Our results showed that SFN-glycoconjugates enhance effectiveness in suppressing inflammation by targeting the p65 NF-ÎºB pathway, without affecting MAPK signalling. SFN-glycoconjugates induce a tolerogenic immune response, characterized by increased IL-10 production and enhanced regulatory T- and B-cell proliferation. These effects surpass those of p65 NF-ÎºB inhibition alone, highlighting a distinct and potent regulatory mechanism independent of MAPK pathways. The integration of food therapeutic strategies not only enhances the stability and delivery of bioactive compounds but also broadens their potential applications in functional foods and therapeutic approaches. In particular, SFN-glycoconjugates represent a promising option as biologically active compounds for inflammatory diseases, offering enhanced anti-inflammatory and immunomodulatory effects through optimized delivery systems and the activation of specific molecular pathways.",
    "para1": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å…·æœ‰é¡¯è‘—å¥åº·ç›Šè™•çš„åŒ–åˆç‰©ï¼Œä½†ç”±æ–¼å…¶æº¶è§£æ€§å·®å’Œå‚³éå›°é›£ï¼Œä½¿ç”¨ä¸Šé¢è‡¨æŒ‘æˆ°ã€‚é€™é …ç ”ç©¶çš„çµæœå¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æä¾›æ–°çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æ”¹å–„ç‚ç—‡ç›¸é—œç–¾ç—…çš„æ²»ç™‚ä¸Šã€‚é€éæ”¹é€²è˜¿è””ç¡«ç´ çš„å‚³éæ–¹å¼ï¼Œå¯èƒ½æœƒè®“é€™ç¨®å¤©ç„¶æˆåˆ†åœ¨æœªä¾†çš„å¥åº·ç”¢å“ä¸­ç™¼æ®æ›´å¤§çš„ä½œç”¨ï¼Œå¹«åŠ©äººå€‘æ›´æœ‰æ•ˆåœ°å°æŠ—æ…¢æ€§ç‚ç—‡å•é¡Œï¼Œé€²è€Œä¿ƒé€²æ•´é«”å¥åº·ã€‚",
    "para2": "é€™é …ç ”ç©¶ä¸»è¦é—œæ³¨è˜¿è””ç¡«ç´ -ç³–è‹·çµåˆç‰©å°æ–¼ç”±è„‚å¤šé†£ï¼ˆLPSï¼‰å¼•èµ·çš„ç‚ç—‡åæ‡‰çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å¸Œæœ›é€éé€™äº›æ–°å‹çš„åŒ–åˆç‰©ä¾†æå‡è˜¿è””ç¡«ç´ åœ¨æ²»ç™‚ç‚ç—‡ç–¾ç—…ä¸­çš„æ½›åŠ›ã€‚å…·é«”è€Œè¨€ï¼Œç ”ç©¶æ¢è¨äº†é€™äº›ç³–è‹·çµåˆç‰©åœ¨å¥åº·ä¾›é«”çš„æ¨¹çªç´°èƒä¸­ï¼Œå¦‚ä½•åœ¨æ…¢æ€§LPSæš´éœ²çš„æƒ…æ³ä¸‹ç™¼æ®æŠ—ç‚å’Œå…ç–«èª¿ç¯€çš„ä½œç”¨ã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…é–‹ç™¼äº†æ–°å‹çš„å–®åƒ¹è˜¿è””ç¡«ç´ -ç³–è‹·çµåˆç‰©ï¼Œä¸¦å°‡å…¶æ‡‰ç”¨æ–¼å¾å¥åº·æè´ˆè€…ç²å¾—çš„å–®æ ¸ç´°èƒè¡ç”Ÿæ¨¹çªç´°èƒã€‚é€™äº›ç´°èƒåœ¨æ…¢æ€§ç‚ç—‡ç’°å¢ƒä¸­æ¥å—äº†é€™äº›ç³–è‹·çµåˆç‰©çš„è™•ç†ã€‚ç ”ç©¶è€…è§€å¯Ÿäº†é€™äº›è™•ç†å°æ¨¹çªç´°èƒçš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯å®ƒå€‘åœ¨æŠ‘åˆ¶ç‚ç—‡å’Œèª¿ç¯€å…ç–«åæ‡‰æ–¹é¢çš„æ•ˆæœï¼Œä¸¦åˆ†æäº†ç›¸é—œçš„åˆ†å­æ©Ÿåˆ¶ã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ -ç³–è‹·çµåˆç‰©åœ¨æŠ‘åˆ¶ç‚ç—‡æ–¹é¢çš„æ•ˆæœé¡¯è‘—ï¼Œç‰¹åˆ¥æ˜¯é€šéé‡å°p65 NF-ÎºBé€”å¾‘ä¾†é”æˆï¼Œè€Œä¸å½±éŸ¿MAPKä¿¡è™Ÿé€šè·¯ã€‚é€™äº›ç³–è‹·çµåˆç‰©èƒ½å¤ èª˜å°è€å—æ€§å…ç–«åæ‡‰ï¼Œå¢åŠ IL-10çš„ç”¢ç”Ÿï¼Œä¸¦ä¿ƒé€²èª¿ç¯€æ€§Tç´°èƒå’ŒBç´°èƒçš„å¢æ®–ã€‚é€™äº›æ•ˆæœè¶…éäº†å–®ç´”æŠ‘åˆ¶p65 NF-ÎºBçš„ä½œç”¨ï¼Œé¡¯ç¤ºå‡ºä¸€ç¨®ç¨ç‰¹ä¸”å¼·å¤§çš„èª¿ç¯€æ©Ÿåˆ¶ï¼Œä¸¦ä¸”ç‚ºåŠŸèƒ½æ€§é£Ÿå“å’Œæ²»ç™‚æ–¹æ³•çš„æ‡‰ç”¨æä¾›äº†æ–°çš„å¯èƒ½æ€§ã€‚",
    "explanation_zh": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å…·æœ‰é¡¯è‘—å¥åº·ç›Šè™•çš„åŒ–åˆç‰©ï¼Œä½†ç”±æ–¼å…¶æº¶è§£æ€§å·®å’Œå‚³éå›°é›£ï¼Œä½¿ç”¨ä¸Šé¢è‡¨æŒ‘æˆ°ã€‚é€™é …ç ”ç©¶çš„çµæœå¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æä¾›æ–°çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æ”¹å–„ç‚ç—‡ç›¸é—œç–¾ç—…çš„æ²»ç™‚ä¸Šã€‚é€éæ”¹é€²è˜¿è””ç¡«ç´ çš„å‚³éæ–¹å¼ï¼Œå¯èƒ½æœƒè®“é€™ç¨®å¤©ç„¶æˆåˆ†åœ¨æœªä¾†çš„å¥åº·ç”¢å“ä¸­ç™¼æ®æ›´å¤§çš„ä½œç”¨ï¼Œå¹«åŠ©äººå€‘æ›´æœ‰æ•ˆåœ°å°æŠ—æ…¢æ€§ç‚ç—‡å•é¡Œï¼Œé€²è€Œä¿ƒé€²æ•´é«”å¥åº·ã€‚\n\né€™é …ç ”ç©¶ä¸»è¦é—œæ³¨è˜¿è””ç¡«ç´ -ç³–è‹·çµåˆç‰©å°æ–¼ç”±è„‚å¤šé†£ï¼ˆLPSï¼‰å¼•èµ·çš„ç‚ç—‡åæ‡‰çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å¸Œæœ›é€éé€™äº›æ–°å‹çš„åŒ–åˆç‰©ä¾†æå‡è˜¿è””ç¡«ç´ åœ¨æ²»ç™‚ç‚ç—‡ç–¾ç—…ä¸­çš„æ½›åŠ›ã€‚å…·é«”è€Œè¨€ï¼Œç ”ç©¶æ¢è¨äº†é€™äº›ç³–è‹·çµåˆç‰©åœ¨å¥åº·ä¾›é«”çš„æ¨¹çªç´°èƒä¸­ï¼Œå¦‚ä½•åœ¨æ…¢æ€§LPSæš´éœ²çš„æƒ…æ³ä¸‹ç™¼æ®æŠ—ç‚å’Œå…ç–«èª¿ç¯€çš„ä½œç”¨ã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶è€…é–‹ç™¼äº†æ–°å‹çš„å–®åƒ¹è˜¿è””ç¡«ç´ -ç³–è‹·çµåˆç‰©ï¼Œä¸¦å°‡å…¶æ‡‰ç”¨æ–¼å¾å¥åº·æè´ˆè€…ç²å¾—çš„å–®æ ¸ç´°èƒè¡ç”Ÿæ¨¹çªç´°èƒã€‚é€™äº›ç´°èƒåœ¨æ…¢æ€§ç‚ç—‡ç’°å¢ƒä¸­æ¥å—äº†é€™äº›ç³–è‹·çµåˆç‰©çš„è™•ç†ã€‚ç ”ç©¶è€…è§€å¯Ÿäº†é€™äº›è™•ç†å°æ¨¹çªç´°èƒçš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯å®ƒå€‘åœ¨æŠ‘åˆ¶ç‚ç—‡å’Œèª¿ç¯€å…ç–«åæ‡‰æ–¹é¢çš„æ•ˆæœï¼Œä¸¦åˆ†æäº†ç›¸é—œçš„åˆ†å­æ©Ÿåˆ¶ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ -ç³–è‹·çµåˆç‰©åœ¨æŠ‘åˆ¶ç‚ç—‡æ–¹é¢çš„æ•ˆæœé¡¯è‘—ï¼Œç‰¹åˆ¥æ˜¯é€šéé‡å°p65 NF-ÎºBé€”å¾‘ä¾†é”æˆï¼Œè€Œä¸å½±éŸ¿MAPKä¿¡è™Ÿé€šè·¯ã€‚é€™äº›ç³–è‹·çµåˆç‰©èƒ½å¤ èª˜å°è€å—æ€§å…ç–«åæ‡‰ï¼Œå¢åŠ IL-10çš„ç”¢ç”Ÿï¼Œä¸¦ä¿ƒé€²èª¿ç¯€æ€§Tç´°èƒå’ŒBç´°èƒçš„å¢æ®–ã€‚é€™äº›æ•ˆæœè¶…éäº†å–®ç´”æŠ‘åˆ¶p65 NF-ÎºBçš„ä½œç”¨ï¼Œé¡¯ç¤ºå‡ºä¸€ç¨®ç¨ç‰¹ä¸”å¼·å¤§çš„èª¿ç¯€æ©Ÿåˆ¶ï¼Œä¸¦ä¸”ç‚ºåŠŸèƒ½æ€§é£Ÿå“å’Œæ²»ç™‚æ–¹æ³•çš„æ‡‰ç”¨æä¾›äº†æ–°çš„å¯èƒ½æ€§ã€‚",
    "fb_post": "æ ¹æ“šã€ŠBritish journal of pharmacologyã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ±ä½ çŸ¥é“å—ï¼Ÿè˜¿è””ä¸åªæ˜¯ç¾å‘³çš„è”¬èœï¼Œå®ƒè£¡é¢é‚„è—è‘—ä¸€ç¨®å«ã€Œè˜¿è””ç¡«ç´ ã€çš„å¥åº·æˆåˆ†ï¼ä¸éï¼Œé€™å€‹å°å‚¢ä¼™æœ‰é»é›£ä»¥é€²å…¥æˆ‘å€‘çš„èº«é«”ï¼Œè®“æˆ‘å€‘ä»Šå¤©ä¾†èŠèŠæœ€æ–°çš„ç ”ç©¶ç™¼ç¾ï¼\n\né€™é …ç ”ç©¶å°ˆæ³¨æ–¼ä¸€ç¨®æ–°å‹çš„è˜¿è””ç¡«ç´ -ç³–è‹·çµåˆç‰©ï¼Œç ”ç©¶äººå“¡å¸Œæœ›é€™äº›åŒ–åˆç‰©èƒ½æ›´æœ‰æ•ˆåœ°å°æŠ—ç”±è„‚å¤šé†£ï¼ˆLPSï¼‰å¼•èµ·çš„ç‚ç—‡åæ‡‰ã€‚ä»–å€‘åœ¨å¥åº·å¿—é¡˜è€…çš„æ¨¹çªç´°èƒä¸­æ¸¬è©¦é€™äº›çµåˆç‰©ï¼Œçœ‹çœ‹å®ƒå€‘åœ¨æ…¢æ€§ç‚ç—‡ç’°å¢ƒä¸­èƒ½ç™¼æ®ä»€éº¼æ¨£çš„æ•ˆæœã€‚\n\nçµæœé¡¯ç¤ºï¼Œé€™äº›ç³–è‹·çµåˆç‰©åœ¨æŠ‘åˆ¶ç‚ç—‡æ–¹é¢çš„è¡¨ç¾éå¸¸å‡ºè‰²ï¼Œç‰¹åˆ¥æ˜¯é€éä¸€ç¨®å«åšp65 NF-ÎºBçš„é€”å¾‘ä¾†é”æˆï¼Œä¸¦ä¸”é‚„èƒ½ä¿ƒé€²å…ç–«ç³»çµ±çš„èª¿ç¯€ã€‚é€™ä¸åƒ…åƒ…æ˜¯æŠ‘åˆ¶ç‚ç—‡ï¼Œè€Œæ˜¯é–‹å•Ÿäº†ä¸€ç¨®å…¨æ–°çš„èª¿ç¯€æ©Ÿåˆ¶ï¼Œè®“æˆ‘å€‘å°æœªä¾†çš„å¥åº·ç”¢å“å……æ»¿æœŸå¾…ï¼\n\nğŸ” é‡é»æ•´ç†ï¼š\n1. è˜¿è””ç¡«ç´ -ç³–è‹·çµåˆç‰©åœ¨æŠ‘åˆ¶ç‚ç—‡æ–¹é¢æ•ˆæœé¡¯è‘—ã€‚\n2. é€™äº›åŒ–åˆç‰©èƒ½ä¿ƒé€²å…ç–«ç³»çµ±çš„èª¿ç¯€ã€‚\n3. ç‚ºæœªä¾†çš„å¥åº·ç”¢å“æä¾›æ–°çš„å¯èƒ½æ€§ï¼",
    "image_prompt": "Create an infographic explaining the experiment and main results of the study on sulforaphane-glucoside compounds. Use a flat design style with a white or light-colored background and soft colors. Include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects like humans or cells, and arrows or flow lines indicating the experimental steps. Add a section highlighting the 'main results', such as protective effects and changes observed.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "ç‚ç—‡ç›¸é—œç–¾ç—… Inflammatory Diseases",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40533430/"
  },
  {
    "id": "41171476",
    "title_en": "Online solid-phase extraction of glucoraphanin and sulforaphane from non-edible plants based on amino acid-functionalized covalent organic frameworks.",
    "pub_date": "2025 Oct",
    "journal": "Mikrochimica acta",
    "abstract_en": "Glucoraphanin (GR) and sulforaphane (SFN) are sulfur-containing compounds with diverse medicinal applications. However, cruciferous vegetables are a single source of GR and SFN, which limits development and utilization in natural resources. Herein, amino acid covalent organic framework (COF-Cys) was synthesized via click reactions and employed as an adsorbent in online solid-phase extraction (online SPE) to determine GR and SFN in non-edible plant samples. The adsorption mechanism was analyzed using density functional theory, revealing that adsorption occurred via electrostatic interaction and hydrogen bonding. Under the optimum conditions, good linearity (4-2500Â ng/mL; R<sup>2</sup>â€‰=â€‰0.9922 and 0.9968) and lower limits of detection (1.0Â ng/mL and 0.6Â ng/mL) were observed. GR and SFN were found in 18 non-edible plant samples, and recoveries of spiked samples were 89.1-109.3% with RSDâ€‰â‰¤â€‰6.9%. The COF-Cys-online SPE-UPLC-MS/MS approach displays great potential for application to detect GR and SFN in non-edible plants and provide valuable support for the development of functional products.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°è˜¿è””ç¡«ç´ å’Œå…¶å‰é©…ç‰©è³ªçš„æ½›åœ¨æ‡‰ç”¨ã€‚é€™äº›åŒ–åˆç‰©ä¾†è‡ªåå­—èŠ±ç§‘è”¬èœï¼Œå·²çŸ¥å…·æœ‰å¤šç¨®è—¥ç”¨ç‰¹æ€§ã€‚é€éé€™é …ç ”ç©¶ï¼Œæˆ‘å€‘å¯ä»¥æ›´æ·±å…¥äº†è§£å¦‚ä½•å¾éé£Ÿç”¨æ¤ç‰©ä¸­æå–é€™äº›æœ‰ç›Šçš„åŒ–åˆç‰©ï¼Œé€²è€Œä¿ƒé€²å¥åº·æˆ–é é˜²æŸäº›ç–¾ç—…çš„å¯èƒ½æ€§ã€‚é€™å°æ–¼å°‹æ‰¾æ–°çš„å¤©ç„¶è³‡æºå’Œé–‹ç™¼åŠŸèƒ½æ€§ç”¢å“å…·æœ‰é‡è¦æ„ç¾©ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨å¦‚ä½•å¾éé£Ÿç”¨æ¤ç‰©ä¸­æå–è˜¿è””ç¡«ç´ å’Œå…¶å‰é©…ç‰©è³ªâ€”â€”è‘¡è„ç³–è˜¿è””ç¡«ç´ ã€‚ç”±æ–¼é€™äº›åŒ–åˆç‰©ä¸»è¦ä¾†è‡ªåå­—èŠ±ç§‘è”¬èœï¼Œå› æ­¤ç ”ç©¶è€…å¸Œæœ›èƒ½æ‰¾åˆ°å…¶ä»–ä¾†æºï¼Œä»¥æ“´å¤§å…¶æ‡‰ç”¨ç¯„åœã€‚ç ”ç©¶çš„é‡é»åœ¨æ–¼é–‹ç™¼ä¸€ç¨®æ–°çš„æ–¹æ³•ï¼Œèƒ½æœ‰æ•ˆåœ°å¾é€™äº›éé£Ÿç”¨æ¤ç‰©ä¸­æª¢æ¸¬å’Œæå–é€™äº›åŒ–åˆç‰©ï¼Œé€™å°æ–¼æœªä¾†çš„è—¥ç‰©é–‹ç™¼å’Œå¥åº·ç”¢å“çš„å‰µæ–°å…·æœ‰é‡è¦æ„ç¾©ã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…åˆæˆäº†ä¸€ç¨®æ°¨åŸºé…¸å…±åƒ¹æœ‰æ©Ÿæ¡†æ¶ï¼ˆCOF-Cysï¼‰ï¼Œä¸¦å°‡å…¶ç”¨ä½œåœ¨ç·šå›ºç›¸èƒå–ï¼ˆonline SPEï¼‰çš„å¸é™„åŠ‘ï¼Œä»¥æª¢æ¸¬éé£Ÿç”¨æ¤ç‰©æ¨£æœ¬ä¸­çš„è‘¡è„ç³–è˜¿è””ç¡«ç´ å’Œè˜¿è””ç¡«ç´ ã€‚ç ”ç©¶è€…åˆ©ç”¨å¯†åº¦æ³›å‡½ç†è«–åˆ†æäº†å¸é™„æ©Ÿåˆ¶ï¼Œç™¼ç¾å¸é™„ä¸»è¦æ˜¯é€šééœé›»ç›¸äº’ä½œç”¨å’Œæ°«éµé€²è¡Œçš„ã€‚åœ¨æœ€ä½³æ¢ä»¶ä¸‹ï¼Œç ”ç©¶è€…è§€å¯Ÿåˆ°è‰¯å¥½çš„ç·šæ€§é—œä¿‚å’Œè¼ƒä½çš„æª¢æ¸¬é™ï¼Œé¡¯ç¤ºå‡ºé€™ç¨®æ–¹æ³•çš„æœ‰æ•ˆæ€§ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾æ˜¯ï¼Œåœ¨18ç¨®éé£Ÿç”¨æ¤ç‰©æ¨£æœ¬ä¸­æª¢æ¸¬åˆ°äº†è‘¡è„ç³–è˜¿è””ç¡«ç´ å’Œè˜¿è””ç¡«ç´ ï¼Œä¸”åœ¨æ·»åŠ æ¨£æœ¬çš„å›æ”¶ç‡é”åˆ°89.1%åˆ°109.3%ä¹‹é–“ï¼Œè®Šç•°ä¿‚æ•¸ä¹Ÿä½æ–¼6.9%ã€‚é€™è¡¨æ˜COF-Cysåœ¨ç·šå›ºç›¸èƒå–-UPLC-MS/MSçš„æ–¹æ³•åœ¨æª¢æ¸¬éé£Ÿç”¨æ¤ç‰©ä¸­çš„é€™äº›åŒ–åˆç‰©æ–¹é¢å…·æœ‰å¾ˆå¤§çš„æ½›åŠ›ï¼Œä¸¦ç‚ºåŠŸèƒ½æ€§ç”¢å“çš„é–‹ç™¼æä¾›äº†æœ‰åƒ¹å€¼çš„æ”¯æŒã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°è˜¿è””ç¡«ç´ å’Œå…¶å‰é©…ç‰©è³ªçš„æ½›åœ¨æ‡‰ç”¨ã€‚é€™äº›åŒ–åˆç‰©ä¾†è‡ªåå­—èŠ±ç§‘è”¬èœï¼Œå·²çŸ¥å…·æœ‰å¤šç¨®è—¥ç”¨ç‰¹æ€§ã€‚é€éé€™é …ç ”ç©¶ï¼Œæˆ‘å€‘å¯ä»¥æ›´æ·±å…¥äº†è§£å¦‚ä½•å¾éé£Ÿç”¨æ¤ç‰©ä¸­æå–é€™äº›æœ‰ç›Šçš„åŒ–åˆç‰©ï¼Œé€²è€Œä¿ƒé€²å¥åº·æˆ–é é˜²æŸäº›ç–¾ç—…çš„å¯èƒ½æ€§ã€‚é€™å°æ–¼å°‹æ‰¾æ–°çš„å¤©ç„¶è³‡æºå’Œé–‹ç™¼åŠŸèƒ½æ€§ç”¢å“å…·æœ‰é‡è¦æ„ç¾©ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨å¦‚ä½•å¾éé£Ÿç”¨æ¤ç‰©ä¸­æå–è˜¿è””ç¡«ç´ å’Œå…¶å‰é©…ç‰©è³ªâ€”â€”è‘¡è„ç³–è˜¿è””ç¡«ç´ ã€‚ç”±æ–¼é€™äº›åŒ–åˆç‰©ä¸»è¦ä¾†è‡ªåå­—èŠ±ç§‘è”¬èœï¼Œå› æ­¤ç ”ç©¶è€…å¸Œæœ›èƒ½æ‰¾åˆ°å…¶ä»–ä¾†æºï¼Œä»¥æ“´å¤§å…¶æ‡‰ç”¨ç¯„åœã€‚ç ”ç©¶çš„é‡é»åœ¨æ–¼é–‹ç™¼ä¸€ç¨®æ–°çš„æ–¹æ³•ï¼Œèƒ½æœ‰æ•ˆåœ°å¾é€™äº›éé£Ÿç”¨æ¤ç‰©ä¸­æª¢æ¸¬å’Œæå–é€™äº›åŒ–åˆç‰©ï¼Œé€™å°æ–¼æœªä¾†çš„è—¥ç‰©é–‹ç™¼å’Œå¥åº·ç”¢å“çš„å‰µæ–°å…·æœ‰é‡è¦æ„ç¾©ã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶è€…åˆæˆäº†ä¸€ç¨®æ°¨åŸºé…¸å…±åƒ¹æœ‰æ©Ÿæ¡†æ¶ï¼ˆCOF-Cysï¼‰ï¼Œä¸¦å°‡å…¶ç”¨ä½œåœ¨ç·šå›ºç›¸èƒå–ï¼ˆonline SPEï¼‰çš„å¸é™„åŠ‘ï¼Œä»¥æª¢æ¸¬éé£Ÿç”¨æ¤ç‰©æ¨£æœ¬ä¸­çš„è‘¡è„ç³–è˜¿è””ç¡«ç´ å’Œè˜¿è””ç¡«ç´ ã€‚ç ”ç©¶è€…åˆ©ç”¨å¯†åº¦æ³›å‡½ç†è«–åˆ†æäº†å¸é™„æ©Ÿåˆ¶ï¼Œç™¼ç¾å¸é™„ä¸»è¦æ˜¯é€šééœé›»ç›¸äº’ä½œç”¨å’Œæ°«éµé€²è¡Œçš„ã€‚åœ¨æœ€ä½³æ¢ä»¶ä¸‹ï¼Œç ”ç©¶è€…è§€å¯Ÿåˆ°è‰¯å¥½çš„ç·šæ€§é—œä¿‚å’Œè¼ƒä½çš„æª¢æ¸¬é™ï¼Œé¡¯ç¤ºå‡ºé€™ç¨®æ–¹æ³•çš„æœ‰æ•ˆæ€§ã€‚\n\nä¸»è¦ç™¼ç¾æ˜¯ï¼Œåœ¨18ç¨®éé£Ÿç”¨æ¤ç‰©æ¨£æœ¬ä¸­æª¢æ¸¬åˆ°äº†è‘¡è„ç³–è˜¿è””ç¡«ç´ å’Œè˜¿è””ç¡«ç´ ï¼Œä¸”åœ¨æ·»åŠ æ¨£æœ¬çš„å›æ”¶ç‡é”åˆ°89.1%åˆ°109.3%ä¹‹é–“ï¼Œè®Šç•°ä¿‚æ•¸ä¹Ÿä½æ–¼6.9%ã€‚é€™è¡¨æ˜COF-Cysåœ¨ç·šå›ºç›¸èƒå–-UPLC-MS/MSçš„æ–¹æ³•åœ¨æª¢æ¸¬éé£Ÿç”¨æ¤ç‰©ä¸­çš„é€™äº›åŒ–åˆç‰©æ–¹é¢å…·æœ‰å¾ˆå¤§çš„æ½›åŠ›ï¼Œä¸¦ç‚ºåŠŸèƒ½æ€§ç”¢å“çš„é–‹ç™¼æä¾›äº†æœ‰åƒ¹å€¼çš„æ”¯æŒã€‚",
    "fb_post": "æ ¹æ“šã€ŠMikrochimica actaã€‹æ–¼ 2025 å¹´ 10 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿè˜¿è””ç¡«ç´ ä¸åƒ…åƒ…æ˜¯å¾è˜¿è””ä¾†çš„ï¼Œå®ƒé‚„æœ‰å¯èƒ½ä¾†è‡ªå…¶ä»–éé£Ÿç”¨æ¤ç‰©ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶è®“æˆ‘å€‘æ›´äº†è§£é€™äº›ç¥ç§˜çš„åŒ–åˆç‰©ã€‚ç ”ç©¶è€…å€‘å°ˆæ³¨æ–¼å¾åå­—èŠ±ç§‘è”¬èœæå–è˜¿è””ç¡«ç´ åŠå…¶å‰é©…ç‰©è³ªï¼Œä¸¦å¸Œæœ›æ‰¾åˆ°æ–°çš„ä¾†æºä¾†æ“´å¤§å®ƒå€‘çš„æ‡‰ç”¨ã€‚ é€™é …ç ”ç©¶çš„éç¨‹ä¸­ï¼Œç ”ç©¶è€…åˆæˆäº†ä¸€ç¨®ç‰¹æ®Šçš„ææ–™ï¼Œå¹«åŠ©ä»–å€‘å¾éé£Ÿç”¨æ¤ç‰©ä¸­æª¢æ¸¬é€™äº›æœ‰ç›Šçš„åŒ–åˆç‰©ã€‚çµæœé¡¯ç¤ºï¼Œåœ¨18ç¨®ä¸åŒçš„éé£Ÿç”¨æ¤ç‰©ä¸­ï¼Œä»–å€‘æˆåŠŸæ‰¾åˆ°äº†è‘¡è„ç³–è˜¿è””ç¡«ç´ å’Œè˜¿è””ç¡«ç´ ï¼Œä¸”æª¢æ¸¬çš„æº–ç¢ºåº¦éå¸¸é«˜ï¼Œå›æ”¶ç‡é”åˆ°äº†89.1%åˆ°109.3%ä¹‹é–“ï¼ é€™ä¸åƒ…ç‚ºæœªä¾†çš„å¥åº·ç”¢å“é–‹ç™¼æä¾›äº†æ–°çš„å¯èƒ½æ€§ï¼Œé‚„è®“æˆ‘å€‘å°è‡ªç„¶ç•Œä¸­çš„è³‡æºæœ‰äº†æ›´æ·±çš„èªè­˜ã€‚ ä¾†çœ‹çœ‹é€™äº›é‡é»ï¼š\n- è˜¿è””ç¡«ç´ ä¾†è‡ªéé£Ÿç”¨æ¤ç‰©çš„æ½›åŠ›è¢«ç™¼ç¾ï¼\n- ç ”ç©¶è€…é–‹ç™¼äº†æ–°çš„æª¢æ¸¬æ–¹æ³•ï¼Œæº–ç¢ºåº¦é«˜ã€‚\n- é€™äº›åŒ–åˆç‰©å¯èƒ½åœ¨å¥åº·ç”¢å“ä¸­ç™¼æ®é‡è¦ä½œç”¨ï¼",
    "image_prompt": "Create an infographic that explains the experimental methods and main results of the study on glucoraphanin and sulforaphane extraction from non-edible plants. Use a flat design style with a light background and soft colors. Include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects (like humans or cells), arrows or flow lines indicating the experimental steps, and a section labeled 'Main Results' showcasing the findings, such as recovery rates and potential health benefits.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": false,
    "disease_name": "",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41171476/"
  },
  {
    "id": "41246347",
    "title_en": "Sulforaphane in cancer precision medicine: from biosynthetic origins to multiscale mechanisms and clinical translation.",
    "pub_date": "2025",
    "journal": "Frontiers in immunology",
    "abstract_en": "Sulforaphane (SFN), an isothiocyanate derived from glucoraphanin in cruciferous vegetables, has evolved from a dietary antioxidant to a sophisticated multi-target agent in oncology. While its roles in nuclear factor erythroid 2-related factor 2 (Nrf2) activation and histone deacetylase (HDAC) inhibition are well-established, this review provides a novel synthesis by integrating disparate research scales-a multiscale perspective that spans from the genetic and epigenetic regulation of glucoraphanin biosynthesis in plants to SFN's recently elucidated effects on ferroptosis, cancer stem cells (CSCs), and the tumor immune microenvironment in humans. We critically evaluate how key host factors, such as gut microbiota composition and glutathione S-transferase (GST) polymorphisms, dictate SFN bioavailability and efficacy, thereby framing a precision nutrition paradigm for its application. Furthermore, we move beyond generic claims of synergy to detail SFN's specific mechanisms in enhancing conventional therapies, including the modulation of drug transporters and immune checkpoints. By integrating advances from plant biochemistry to molecular oncology, this review establishes an updated and mechanism-oriented framework for realizing SFN's compelling potential in cancer prevention and therapy through a precision medicine approach.",
    "para1": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å¾åå­—èŠ±ç§‘è”¬èœä¸­æå–çš„åŒ–åˆç‰©ï¼Œè¿‘å¹´ä¾†è¢«èªç‚ºåœ¨ç™Œç—‡é é˜²å’Œæ²»ç™‚ä¸­å…·æœ‰æ½›åœ¨çš„åƒ¹å€¼ã€‚é€™é …ç ”ç©¶æä¾›äº†æ–°çš„è¦‹è§£ï¼Œé¡¯ç¤ºè˜¿è””ç¡«ç´ ä¸åƒ…åƒ…æ˜¯ä¸€ç¨®æŠ—æ°§åŒ–åŠ‘ï¼Œé‚„èƒ½å½±éŸ¿ç™Œç´°èƒçš„å¤šç¨®ç”Ÿç‰©æ©Ÿåˆ¶ã€‚é€éäº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ‰¾åˆ°æ›´æœ‰æ•ˆçš„æ–¹å¼ä¾†é é˜²ç–¾ç—…ï¼Œç‰¹åˆ¥æ˜¯åœ¨ç™Œç—‡é€™å€‹é ˜åŸŸã€‚é€™æé†’æˆ‘å€‘ï¼Œé£²é£Ÿä¸­åŒ…å«é€™é¡è”¬èœå¯èƒ½å°å¥åº·æœ‰æ­£é¢çš„å½±éŸ¿ï¼Œä¸¦ä¸”åœ¨æœªä¾†çš„ç–¾ç—…é é˜²ç­–ç•¥ä¸­ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æœƒæ‰®æ¼”é‡è¦è§’è‰²ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡é é˜²å’Œæ²»ç™‚ä¸­çš„ä½œç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡ŒåŒ…æ‹¬è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·ã€å‡‹äº¡ä»¥åŠè…«ç˜¤å¾®ç’°å¢ƒçš„è®ŠåŒ–ã€‚ç‰¹åˆ¥æ˜¯ï¼Œç ”ç©¶è‘—é‡æ–¼è˜¿è””ç¡«ç´ åœ¨åŸºå› å’Œè¡¨è§€éºå‚³èª¿æ§ä¸­çš„è§’è‰²ï¼Œä¸¦ä¸”åˆ†æå…¶å°ç™Œç—‡å¹¹ç´°èƒå’Œéµæ­»äº¡ç­‰ç¾è±¡çš„å½±éŸ¿ã€‚é€™äº›å•é¡Œçš„æ¢è¨æœ‰åŠ©æ–¼æˆ‘å€‘æ›´æ·±å…¥äº†è§£è˜¿è””ç¡«ç´ çš„æ½›åŠ›ï¼Œä¸¦ç‚ºæœªä¾†çš„è‡¨åºŠæ‡‰ç”¨æä¾›åŸºç¤ã€‚",
    "para3": "åœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…æ¡ç”¨äº†å¤šå±¤æ¬¡çš„åˆ†ææ–¹æ³•ï¼Œå¾æ¤ç‰©çš„åŸºå› èª¿æ§é–‹å§‹ï¼Œæ¢è¨è˜¿è””ç¡«ç´ çš„ç”Ÿç‰©åˆæˆï¼Œç›´åˆ°å…¶åœ¨äººé«”ä¸­çš„ä½œç”¨ã€‚ç ”ç©¶è€…è©•ä¼°äº†å®¿ä¸»å› ç´ ï¼Œä¾‹å¦‚è…¸é“å¾®ç”Ÿç‰©çµ„çš„çµ„æˆå’Œè°·èƒ±ç”˜è‚½S-è½‰ç§»é…¶çš„å¤šæ…‹æ€§ï¼Œé€™äº›å› ç´ æœƒå½±éŸ¿è˜¿è””ç¡«ç´ çš„ç”Ÿç‰©åˆ©ç”¨åº¦å’Œç™‚æ•ˆã€‚é€™æ¨£çš„å¯¦é©—è¨­è¨ˆä¸åƒ…æ¶µè“‹äº†åŸºç¤ç§‘å­¸ï¼Œé‚„åŒ…æ‹¬è‡¨åºŠæ‡‰ç”¨çš„æ½›åŠ›ï¼Œè®“æˆ‘å€‘èƒ½å¤ å¾å¤šå€‹è§’åº¦ç†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ã€‚",
    "para4": "é€™é …ç ”ç©¶çš„ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨å¢å¼·å‚³çµ±æ²»ç™‚æ•ˆæœæ–¹é¢å…·æœ‰æ½›åŠ›ï¼Œç‰¹åˆ¥æ˜¯åœ¨èª¿ç¯€è—¥ç‰©é‹è¼¸å’Œå…ç–«æª¢æŸ¥é»æ–¹é¢ã€‚ç ”ç©¶è€…æŒ‡å‡ºï¼Œè˜¿è””ç¡«ç´ çš„å…·é«”ä½œç”¨æ©Ÿåˆ¶å¯èƒ½æœƒå½±éŸ¿ç™Œç—‡æ²»ç™‚çš„æˆæ•ˆï¼Œä¸¦ä¸”æä¾›äº†ä¸€å€‹ç²¾æº–ç‡Ÿé¤Šçš„æ¡†æ¶ï¼Œè®“æˆ‘å€‘èƒ½å¤ æ›´å¥½åœ°åˆ©ç”¨é€™ç¨®åŒ–åˆç‰©ã€‚é›–ç„¶ç ”ç©¶çµæœé¡¯ç¤ºè˜¿è””ç¡«ç´ åœ¨ç™Œç—‡é é˜²å’Œæ²»ç™‚ä¸­æœ‰å…¶å¸å¼•åŠ›ï¼Œä½†ä»éœ€é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå…¶å…·é«”æ•ˆæœå’Œæ‡‰ç”¨ã€‚",
    "explanation_zh": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å¾åå­—èŠ±ç§‘è”¬èœä¸­æå–çš„åŒ–åˆç‰©ï¼Œè¿‘å¹´ä¾†è¢«èªç‚ºåœ¨ç™Œç—‡é é˜²å’Œæ²»ç™‚ä¸­å…·æœ‰æ½›åœ¨çš„åƒ¹å€¼ã€‚é€™é …ç ”ç©¶æä¾›äº†æ–°çš„è¦‹è§£ï¼Œé¡¯ç¤ºè˜¿è””ç¡«ç´ ä¸åƒ…åƒ…æ˜¯ä¸€ç¨®æŠ—æ°§åŒ–åŠ‘ï¼Œé‚„èƒ½å½±éŸ¿ç™Œç´°èƒçš„å¤šç¨®ç”Ÿç‰©æ©Ÿåˆ¶ã€‚é€éäº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ‰¾åˆ°æ›´æœ‰æ•ˆçš„æ–¹å¼ä¾†é é˜²ç–¾ç—…ï¼Œç‰¹åˆ¥æ˜¯åœ¨ç™Œç—‡é€™å€‹é ˜åŸŸã€‚é€™æé†’æˆ‘å€‘ï¼Œé£²é£Ÿä¸­åŒ…å«é€™é¡è”¬èœå¯èƒ½å°å¥åº·æœ‰æ­£é¢çš„å½±éŸ¿ï¼Œä¸¦ä¸”åœ¨æœªä¾†çš„ç–¾ç—…é é˜²ç­–ç•¥ä¸­ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æœƒæ‰®æ¼”é‡è¦è§’è‰²ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡é é˜²å’Œæ²»ç™‚ä¸­çš„ä½œç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡ŒåŒ…æ‹¬è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·ã€å‡‹äº¡ä»¥åŠè…«ç˜¤å¾®ç’°å¢ƒçš„è®ŠåŒ–ã€‚ç‰¹åˆ¥æ˜¯ï¼Œç ”ç©¶è‘—é‡æ–¼è˜¿è””ç¡«ç´ åœ¨åŸºå› å’Œè¡¨è§€éºå‚³èª¿æ§ä¸­çš„è§’è‰²ï¼Œä¸¦ä¸”åˆ†æå…¶å°ç™Œç—‡å¹¹ç´°èƒå’Œéµæ­»äº¡ç­‰ç¾è±¡çš„å½±éŸ¿ã€‚é€™äº›å•é¡Œçš„æ¢è¨æœ‰åŠ©æ–¼æˆ‘å€‘æ›´æ·±å…¥äº†è§£è˜¿è””ç¡«ç´ çš„æ½›åŠ›ï¼Œä¸¦ç‚ºæœªä¾†çš„è‡¨åºŠæ‡‰ç”¨æä¾›åŸºç¤ã€‚\n\nåœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…æ¡ç”¨äº†å¤šå±¤æ¬¡çš„åˆ†ææ–¹æ³•ï¼Œå¾æ¤ç‰©çš„åŸºå› èª¿æ§é–‹å§‹ï¼Œæ¢è¨è˜¿è””ç¡«ç´ çš„ç”Ÿç‰©åˆæˆï¼Œç›´åˆ°å…¶åœ¨äººé«”ä¸­çš„ä½œç”¨ã€‚ç ”ç©¶è€…è©•ä¼°äº†å®¿ä¸»å› ç´ ï¼Œä¾‹å¦‚è…¸é“å¾®ç”Ÿç‰©çµ„çš„çµ„æˆå’Œè°·èƒ±ç”˜è‚½S-è½‰ç§»é…¶çš„å¤šæ…‹æ€§ï¼Œé€™äº›å› ç´ æœƒå½±éŸ¿è˜¿è””ç¡«ç´ çš„ç”Ÿç‰©åˆ©ç”¨åº¦å’Œç™‚æ•ˆã€‚é€™æ¨£çš„å¯¦é©—è¨­è¨ˆä¸åƒ…æ¶µè“‹äº†åŸºç¤ç§‘å­¸ï¼Œé‚„åŒ…æ‹¬è‡¨åºŠæ‡‰ç”¨çš„æ½›åŠ›ï¼Œè®“æˆ‘å€‘èƒ½å¤ å¾å¤šå€‹è§’åº¦ç†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨å¢å¼·å‚³çµ±æ²»ç™‚æ•ˆæœæ–¹é¢å…·æœ‰æ½›åŠ›ï¼Œç‰¹åˆ¥æ˜¯åœ¨èª¿ç¯€è—¥ç‰©é‹è¼¸å’Œå…ç–«æª¢æŸ¥é»æ–¹é¢ã€‚ç ”ç©¶è€…æŒ‡å‡ºï¼Œè˜¿è””ç¡«ç´ çš„å…·é«”ä½œç”¨æ©Ÿåˆ¶å¯èƒ½æœƒå½±éŸ¿ç™Œç—‡æ²»ç™‚çš„æˆæ•ˆï¼Œä¸¦ä¸”æä¾›äº†ä¸€å€‹ç²¾æº–ç‡Ÿé¤Šçš„æ¡†æ¶ï¼Œè®“æˆ‘å€‘èƒ½å¤ æ›´å¥½åœ°åˆ©ç”¨é€™ç¨®åŒ–åˆç‰©ã€‚é›–ç„¶ç ”ç©¶çµæœé¡¯ç¤ºè˜¿è””ç¡«ç´ åœ¨ç™Œç—‡é é˜²å’Œæ²»ç™‚ä¸­æœ‰å…¶å¸å¼•åŠ›ï¼Œä½†ä»éœ€é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå…¶å…·é«”æ•ˆæœå’Œæ‡‰ç”¨ã€‚",
    "fb_post": "æ ¹æ“šã€ŠFrontiers in immunologyã€‹æ–¼ 2025 å¹´ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ±ä½ çŸ¥é“å—ï¼Ÿè˜¿è””ç¡«ç´ é€™ç¨®ä¾†è‡ªåå­—èŠ±ç§‘è”¬èœçš„åŒ–åˆç‰©ï¼Œå¯èƒ½å°ç™Œç—‡çš„é é˜²å’Œæ²»ç™‚æœ‰è‘—æ„æƒ³ä¸åˆ°çš„å¹«åŠ©ï¼æœ€è¿‘çš„ä¸€é …ç ”ç©¶æ­ç¤ºï¼Œè˜¿è””ç¡«ç´ ä¸åƒ…åƒ…æ˜¯ä¸€ç¨®æŠ—æ°§åŒ–åŠ‘ï¼Œé‚„èƒ½å½±éŸ¿ç™Œç´°èƒçš„å¤šç¨®ç”Ÿç‰©æ©Ÿåˆ¶ï¼Œé€™çœŸæ˜¯å¤ªé…·äº†ï¼\n\né€™é …ç ”ç©¶ä¸»è¦æ¢è¨äº†è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·å’Œæ­»äº¡ï¼Œé‚„æœ‰å®ƒåœ¨è…«ç˜¤å¾®ç’°å¢ƒä¸­çš„è®ŠåŒ–ã€‚ç ”ç©¶è€…å€‘å¾æ¤ç‰©çš„åŸºå› èª¿æ§é–‹å§‹ï¼Œåˆ†æäº†è˜¿è””ç¡«ç´ çš„åˆæˆéç¨‹ï¼Œä¸¦è§€å¯Ÿäº†å®ƒåœ¨äººé«”ä¸­çš„ä½œç”¨ï¼Œç”šè‡³è€ƒæ…®äº†è…¸é“å¾®ç”Ÿç‰©çš„å½±éŸ¿ï¼\n\næœ€æœ‰è¶£çš„æ˜¯ï¼Œç ”ç©¶ç™¼ç¾è˜¿è””ç¡«ç´ å¯èƒ½å¢å¼·å‚³çµ±æ²»ç™‚çš„æ•ˆæœï¼Œç‰¹åˆ¥æ˜¯åœ¨èª¿ç¯€è—¥ç‰©é‹è¼¸å’Œå…ç–«ç³»çµ±æ–¹é¢ã€‚é›–ç„¶é€™äº›çµæœéå¸¸å¸å¼•äººï¼Œä½†ä»éœ€è¦æ›´å¤šç ”ç©¶ä¾†ç¢ºèªé€™äº›æ½›åœ¨çš„å¥½è™•ã€‚\n\nğŸ”é‡é»æ•´ç†ï¼š\n1. è˜¿è””ç¡«ç´ ä¾†è‡ªåå­—èŠ±ç§‘è”¬èœï¼Œå¯èƒ½å°ç™Œç—‡æœ‰é é˜²å’Œæ²»ç™‚æ•ˆæœã€‚\n2. å®ƒå½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·èˆ‡æ­»äº¡ï¼Œä¸¦èª¿ç¯€è…«ç˜¤å¾®ç’°å¢ƒã€‚\n3. å¯èƒ½å¢å¼·å‚³çµ±æ²»ç™‚æ•ˆæœï¼Œä½†éœ€é€²ä¸€æ­¥ç ”ç©¶ç¢ºèªã€‚",
    "image_prompt": "Create an infographic that explains the experimental methods and main findings of a study on sulforaphane, a compound found in cruciferous vegetables. The design should feature simple illustrations of broccoli or sulforaphane, along with simplified representations of experimental subjects like humans or cells. Include arrows or flow lines to indicate the steps of the experiment. There should also be a section labeled 'Main Findings' highlighting protective effects or changes observed. Use a flat design style with a white or light background and soft colors.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "ç™Œç—‡ Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41246347/"
  },
  {
    "id": "41056875",
    "title_en": "Sulforaphane inhibits gastric cancer progression by regulating the YY1/PSMB8-AS1/miR-888-5p/SLC4A7 axis.",
    "pub_date": "2025 Oct",
    "journal": "Biochemical and biophysical research communications",
    "abstract_en": "Sulforaphane (SFN) plays a vital role in many types of cancer as a natural extract from plants. However, whether SFN can inhibit gastric carcinogenesis by regulating the lncRNA-miRNA-mRNA axis is unclear. In the current work, the significantly differentially expressed lncRNA PSMB8AS1 was obtained by performing high-throughput sequencing of gastric cancer cells treated with SFN. The qRT-PCR assay results confirmed the inhibitory effect of SFN on PSM8AS1. Subsequently, using gastric cancer data from TCGA and 11 pairs of clinical samples from gastric and paracancerous tissues, we found that PSMB8-AS1 was upregulated in gastric cancer, and high expression of PSMB8-AS1 was associated with low survival of patients with gastric cancer. MTT, cell colony formation, scratch healing, flow cytometry, and qRT-PCR assays showed that the knockdown of PSMB8-AS1 significantly reduced the proliferation and migration of gastric cancer cells as well as promoted apoptosis. Dual luciferase reporter gene and RNA immunoprecipitation (RIP) assay confirmed that PSMB8-AS1 can function as the molecular sponge for miR-888-5p. Meanwhile, bioinformatics analysis and dual-luciferase reporter gene assay showed that miR-888-5p regulates SLC4A7. Overexpression of miR-888-5p or knockdown of SLC4A7 reduced the proliferation and migration of gastric cancer cells. In addition, rescue experiments confirmed that the inhibitory effects of the knockdown of PSMB8-AS1 or the knockdown of SLC4A7 on the proliferation and migration of gastric cancer cells could be reversed by miR-888-5p inhibitor treatment. Subcutaneous tumor formation experiments in nude mice demonstrated that the tumor volume of nude mice transplanted with PSMB8-AS1-knockdown gastric cancer cells was significantly reduced compared with that of the control group. Transcription factors can usually bind to the promoter regions of lncRNAs and regulate the transcription of lncRNAs. We demonstrated through website prediction and experiments that SFN can inhibit the level of PSMB8-AS1 by regulating the transcription factor YY1. These results suggest that SFN inhibits gastric cancer growth through the YY1/PSMB8-AS1/miR-888-5p/SLC4A7 axis. Therefore, SFN might be a promising therapeutical agent for GC prevention and therapy.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›æœ‰é—œå¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨èƒƒç™Œçš„é˜²æ²»æ–¹é¢ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éèª¿æ§ç‰¹å®šçš„åˆ†å­è·¯å¾‘ä¾†æŠ‘åˆ¶èƒƒç™Œçš„ç™¼å±•ã€‚é€™æ„å‘³è‘—ï¼Œé€éé£²é£Ÿä¸­å¢åŠ é’èŠ±æ¤°èœç­‰å¯Œå«è˜¿è””ç¡«ç´ çš„é£Ÿç‰©ï¼Œå¯èƒ½å°é™ä½èƒƒç™Œé¢¨éšªæœ‰å¹«åŠ©ï¼Œé€²è€Œä¿ƒé€²æ•´é«”å¥åº·ã€‚ä¸éï¼Œé€™äº›ç™¼ç¾ä»éœ€é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå…¶å…·é«”æ•ˆæœå’Œæ©Ÿåˆ¶ï¼Œä»¥ä¾¿èƒ½æ›´å¥½åœ°æ‡‰ç”¨æ–¼è‡¨åºŠå’Œæ—¥å¸¸ç”Ÿæ´»ä¸­ã€‚",
    "para2": "æœ¬ç ”ç©¶ä¸»è¦é—œæ³¨çš„æ˜¯è˜¿è””ç¡«ç´ åœ¨èƒƒç™Œç™¼å±•ä¸­çš„ä½œç”¨ï¼Œç‰¹åˆ¥æ˜¯å®ƒæ˜¯å¦èƒ½é€šéèª¿ç¯€é•·éˆéç·¨ç¢¼RNAï¼ˆlncRNAï¼‰èˆ‡å…¶ä»–åˆ†å­ä¹‹é–“çš„ç›¸äº’ä½œç”¨ä¾†æŠ‘åˆ¶èƒƒç™Œçš„å½¢æˆã€‚ç ”ç©¶è€…å€‘å¸Œæœ›èƒ½å¤ æ­ç¤ºé€™äº›åˆ†å­ä¹‹é–“çš„é—œä¿‚ï¼Œä¸¦äº†è§£å®ƒå€‘å¦‚ä½•å½±éŸ¿èƒƒç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»ï¼Œé€²è€Œç‚ºèƒƒç™Œçš„é é˜²å’Œæ²»ç™‚æä¾›æ–°çš„æ€è·¯ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…é¦–å…ˆå°æ¥å—è˜¿è””ç¡«ç´ è™•ç†çš„èƒƒç™Œç´°èƒé€²è¡Œé«˜é€šé‡æ¸¬åºï¼Œä»¥æ‰¾å‡ºé¡¯è‘—è¡¨é”å·®ç•°çš„lncRNAï¼Œç™¼ç¾PSMB8-AS1çš„è¡¨é”é¡¯è‘—ä¸Šå‡ã€‚æ¥è‘—ï¼Œç ”ç©¶è€…ä½¿ç”¨TCGAçš„èƒƒç™Œæ•¸æ“šä»¥åŠ11å°è‡¨åºŠæ¨£æœ¬é€²è¡Œåˆ†æï¼Œç¢ºèªPSMB8-AS1åœ¨èƒƒç™Œä¸­çš„ä¸Šèª¿æƒ…æ³ï¼Œä¸¦æ¢è¨å…¶èˆ‡æ‚£è€…ç”Ÿå­˜ç‡çš„é—œè¯ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„é€²è¡Œäº†å¤šç¨®ç´°èƒå¯¦é©—ä¾†è©•ä¼°PSMB8-AS1çš„åŠŸèƒ½ï¼ŒåŒ…æ‹¬ç´°èƒå¢æ®–ã€é·ç§»å’Œå‡‹äº¡ç­‰æ–¹é¢çš„æ¸¬è©¦ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼ŒPSMB8-AS1çš„æŠ‘åˆ¶èƒ½é¡¯è‘—æ¸›å°‘èƒƒç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»ï¼Œä¸¦ä¿ƒé€²ç´°èƒå‡‹äº¡ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼ŒPSMB8-AS1å¯ä»¥ä½œç‚ºmiR-888-5pçš„åˆ†å­æµ·ç¶¿ï¼Œä¸¦ä¸”miR-888-5pèƒ½èª¿æ§SLC4A7çš„è¡¨é”ã€‚é€²ä¸€æ­¥çš„å¯¦é©—è­‰å¯¦ï¼ŒæŠ‘åˆ¶PSMB8-AS1æˆ–SLC4A7çš„è¡¨é”èƒ½é™ä½èƒƒç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»ï¼Œé€™äº›æ•ˆæœå¯ä»¥è¢«miR-888-5pçš„æŠ‘åˆ¶åŠ‘é€†è½‰ã€‚æ­¤å¤–ï¼Œåœ¨è£¸é¼ çš„è…«ç˜¤å½¢æˆå¯¦é©—ä¸­ï¼ŒPSMB8-AS1è¢«æŠ‘åˆ¶çš„èƒƒç™Œç´°èƒç§»æ¤å¾Œçš„è…«ç˜¤é«”ç©é¡¯è‘—æ¸›å°‘ï¼Œé€™äº›çµæœè¡¨æ˜è˜¿è””ç¡«ç´ å¯èƒ½é€éYY1/PSMB8-AS1/miR-888-5p/SLC4A7çš„è·¯å¾‘ä¾†æŠ‘åˆ¶èƒƒç™Œçš„ç”Ÿé•·ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›æœ‰é—œå¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨èƒƒç™Œçš„é˜²æ²»æ–¹é¢ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éèª¿æ§ç‰¹å®šçš„åˆ†å­è·¯å¾‘ä¾†æŠ‘åˆ¶èƒƒç™Œçš„ç™¼å±•ã€‚é€™æ„å‘³è‘—ï¼Œé€éé£²é£Ÿä¸­å¢åŠ é’èŠ±æ¤°èœç­‰å¯Œå«è˜¿è””ç¡«ç´ çš„é£Ÿç‰©ï¼Œå¯èƒ½å°é™ä½èƒƒç™Œé¢¨éšªæœ‰å¹«åŠ©ï¼Œé€²è€Œä¿ƒé€²æ•´é«”å¥åº·ã€‚ä¸éï¼Œé€™äº›ç™¼ç¾ä»éœ€é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå…¶å…·é«”æ•ˆæœå’Œæ©Ÿåˆ¶ï¼Œä»¥ä¾¿èƒ½æ›´å¥½åœ°æ‡‰ç”¨æ–¼è‡¨åºŠå’Œæ—¥å¸¸ç”Ÿæ´»ä¸­ã€‚\n\næœ¬ç ”ç©¶ä¸»è¦é—œæ³¨çš„æ˜¯è˜¿è””ç¡«ç´ åœ¨èƒƒç™Œç™¼å±•ä¸­çš„ä½œç”¨ï¼Œç‰¹åˆ¥æ˜¯å®ƒæ˜¯å¦èƒ½é€šéèª¿ç¯€é•·éˆéç·¨ç¢¼RNAï¼ˆlncRNAï¼‰èˆ‡å…¶ä»–åˆ†å­ä¹‹é–“çš„ç›¸äº’ä½œç”¨ä¾†æŠ‘åˆ¶èƒƒç™Œçš„å½¢æˆã€‚ç ”ç©¶è€…å€‘å¸Œæœ›èƒ½å¤ æ­ç¤ºé€™äº›åˆ†å­ä¹‹é–“çš„é—œä¿‚ï¼Œä¸¦äº†è§£å®ƒå€‘å¦‚ä½•å½±éŸ¿èƒƒç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»ï¼Œé€²è€Œç‚ºèƒƒç™Œçš„é é˜²å’Œæ²»ç™‚æä¾›æ–°çš„æ€è·¯ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…é¦–å…ˆå°æ¥å—è˜¿è””ç¡«ç´ è™•ç†çš„èƒƒç™Œç´°èƒé€²è¡Œé«˜é€šé‡æ¸¬åºï¼Œä»¥æ‰¾å‡ºé¡¯è‘—è¡¨é”å·®ç•°çš„lncRNAï¼Œç™¼ç¾PSMB8-AS1çš„è¡¨é”é¡¯è‘—ä¸Šå‡ã€‚æ¥è‘—ï¼Œç ”ç©¶è€…ä½¿ç”¨TCGAçš„èƒƒç™Œæ•¸æ“šä»¥åŠ11å°è‡¨åºŠæ¨£æœ¬é€²è¡Œåˆ†æï¼Œç¢ºèªPSMB8-AS1åœ¨èƒƒç™Œä¸­çš„ä¸Šèª¿æƒ…æ³ï¼Œä¸¦æ¢è¨å…¶èˆ‡æ‚£è€…ç”Ÿå­˜ç‡çš„é—œè¯ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„é€²è¡Œäº†å¤šç¨®ç´°èƒå¯¦é©—ä¾†è©•ä¼°PSMB8-AS1çš„åŠŸèƒ½ï¼ŒåŒ…æ‹¬ç´°èƒå¢æ®–ã€é·ç§»å’Œå‡‹äº¡ç­‰æ–¹é¢çš„æ¸¬è©¦ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼ŒPSMB8-AS1çš„æŠ‘åˆ¶èƒ½é¡¯è‘—æ¸›å°‘èƒƒç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»ï¼Œä¸¦ä¿ƒé€²ç´°èƒå‡‹äº¡ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼ŒPSMB8-AS1å¯ä»¥ä½œç‚ºmiR-888-5pçš„åˆ†å­æµ·ç¶¿ï¼Œä¸¦ä¸”miR-888-5pèƒ½èª¿æ§SLC4A7çš„è¡¨é”ã€‚é€²ä¸€æ­¥çš„å¯¦é©—è­‰å¯¦ï¼ŒæŠ‘åˆ¶PSMB8-AS1æˆ–SLC4A7çš„è¡¨é”èƒ½é™ä½èƒƒç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»ï¼Œé€™äº›æ•ˆæœå¯ä»¥è¢«miR-888-5pçš„æŠ‘åˆ¶åŠ‘é€†è½‰ã€‚æ­¤å¤–ï¼Œåœ¨è£¸é¼ çš„è…«ç˜¤å½¢æˆå¯¦é©—ä¸­ï¼ŒPSMB8-AS1è¢«æŠ‘åˆ¶çš„èƒƒç™Œç´°èƒç§»æ¤å¾Œçš„è…«ç˜¤é«”ç©é¡¯è‘—æ¸›å°‘ï¼Œé€™äº›çµæœè¡¨æ˜è˜¿è””ç¡«ç´ å¯èƒ½é€éYY1/PSMB8-AS1/miR-888-5p/SLC4A7çš„è·¯å¾‘ä¾†æŠ‘åˆ¶èƒƒç™Œçš„ç”Ÿé•·ã€‚",
    "fb_post": "æ ¹æ“šã€ŠBiochemical and biophysical research communicationsã€‹æ–¼ 2025 å¹´ 10 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ½ï¸ ä½ çŸ¥é“å—ï¼Ÿé’èŠ±æ¤°èœä¸åƒ…ç¾å‘³ï¼Œé‚„å¯èƒ½å°æˆ‘å€‘çš„å¥åº·å¤§æœ‰å¹«åŠ©ï¼æœ€è¿‘çš„ä¸€é …ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ ï¼ˆé€™æ˜¯ä¸€ç¨®åœ¨é’èŠ±æ¤°èœä¸­æ‰¾åˆ°çš„å¤©ç„¶æˆåˆ†ï¼‰å¯èƒ½æœ‰åŠ©æ–¼é é˜²èƒƒç™Œã€‚é€™é …ç ”ç©¶å°ˆæ³¨æ–¼è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿èƒƒç™Œç´°èƒçš„å¢é•·ï¼Œä¸¦ä¸”ç™¼ç¾äº†ä¸€äº›æœ‰è¶£çš„çµæœï¼\n\nç ”ç©¶äººå“¡é¦–å…ˆå°æ¥å—è˜¿è””ç¡«ç´ çš„èƒƒç™Œç´°èƒé€²è¡Œäº†æ¸¬è©¦ï¼Œç™¼ç¾ä¸€ç¨®å«åšPSMB8-AS1çš„åˆ†å­åœ¨é€™äº›ç´°èƒä¸­è¡¨é”å¢åŠ ã€‚æ¥è‘—ï¼Œä»–å€‘åˆ†æäº†è‡¨åºŠæ¨£æœ¬ï¼Œç¢ºèªäº†é€™ç¨®åˆ†å­èˆ‡èƒƒç™Œçš„é—œè¯ã€‚æœ€é‡è¦çš„æ˜¯ï¼Œç•¶ä»–å€‘æŠ‘åˆ¶PSMB8-AS1çš„è¡¨é”æ™‚ï¼Œèƒƒç™Œç´°èƒçš„å¢é•·å’Œé·ç§»æ˜é¡¯æ¸›å°‘ï¼Œç”šè‡³ä¿ƒé€²äº†ç´°èƒçš„æ­»äº¡ï¼\n\né€™äº›ç™¼ç¾è®“æˆ‘å€‘å°è˜¿è””ç¡«ç´ çš„æ½›åŠ›å……æ»¿æœŸå¾…ï¼Œä½†ä»éœ€è¦æ›´å¤šç ”ç©¶ä¾†æ·±å…¥äº†è§£å®ƒçš„ä½œç”¨æ©Ÿåˆ¶ã€‚ \n\nğŸ” é€™è£¡æœ‰å¹¾å€‹é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼é™ä½èƒƒç™Œé¢¨éšªã€‚\n2. PSMB8-AS1çš„æŠ‘åˆ¶å¯æ¸›å°‘èƒƒç™Œç´°èƒçš„å¢é•·å’Œé·ç§»ã€‚\n3. é€²ä¸€æ­¥çš„ç ”ç©¶å°‡å¹«åŠ©æˆ‘å€‘æ›´å¥½åœ°ç†è§£é€™äº›ç™¼ç¾ï¼",
    "image_prompt": "Create a flat design infographic explaining the experimental methods and main results of a study on sulforaphane. Include symbols representing broccoli and sulforaphane, simplified illustrations of experimental subjects like human cells or animals, arrows or flow lines to indicate the experimental steps, and a section highlighting the main results, such as protective effects or changes observed.",
    "is_human_study": true,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "èƒƒç™Œ Gastric Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41056875/"
  },
  {
    "id": "41235157",
    "title_en": "Novel magnolol-sulforaphane hybrids as potent antitumor agents: synthesis and biological characterization.",
    "pub_date": "2025 Oct",
    "journal": "RSC medicinal chemistry",
    "abstract_en": "The natural product-based hybrid strategy is a promising approach for innovative drug discovery. Leveraging the privileged architecture of sulforaphane-a prominent anticancer natural product-we engineered a novel library of magnolol-sulforaphane molecular hybrids for antitumor evaluation through a concise synthetic strategy for the pharmacophore of sulforaphane (SFN), culminating in the identification of CTNPC8 as a promising anticancer compound. Notably, CTNPC8 not only displays exceptional broad-spectrum anticancer activity with potency surpassing both parent compounds and cisplatin, but also exhibits potent <i>in vitro</i> efficacy against the challenging nasopharyngeal carcinoma (NPC) cell model. Mechanistic studies in nasopharyngeal carcinoma models reveal that CTNPC8 triggers mitochondrial-mediated apoptosis through regulating ROS generation and induces G<sub>2</sub>/M phase arrest. Transcriptomic profiling coupled with validation experiments reveals that CTNPC8 exerts its anti-NPC activity primarily by modulating the Akt/mTOR pathway. The present study provided a valuable strategy for discovering new antitumor agents through hybrid molecular design, nominating CTNPC8 as a promising hit compound for anti-NPC research.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€å€‹æœ‰è¶£çš„æ–¹å‘ï¼Œå¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æœ‰å•Ÿç¤ºã€‚ç ”ç©¶è€…å€‘å°ˆæ³¨æ–¼é–‹ç™¼æ–°çš„æŠ—ç™Œè—¥ç‰©ï¼Œå°¤å…¶æ˜¯é‡å°é›£æ²»çš„é¼»å’½ç™Œã€‚é€éçµåˆå¤©ç„¶ç”¢ç‰©çš„ç‰¹æ€§ï¼Œé€™ç¨®å‰µæ–°çš„è—¥ç‰©è¨­è¨ˆæ–¹æ³•å¯èƒ½ç‚ºæœªä¾†çš„ç™Œç—‡æ²»ç™‚æä¾›æ–°çš„é¸æ“‡ï¼Œå°¤å…¶æ˜¯å°æ–¼é‚£äº›ç›®å‰æ²»ç™‚æ•ˆæœä¸ä½³çš„ç™Œç—‡é¡å‹ã€‚é€™æ¨£çš„ç ”ç©¶ä¸åƒ…æœ‰åŠ©æ–¼ç†è§£ç™Œç—‡çš„æ©Ÿåˆ¶ï¼Œé‚„å¯èƒ½ä¿ƒé€²æ–°è—¥çš„ç™¼ç¾ï¼Œé€²è€Œæ”¹å–„æ‚£è€…çš„ç”Ÿæ´»å“è³ªå’Œé å¾Œã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯é–‹ç™¼ä¸€ç¨®æ–°å‹çš„æŠ—ç™ŒåŒ–åˆç‰©ï¼Œç‰¹åˆ¥æ˜¯é‡å°é¼»å’½ç™Œã€‚ç ”ç©¶è€…å€‘åˆ©ç”¨è˜¿è””ç¡«ç´ é€™ç¨®å¤©ç„¶æŠ—ç™Œæˆåˆ†ï¼Œè¨­è¨ˆå‡ºä¸€ç³»åˆ—æ–°çš„åˆ†å­é›œäº¤ç‰©ï¼Œä¸¦é€²è¡ŒæŠ—è…«ç˜¤è©•ä¼°ã€‚é€™é …ç ”ç©¶é—œå¿ƒçš„å•é¡Œæ˜¯å¦‚ä½•åˆ©ç”¨å¤©ç„¶ç”¢å“çš„çµæ§‹å„ªå‹¢ï¼Œå‰µé€ å‡ºæ›´æœ‰æ•ˆçš„æŠ—ç™Œè—¥ç‰©ï¼Œä¸¦æ¢ç´¢å…¶ä½œç”¨æ©Ÿåˆ¶ï¼Œä»¥æœŸæ‰¾åˆ°æ›´å¥½çš„æ²»ç™‚æ–¹æ¡ˆã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å€‘é¦–å…ˆåˆæˆäº†ä»¥è˜¿è””ç¡«ç´ ç‚ºåŸºç¤çš„åˆ†å­é›œäº¤ç‰©ï¼Œä¸¦é€²è¡ŒæŠ—è…«ç˜¤æ´»æ€§è©•ä¼°ã€‚é€™äº›åŒ–åˆç‰©çš„æ•ˆèƒ½æ˜¯åœ¨ç´°èƒæ¨¡å‹ä¸­æ¸¬è©¦çš„ï¼Œç‰¹åˆ¥æ˜¯é‡å°é¼»å’½ç™Œç´°èƒã€‚ç ”ç©¶è€…å€‘é‚„é€²ä¸€æ­¥æ¢è¨äº†é€™äº›åŒ–åˆç‰©çš„ä½œç”¨æ©Ÿåˆ¶ï¼ŒåŒ…æ‹¬å®ƒå€‘å¦‚ä½•å½±éŸ¿ç´°èƒå…§çš„ä¿¡è™Ÿå‚³éè·¯å¾‘ï¼Œä¸¦å¼•ç™¼ç´°èƒå‡‹äº¡ã€‚é€™æ¨£çš„å¯¦é©—è¨­è¨ˆæ—¨åœ¨æ‰¾å‡ºæœ€å…·æ½›åŠ›çš„æŠ—ç™ŒåŒ–åˆç‰©ï¼Œä¸¦äº†è§£å…¶èƒŒå¾Œçš„ç”Ÿç‰©å­¸æ©Ÿåˆ¶ã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾æ˜¯ï¼ŒCTNPC8é€™ç¨®æ–°å‹åŒ–åˆç‰©å±•ç¾å‡ºå“è¶Šçš„æŠ—ç™Œæ´»æ€§ï¼Œç”šè‡³è¶…éäº†å…¶æ¯é«”åŒ–åˆç‰©å’Œé †é‰‘ã€‚å®ƒåœ¨é¼»å’½ç™Œç´°èƒæ¨¡å‹ä¸­é¡¯ç¤ºå‡ºå¼·å¤§çš„é«”å¤–æ•ˆèƒ½ï¼Œä¸¦ä¸”é€šéèª¿ç¯€æ´»æ€§æ°§çš„ç”Ÿæˆä¾†èª˜å°ç·šç²’é«”ä»‹å°çš„ç´°èƒå‡‹äº¡ã€‚æ­¤å¤–ï¼ŒCTNPC8é‚„èƒ½å¼•èµ·ç´°èƒé€±æœŸçš„G2/MæœŸåœæ»¯ï¼Œä¸¦ä¸»è¦é€šéèª¿ç¯€Akt/mTORé€šè·¯ä¾†ç™¼æ®å…¶æŠ—é¼»å’½ç™Œçš„ä½œç”¨ã€‚é€™äº›çµæœé¡¯ç¤ºCTNPC8æ˜¯ä¸€å€‹æœ‰å‰æ™¯çš„æŠ—è…«ç˜¤åŒ–åˆç‰©ï¼Œç‚ºæœªä¾†çš„æŠ—é¼»å’½ç™Œç ”ç©¶æä¾›äº†æ–°çš„æ–¹å‘ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€å€‹æœ‰è¶£çš„æ–¹å‘ï¼Œå¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æœ‰å•Ÿç¤ºã€‚ç ”ç©¶è€…å€‘å°ˆæ³¨æ–¼é–‹ç™¼æ–°çš„æŠ—ç™Œè—¥ç‰©ï¼Œå°¤å…¶æ˜¯é‡å°é›£æ²»çš„é¼»å’½ç™Œã€‚é€éçµåˆå¤©ç„¶ç”¢ç‰©çš„ç‰¹æ€§ï¼Œé€™ç¨®å‰µæ–°çš„è—¥ç‰©è¨­è¨ˆæ–¹æ³•å¯èƒ½ç‚ºæœªä¾†çš„ç™Œç—‡æ²»ç™‚æä¾›æ–°çš„é¸æ“‡ï¼Œå°¤å…¶æ˜¯å°æ–¼é‚£äº›ç›®å‰æ²»ç™‚æ•ˆæœä¸ä½³çš„ç™Œç—‡é¡å‹ã€‚é€™æ¨£çš„ç ”ç©¶ä¸åƒ…æœ‰åŠ©æ–¼ç†è§£ç™Œç—‡çš„æ©Ÿåˆ¶ï¼Œé‚„å¯èƒ½ä¿ƒé€²æ–°è—¥çš„ç™¼ç¾ï¼Œé€²è€Œæ”¹å–„æ‚£è€…çš„ç”Ÿæ´»å“è³ªå’Œé å¾Œã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯é–‹ç™¼ä¸€ç¨®æ–°å‹çš„æŠ—ç™ŒåŒ–åˆç‰©ï¼Œç‰¹åˆ¥æ˜¯é‡å°é¼»å’½ç™Œã€‚ç ”ç©¶è€…å€‘åˆ©ç”¨è˜¿è””ç¡«ç´ é€™ç¨®å¤©ç„¶æŠ—ç™Œæˆåˆ†ï¼Œè¨­è¨ˆå‡ºä¸€ç³»åˆ—æ–°çš„åˆ†å­é›œäº¤ç‰©ï¼Œä¸¦é€²è¡ŒæŠ—è…«ç˜¤è©•ä¼°ã€‚é€™é …ç ”ç©¶é—œå¿ƒçš„å•é¡Œæ˜¯å¦‚ä½•åˆ©ç”¨å¤©ç„¶ç”¢å“çš„çµæ§‹å„ªå‹¢ï¼Œå‰µé€ å‡ºæ›´æœ‰æ•ˆçš„æŠ—ç™Œè—¥ç‰©ï¼Œä¸¦æ¢ç´¢å…¶ä½œç”¨æ©Ÿåˆ¶ï¼Œä»¥æœŸæ‰¾åˆ°æ›´å¥½çš„æ²»ç™‚æ–¹æ¡ˆã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å€‘é¦–å…ˆåˆæˆäº†ä»¥è˜¿è””ç¡«ç´ ç‚ºåŸºç¤çš„åˆ†å­é›œäº¤ç‰©ï¼Œä¸¦é€²è¡ŒæŠ—è…«ç˜¤æ´»æ€§è©•ä¼°ã€‚é€™äº›åŒ–åˆç‰©çš„æ•ˆèƒ½æ˜¯åœ¨ç´°èƒæ¨¡å‹ä¸­æ¸¬è©¦çš„ï¼Œç‰¹åˆ¥æ˜¯é‡å°é¼»å’½ç™Œç´°èƒã€‚ç ”ç©¶è€…å€‘é‚„é€²ä¸€æ­¥æ¢è¨äº†é€™äº›åŒ–åˆç‰©çš„ä½œç”¨æ©Ÿåˆ¶ï¼ŒåŒ…æ‹¬å®ƒå€‘å¦‚ä½•å½±éŸ¿ç´°èƒå…§çš„ä¿¡è™Ÿå‚³éè·¯å¾‘ï¼Œä¸¦å¼•ç™¼ç´°èƒå‡‹äº¡ã€‚é€™æ¨£çš„å¯¦é©—è¨­è¨ˆæ—¨åœ¨æ‰¾å‡ºæœ€å…·æ½›åŠ›çš„æŠ—ç™ŒåŒ–åˆç‰©ï¼Œä¸¦äº†è§£å…¶èƒŒå¾Œçš„ç”Ÿç‰©å­¸æ©Ÿåˆ¶ã€‚\n\nä¸»è¦çš„ç™¼ç¾æ˜¯ï¼ŒCTNPC8é€™ç¨®æ–°å‹åŒ–åˆç‰©å±•ç¾å‡ºå“è¶Šçš„æŠ—ç™Œæ´»æ€§ï¼Œç”šè‡³è¶…éäº†å…¶æ¯é«”åŒ–åˆç‰©å’Œé †é‰‘ã€‚å®ƒåœ¨é¼»å’½ç™Œç´°èƒæ¨¡å‹ä¸­é¡¯ç¤ºå‡ºå¼·å¤§çš„é«”å¤–æ•ˆèƒ½ï¼Œä¸¦ä¸”é€šéèª¿ç¯€æ´»æ€§æ°§çš„ç”Ÿæˆä¾†èª˜å°ç·šç²’é«”ä»‹å°çš„ç´°èƒå‡‹äº¡ã€‚æ­¤å¤–ï¼ŒCTNPC8é‚„èƒ½å¼•èµ·ç´°èƒé€±æœŸçš„G2/MæœŸåœæ»¯ï¼Œä¸¦ä¸»è¦é€šéèª¿ç¯€Akt/mTORé€šè·¯ä¾†ç™¼æ®å…¶æŠ—é¼»å’½ç™Œçš„ä½œç”¨ã€‚é€™äº›çµæœé¡¯ç¤ºCTNPC8æ˜¯ä¸€å€‹æœ‰å‰æ™¯çš„æŠ—è…«ç˜¤åŒ–åˆç‰©ï¼Œç‚ºæœªä¾†çš„æŠ—é¼»å’½ç™Œç ”ç©¶æä¾›äº†æ–°çš„æ–¹å‘ã€‚",
    "fb_post": "æ ¹æ“šã€ŠRSC medicinal chemistryã€‹æ–¼ 2025 å¹´ 10 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ½ï¸ ä½ çŸ¥é“å—ï¼Ÿåƒè˜¿è””ä¸åªæ˜¯ç‚ºäº†å¥åº·ï¼Œé‚„å¯èƒ½å°ç™Œç—‡ç ”ç©¶æœ‰å¹«åŠ©ï¼æœ€è¿‘æœ‰ä¸€é …æœ‰è¶£çš„ç ”ç©¶ï¼Œå°ˆæ³¨æ–¼é–‹ç™¼é‡å°é¼»å’½ç™Œçš„æ–°å‹æŠ—ç™Œè—¥ç‰©ï¼Œé€™å¯æ˜¯å€‹å¤§æ–°èï¼ç ”ç©¶è€…å€‘åˆ©ç”¨è˜¿è””ä¸­çš„ä¸€ç¨®å¤©ç„¶æˆåˆ†â€”â€”è˜¿è””ç¡«ç´ ï¼Œè¨­è¨ˆå‡ºäº†ä¸€ç³»åˆ—æ–°çš„åŒ–åˆç‰©ï¼Œä¸¦åœ¨å¯¦é©—å®¤ä¸­æ¸¬è©¦å®ƒå€‘çš„æŠ—è…«ç˜¤æ•ˆæœã€‚ \n\nä»–å€‘é¦–å…ˆåˆæˆäº†é€™äº›æ–°åŒ–åˆç‰©ï¼Œç„¶å¾Œåœ¨ç´°èƒæ¨¡å‹ä¸­é€²è¡Œæ¸¬è©¦ï¼Œç‰¹åˆ¥æ˜¯é‡å°é¼»å’½ç™Œç´°èƒã€‚ç ”ç©¶è€…å€‘ç™¼ç¾ï¼Œé€™äº›åŒ–åˆç‰©ä¸åƒ…èƒ½æœ‰æ•ˆèª˜å°ç™Œç´°èƒå‡‹äº¡ï¼Œé‚„èƒ½å½±éŸ¿ç´°èƒå…§çš„ä¿¡è™Ÿå‚³éï¼Œè®“ç™Œç´°èƒç„¡æ³•ç¹¼çºŒç”Ÿé•·ã€‚ \n\næœ€ä»¤äººèˆˆå¥®çš„æ˜¯ï¼Œç ”ç©¶ä¸­ç™¼ç¾çš„CTNPC8åŒ–åˆç‰©å±•ç¾å‡ºè¶…å¼·çš„æŠ—ç™Œæ´»æ€§ï¼Œç”šè‡³æ¯”ç›®å‰çš„æ²»ç™‚æ–¹æ³•é‚„è¦æœ‰æ•ˆï¼é€™æ¨£çš„ç™¼ç¾ä¸åƒ…è®“æˆ‘å€‘å°ç™Œç—‡çš„æ²»ç™‚å……æ»¿å¸Œæœ›ï¼Œä¹Ÿç‚ºæœªä¾†çš„ç ”ç©¶æŒ‡æ˜äº†æ–¹å‘ã€‚ \n\nğŸ” ä¸»è¦é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æˆç‚ºæ–°å‹æŠ—ç™Œè—¥ç‰©çš„é—œéµæˆåˆ†ã€‚\n2. CTNPC8åŒ–åˆç‰©åœ¨å¯¦é©—ä¸­å±•ç¾å‡ºå¼·å¤§çš„æŠ—ç™Œæ•ˆæœã€‚\n3. é€™é …ç ”ç©¶ç‚ºé›£æ²»çš„é¼»å’½ç™Œæ²»ç™‚æä¾›äº†æ–°çš„å¯èƒ½æ€§ï¼",
    "image_prompt": "Create an informative illustration that explains the experimental process and main results of the study on a new anti-cancer compound derived from sulforaphane found in radishes. Use a flat design style with a light background and soft colors. Include symbols representing radishes or sulforaphane, simplified icons of experimental subjects like cells, and arrows or flow lines to indicate the steps of the experiment. Add a section labeled 'Main Results' highlighting the protective effects and changes observed.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "é¼»å’½ç™Œ Nasopharyngeal Carcinoma",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41235157/"
  },
  {
    "id": "41181585",
    "title_en": "Sulforaphane alleviates hepatocyte pyroptosis via activating Nrf2-HO-1 signaling during septic acute liver injury.",
    "pub_date": "2025",
    "journal": "Frontiers in pharmacology",
    "abstract_en": "Acute liver injury (ALI) caused by sepsis is a fatal disease with a high mortality rate and poor prognosis. Sulforaphane (SFN) is a natural isothiocyanate that has robust antioxidant and anti-inflammatory properties. The aim of this study was to identify the pharmacological effects and therapeutic mechanisms of SFN in lipopolysaccharide (LPS)-induced ALI. The role of SFN in ALI was investigated using a mouse model of LPS-induced ALI. Briefly, eighteen mice were divided into three groups: control, LPS, and LPS + SFN, which were intraperitoneally injected for 2Â days before LPS treatment. 24Â h after the LPS injection, blood and liver tissues were collected for further analysis. The hematoxylin and eosin (HE) staining showed a lot of visible necrosis areas, inflammatory cell infiltration, and congestion in liver. Meanwhile, Ly6G and F4/80 staining showed increased infiltration of neutrophils and macrophages in liver, these results indicated that LPS induced sever ALI. As inflammatory response plays a vital role in the pathogenesis of LPS-induced ALI, we detected the occurrence of pyroptosis in liver by ribonucleic acid (RNA) sequencing. The results showed that pyroptosis was significantly promoted by LPS, as indicated by gene ontology (GO) and kyoto encyclopedia of genes and genomes (KEGG) pathway enrichment analyses, revealing the activation of pyroptosis, interleukin (IL)-1 production, IL-18 production, and inflammatory signaling pathways. Then, we explored the effect of SFN on LPS-induced ALI. The results showed that SFN obviously reduced LPS-induced plasma alanine aminotransferase and aspartate aminotransferase level, pathological injuries and TdT-mediated dUTP nick-end labeling (TUNEL) positive cells, indicating protective effect of SFN on ALI. Furthermore, SFN also showed robust effect on LPS-induced inflammatory response in liver, as reflected by suppressing the infiltration of neutrophils and macrophages, and downregulating mRNA levels of C-X-C motif chemokine ligand 9, IL-6, monocyte chemoattractant protein-1, and tumor necrosis factor-Î± in liver of LPS treated mice. Furthermore, SFN blocked hepatocyte pyroptosis, and suppressed plasma IL-1Î² and IL-18 levels of LPS treated mice. Mechanistically, SFN selectively activated nuclear factor erythroid 2-related factor 2 (Nrf2)/heme oxygenase-1 (HO-1) signaling to mediate pyroptotic cell death. SFN also reversed the inhibited superoxide dismutase activity and induced malondialdehyde content in liver of LPS exposed mice. SFN ameliorated liver injury and inflammation during LPS-induced ALI by suppressing hepatocyte pyroptosis via the activation of Nrf2/HO-1 signaling. This study provides new evidence for the potential treatment of ALI with SFN.",
    "para1": "æ€¥æ€§è‚æå‚·ï¼ˆALIï¼‰æ˜¯ä¸€ç¨®ç”±æ•—è¡€ç—‡å¼•èµ·çš„è‡´å‘½ç–¾ç—…ï¼Œæ­»äº¡ç‡é«˜ä¸”é å¾Œä¸ä½³ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ åœ¨é€™ç¨®æƒ…æ³ä¸‹çš„æ½›åœ¨ç™‚æ•ˆï¼Œå¯èƒ½ç‚ºå¥åº·å’Œç–¾ç—…é é˜²æä¾›æ–°çš„è¦‹è§£ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å¤©ç„¶çš„ç•°ç¡«æ°°é…¸é…¯ï¼Œå…·æœ‰å¼·å¤§çš„æŠ—æ°§åŒ–å’ŒæŠ—ç™¼ç‚ç‰¹æ€§ï¼Œé€™ä½¿å¾—å®ƒåœ¨å°æŠ—è‚æå‚·æ–¹é¢å¼•èµ·äº†ç ”ç©¶è€…çš„é—œæ³¨ã€‚äº†è§£é€™äº›ç‰¹æ€§å¦‚ä½•å½±éŸ¿æ€¥æ€§è‚æå‚·çš„ç™¼å±•ï¼Œå¯èƒ½æœ‰åŠ©æ–¼é–‹ç™¼æ–°çš„æ²»ç™‚ç­–ç•¥ï¼Œæ”¹å–„æ‚£è€…çš„é å¾Œã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°ç”±è„‚å¤šé†£ï¼ˆLPSï¼‰å¼•èµ·çš„æ€¥æ€§è‚æå‚·çš„è—¥ç†ä½œç”¨åŠå…¶æ²»ç™‚æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿é€™ç¨®ç”±æ•—è¡€ç—‡å¼•èµ·çš„è‚æå‚·ï¼Œä¸¦æ‰¾å‡ºå…¶å¯èƒ½çš„ä½œç”¨æ©Ÿåˆ¶ã€‚é€™æ˜¯ä¸€å€‹é‡è¦çš„ç ”ç©¶é ˜åŸŸï¼Œå› ç‚ºæ€¥æ€§è‚æå‚·çš„é«˜æ­»äº¡ç‡å’Œä¸è‰¯é å¾Œä½¿å¾—å°‹æ‰¾æœ‰æ•ˆçš„æ²»ç™‚æ–¹æ³•è®Šå¾—è‡³é—œé‡è¦ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ä¸€å€‹å°é¼ æ¨¡å‹ä¾†æ¨¡æ“¬LPSå¼•èµ·çš„æ€¥æ€§è‚æå‚·ã€‚å¯¦é©—å…±ä½¿ç”¨äº†åå…«éš»å°é¼ ï¼Œåˆ†ç‚ºä¸‰çµ„ï¼šå°ç…§çµ„ã€LPSçµ„å’ŒLPS + è˜¿è””ç¡«ç´ çµ„ã€‚é€™äº›å°é¼ åœ¨LPSè™•ç†å‰çš„å…©å¤©å…§æ¥å—äº†è…¹è…”æ³¨å°„ï¼Œç„¶å¾Œåœ¨LPSæ³¨å°„å¾Œ24å°æ™‚æ”¶é›†è¡€æ¶²å’Œè‚è‡Ÿçµ„ç¹”é€²è¡Œé€²ä¸€æ­¥åˆ†æã€‚ç ”ç©¶è€…ä½¿ç”¨äº†çµ„ç¹”å­¸æŸ“è‰²å’ŒåŸºå› æ¸¬åºç­‰æ–¹æ³•ä¾†è©•ä¼°è‚è‡Ÿçš„æå‚·ç¨‹åº¦å’Œç‚ç—‡åæ‡‰ã€‚",
    "para4": "ä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ¸›å°‘ç”±LPSå¼•èµ·çš„è‚è‡Ÿæå‚·å’Œç‚ç—‡åæ‡‰ã€‚ç ”ç©¶çµæœæŒ‡å‡ºï¼Œè˜¿è””ç¡«ç´ é™ä½äº†è¡€æ¼¿ä¸­çš„è‚é…¶æ°´å¹³ï¼Œä¸¦æ¸›å°‘äº†è‚è‡Ÿä¸­çš„ç—…ç†æå‚·å’Œç´°èƒå‡‹äº¡ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„æŠ‘åˆ¶äº†ç‚ç—‡ç´°èƒçš„æµ¸æ½¤ï¼Œä¸¦èª¿ç¯€äº†å¤šç¨®èˆ‡ç‚ç—‡ç›¸é—œçš„åŸºå› è¡¨é”ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€šéæ¿€æ´»ç‰¹å®šçš„ä¿¡è™Ÿé€šè·¯ä¾†ä¿è­·è‚è‡Ÿï¼Œé›–ç„¶é€™äº›ç™¼ç¾æä¾›äº†æ–°çš„æ²»ç™‚æ€è·¯ï¼Œä½†ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ä¾†ç¢ºå®šå…¶è‡¨åºŠæ‡‰ç”¨çš„æ½›åŠ›ã€‚",
    "explanation_zh": "æ€¥æ€§è‚æå‚·ï¼ˆALIï¼‰æ˜¯ä¸€ç¨®ç”±æ•—è¡€ç—‡å¼•èµ·çš„è‡´å‘½ç–¾ç—…ï¼Œæ­»äº¡ç‡é«˜ä¸”é å¾Œä¸ä½³ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ åœ¨é€™ç¨®æƒ…æ³ä¸‹çš„æ½›åœ¨ç™‚æ•ˆï¼Œå¯èƒ½ç‚ºå¥åº·å’Œç–¾ç—…é é˜²æä¾›æ–°çš„è¦‹è§£ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å¤©ç„¶çš„ç•°ç¡«æ°°é…¸é…¯ï¼Œå…·æœ‰å¼·å¤§çš„æŠ—æ°§åŒ–å’ŒæŠ—ç™¼ç‚ç‰¹æ€§ï¼Œé€™ä½¿å¾—å®ƒåœ¨å°æŠ—è‚æå‚·æ–¹é¢å¼•èµ·äº†ç ”ç©¶è€…çš„é—œæ³¨ã€‚äº†è§£é€™äº›ç‰¹æ€§å¦‚ä½•å½±éŸ¿æ€¥æ€§è‚æå‚·çš„ç™¼å±•ï¼Œå¯èƒ½æœ‰åŠ©æ–¼é–‹ç™¼æ–°çš„æ²»ç™‚ç­–ç•¥ï¼Œæ”¹å–„æ‚£è€…çš„é å¾Œã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°ç”±è„‚å¤šé†£ï¼ˆLPSï¼‰å¼•èµ·çš„æ€¥æ€§è‚æå‚·çš„è—¥ç†ä½œç”¨åŠå…¶æ²»ç™‚æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿é€™ç¨®ç”±æ•—è¡€ç—‡å¼•èµ·çš„è‚æå‚·ï¼Œä¸¦æ‰¾å‡ºå…¶å¯èƒ½çš„ä½œç”¨æ©Ÿåˆ¶ã€‚é€™æ˜¯ä¸€å€‹é‡è¦çš„ç ”ç©¶é ˜åŸŸï¼Œå› ç‚ºæ€¥æ€§è‚æå‚·çš„é«˜æ­»äº¡ç‡å’Œä¸è‰¯é å¾Œä½¿å¾—å°‹æ‰¾æœ‰æ•ˆçš„æ²»ç™‚æ–¹æ³•è®Šå¾—è‡³é—œé‡è¦ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ä¸€å€‹å°é¼ æ¨¡å‹ä¾†æ¨¡æ“¬LPSå¼•èµ·çš„æ€¥æ€§è‚æå‚·ã€‚å¯¦é©—å…±ä½¿ç”¨äº†åå…«éš»å°é¼ ï¼Œåˆ†ç‚ºä¸‰çµ„ï¼šå°ç…§çµ„ã€LPSçµ„å’ŒLPS + è˜¿è””ç¡«ç´ çµ„ã€‚é€™äº›å°é¼ åœ¨LPSè™•ç†å‰çš„å…©å¤©å…§æ¥å—äº†è…¹è…”æ³¨å°„ï¼Œç„¶å¾Œåœ¨LPSæ³¨å°„å¾Œ24å°æ™‚æ”¶é›†è¡€æ¶²å’Œè‚è‡Ÿçµ„ç¹”é€²è¡Œé€²ä¸€æ­¥åˆ†æã€‚ç ”ç©¶è€…ä½¿ç”¨äº†çµ„ç¹”å­¸æŸ“è‰²å’ŒåŸºå› æ¸¬åºç­‰æ–¹æ³•ä¾†è©•ä¼°è‚è‡Ÿçš„æå‚·ç¨‹åº¦å’Œç‚ç—‡åæ‡‰ã€‚\n\nä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ¸›å°‘ç”±LPSå¼•èµ·çš„è‚è‡Ÿæå‚·å’Œç‚ç—‡åæ‡‰ã€‚ç ”ç©¶çµæœæŒ‡å‡ºï¼Œè˜¿è””ç¡«ç´ é™ä½äº†è¡€æ¼¿ä¸­çš„è‚é…¶æ°´å¹³ï¼Œä¸¦æ¸›å°‘äº†è‚è‡Ÿä¸­çš„ç—…ç†æå‚·å’Œç´°èƒå‡‹äº¡ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„æŠ‘åˆ¶äº†ç‚ç—‡ç´°èƒçš„æµ¸æ½¤ï¼Œä¸¦èª¿ç¯€äº†å¤šç¨®èˆ‡ç‚ç—‡ç›¸é—œçš„åŸºå› è¡¨é”ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€šéæ¿€æ´»ç‰¹å®šçš„ä¿¡è™Ÿé€šè·¯ä¾†ä¿è­·è‚è‡Ÿï¼Œé›–ç„¶é€™äº›ç™¼ç¾æä¾›äº†æ–°çš„æ²»ç™‚æ€è·¯ï¼Œä½†ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ä¾†ç¢ºå®šå…¶è‡¨åºŠæ‡‰ç”¨çš„æ½›åŠ›ã€‚",
    "fb_post": "æ ¹æ“šã€ŠFrontiers in pharmacologyã€‹æ–¼ 2025 å¹´ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿæœ‰ä¸€ç¨®å¤©ç„¶æˆåˆ†å«è˜¿è””ç¡«ç´ ï¼Œå¯èƒ½å°æˆ‘å€‘çš„è‚è‡Ÿå¥åº·æœ‰å¹«åŠ©ï¼æœ€è¿‘çš„ç ”ç©¶æ­ç¤ºäº†å®ƒåœ¨æ€¥æ€§è‚æå‚·ï¼ˆALIï¼‰ä¸­çš„æ½›åŠ›ï¼Œé€™æ˜¯ä¸€ç¨®ç”±æ•—è¡€ç—‡å¼•èµ·çš„åš´é‡ç–¾ç—…ï¼Œæ­»äº¡ç‡é«˜ï¼Œä¸”é å¾Œä¸ä½³ã€‚ç ”ç©¶è€…å€‘å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿é€™ç¨®æƒ…æ³ï¼Œä¸¦æ‰¾å‡ºå®ƒçš„ä½œç”¨æ©Ÿåˆ¶ã€‚  \n  \nåœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç§‘å­¸å®¶å€‘ç”¨å°é¼ æ¨¡æ“¬äº†ç”±è„‚å¤šé†£ï¼ˆLPSï¼‰å¼•èµ·çš„è‚æå‚·ï¼Œå°‡å°é¼ åˆ†ç‚ºä¸‰çµ„ï¼šå°ç…§çµ„ã€LPSçµ„å’ŒLPS + è˜¿è””ç¡«ç´ çµ„ã€‚ç¶“éå¯¦é©—ï¼Œä»–å€‘ç™¼ç¾è˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ¸›å°‘è‚è‡Ÿæå‚·å’Œç‚ç—‡åæ‡‰ï¼Œä¸¦é™ä½äº†è‚é…¶æ°´å¹³ï¼Œé€™äº›éƒ½æ˜¯è‚è‡Ÿå¥åº·çš„é‡è¦æŒ‡æ¨™ã€‚  \n  \nç¸½çµä¸€ä¸‹é€™é …ç ”ç©¶çš„é‡é»ï¼š  \n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘ç”±æ•—è¡€ç—‡å¼•èµ·çš„è‚æå‚·ã€‚  \n2. å®ƒèƒ½é™ä½è‚è‡Ÿä¸­çš„ç—…ç†æå‚·å’Œç´°èƒæ­»äº¡ã€‚  \n3. é€™äº›ç™¼ç¾ç‚ºæœªä¾†çš„æ²»ç™‚æ–¹æ³•æä¾›äº†æ–°çš„æ€è·¯ï¼Œä½†ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ä¾†ç¢ºèªè‡¨åºŠæ‡‰ç”¨çš„æ½›åŠ›ã€‚",
    "image_prompt": "Create a simple and informative illustration that explains the experiment and main results of a study on the effects of sulforaphane on acute liver injury. Use a flat design style with a white or light background and soft colors. Include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects like mice or cells, arrows or flow lines to indicate the experimental steps, and a section highlighting the main results, such as protective effects and changes observed.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "æ€¥æ€§è‚æå‚· Acute Liver Injury",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41181585/"
  },
  {
    "id": "41099966",
    "title_en": "Sulforaphane improves exercise-induced NRF2 signaling in older adults: an in vivo-ex vivo approach.",
    "pub_date": "2025 Oct",
    "journal": "GeroScience",
    "abstract_en": "Redox signaling is a key mechanism of exercise-induced adaptation. However, studies have demonstrated impaired responses to acute exercise in older organisms. Adjunctive therapies to augment exercise effects may overcome these deficits. Sulforaphane (SFN), a phytochemical from cruciferous vegetables, stimulates NRF2. This study tested the hypothesis that combining acute exercise (in vivo stimulus) with ex vivo SFN treatment would induce greater NRF2 activation and signaling in older adults compared to either treatment alone. Twenty-five older adults (12 men, 13 women; mean age: 67â€‰Â±â€‰5Â years) performed 30-min cycling exercise (AET). Blood was drawn before and immediately after the AET to isolate PBMCs and incubate with and without SFN (5Â ÂµM) treatment (four conditions: DMSO (CON), SFN, exercise (EX), and EXâ€‰+â€‰SFN). PBMCs were harvested after 2-h or 5-h incubation for measures of NRF2 or gene expression for NQO1, HO-1, GR, and GCLC targets, respectively. All treatments (SFN, EX, EXâ€‰+â€‰SFN) increased NRF2 activation compared to CON (pâ€‰<â€‰0.05). The response to EXâ€‰+â€‰SFN was significantly greater than either SFN or EX alone (2.1-fold versus 1.5-fold, pâ€‰=â€‰0.01). SFN stimulation resulted in a significant upregulation of all four genes compared to control (pâ€‰<â€‰0.001). EXâ€‰+â€‰SFN treatment stimulated a greater increase in gene expression compared to EX (pâ€‰<â€‰0.05); however, SFN did not differ statistically from EXâ€‰+â€‰SFN, suggesting a possible ceiling effect of the SFN concentration in terms of gene expression. There were no significant sex differences in any of the responses. These data suggest that combining exercise with SFN may amplify the strength of NRF2/ARE redox signaling in older adults. ClinicalTrials.gov ID: NCT04848792.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°å¹´é•·è€…çš„é‹å‹•é©æ‡‰èƒ½åŠ›ã€‚éš¨è‘—å¹´é½¡å¢é•·ï¼Œèº«é«”å°æ–¼é‹å‹•çš„åæ‡‰å¯èƒ½æœƒæ¸›å¼±ï¼Œé€™ä½¿å¾—å¹´é•·è€…åœ¨é€²è¡Œé‹å‹•æ™‚ï¼Œå¯èƒ½ç„¡æ³•ç²å¾—å¹´è¼•äººé‚£æ¨£çš„å¥åº·ç›Šè™•ã€‚å› æ­¤ï¼Œå°‹æ‰¾èƒ½å¤ å¢å¼·é‹å‹•æ•ˆæœçš„è¼”åŠ©ç™‚æ³•ï¼Œå°æ–¼æ”¹å–„å¹´é•·è€…çš„å¥åº·ç‹€æ³éå¸¸é‡è¦ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ èˆ‡é‹å‹•çµåˆçš„æ•ˆæœï¼Œå¯èƒ½ç‚ºå¹´é•·è€…æä¾›ä¸€ç¨®æ–°çš„å¥åº·ä¿ƒé€²ç­–ç•¥ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰èˆ‡é‹å‹•çµåˆå°å¹´é•·è€…çš„å½±éŸ¿ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œå¹´é•·è€…åœ¨é€²è¡Œæ€¥æ€§é‹å‹•æ™‚ï¼Œæ˜¯å¦èƒ½é€éè˜¿è””ç¡«ç´ çš„è¼”åŠ©ä¾†å¢å¼·èº«é«”çš„åæ‡‰ï¼Œç‰¹åˆ¥æ˜¯å°æ–¼NRF2é€™å€‹é—œéµä¿¡è™Ÿé€šè·¯çš„æ¿€æ´»ã€‚NRF2åœ¨èº«é«”çš„æŠ—æ°§åŒ–å’Œç´°èƒä¿è­·ä¸­æ‰®æ¼”è‘—é‡è¦è§’è‰²ï¼Œå› æ­¤äº†è§£å¦‚ä½•æå‡å…¶æ´»æ€§å°æ–¼å¹´é•·è€…çš„å¥åº·è‡³é—œé‡è¦ã€‚",
    "para3": "é€™é …ç ”ç©¶æ‹›å‹Ÿäº†25ä½å¹´é•·è€…ï¼ˆ12ä½ç”·æ€§å’Œ13ä½å¥³æ€§ï¼Œå¹³å‡å¹´é½¡67æ­²ï¼‰ï¼Œè®“ä»–å€‘é€²è¡Œ30åˆ†é˜çš„é¨è‡ªè¡Œè»Šé‹å‹•ã€‚ç ”ç©¶è€…åœ¨é‹å‹•å‰å’Œé‹å‹•å¾Œç«‹å³æŠ½å–è¡€æ¶²ï¼Œä¸¦åˆ†é›¢å¤–å‘¨è¡€å–®æ ¸ç´°èƒï¼ˆPBMCsï¼‰ï¼Œç„¶å¾Œå°‡é€™äº›ç´°èƒåˆ†åˆ¥èˆ‡å’Œä¸èˆ‡è˜¿è””ç¡«ç´ ï¼ˆ5ÂµMï¼‰è™•ç†ï¼Œå½¢æˆå››ç¨®ä¸åŒçš„å¯¦é©—æ¢ä»¶ï¼šå°ç…§çµ„ï¼ˆDMSOï¼‰ã€è˜¿è””ç¡«ç´ çµ„ã€é‹å‹•çµ„å’Œé‹å‹•åŠ è˜¿è””ç¡«ç´ çµ„ã€‚æ¥è‘—ï¼Œç ”ç©¶è€…åœ¨2å°æ™‚æˆ–5å°æ™‚å¾Œæ”¶é›†é€™äº›ç´°èƒï¼Œä»¥æ¸¬é‡NRF2çš„æ´»æ€§å’Œç›¸é—œåŸºå› çš„è¡¨é”ã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼Œæ‰€æœ‰è™•ç†çµ„ï¼ˆè˜¿è””ç¡«ç´ ã€é‹å‹•ã€é‹å‹•åŠ è˜¿è””ç¡«ç´ ï¼‰ç›¸æ¯”å°ç…§çµ„ï¼Œéƒ½é¡¯è‘—å¢åŠ äº†NRF2çš„æ´»æ€§ã€‚ç‰¹åˆ¥æ˜¯é‹å‹•åŠ è˜¿è””ç¡«ç´ çµ„çš„åæ‡‰é¡¯è‘—é«˜æ–¼å–®ç¨çš„è˜¿è””ç¡«ç´ æˆ–é‹å‹•çµ„ï¼Œé¡¯ç¤ºå‡ºé€™å…©è€…çš„çµåˆå¯èƒ½æœƒæœ‰æ›´å¼·çš„æ•ˆæœã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ çš„åˆºæ¿€ä¹Ÿé¡¯è‘—æé«˜äº†å››å€‹åŸºå› çš„è¡¨é”æ°´å¹³ã€‚é›–ç„¶é‹å‹•åŠ è˜¿è””ç¡«ç´ çµ„çš„åŸºå› è¡¨é”å¢å¼·ç¨‹åº¦é«˜æ–¼åƒ…é‹å‹•çµ„ï¼Œä½†è˜¿è””ç¡«ç´ çµ„çš„è¡¨ç¾èˆ‡é‹å‹•åŠ è˜¿è””ç¡«ç´ çµ„æ²’æœ‰çµ±è¨ˆä¸Šçš„é¡¯è‘—å·®ç•°ï¼Œé€™å¯èƒ½æš—ç¤ºäº†è˜¿è””ç¡«ç´ æ¿ƒåº¦åœ¨åŸºå› è¡¨é”ä¸Šçš„æŸç¨®ä¸Šé™æ•ˆæ‡‰ã€‚ç ”ç©¶ä¸­æ²’æœ‰ç™¼ç¾æ€§åˆ¥å°åæ‡‰çš„é¡¯è‘—å½±éŸ¿ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°å¹´é•·è€…çš„é‹å‹•é©æ‡‰èƒ½åŠ›ã€‚éš¨è‘—å¹´é½¡å¢é•·ï¼Œèº«é«”å°æ–¼é‹å‹•çš„åæ‡‰å¯èƒ½æœƒæ¸›å¼±ï¼Œé€™ä½¿å¾—å¹´é•·è€…åœ¨é€²è¡Œé‹å‹•æ™‚ï¼Œå¯èƒ½ç„¡æ³•ç²å¾—å¹´è¼•äººé‚£æ¨£çš„å¥åº·ç›Šè™•ã€‚å› æ­¤ï¼Œå°‹æ‰¾èƒ½å¤ å¢å¼·é‹å‹•æ•ˆæœçš„è¼”åŠ©ç™‚æ³•ï¼Œå°æ–¼æ”¹å–„å¹´é•·è€…çš„å¥åº·ç‹€æ³éå¸¸é‡è¦ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ èˆ‡é‹å‹•çµåˆçš„æ•ˆæœï¼Œå¯èƒ½ç‚ºå¹´é•·è€…æä¾›ä¸€ç¨®æ–°çš„å¥åº·ä¿ƒé€²ç­–ç•¥ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰èˆ‡é‹å‹•çµåˆå°å¹´é•·è€…çš„å½±éŸ¿ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œå¹´é•·è€…åœ¨é€²è¡Œæ€¥æ€§é‹å‹•æ™‚ï¼Œæ˜¯å¦èƒ½é€éè˜¿è””ç¡«ç´ çš„è¼”åŠ©ä¾†å¢å¼·èº«é«”çš„åæ‡‰ï¼Œç‰¹åˆ¥æ˜¯å°æ–¼NRF2é€™å€‹é—œéµä¿¡è™Ÿé€šè·¯çš„æ¿€æ´»ã€‚NRF2åœ¨èº«é«”çš„æŠ—æ°§åŒ–å’Œç´°èƒä¿è­·ä¸­æ‰®æ¼”è‘—é‡è¦è§’è‰²ï¼Œå› æ­¤äº†è§£å¦‚ä½•æå‡å…¶æ´»æ€§å°æ–¼å¹´é•·è€…çš„å¥åº·è‡³é—œé‡è¦ã€‚\n\né€™é …ç ”ç©¶æ‹›å‹Ÿäº†25ä½å¹´é•·è€…ï¼ˆ12ä½ç”·æ€§å’Œ13ä½å¥³æ€§ï¼Œå¹³å‡å¹´é½¡67æ­²ï¼‰ï¼Œè®“ä»–å€‘é€²è¡Œ30åˆ†é˜çš„é¨è‡ªè¡Œè»Šé‹å‹•ã€‚ç ”ç©¶è€…åœ¨é‹å‹•å‰å’Œé‹å‹•å¾Œç«‹å³æŠ½å–è¡€æ¶²ï¼Œä¸¦åˆ†é›¢å¤–å‘¨è¡€å–®æ ¸ç´°èƒï¼ˆPBMCsï¼‰ï¼Œç„¶å¾Œå°‡é€™äº›ç´°èƒåˆ†åˆ¥èˆ‡å’Œä¸èˆ‡è˜¿è””ç¡«ç´ ï¼ˆ5ÂµMï¼‰è™•ç†ï¼Œå½¢æˆå››ç¨®ä¸åŒçš„å¯¦é©—æ¢ä»¶ï¼šå°ç…§çµ„ï¼ˆDMSOï¼‰ã€è˜¿è””ç¡«ç´ çµ„ã€é‹å‹•çµ„å’Œé‹å‹•åŠ è˜¿è””ç¡«ç´ çµ„ã€‚æ¥è‘—ï¼Œç ”ç©¶è€…åœ¨2å°æ™‚æˆ–5å°æ™‚å¾Œæ”¶é›†é€™äº›ç´°èƒï¼Œä»¥æ¸¬é‡NRF2çš„æ´»æ€§å’Œç›¸é—œåŸºå› çš„è¡¨é”ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œæ‰€æœ‰è™•ç†çµ„ï¼ˆè˜¿è””ç¡«ç´ ã€é‹å‹•ã€é‹å‹•åŠ è˜¿è””ç¡«ç´ ï¼‰ç›¸æ¯”å°ç…§çµ„ï¼Œéƒ½é¡¯è‘—å¢åŠ äº†NRF2çš„æ´»æ€§ã€‚ç‰¹åˆ¥æ˜¯é‹å‹•åŠ è˜¿è””ç¡«ç´ çµ„çš„åæ‡‰é¡¯è‘—é«˜æ–¼å–®ç¨çš„è˜¿è””ç¡«ç´ æˆ–é‹å‹•çµ„ï¼Œé¡¯ç¤ºå‡ºé€™å…©è€…çš„çµåˆå¯èƒ½æœƒæœ‰æ›´å¼·çš„æ•ˆæœã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ çš„åˆºæ¿€ä¹Ÿé¡¯è‘—æé«˜äº†å››å€‹åŸºå› çš„è¡¨é”æ°´å¹³ã€‚é›–ç„¶é‹å‹•åŠ è˜¿è””ç¡«ç´ çµ„çš„åŸºå› è¡¨é”å¢å¼·ç¨‹åº¦é«˜æ–¼åƒ…é‹å‹•çµ„ï¼Œä½†è˜¿è””ç¡«ç´ çµ„çš„è¡¨ç¾èˆ‡é‹å‹•åŠ è˜¿è””ç¡«ç´ çµ„æ²’æœ‰çµ±è¨ˆä¸Šçš„é¡¯è‘—å·®ç•°ï¼Œé€™å¯èƒ½æš—ç¤ºäº†è˜¿è””ç¡«ç´ æ¿ƒåº¦åœ¨åŸºå› è¡¨é”ä¸Šçš„æŸç¨®ä¸Šé™æ•ˆæ‡‰ã€‚ç ”ç©¶ä¸­æ²’æœ‰ç™¼ç¾æ€§åˆ¥å°åæ‡‰çš„é¡¯è‘—å½±éŸ¿ã€‚",
    "fb_post": "æ ¹æ“šã€ŠGeroScienceã€‹æ–¼ 2025 å¹´ 10 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ‘µğŸ‘´ éš¨è‘—å¹´é½¡å¢é•·ï¼Œæˆ‘å€‘çš„èº«é«”å°é‹å‹•çš„åæ‡‰æœƒè®Šå¾—ä¸å¦‚ä»¥å‰ï¼Œä½†åˆ¥æ“”å¿ƒï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ ï¼ˆé€™æ˜¯ä¸€ç¨®ä¾†è‡ªé’èŠ±æ¤°èœçš„å¤©ç„¶åŒ–åˆç‰©ï¼‰å¯èƒ½èƒ½å¹«åŠ©å¹´é•·è€…æ›´å¥½åœ°å¾é‹å‹•ä¸­ç²ç›Šã€‚é€™é …ç ”ç©¶ç‰¹åˆ¥é‡å°å¹´é•·è€…é€²è¡Œï¼Œçœ‹çœ‹åœ¨é‹å‹•æ™‚åŠ ä¸Šè˜¿è””ç¡«ç´ ï¼Œæ˜¯å¦èƒ½å¢å¼·èº«é«”çš„åæ‡‰ã€‚ç ”ç©¶è€…æ‹›å‹Ÿäº†25ä½å¹´é•·è€…ï¼Œè®“ä»–å€‘é¨è‡ªè¡Œè»Šé‹å‹•30åˆ†é˜ï¼Œä¸¦åœ¨é‹å‹•å‰å¾Œæª¢æ¸¬ä»–å€‘çš„è¡€æ¶²å’Œç´°èƒåæ‡‰ã€‚çµæœé¡¯ç¤ºï¼Œç„¡è«–æ˜¯å–®ç¨é‹å‹•é‚„æ˜¯åŠ ä¸Šè˜¿è””ç¡«ç´ ï¼Œæ‰€æœ‰çµ„åˆ¥çš„èº«é«”åæ‡‰éƒ½æœ‰æ‰€æå‡ï¼å°¤å…¶æ˜¯åŒæ™‚é‹å‹•å’Œæ”å–è˜¿è””ç¡«ç´ çš„çµ„åˆ¥ï¼Œæ•ˆæœæ›´æ˜¯é¡¯è‘—ï¼Œè®“ä»–å€‘çš„èº«é«”ç²å¾—æ›´å¤šä¿è­·ã€‚é€™è®“æˆ‘å€‘çœ‹åˆ°ï¼Œçµåˆé‹å‹•èˆ‡å¥åº·é£²é£Ÿï¼Œæˆ–è¨±èƒ½è®“å¹´é•·è€…çš„ç”Ÿæ´»å“è³ªæ›´ä¸Šä¸€å±¤æ¨“ï¼\n\nğŸ”‘ é‡é»æ•´ç†ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½å¹«åŠ©å¹´é•·è€…æå‡é‹å‹•æ•ˆæœã€‚\n2. é‹å‹•åŠ è˜¿è””ç¡«ç´ çµ„çš„èº«é«”åæ‡‰æ˜é¡¯é«˜æ–¼å–®ç¨é‹å‹•ã€‚\n3. çµåˆé‹å‹•èˆ‡å¥åº·é£²é£Ÿï¼Œå°å¹´é•·è€…çš„å¥åº·æœ‰æ­£é¢å½±éŸ¿ã€‚",
    "image_prompt": "Create a flat design infographic explaining an experiment on the effects of sulforaphane (from broccoli) combined with exercise on elderly individuals. Include simple icons representing broccoli or sulforaphane, simplified illustrations of human figures or cells as experimental subjects, arrows or flow lines showing the experimental steps, and a section highlighting the main results such as increased protective effects or enhanced body responses.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "",
    "is_clinical_trial": true,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41099966/"
  }
]